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ABSTRACT 
Standards in Clinical Digital X-ray Imaging
Dual Energy X-ray Absorptiometry (DXA) is a digital x-ray technique designed to 
quantify bone mineral density (BMD), primarily of the lumbar spine and hip, and 
hence to provide a measure of bone strength and propensity to fracture. The 
original technology was based on a pencil beam x-ray source but later systems 
use a fan beam. Additional functionality includes measurement of hand BMD 
and vertebral fracture assessment (VFA). Smaller devices have also been 
developed to measure BMD at peripheral sites in the body. As the numerical 
value of BMD resulting from this technique is used directly in diagnosis and 
decisions over patient clinical management, it is critical that the measurements 
are accurate and precise.
The work presented in this thesis includes evaluation of the original pencil beam 
systems, later fan-beam technology, peripheral devices and additional 
functionality of DXA. This added to the knowledge of the technical capabilities 
and limitations of the technology providing an indication of precision, factors that 
may affect accuracy, radiation dose and machine comparison. Novel quality 
assurance phantoms were designed and constructed for assessing accuracy, 
precision and long-term stability of DXA-based hand and lateral morphometry 
techniques.
Research was also conducted into factors associated with BMD, treatment 
compliance and effectiveness and the role of lateral vertebral assessment. This 
contributes to the growing body of knowledge on clinical risk factors, medical 
management and the appropriate use of DXA and VFA.
The thesis also includes the author's contribution to the national training scheme 
and development of guidelines which have helped raise standards of the 
technique nationally.
These three areas of work contribute to ensuring the safe use of the new and 
developing technology and appropriate application within the clinical 
environment supported by highly trained operators and guidelines.
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In the context of DXA accuracy is the agreement between measured 
(i.e. biased) BMD and true BMD. A measure of ashed weight of bone 
is the gold standard.
Bone Mineral Density measured using DXA. This is an areal 
measurement of bone mineral content per unit area:
BMD =
Specificity
Bone Area (cm 2 ) 
Dual Energy X-ray Absorptiometry
Hormone Replacement Therapy is a therapeutic treatment used in 
women to replace hormones that the body no longer produces 
following the menopause. The hormones are oestrogen and 
progesterone.
The Ionising Radiation (Medical Exposure) Regulations 2000 is a 
statutory instrument designed to protect patients and research 
subjects from unnecessary radiation exposure. In November 2006 
enforcement of the regulations was transferred from the 
Department of Health to the Healthcare Commission.
Lateral Vertebral Assessment is the terminology used by GE-Lunarfor 
the measurement of vertebral height by DXA on their equipment.
Morphometric X-ray Absoptiometry which is a DXA technique for 
measurement of vertebral height. This later became known as 
Lateral Vertebral Assessment (LVA) and current nomenclature is 
Vertebral Fracture Assessment (VFA) which is a generic term for all 
technologies.
The National Osteoporosis Society is a charity established in the 
United Kingdom in 1986. The charity is dedicated to improving the 
diagnosis, prevention and treatment of osteoporosis.
A measure of reproducibility ie. degree of agreement of repeated 
measures. Determined by the root mean square coefficient of 
variation (rmsCV%).
In the context of peripheral DXA is the ability of the measurement to 
identify those with the disease (in this case osteoporosis as defined 
by a T-score of below -2.5 at spine or hip by DXA). 
Sensitivity is True positives identified as a proportion of all those 
with osteoporosis.
In the context of peripheral DXA is the ability of the measurement to 
identify those without osteoporosis as defined by spine or hip DXA.
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Specificity is True negatives as a proportion of all those without 
osteoporosis.
T-score Describes BMD relative to a young normal population in terms of 
number of standard deviations from the young normal mean BMD:
T-score = Measured BMD - Young Normal Mean BMD
Standard Deviation of Young Normal Population
VFA Vertebral Facture Assessment is the determination of vertebral 
morphometry using medical imaging techniques to diagnose 
vertebral fracture. The techniques include lateral spine DXAand 
standard x-rays.
Z-score Describes BMD relative to a normal population of the same age in 
terms of number of standard deviation from the age-matched mean 
BMD:
Z-score = Measured BMD-Age-Matched Mean BMD





The introduction of Dual Energy X-ray Absorptiometry (DXA) in the late 
1980s provided a practical diagnostic tool for prediction of propensity to 
fragility fracture. Unlike other clinical diagnostic technologies such as 
standard radiography (x-ray), Computed Tomography (CT) and Magnetic 
Resonance Imaging (MRI), DXA had only one application, the measurement 
of bone mineral density (BMD). DXA also appeared to be a relatively simple 
technique which provided a quantitative measure of bone strength that could 
be compared with a normal reference range. Hence the technique was 
primarily adopted by clinicians whose patient group included those at risk of 
osteoporosis and fragility fracture. With the introduction of a definition for 
osteoporosis based on a measure of BMD by DXA and the development of 
more bone protective drugs, there was increasing interest in the use of DXA.
At the time there was little independent evaluation of the equipment and a 
lack of training, procedures and guidelines to ensure optimisation of the 
results achieved. As a minor change in BMD is associated with a major 
change in fracture risk, equipment quality assurance and adherence to good 
operating technique is paramount. However, few DXA systems were placed 
within a scientific and technological healthcare environment that could 
adequately address these requirements.
At the author's unit in Hull, where most of the research presented in this 
thesis was carried out, the first DXA system to be installed was placed within 
the Nuclear Medicine Department which is part of the Medical Physics 
Service. This provided the appropriate environment, equipment and skilled 
staff to conduct the independent assessments necessary for equipment 
evaluation and validation. Being a new technology within the clinical field, 
protocols and standard operating procedures were required, and policies 
and guidance on appropriate clinical application.
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1.2 Aim
The work presented within this thesis was conducted with the aim of 
ensuring safe use of this new and developing technology and appropriate 
application within the clinical environment supported by highly trained 
operators and guidelines.
This aim was achieved by research into the following three aspects of DXA 
technology and its application.
1.2.1 Equipment
The work presented in this thesis includes commissioning and 
acceptance testing, radiation protection assessments, in-vitro and in-vivo 
precision, resolution and evaluation of new functionality of various types 
of DXA units from the original pencil beam systems through fan-beam 
rotating C-arm to semi-fan beam and peripheral units. Bespoke test 
equipment to confirm equipment accuracy and precision was designed 
and constructed and these devices remain in weekly use for the 
monitoring of scanner performance and precision.
1.2.2 Clinical Application
Also presented is research into the clinical application of DXA including 
an assessment of the technical and logistical feasibility of population 
screening, investigation of risk factors for osteoporosis and use of DXA 
based vertebral morphometry.
1.2.3 Standards
Finally, the author's contribution to national guidelines and a training 
scheme for DXA operators is detailed. These were developed with the 
aim of raising the understanding, quality and standards of the technique 
nationally.
1.3 Contribution to Knowledge
The work performed by the author over the years has added significantly to 
the growing body of knowledge on the performance, limitations and utility of 
the DXA technique and evolving technology. This thesis claims the following
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contribution to knowledge in the three areas outlined above:
1.3.1 Equipment
1.3.1.1 The comparison of 4 DXA systems from the same manufacturer (section 
2.3) was one of the first to indicate the importance of ensuring patient 
follow-up on the same machine, a recommendation that is still relevant 
today. This work also demonstrated the inherent errors associated with 
soft tissue inhomogeneities that may affect accuracy of BMD particularly 
in the elderly.
1.3.1.2 The radiation assessment of the Lunar Expert-XL (section 2.4) was the 
first to be performed on the new generation of higher resolution DXA 
systems. The findings confirmed the increased radiation burden to 
patients and staff. As a result this device was subsequently discontinued 
as users favoured alternative, lower dose systems in order to comply 
with the need to keep radiation doses as low as reasonably achievable.
1.3.1.3 Two phantoms were designed and constructed that were the first 
available for use in evaluation and quality assurance of bone mineral 
density of the hand and morphometry of the spine using DXA equipment 
(section 2.6). These proved to be of significant interest particularly to 
University based DXA units and have been used by sites in the UK and 
Europe.
1.3.1.4 The initial research work with the hand phantom demonstrated that the 
original pencil beams proved inadequate for performing in-vivo bone 
densitometry of the hand (section 2.6.1), a procedure which 
rheumatologists at the time were interested in for the management of 
patients with rheumatoid disease. The Expert-XL was later found to be 
more suitable for this application.
1.3.1.5 Evaluation of a new heel DXA device incorporating a laser measure of 
heel thickness demonstrated that this gives improved precision over a 
standard DXA heel device. There were no diagnostic thresholds in 
existence at the time so these were established and incorporated in 
national guidance on clinical use of the device (section 2.7.2).
1.3.1.6 The evaluation of an x-ray based technique for measuring only hand 
bone density provides an indication of precision and appropriate 
thresholds for use as a clinical triage tool (section 2.7.3).
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1.3.2 Clinical Application
The work presented in this thesis has also contributed to an improved 
understanding of the clinical role of DXA.
1.3.2.1 A paper on the technical and logistical feasibility of population screening 
was a seminal paper which demonstrated the robustness of the 
equipment and acceptability of the technique although such screening is 
not currently supported on cost effectiveness grounds.
1.3.2.2 A study of patients with coeliac disease confirmed an adverse effect of 
this condition on BMD even after matching for height, weight, 
menopausal status and menopausal age (section 3.4.3). The presence 
of coeliac disease was therefore included in the local referral criteria for 
DXA.
1.3.2.3 Papers on the adherence to (section 3.5.1) and the bone protective 
effects of (section 3.5.2) hormone replacement therapy provided insight 
into patient acceptability of HRT in a normal clinical setting and 
subsequent effect on bone of a short course of therapy. The latter was 
particularly relevant following the adverse publicity around the side 
effects of HRT and concerns over the reported increased cancer and 
heart disease risks associated with long term medication.
1.3.2.4 A comparison of targeted versus routine use of lateral imaging of the 
spine by DXA for diagnosis of vertebral fractures included the largest 
reported cohort of patients at the time to undergo the technique (section 
3.6). This has proved of interest to those looking at the potential of 
introducing this into their clinical practice and will help groups involved in 
developing guidance on the use of DXA based spine morphometry.
1.3.3 Standards
1.3.3.1 A training scheme was developed which was the first national scheme 
for certification of bone densitometry operators (section 4.3). 
Contributions towards its design, literature, teaching materials and 
marking scheme are presented. The scheme has been attended to date 
by 589 students with 264 proceeding to full certification. The scheme is 
endorsed by the College of Radiographers and the Institute of Physics in 
Engineering and Medicine and recognised by the Royal College of 
Physicians. Evidence of successful completion of this scheme is now
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included by some employers in the person specification for applicants to 
bone densitometry vacancies.
1.3.3.2 Guidelines on the setting up of a DXA based bone densitometry service 
were the first available nationally to aid commissioners, service providers 
and practitioners and also provide a benchmark for auditing of existing 
services (section 4.4.1).
1.3.3.3 Guidance on interpretation of DXA results was the first available in the 
UK to help practitioners involved in the scientific and clinical 
interpretation of DXA scans and provision of a report to the referring 
clinician (section 4.4.2).
1.4 Thesis Structure
The following three chapters take each of the areas of work in turn: 
equipment, clinical application and standards, identifying the gaps in 
knowledge at the time, explaining the motivation for the activities and how 
the results contribute to the understanding and appropriate application of the 
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Figure 1.1 Diagram of Thesis Structure
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CHAPTER 2 
EQUIPMENT EVALUATION AND QUALITY ASSURANCE
2.1 Outline of the State of Knowledge at the Time
2.1.1 Introduction
The work presented in this thesis is based on the evaluation and clinical 
application of DXA which was designed to quantify bone mineral density, primarily 
of the lumbar spine and hip, and hence provide a measure of bone strength and 
propensity to fracture1 2 3 . The technique is based on the attenuation of two 
different energy x-rays by the body. Background information on the production 
and attenuation of x-rays and the development of DXA is provided in Appendix I. 
By selecting two x-ray photon energies of around 40 and 80 keV, it is possible to 
differentiate between the attenuation due to bone and soft tissue. On passing 
through the human body, the low energy x-rays are attenuated more than the 
high energy, but especially so by bone. The transmitted x-ray signals are 
digitally stored on personal computers (PCs) containing dedicated software 
packages for image display and analysis. The system is calibrated to give an 
areal bone mineral density (BMD) in gem"2 using bone and tissue standards of 
known density. As the numerical value of BMD resulting from this technique is 
used directly in diagnosis and decisions over patient clinical management, it is 
critical that the measurements are accurate. Patients may be followed up with 
repeat DXA measurements to monitor changes in BMD due to disease 
progression or treatment-related changes with minor changes in BMD reflecting 
major changes in fracture risk. Consequently, the DXA systems must be capable 
of providing a precise measure of BMD both short- and long-term.
With the introduction in 1994 of the WHO definition for osteoporosis based on a 
measurement of BMD by DXA (Appendix II 1.3) the status of reduced bone 
mineral density and susceptibility to fracture following minimal trauma became 
identifiable as a disease status even in the absence of an existing fracture. This 
opened up possibilities of screening patients, identifying those at high risk, and 
prescribing bone protective treatments in an attempt to prevent fractures. There 
was a consequent rapid deployment of DXA equipment with no guidance or 
controls over operation or usage. There were and remain two major 
manufacturers involved, both U.S. based, who enforced customer brand loyalty
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through lack of agreement on software algorithms for determination of BMD and 
inconsistencies of reference databases. Device specific dedicated software was 
developed and reference databases established for comparison. This was a new 
and fast developing Quantitative digital imaging technique in medicine where 
relatively small changes in the parameter being quantified (BMD) became 
clinically very significant4 .
2.1.2DPXL
The early DXA devices used a pencil beam of xrays and a sodium iodide 
scintillation detector. The two were mounted onto a C-arm and moved in unison 
in a rectilinear fashion over the area of interest. One such system was the Lunar 
DPX (GE-Lunar, Madison, Wise.) illustrated in figure 2.1.
Figure 2.1 Lunar DPX bone densitometer
These machines had an x-ray tube operating at 80kV and used energy-selective 
filtration via a Cerium k-edge filter to achieve the spectral characteristics 
required. Scans could be performed of the lumbar spine and hip up to 167 lines, 
1.2 mm apart consisting of 1.2 mm spaced sample points. Total body scans of 
205 lines were possible and the DPXL version enabled lateral scans of the 
lumbar spine. Different scan speeds were provided to accommodate varying 
tissue thicknesses. Medium speed was generally used giving a scan time of 4 
minutes and skin entrance radiation dose of less than 15 uSv. For patients less 
than 22 cm thick within the scan area, fast scan mode could be used with a scan 
time of about 1 minute and radiation dose of 5 uSv. For larger patients, over 26
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cm thick, slow mode was recommended to compensate for reduced counting 
statistics due to increased attenuation. Scan times were increased to 8 minutes 
and doses to about 30 uSv.
In the early days following the introduction of DXA there was little independent 
equipment evaluation in particular regarding inter-machine variability and the 
effect of physiological variations in tissue thickness or composition. The concept 
of Dual Energy X-ray to differentiate between the attenuation through the two 
main components of the volume being scanned assumes that soft tissue is of a 
constant composition across the region of interest. However, soft tissue is 
composed of lean tissue (muscle) and fat tissue in varying proportions between 
individuals and, probably more critically, the proportion of red (lean) and yellow 
(fatty) bone marrow differs with age. Another anatomical variant which could 
affect accuracy of DXA is thickness of the body in the region being scanned. 
This can lead to beam hardening or detector saturation as described in 
Appendix I (2.9) and to area measurement errors due to the changed position of 
the bone relative to x-ray source and detector. In the early days of DXA there 
was a need for independent evaluation of these patient-related potential 
artefacts. Also, as there was a possibility of longitudinal monitoring of BMD 
changes, advice was required on whether follow-up scans could be performed 
on any scanner from the same manufacturer.
There was limited knowledge at the time of short and long term 
precision which could inform the user of the ability of DXA to 
measure and monitor changes in bone mineral density to the 
degree of accuracy and precision required.
2.1.3 Expert-XL
The Lunar Expert-XL, one of the first fan beam DXA systems, provides faster, 
higher resolution images but at an increased radiation dose (Figure 2.2). The 
Expert-XL uses a fan beam of x-rays and an array of solid state scintillation 
detectors, the x-ray tube and detectors being mounted on a C-arm which may 
be rotated to enable both anteroposterior and lateral imaging. The detector array 
eliminates the need for the rectilinear scanning motion required with traditional 
pencil beam systems, the emitter/detector assembly moving only longitudinally. 
The x-ray tube operates at a voltage of 134 kV and maximum tube current of 5 
mA with 2 mm aluminium filtration. Dual energy discrimination is achieved at the
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detector by one row of elements recording the low-energy and one the higher- 
energy x-rays. The system is capable of performing bone densitometry 
assessment of the lumbar spine, femoral neck, whole body, forearm, hand and 
morphometric assessment of the thoracic and lumbar vertebrae.
Figure 2.2 Lunar Expert-XL bone densitometer
Fan beam DXA systems involve an increased radiation burden for both patient 
and staff compared to the original pencil beam systems.
Njeh et al.s examined the doses involved for a prototype 
Expert DXA system but there was no independent 
assessment of the Expert-XL.
Digital imaging produces a course representation of bone edges resulting in 
some pixels containing both bone and soft tissue. This can introduce errors in 
edge detection and hence in measured bone area which in turn affects BMD. 
The improved resolution and faster scan speeds of the Expert-XL potentially 
offered improved precision through reduction in edge detection errors and 
motion artefacts. The almost radiographic quality images opened up the 
possibility of deriving morphometric parameters particularly of the vertebral 
bodies. The proprietary literature states a range of maximal resolutions from 2 to
21
1.6 line pairs(lps)/mm (0.5 mm to 0.625 mm) and others reported resolution of 
0.95 to 0.7 Ips/mm (1.05 to 1.43 mm) for the prototype Expert 6 .
However, there was no independent assessment of image 
resolution of the Expert-XL to indicate the degree of accuracy 
of this procedure.
2.1.4 Prodigy
In 2001 the Lunar Prodigy narrow fan beam system (Figure 2.3) was introduced 
which offered improved resolution but at a lower radiation dose than the Expert- 
XL. The Prodigy utilises a narrow fan beam in the cranio-caudal direction which 
performs a raster-type scan across the area of interest. The x-ray tube, which is 
mounted below the table, operates at a constant potential of 80 kVand uses a k- 
edge filter (Cerium) to provide 2 energies of around 40 and 70 keV 
(Appendix 1:2.2).
However, there was no independent report on the Prodigy 
densitometer and no indication of how well the results agreed 
with the DPX systems which they were often replacing.
Figure 2.3 Lunar Prodigy bone densitometer
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2.1.5 Quality Assurance Devices
DXA hardware and software developments continued through the 1990's with 
the introduction of additional functionality.
2.1.5.1 Hand DXA
Development of DXA software during the 1990s included the introduction of 
protocols for hand bone density on the Lunar DPX which was seized by some 
rheumatologists as a means of staging and monitoring rheumatoid disease by 
examining changes in peri-articular BMD of the hand.
Hand acquisition and analysis software was also made available for the later 
introduced Expert-XL (Figure 2.4).
JO.SviMf* OSIl'JS Aul.wiB): II.O&04 ll.GStf 11.92:
1745cm 14.0^8 *'«!": female Willed: II.WilM 11 lri..<: (I.V>
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Figure 2.4 Hand scan performed on a Lunar Expert-XL 
showing a measurement of hand BMD
In 1994 Peel et al. studied 70 postmenopausal women with established 
rheumatoid arthritis on a Hologic 1000 and compared them to 20 controls and 
20 early RA cases. They concluded that the technique was accurate and precise 
and could provide a marker for disease progression7 .
However, no quality assurance device existed that was 
suitable for the smaller tissue volumes and lower bone density 
seen in the hand.
2.1.5.2 MXA
With the advent of the Expert-XL fan beam DXA system, measurement of 
vertebral deformity by lateral imaging became possible. The improved resolution 
also facilitated accurate identification of vertebral endplates in order to 
determine deformities from a change in anterior, mid and posterior heights. 
Morphometric x-ray absorptiometry (MXA) provided the potential for identifying 
undiagnosed vertebral fractures at the same time as obtaining the diagnostic 
spine and hip BMD without the need for additional, higher radiation dose 
radiographic procedures. This became important in clinical management of the 
patient as emerging evidence identified prior fragility fracture as a major risk 
factor for future fracture8 9 10 although fragility fractures of the spine often go 
undetected and unreported 11 .
The technique lacked a quality assurance tool for use in in- 
vitro validation, stability and precision. Also, there was no 
information on the effect of kyphosis and scoliosis, features 
common in the patient population studied with this technique.
2.1.6 Peripheral DXA Devices
Many regions in the UK still do not have access to DXA services locally and 
cannot obtain the financial support to establish a service. As a newly 
'discovered' disease, osteoporosis does not figure highly alongside the long 
established and high profile diseases such as cancer, heart disease and 
diabetes. Also, diagnosis and management of a pre-morbid, symptom free 
condition may be considered more suitable for management within primary care 
and not requiring the specialist services of secondary care.
With the change in NHS financing introduced in the 1990's, the newly 
established Primary Care Trusts (PCTs) became the NHS fund-holders, 
purchasers and commissioners of healthcare. The PCTs were obliged to 
allocate a proportion of their budget to nominated key disease areas through the
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Local Delivery Plans with secondary care services, but the remainder was 
increasingly being invested in establishment of services within Primary Care. 
Equipment manufacturers quickly recognised the potential of smaller, cheaper, 
portable devices that could measure bone density and prove more suitable for 
placement in a Primary Care setting.
2.1.6.1 PIXI
The PIXI (Ge-Lunar Corp) peripheral densitometer was introduced in 1998 
(Figure 2.5). This uses a cone beam x-ray source of SOkVp and tube current 
400|aA The xrays are filtered using a polycarbonate and brass/zinc/copper 





Figure 2.5 The PIXI peripheral bone densitometer (GE-Lunar, Madison Wise). 
In configuration for heel BMD (above) and results printout (below).
The device is designed to be floor standing for measurement of calcaneal BMD 
(see Figure 2.5) or inverted and placed on a bench top for measurement of 
forearm BMD. The PIXI was marketed as a simple, portable device that could be 
utilised in Primary Care.
However, there was no independent guidance on appropriate 
application of this technique or on interpretation of the results 
in terms of patient management.
2.1.6.2Calscan
A new peripheral device for calcaneal BMD using fan beam configuration DXA 
was introduced in 2000. The DXL Calscan (Demetech AB, Sweden etc.) also 
incorporates a laser measurement of heel thickness in an attempt to improve the 
accuracy of calcaneal BMD (Figure 2.6). The heel thickness is used to correct 
inaccuracies introduced by the assumption in normal DXA systems that there is 
a homogeneous distribution of lean and adipose tissue within soft tissue1213 . 
Attempts at utilising 3 x-ray energies to overcome the problem of 
inhomogeneous soft tissue was suboptimal due to increased scan times and 
radiation dose14 15 .The measurement of heel width was found to provide the 
third component needed 16 .
Figure 2.6 The DXL Calscan heel DXA device and results display.
There was no independent evaluation of this device or 
comparison with other standard heel DXA devices.
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2.1.6.3 Metriscan
Peripheral devices are also available for quantifying bone mineral density of the 
hand. The Metriscan is a compact digital radiographic absorptiometry device 
capable of measuring bone mineral content of the second phalanges of the 
middle three digits (Alara Incorporated, Hayward, California, USA) (Figure 2.7). 
The device uses a cone beam x-ray (tube voltage 60 kV, current 0.333 mA) and 
the image is projected onto a curved storage phosphor plate mounted on a 
rotating drum. The drum is rotated, and scanned by laser, to excite photons from 
the surface of the exposed phosphor plate, with a photosensitive detector 
converting these photons to an electronic signal pulse proportional to the 
number of incident photons. A second light source then erases the plate ready 
for the next acquisition. An aluminium step wedge of known thickness built into 
the device within the region of interest provides calibration for each image. Bone 
mass estimates are determined through comparison with the step-wedge, and 
T- and Z scores are derived from reference data. Results are expressed as 
BMD, but as there is no comparison against a known bone-standard, the BMD 
score given is an arbitrary unit (BMD au), rather than the usual gem"2 . Although 
not a DXA device, this was marketed similarly to the peripheral DXA systems 
and is included for completeness.
At the time there was little independent evaluation of this 
technique and no advice on interpretation of the results for 
patient management.
Figure 2.7 The Metriscan digital radiographic absorptiometer
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2.2 Outline of the Motivation and Significance of the Work 
Undertaken
The motivation for the work presented in Appendix III was to contribute to the 
understanding of factors associated with the measurement of bone mineral 
density and additional DXA functionality. This knowledge was used locally to 
inform policies and procedures governing the use of the technology within a 
routine clinical environment. Also, through publications and presentations, the 
work contributed to the growing body of knowledge on the subject. The areas to 
be investigated evolved over the years with the development of improved 
technology, additional functionality and introduction of new devices.
The following objectives were set to address the shortcomings raised above in 
this chapter.
2.2.1 Objective 1 was to evaluate the DPXL pencil beam densitometers, 
assessing accuracy, precision, effect of tissue depth and composition on BMD 
and the inter-machine variability. This helped to determine equipment and 
patient related factors which could influence the measurement of BMD. 
This objective is addressed in Section 2.3.
2.2.2 Objective 2 was to evaluate the later introduced Expert-XL fan beam 
densitometer, determining radiation dose, precision and resolution. This helped 
inform decision on the appropriate use of this improved resolution but higher 
radiation does device. 
This objective is addressed in Section 2.4.
2.2.3 Objective 3 was to assess the precision and radiation dose of the Prodigy 
densitometers and examine the relationship between BMD determined using 
this device compared to the DPXL. 
This objective is addressed in Section 2.5.
2.2.4 Objective 4 was to design a phantom for quality assurance of hand BMD 
by DXA. No such phantom existed at the time to assess the accuracy and 
precision of this new DXA development. 
This objective is addressed in Section 2.6.1.
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2.2.5 Objective 5 was to design a phantom for quality assurance of 
Morphometric X-ray Absorptiometry (MXA) and use this to determine affect of 
patient positioning on vertebral height measurement. Again, there was no 
phantom at the time to determine and monitor accuracy and precision of this 
new technique. 
This objective is addressed in Section 2.6.2.
2.2.6. Objective 6 was to evaluate the PIXI peripheral DXA system and 
examine the relationship between heel BMD and axial BMD. This was to 
determine the reliability of these measurements and whether they were related 
to BMD measured by standard hip and spine DXA in order to inform decisions 
on appropriate use. 
This objective is addressed in Section 2.7.1.
2.2.7. Objective 7 - to evaluate the DXL Calscan heel densitometer and derive 
triage thresholds for clinical use. As above, this helped development of 
operating protocols and provided guidance for users on patient management 
based on the BMD result. 
This objective is addressed in Section 2.7.2.
2.2.8. Objective 8 - to evaluate the Metriscan hand densitometer and derive 
triage threshold for clinical use. Again, this helped with consideration of 
appropriate placement of this technology in the clinical arena and provided 
patient management guidance based on the result. 
This objective is addressed in Section 2.7.3.
2.3 Objective 1: Evaluation of Lunar DPX Bone Densitometers
2.3.1 Inter-machine Variability and Accuracy
The equipment evaluation presented in this chapter stems from a thorough 
understanding of the DPX technology gleaned whilst undertaking a project as 
part of an MSc. This is presented here as it establishes the basis of the 
techniques used for assessment of later technologies. Work was carried out to
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determine the difference in measurement of BMD between 4 Lunar DPX 
machines and the effect of anatomical variants that may affect this 
measurement. Repeat scans were performed of an aluminium spine phantom on 
4 Lunar DPX pencil beam DXA systems. The results demonstrated that although 
phantom BMD was within ± 2% of the manufacturer's stated value on all 
systems, there was a small but significant variation between the machines.
The recommendation was made that if repeat scans are required to monitor 
change, they should be performed where possible on the same scanner.
DXA theory assumes that the body is composed of only two components, bone 
and soft tissue. However, soft tissue is composed of lean and fat tissue which 
have slightly different attenuation properties at the energies used in DXA. There 
are variations in fat content of soft tissues between individuals and within 
individuals over time. This should be compensated for by the software as the k 
value (or R value on Lunar systems) is determined at the time of scanning. This 
value is derived from the ratio of attenuation of the high and low energy x-rays 
through the soft tissue area. Investigations using a soft tissue substitute of 
varying fat composition confirmed that BMD was not significantly affected by 
changes in fat to lean composition that would be encountered in clinical practice.
The software compensation for variable soft tissue composition described in the 
previous paragraph assumes that the soft tissue composition within the path of 
the x-ray beam over the bone area is the same as that adjacent to the bone. 
This may not always be the case especially with increasing age and 
replacement of red bone marrow with more yellow (fatty) marrow. Using varying 
thicknesses of a fat equivalent material to displace the water overlying the 
phantom only, leaving the adjacent 'soft tissue' areas constant, there was found 
to be a highly significant drop in BMD of 4.3% per cm of excess fat in the bone 
area. This is due to the correction for soft tissue being based on the differential 
attenuation in the areas adjacent to bone. In clinical practice, the fat content 
between the bone region and adjacent soft tissue may vary from -2.7 to 18.7% 17 
hence this may have a significant effect on measurement of BMD. Others later 
demonstrated errors of around 5%18 although a cadaver study suggested the 
errors were within acceptable limits19 .
The position of the spine may vary relative to the bed due to increased soft 
tissue thickness or spinal curvature which may affect estimate of BMD by DXA. 
Using a stepped holder for the spine phantom purpose designed by the author, 
a significant decrease in BMD with increasing height of the phantom was 
demonstrated on two of the four DPX pencil beam systems.
The effect of variations in soft tissue thickness within the scan area on 
measured BMD was also investigated. It is possible that in obese patients beam 
hardening due to selective attenuation of the low energy x-ray component can 
artificially raise measured BMD. Alternatively, in very thin individuals there will 
be reduced attenuation of the x-rays leading perhaps to detector saturation. The 
DXA software provides different scan modes which vary the photon flux and 
scan speed to accommodate these variations but there was a lack of 
independent validation. It was found that use of appropriate scan mode 
minimised potential overestimate of BMD in cases of increased tissue thickness.
This work provided insight into the factors affecting measurement of BMD using 
a pencil beam densitometer and the potential of the equipment for monitoring 
longitudinal changes in BMD. This contributed to the design of further research 
activity presented below involving the newer technology fan-beam and semi-fan- 
beam densitometers (sections 2.4 and 2.5) and peripheral densitometers 
(section 2.7).
2.3.2 Long Term Precision of DPXL
A meta analysis by Marshall et al. reported that a reduction in BMD equivalent to 
one standard deviation (equivalent to approximately 10% change in BMD) of the 
reference population is associated with an approximate doubling of risk of 
fragility fracture 4 . Consequently, the DXA systems must be capable of providing 
a precise measure of BMD both short- and long-term. A rigorous quality 
assurance procedure was introduced by the author which involved daily 
scanning of spine phantoms on each of three DXA systems and scanning of one 
phantom on all three systems for cross calibration purposes. This enabled a 
detailed analysis of equipment stability and effect of component failure and 
replacement (Abstract 1). Over a seven year period, the systems were found to 



















mean (SD) BMD 









Table 2.1 Long term (7 year) precision of 3 DPX(L) scanners
The three systems were found to give similar BMD results for the cross- 
























Table 2.2 Correlation between machines using same phantom 
(reference BMD 1.267 gem"2)
Detector deterioration on all systems caused a decline in spine phantom BMD of 
about 0.05% over 1 month but component replacement restored values to 
original levels. This deterioration was not readily identified by reference to daily 
quality assurance results but was highlighted by observation of the 'spillover' 
(recording of high energy x-rays in the low energy window) and ratio of counts 
in air for the high and low energy x-rays.
2.4 Objective 2: Evaluation of the Lunar Expert-XL Bone 
Densitometer
2.4.1 Radiation Dose Assessment
An Expert-XL was installed in the author's department in 1996 primarily for 
research applications. As part of the commissioning and acceptance testing, a 
detailed dose assessment was conducted (Paper 1). Scatter doses to the 







































Table 2.3 Scatter doses at 1 m from centre of scanning table
With an expected workload of 4 patients per hour, it was suggested that steps 
be taken to reduce the dose to the operator. This could include increasing the 
operator's distance from the scan table or installing a protective screen. The 
radiation dose to the patient was also found to be higher than for pencil beam 
DXA systems but appeared to be proportionate to the added clinical benefits of 
improved resolution and availability of MXA (Table 2.4).
Scan Mode
AP spine (fast)












































'assumes ovary within primary field, **assumes ovary outside primary field
Table 2.4 Effective doses to patient from standard procedures 
on Lunar Expert-XL
A decision was taken to install a lead glass screen to ensure scatter doses to 
the operator were kept as low as reasonably achievable.
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This work is cited by 11 other authors in international peer-reviewed journals*. 
The work is also cited by the IAEA (International Atomic Energy Authority: 
rpop.iaea.org/RPOP/RPoP) on their website under information for Health 
Professionals on radiation protection of staff using DXA and by Health Canada 
under the section on Environmental and Workplace Health (www.hc-sc.gc.ca).
2.4.2 Image Resolution of the Expert-XL
A further study was designed and carried out to determine spatial resolution of 
the various scan modes using commercially available resolution test patterns 
(Paper 2). Spatial resolution is a measure of an imaging systems ability to 
distinguish between small features usually determined by how close lines can be 
together and still be resolved.
Fan-beam densitometry distorts and magnifies the lateral (x-axis) dimension of 
the image by an amount dependent on the relative positions of x-ray tube, object 
and detector. Conventional cone-beam radiographs distort both lateral and 
longitudinal dimensions. The lateral and longitudinal resolutions achieved for 













































*Resolution in Ips/mm = 1/resolution in mm
Table 2.5 Image resolution of the Expert-XL
* Citation searches throughout the thesis were performed using Web of Science and exclude those 
with which the author was involved
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The test pattern used (07-541 Nuclear Associates, Carle Place, NY) contains 15 
sets of lead line pairs arranged horizontally and vertically covering a range of 0.6 
to 3.4 line pairs per millimetre. Resolution was found to be about 1mm, which is 
around half that of the older technology pencil beam DXA systems but not as 
good as that stated by the manufacturers. Resolution was found to be affected 
by thickness of attenuator and bed height but even the optimal resolution 
attainable (0.83mm) does not approach that of standard radiographic 
procedures which reach 3.5 Ips/mm (0.29mm) for lateral spine imaging 20 .
More research was required to inform decisions around the potential clinical use 
of the additional functionality of this DXA equipment. Further reports in peer- 
reviewed journals by 8 other authors cite the work presented above.
2.4.3 Accuracy and Precision of the Expert-XL
The evaluation work carried out on the pencil beam DPXL systems was 
repeated on the Expert-XL fan beam densitometer under the author's 
supervision. The findings demonstrated that errors due to tissue thickness could 
be minimised through use of appropriate scan modes but that these were not as 
recommended by the manufacturer at the time. The optimal scan modes were 
found to be the 5mA fast mode for most patients and 2mA fast for those with 
less than 15 cm soft tissue within the scan region (Abstract 2). These gave the 
most consistent results over a range of tissue thicknesses rather than the high 
precision turbo scan modes which were introduced by the manufacturers to 
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Figure 2.8 BMD (L2-L4) of Lunar Spine Phantom using varying depths of water 
at each scan mode.
As a consequence, the fast scan modes continued to be used for routine clinical 
application in the author's department.
The work above was conducted using phantoms and tissue mimicking material 
which may not accurately reflect precision attainable in patients. There was a 
need to derive in-vivo precision in-house for the population involved in order to 
determine whether a change in BMD during longitudinal follow-up is statistically 
significant and to help determine appropriate follow-up intervals.
Although bone protective treatments are proven to be effective through large, 
international phase III clinical trials, many clinicians still prefer to have 
demonstrable evidence of effectiveness on the individual. There is also a 
requirement to monitor some patients on drugs known to have a detrimental 
effect on bone. Hence, many requests are made for longitudinal measurements 
to monitor change in BMD.
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To avoid unnecessary radiation exposure of patients attending for routine bone 
density assessment, the data accumulated on patients participating in clinical 
trials involving the Expert-XL was utilised. Two cohorts were analysed by the 
author, 121 post-menopausal women undergoing repeat spine BMD (with 
repositioning) as part of the trial and 27 post-menopausal women with repeat 
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Table 2.6 In-vivo precision results for 2 study groups on the Expert-XL. Scan 
mode 5mA fast with repositioning between scans.
The precision as percent coefficient of variation (%CV) for spine BMD on the 
Expert-XL was found to be between 1.7% and 2.2% depending on the mean 
BMD of the study population (Table 2.6).
Precision of hip BMD for the 27 subjects, mean hip T-score of -0.6, was 0.94 at 
the total hip site or 1.46 for femoral neck. However, hip BMD was performed 
using a hip positioner (Osteodyne HPS) as required by the study protocol and 
therefore may not represent in-vivo precision using standard recommended 
procedures.
The precision of spine BMD is poorer than that of 0.7% to 1.6% reported for the 
pencil beam systems so the recommendation was that for routine assessment of 
spine BMD, the pencil beam system was preferred due to improved precision 
and lower radiation dose.
The work on the Expert-XL confirmed the higher spatial resolution but at a 
higher radiation dose and lower precision compared to the pencil beam devices. 
The Expert-XL was therefore utilised for research applications and vertebral 
morphometry (see 2.6.2) where improved spatial resolution outweighed the 
increased radiation burden and reduced precision.
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2.5 Objective 3: Evaluation of Lunar Prodigy Bone Densitometers
A Prodigy was installed in the author's department in 2001 as a replacement for 
a Lunar DPXL. The Centre still housed another DPXL and the Expert-XL. The 
proposal was for the Prodigy to supplement the DPXL in providing the routine 
clinical service and that patients formerly scanned on the decommissioned 
DPXL would be transferred to the Prodigy.
2.5.1 Radiation Dose Assessment of the Prodigy
A radiation assessment of both patient dose and scatter dose to the operator 
was conducted (Abstract 4). The scatter dose to the operator was found to be 
3 uSv/h which confirms that stated by the manufacturers. The radiation dose 
from the Prodigy was too low to utilise the anthropomorphic phantom as used for 
the dose assessment on the Expert-XL(see 2.4.1). Hence, skin entrance doses 
only were determined using an ionisation chamber under a water phantom. The 
dose to patients using each of the scan modes was also found to be similar to 



























Table 2.7 Radiation dose to patients using available scan modes on the 
Prodigy.
2.5.2 Precision of the Prodigy and Correlation with DPXL and Expert-XL
In-vitro and in-vivo precision of BMD using the Prodigy densitometer was 
determined by the author. Short-term in-vitro precision was calculated using 10 
repeat scans, with repositioning, on one day of the Lunar aluminium phantom 
and a Hologic phantom (Abstract 4). Precision was found to be 0.3% for both 
phantoms. Long term precision was determined by analysis of the daily phantom 
scans over a period of 1 year. This was found to be 0.4% using the Lunar 
phantom and 0.5% using the Hologic phantom. Precision is therefore better than
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that for the DPXL and Expert-XL systems.
Due to the possibility of patients being transferred from another scanner within 
the department following equipment failure or replacement, daily scanning of 
one aluminium phantom and one Hologic phantom on all systems in the 








































Table 2.8 In-vitro Inter-Machine Comparison
Using the aluminium phantom, BMD was found to be 1.7% below that 
determined for the same phantom measured on the DPXL and 1.9% below that 
on the Expert-XL (Table 2.8).
The phantom BMD results above only provide a guide to the machine 
differences and may not be applicable in patients 21 . The author therefore carried 
out in-vivo studies to determine precision and inter-machine variability between 




















Table 2.9 In-vivo precision of the Prodigy from duplicate scans of 36 women
Precision was determined using repeat spine and hip BMD of 36 post- 
menopausal women recruited for a randomised clinical trial. The women were 
aged 46 to 67 years and all were osteopenic (T score -1 to -2.5). In-vivo
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precision was found to be 0.9% at spine, 1.4% at femoral neck and 1.0% at 
Total Hip (Table 2.9) which is comparable to that reported for the pencil beam 
DXA systems and better than that of the Expert-XL fan beam densitometer as 
presented previously (section 2.4.3 and Table 2.6).
The findings above led to the Prodigy being chosen as the densitometer of 
choice for replacement of the remaining DXA scanners as the time arose.
The in-vivo difference between the scanners was calculated using a group of 31 
postmenopausal women attending as part of a nine year longitudinal study of 
peri- and post-menopausal changes in BMD (Abstract 5). The women 
underwent BMD of spine and hip on both the Prodigy and DPXL. The inter- 
machine variability was found to be not so large at the spine (0.6% below) than 
for the in-vitro study. However, femoral neck BMD was 2% higher on the Prodigy 




















(-0.089 to 0.1 25)
Table 2.10 BMD of 31 women scanned on both the DPXL 
and Prodigy on the same day.
These results demonstrate that cross calibration based on phantom studies is 
inappropriate. However, because of the wide variation in in-vivo BMD between 
the scanners, cross calibration may only be of use in large population studies 
and not for correction of individual results.
Others have since reported slightly better in-vivo agreement between a DXPL 
and Prodigy 22 with a mean difference at spine of 0.001 gem"2 and at femoral
40
neck of -0.003 gem"2 . Cross calibration results are therefore not transferable to 
other scanners even where the same types of scanner are being compared.
The work outlined in this section demonstrates the improved precision and lower 
radiation dose of the Prodigy systems compared to the Expert-XL. 
Consequently, the Prodigy systems were chosen as the devices to be used for 
routine assessment of spine and hip BMD in the author's department.
2.6 Development of DXA Quality Assurance Devices
2.6.1 Objective 4: Development of a Phantom for Hand BMD Quality 
Assurance
The aim was to develop a phantom to assess precision and linearity of the DPX 
and DPXL densitometers at the low BMD values (0.3 to 0.9 gem"2) found in the 
hand (Paper 3). The phantom should also be robust enough for use in 
monitoring long-term precision. Through pilot work carrid out by the author using 
various thicknesses of aluminium and Perspex representing bone mineral and 
lean soft tissue respectively, appropriate dimensions of the simulated phalanges 
were determined. These were embedded in a Perspex block drilled precisely to 
fit. A phantom suitable for use with the original pencil beam DXA devices was 
designed by the author and constructed in-house (Figure 2.9).
















































Table 2.11 Mean BMD and precision for the 3 regions of interest using each of 
the 4 scan modes of Lunar small animal software
As can be seen from Table 2.11, the trend of increasing BMD with increasing 
resolution for the higher BMD regions is reversed in the low BMD 'distal 
phalanges' region of the phantom. This was found to be due to failure of the 





















































Table 2.12 Mean area and precision for the 3 regions of interest using each of 
the 4 scan modes of Lunar small animal software. Actual projected areas 
containing 'bone' within each region are indicated.
The areas determined by the software to contain bone or bone equivalent 
material within the distal phalanges region of the phantom were underestimated 
by 21% to 62% depending on scan mode (Table 2.12).
This work demonstrated that the DPX systems were incapable of detecting BMD 
below a threshold of around 0.3gcm~2 , a value which is not unusual in-vivo in the 
hand. Improved recognition of low bone density values was achieved with the 
higher resolution fan beam Lunar Expert-XL (section 2.4) introduced in the mid
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1990s and the hand phantom was redesigned for use with this system. As a 
consequence, the Expert-XL was chosen as the system to be used for 
measurement and monitoring of BMD of the hand. This work has been cited by 
3 other authors.
2.6.2 Objective 5: Development of a Phantom for Quality Assurance of 
MXA
The Expert-XL DXA systems are mounted on a C-arm that can be rotated to 
enable lateral imaging of the spine with the patient in the supine position (Figure 
2.10).
MXA of normal spine MXA showing fractures of T12
Figure 2.10 Lateral spine images produced using an Expert-XL scanner
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A morphometry phantom suitable for MXA was designed by the author and 
constructed in-house (Figure 2.11). The phantom consists of 3 components; a 
Perspex torso-mimicking block with a drilled core and two aluminium and 
Perspex inserts (Paper 4). The inserts are constructed of 12 cylinders of 
aluminium with phosphor-bronze endplates, one column being of regular shaped 
cylinders designed to check alignment, positioning and mechanical movements 
and one of irregular cylinders representing vertebral deformities.
Figure 2.11 MXA Phantom
Use of this phantom on the Expert-XL fan beam densitometer demonstrated a 
precision of 0.6% to 1.1% in measurement of vertebral height depending on the 
complexity of the shape. There was also found to be a consistent underestimate 
of vertebral height by 5% but this may not be clinically significant as the degree 
of vertebral deformity is generally determined relative to the heights of the 2nd to 
4th lumbar vertebrae (L2-L4).
The Hull MXA phantom was the first of its kind and proved to be invaluable for 
assessing the accuracy of MXA, inter- and intra-operator variability and to 
monitor long-term precision. The phantom continues to be used weekly on all 
DXA scanners in the Centre. The work is cited by 4 later reports evaluating 
precision and application of the VFA technique.
A further study was designed and carried out under the author's supervision 
using the morphometry phantom to examine the effect of patient positioning, 
scoliosis and kyphosis on the MXA technique using the Expert-XL. This work 
demonstrated that kyphosis of up to 6% had a minimal effect on MXA but 
scoliosis of greater than 4.6% significantly affects the measurement (Paper 5).
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The work earned the young investigator award from the National Osteoporosis 
Society in 1998 for the research assistant Jonathan Thorpe and is cited by Rea 
et a/, in their report on development of a similar phantom in 2001 23 .
Results of the work above helped inform the decision to introduce MXA into 
routine clinical practice in Hull, initially on selected patients with strong indication 
for vertebral fracture but later as a screening tool in all those over 65 years 
attending for DXA These two strategies were later compared and the findings 
presented in the Clinical Application chapter of this thesis (section 3.6: Paper 
14). The work was also cited by the International Society for Clinical 
Densitometry in the development of their position statements on the use of 
VFA24 .
2.7 Peripheral Densitometry
2.7.1 Objective 6: Evaluation of the PIXI heel DXA device
A peripheral DXA device, the PIXI, was purchased for the Centre in 1999 by the 
local charity OSPREY. A proposal was made to the local Osteoporosis Strategy 
Group that the device could be utilised for community based BMD in females 
aged 70 to 75 years who may benefit most from the convenience and reduced 
travel. Prior to this, an assessment of in-vivo precision of the device was 
required which was determined using duplicate measurements on 105 women 
aged 70 to 76 years. This was found to be 1.9% compared to 1.6% for spine 
BMD in the same population (Abstract 6).
As the WHO definition of Osteoporosis is not applicable to the heel, a working 
threshold was also derived by the author which best predicted BMD status at 
spine and hip. The 105 subjects also underwent spine and hip BMD (Lunar 
Prodigy). The correlation between heel and spine or hip BMD was found to be 
0.54 and 0.53 respectively compared to 0.64 for spine versus hip BMD. The 
agreement between the techniques was examined using Bland-Altman plots to 
compare T-scores (Figures 2.12 and 2.13). These display scatter plots of the 
differences in the T-scores between the two techniques against the mean of the 
two measurements. Horizontal lines are drawn at the mean difference, and at 
the limits of agreement (mean difference +/-1.96 times the standard deviation of
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the differences). The results indicate a significant difference between the two 
measurements (mean diff. spine-heel -0.25; p=0.05 and mean diff. hip-heel - 
0.32; p<0.01). The mean difference is also correlated with BMD both for spine- 
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Figure 2.12 Bland-Altman plot of difference against mean of
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Figure 2.13 Bland-Altman plot of difference against mean of 
hip and heel BMD
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Using ROC analysis a T-score threshold of around -1.7 for heel BMD by PIXI 
was found to minimise the proportion of patients who would be over- or under- 
referred if the technique was used as a pre-screen for DXA spine and hip. 
Sensitivity and specificity for osteoporosis at spine or hip using a threshold of 
-1.7 is 72% and 74% respectively. This also identified the same proportion of the 
population as being at risk as by using a T-score of -2.5 for spine and hip BMD. 
These findings are in concordance with later published work25 . The T-score 
threshold of -1.7 was utilised for the community-based pilot project of screening 
elderly women in the Hull area. The results of the work were awarded with Best 
Poster at an international conference in Rio de Janeiro in 2000.
2.7.2 Objective 7: Evaluation of the DXL Calscan
A study was carried out by the author to determine the in-vitro and in-vivo 
operating conditions of the DXL Calscan and to consider its clinical role, through 
comparisons with both axial BMD and with peripheral BMD using the PIXI 
(Paper 6).
The effectiveness, application and stability of the Calscan were examined 
through a series of in-vivo and in-vitro tests. The device proved to be easy to 
use, stable when used within recommended environmental conditions and 
involved a very low radiation dose of less than O.luSv. In-vivo precision at 1.2% 
was slightly better than that for the PIXI (1.9%). Triage thresholds were also 
determined to categorise patients for 'reassurance', 'referral" for spine and hip 
DXA or 'treatment in accordance with the recently published National 



























Figure 2.14 DXL Calscan upper and lower triage thresholds for the non- 
dominant heel.
From the subjects in the study, 53% were found to have a heel BMD within the 
'refer' category. However, this sample does not represent the ratio of 
osteoporotic to non-osteoporotic as seen in routine clinical referrals. Correction 
for this indicates around 40% of patients would require referral for confirmation 
of bone status by spine and hip DXA requiring therefore heel DXA cost per case 
to be less than 60% of a spine and hip measurement to result in a net saving.
The findings of this study are incorporated in the list of device specific thresholds 
collated by the National Osteoporosis Society27 . The work has also been cited 
by 2 other authors conducting further evaluation of the device and is cited in the 
position statement on pDXA by the International Society of Clinical 
Densitometry28 .
2.7.3 Objective 8: Evaluation of the Alara Metriscan
An evaluation of the Alara Metriscan hand densitometer was also carried out to 
determine the in-vitro and in-vivo operating conditions and to determine triage 
thresholds as for the Calscan (Paper 7). One hundred and seventy women 
attending for routine spine and hip DXA also underwent measurement of the 
hand using the Metriscan. The device was simple to operate and radiation dose 
to the patient and scatter dose to staff was very low. In-vivo precision at 1.42% 




















Figure 2.15 Alara Metriscan upper and lower triage thresholds for non-dominant 
hand
The triage thresholds, determined in accordance with the NOS guidelines 26 , 
identified around 44% of patients requiring referral for confirmation of bone 
status by spine and hip DXA (Figure 2.15). This is a larger proportion than that 
when heel BMD is used as a triage tool.
The findings of this study are incorporated in the list of device specific thresholds 
collated by the National Osteoporosis Society27 .
2.8 Summary
The work presented above addressed the objectives set out in section 2.2.
Objective 1 - Evaluation of the DXPL densitometers was carried out and the 
following results presented:
a) Accuracy - phantom BMD was within +/- 2% of manufacturer's value 
which confirms acceptable level of accuracy of BMD measurement.
b) Long term precision was found to be 0.8% which demonstrates good 
reproducibility and stability of the equipment over time.
c) Effect of tissue depth and composition - Although errors in BMD 
could be introduced with increasing or decreasing tissue depth,
49
representing over-/underweight patients, these were minimised by 
using the appropriate scan modes available. The automated 
selection of scan mode by the software based on patient weight and 
height was observed in practice to be unreliable hence a procedure 
was introduced for measurement of tissue depth within the scan 
region and manual selection of appropriate scan mode. 
Measurement of BMD is not significantly affected by variations in fat 
to lean composition of soft tissues that are encountered in clinical 
practice. However, discrepancy in soft tissue composition within the 
projected bone region as opposed to that either side can significantly 
affect BMD. Further work is needed to determine the clinical 
significance of this especially in view of the increasing proportion of 
yellow (fatty) marrow with age. In 2009, Blake et a/, demonstrated 
that a change in vertebral marrow fat content from 0 to 100% led to a 
difference in BMD equivalent to approximately 1.3 T-score units29 . 
However, this did not significantly affect the ability of spine BMD to 
predict fracture risk.
d) Inter-machine variability - There was found to be a significant 
variation between the machines which reinforced the 
recommendation that follow-up scans where needed should be 
performed as far as possible on the same scanner.
This work provided a benchmark for comparison and established the 
techniques for evaluation of later densitometry equipment. The 
experience gained in identifying the factors that influence accuracy 
and precision led the author to establish rigorous quality assurance 
procedures locally and ensure operators were well trained and 
following standard operating procedures. This approach was later 
incorporated into a national training scheme as described in section 
4.3.
Objective 2 - evaluation of the Expert-XL:
a) Radiation Dose - effective dose to the patient was found to be 
between 40 and 75 i^Sv depending upon scan site and scan mode 
used. These are higher than that for the pencil beam DPXL systems.
Scatter dose to the operator was found to be around 0.5 jaSv for
50
spine and hip BMD but higher for lateral or whole body scanning. 
Depending on patient throughput, scan mix, and room size, a lead 
glass screen may be required to ensure operator dose remains 
below recommended limits.
b) Precision - In-vivo precision of the spine was found to be 1.7 to 2.2% 
which is poorer than for the DPXL (0.7 to 1.6%).
c) Resolution - Using a test pattern, resolution was about 1mm which is 
much better than that of pencil beam systems.
These findings supported the continued use of the DPXL machines 
for routine BMD to keep doses as low as reasonably practicable. The 
Expert-XL was reserved for research and applications where the 
improved resolution and additional functionality such as lateral 
vertebral assessment outweighed the additional radiation burden.
Objective 3 - evaluation of the Prodigy Densitometers:
a) Precision - in-vitro precision using the Lunar spine phantom was 
0.4% and the Hologic phantom 0.5%. In-vivo precision based on a 
group of osteopenic women was 0.9% at spine, 1.9% at femoral neck 
and 1.0% at the total hip site. This is similar to that of the pencil 
beam DPXL systems and better than the wide angle fan beam 
Expert-XL.
b) Radiation dose - scatter dose to the operator was found to be 
3 uSv/h. The skin entrance dose to the patient for a standard spine 
scan was 43 uGy which is similar to that stated by the manufacturers 
(37 uGy). This equates to an effective dose of approximately 6 uSv.
c) Comparison with DPXL - using a cohort of 31 postmenopausal 
women scanned on both Prodigy and DPXL on the same day, spine 
BMD on the Prodigy was found to be on average only 0.6% below 
that using the DPXL but hip BMD was 2% higher.
The findings supported the continued use of the Prodigy in routine 
clinical practice.
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Objective 4 - development of a hand phantom:
a) Construction - A phantom for use in quality assurance of hand BMD 
by DXA was designed initially for use on the DPXL.
b) Use on the DPXL - use of the phantom on the DPXL demonstrated 
that they are incapable of detecting BMD below a threshold of around 
0.3 gem 2 , a value which is not unusual in-vivo in the hand.
c) Redesign for Expert-XL - The phantom was later redesigned to suit 
the Expert-XL which had improved recognition of low bone density 
values. As a consequence, the Expert-XL was chosen as the system 
to be used for measurement and monitoring of BMD of the hand.
Objective 5 -evaluation of MXA technique:
a) Phantom development - A phantom was designed and constructed 
for evaluation and use in quality assurance of MXA. Using this 
phantom on the Expert-XL demonstrated a precision of 0.6% to 1.1% 
in measurement of vertebral height depending on the complexity of 
the shape. There was also found to be an underestimate of vertebral 
height by 5% which may not affect diagnostic value as the degree of 
vertebral deformity is generally determined relative to the heights of 
the 2nd to 4th lumbar vertebrae.
b) Patient positioning effects - results using the phantom also 
demonstrated that kyphosis of up to 6% had a minimal effect on MXA 
but scoliosis of greater than 4.6% significantly affects the 
measurement.
Results of the work helped inform the decision to introduce MXA into 
routine clinical practice. The exclusion criteria in the standard 
operating procedure for MXA include patients with severe kyphosis 
or scoliosis. The work also paved the way for further research 
presented in the next chapter on the appropriate targeting of the 
technique (section 3.6).
Objective 6 - evaluation of the PIXI peripheral DXA system:
a) In-vivo precision - Using duplicate measurements on 105 women 
aged 70 to 76 years, mean heel T-score -1.0 (-1.2 at spine) precision 
was found to be 1.9%.
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b) Relationship with axial BMD - The same subjects underwent spine 
and hip BMD on the Lunar Prodigy. The correlation between heel and 
spine or hip BMD was found to be 0.54 and 0.53 respectively 
compared to 0.64 for spine versus hip BMD.
c) Threshold for clinical use - A T-score threshold of -1.7 was found to 
optimise use of the PIXI in a pre-screen role.
The findings confirmed that the device was suitable for use as an 
adjunct to an axial DXA service and enabled a community-based 
pilot project of screening elderly women in the Hull area to proceed.
Objective 7 - evaluation of the DXL Calscan heel densitometer:
a) Accuracy and Precision - Phantom BMD did not differ from the 
manufacturer's reference value. Short term precision was found to be 
0.8% and long-term derived from daily phantom scanning over a 6 
month period was 0.7%.
b) Radiation dose - dose to the patient was found to be very low at less 
than 0.1 uSv and scatter dose to the operator well below annual dose 
limits.
c) In-vivo precision - using duplicate measurement on 140 subjects with 
a mean heel T-score of -2 (-2 at spine), precision was 1.2% which is 
slightly better than that for the Lunar PIXI (1.9%) especially 
considering the lower bone density of the Calscan subjects.
d) Triage thresholds - thresholds were determined to categorise 
patients for 'reassurance' (above T-score of -1.4), 'referral for spine 
and hip DXA (T-score between -1.4 and -2.7) or 'treatment (below - 
2.7).
The findings of this study helped development of operating protocols 
and provided guidance for users on patient management based on 
the BMD result. The triage thresholds are incorporated in the list of 
device specific thresholds collated by the National Osteoporosis 
Society27 .
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Objective 8 -evaluation of the Metriscan hand densitometer.
a) Radiation dose - dose to the patient was found to be very low at less 
than 0.1 uSv and scatter dose to the operator well below annual dose 
limits.
b) In-Vitro Precision - short term precision was 0.2% and long-term 
derived from daily phantom scanning over a 6 month period was 0.3%
c) In-Vivo Precision - using duplicate measurements on 170 subjects, 
mean T-score -1 (-2.0 at spine) precision was found to be 1.4%.
d) Triage thresholds - thresholds were determined to categorise patients 
for 'reassurance' (above T-score of -0.5), 'referral' for spine and hip 
DXA (T-score between -0.5 and -2) or 'treatment (below -2).
Again, this work helped with consideration of appropriate placement of 
this technology in the clinical arena and provided patient management 
guidance based on the result. As for the DXL Calscan, the derived 
triage thresholds for the Metriscan are incorporated in the NOS device 
specific thresholds.
In summary, this chapter demonstrates the authors contribution to knowledge of 
factors associated with the measurement of BMD by axial DXA using pencil, fan- 
beam and semi-fan-beam technology and by peripheral DXA and the potential of 
additional functionality of spine morphometry.
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CHAPTER 3 
CLINICAL APPLICATION OF DXA
3.1 State of Knowledge at the Time
3.1.1 Identification of High Risk Groups
At the time DXA was introduced, there was debate over the appropriate target 
population for this diagnostic test. The natural history of osteoporosis, having a 
long lead time, presents an opportunity to detect using DXA those at risk prior to 
the first fracture and offering preventative treatment. As low bone mass is 
symptomless, this primary prevention approach would entail population 
screening. However, a report commissioned by the Department of Health 
concluded that on the basis of evidence at the time, population screening of 
postmenopausal women was not justified 30 . They cited lack of scientific trials on 
screening to prevent fractures, lack of evidence of Hormone Replacement 
Therapy effectiveness in fracture prevention, poor compliance with treatment 
and concerns over the precision and predictive accuracy of BMD by DXA. 
Studies had demonstrated that reduction in BMD was associated with an 
increase in fracture risk31 32 " although an overlap in BMD between hip fracture 
patients and age matched controls was reported 34 . Population screening is 
thought to be unjustified in view of the reduced sensitivity and specificity for 
predicting fragility fracture, associated radiation burden and cost.
Guidance was needed on appropriate use of this new 
technique within a clinical setting.
3.1.2 Factors associated with low Bone Mass
There was a growing body of knowledge on factors associated with attainment 
of peak bone mass and bone loss. Peak bone mass was reported as being 
determined by genetic potential modified by hormonal status, exercise and 
nutrition. Studies of twins demonstrated that genetic factors were more 
important in youth but were later superseded by environmental factors35 . 
Athletes who became amenorrhoeic were found to have lower BMD 36 although 
the mode of action of sex hormones on the skeleton was unknown. Association 
between bone mass and physical activity was reported 37 ' 38 and studies
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identified the role of calcium in skeletal health 39 40 . There was general 
consensus that age and oestrogen deficiency were strongly associated with 
bone loss41 whilst low calcium intake42 and reduced physical activity43 were 
thought to be contributory factors.
More research was required into factors which may be 
associated with bw bone mass and hence increased fracture 
risk.
3.1.3 Hormone Replacement Therapy
Oestrogen is known to play a role in bone turnover44 with loss of oestrogen 
leading to an imbalance of bone formation and resorption with a consequent 
loss of bone mass45 . At the time of introduction of DXA, Hormone Replacement 
Therapy (HRT) was the treatment of choice for prevention of post menopausal 
bone loss to the extent that universal treatment of low bone mass with HRT had 
been advocated 46 . HRT reduces bone loss47 and confers other benefits in terms 
of relieving menopausal symptoms. However, reports in 2002-03 from the 
Women's Health Initiative (WHI) study demonstrated increased incidence of 
breast cancer, cardiovascular disease and stroke in women taking HRT48 . The 
increased risks were small amounting to an additional number of cases per 
10,000 of 8, 7 and 8 respectively. The media focussed on these negative 
findings at the expense of the positive confirmation that HRT reduces the risk of 
hip fracture49 . However, poor adherence to treatment has been reported but 
these studies were generally in a small sample over short periods of time50 .
Evidence at the time suggested that HRT needed to be taken for at least 5 years 
to confer lasting benefits on bone47 49 . However, due to tie reported adverse 
effects, shorter courses of HRT for the control of menopausal symptoms were 
favoured. The effect of such intervention on bone in the medium term was 
unknown.
More information was required on compliance to HRT and 
effectiveness of short courses in preventing bone loss.
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3.1.4 Utility of MXA
Vertebral fractures were reported as being the most common osteoporotic 
fractures 8 with prevalence rising to 25% in women over 50 years9 although many 
of these fractures go undetected. These fractures are associated with a 
significant increase in risk of future vertebral and other fractures 10 51 52 . Lack of 
knowledge of vertebral fracture status can thus lead to a substantial 
underestimate of fracture risk. The addition of baseline spine x-ray information 
substantially improves the ability of risk factor models to predict an incident 
fracture53 but spine x-rays are not a practical method of screening for fracture.
As reported in 2.6.2 above, technological and software 
developments enable modern DXA scanners to be used for 
vertebral fracture assessment although there were no 
recommendations as to when this additional diagnostic 
procedure should be used.
3.2 Outline of the motivation and significance of the work 
undertaken
The motivation for the work presented in Appendix IV was to contribute to the 
debate over the appropriate use of DXA and MXA and add to the understanding 
of factors thought to be associated with bone loss and fracture risk. The findings 
helped with the development of local guidelines for referral and management of 
osteoporosis and contributed to the growing body of knowledge though 
publication and presentations. The areas to be investigated reflected the 
requirements of the clinical service and interests of the investigator.
The following objectives were set to help address the gaps in knowledge 
detailed above in this chapter.
3.2.1 Objective 1 was to investigate the feasibility of population screening by 
DXA in a peri-menopausal population. This included examining the technical 
capabilities of the equipment, establishing action thresholds, assessing the 
support of healthcare professional in Primary Care and willingness of women to 
participate and comply with the treatment regime. 
This objective is addressed in Section 3.3.
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3.2.1 Objective 2 was to examine factors that may be associated with 
attainment of peak bone mass or bone loss. The study on effect of Coeliac 
disease on BMD was of interest due to the finding of a high proportion of 
previously undiagnosed Coeliac disease in those found to have low BMD as part 
of the logistical feasibility study. 
This objective is addressed in Section 3.4.
3.2.2 Objective 3 was to explore factors associated with adherence to HRT 
and the effect of short courses of treatment on BMD. 
This objective is addressed in Section 3.5.
3.2.3 Objective 4 was to use the vast database and experience accumulated 
on use of MXA to help determine appropriate and effective use of the technique. 
This objective is addressed in Section 3.6.
3.3 Objective 1: Feasibility of population screening by DXA
A logistical and technical feasibility study was undertaken by the author which 
involved screening by DXA of 6282 peri-menopausal women (Paper 8). As a 
consequence of the equipment evaluation reported previously (section 2.3) a 
rigorous quality assurance programme, procedures and protocols were 
introduced to optimise accuracy of the results. The feasibility study which lasted 
3 years demonstrated that the pencil beam DXA systems were reliable, precise 
and capable of examining up to 12 patients a day with a down time for 
maintenance or malfunction of only about 2 days per year. Age matched 
reference ranges were established by the author and a threshold derived for 
recommendation of HRT for bone protection. Screening was acceptable to the 
GPs (61 of 62 participated) and the patients (83% attendance). However, 2 year 
compliance with bone protective treatment (HRT) was only 48% primarily due to 
a return to cyclic bleeding or a fear of breast cancer.
The author played a key role in eliciting the support and participation of the 
general practitioners in the screening programme. This collaboration evolved 
into the formation in 1993 of the Osteoporosis Strategy Group of which the 
author was a founder member and latterly vice-chair. Using the findings of the 
study agreed indications for bone densitometry were established and local
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guidelines developed 54 supported by the local health purchasing authority. The 
criteria for referral are broadly in line with those later introduced by the National 
Osteoporosis Society55 and the Royal College of Physicians 56 . However, the 
appropriate use and interpretation of DXA remains an area for debate 57 58 .
3.4 Objective 2: Effect of Coeliac Disease on BMD
Coeliac disease is a malabsorption syndrome which may affect the absorption of 
calcium from the diet. Previous studies identified biochemical and skeletal 
disturbances thought to be due primarily to impaired absorption of Vitamin D 
leading to malabsorption of calcium and other smaller studies had suggested a 
link between coeliac disease and BMD.
A study of 81 women with coeliac disease was carried out by the author (Paper 
9). All underwent BMD of spine and hip by DXA and each was carefully matched 
to a control subject from an age-matched population if post-menopausal or from 
a young adult group if pre-menopausal. This process was performed to exclude 
confounding factors. The study confirmed that coeliac disease has an adverse 
effect on BMD even after adjusting for height, weight, menopausal status and 
menopausal age. Interestingly, in the pre-menopausal group this manifested 
itself only in hip BMD which could be due to the increased proportion of cortical 
bone at this site. The exact mechanisms were not fully understood and although 
more is now known about the disease process and its effect on bone, there 
remain unanswered questions59 . However, a review in 2008 of published work 
involving a total of 20,995 coeliac patients, confirmed a significant association 
between bone fractures and coeliac disease60 .
There were few non-adherers to a gluten free diet so it was not possible to 
assess the influence of diet on BMD. This required a larger prospective study. 
Later studies demonstrated a beneficial effect on bone in children with coeliac 
disease adhering to a gluten free diet61 .
The results of the author's study led to the recommendation that DXA at spine 
and hip be performed at the time of diagnosis of coeliac disease to act as a 
baseline. This was added to the local referral criteria for DXA. The work is cited 
by a guideline development group 62 and by 41 other authors.
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3.5 Objective 3: Investigation of the Influence of HRT
3.5.1 Factors affecting compliance
Diagnosis of low bone mass in peri-menopausal women is fruitless if there is 
resistance to the treatment offered to prevent further bone loss. HRT was the 
treatment of choice at the time but some reported low adherence rates in 
women found to have low bone mass. Paper 10 describes results from a 5 year 
follow-up conducted by the author of 1,462 women with low BMD diagnosed 
during the screening programme described in 3.3 above. As part of the study, 
data were recorded on a computerised database of BMD, patient demographic 
and physical details and medical and social factors thought to influence BMD. 
Software and hardware changes during the study required corrections to be 
made to the follow-up data to allow for effect on BMD. Adherence to HRT at 5 
years was found to be 61% with the largest discontinuation rate being during the 
first 2 years. This was one of the highest reported adherence rates in a clinical 
setting which may be attributable to knowledge of fracture risk and regular 
follow-up. The findings may not be representative of the larger population as 
36% of the study group were lost to follow-up. However, others have since 
confirmed that close follow-up improves compliance63 .
3.5.2 Effect on BMD
Following the adverse findings of the WHI study in 2002, HRT was no longer 
recommended for prevention of postmenopausal bone loss. It is still licensed for 
the relief of menopausal symptoms although these courses of treatment tend to 
be shorter than the 5 years recommended for bone protection. Paper 11 
describes a study of effectiveness of short-term HRT in 587 women followed up 
at 2, 5 and 9 years after screening as part of the feasibility study discussed in 
3.4 above. Results suggest that the protective benefits conferred on bone by a 
short course of HRT (2 to 4 years) remain for up to 5 years after the treatment is 
withdrawn. Women taking a short course of HRT after the menopause on 
average had no significant loss in BMD over 9 years.
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3.6 Objective 4: Utility of MXA
As a consequence of the previous validation work on MXA reported above 
(2.6.2), the technique was introduced in the author's centre with the approval of 
the local Osteoporosis Strategy Group. Initially, only those presenting for spine 
and hip DXA with reason to suspect a fracture were considered but from 2005 
all women over 65 years attending for DXA underwent a vertebral fracture 
assessment (VFA) if physically able to do so. Using data collected on the initial 
'targeted' group (6,388 women) and the later 'routine' group (2,176 women), the 
author compared the two screening strategies (Paper 12). This was the largest 
study reported on routine use of VFA. It was found that routine screening 
detected vertebral fractures in 20% of the women over 65 years attending for 
DXA and that 77% of these were previously undiagnosed. Targeted screening 
minimised resource implications as only 5% of those attending for DXA 
underwent VFA but this strategy identified less than 10% of those with a 
vertebral fracture.
Although the paper was published less than 1 year ago, the work has already 
been cited once by El Maghraoui et a/, studying the prevalence and risk factors 
of vertebral fractures using VFA in asymptomatic Moroccan women64 . The 
findings also led to further work to try and refine the selection of women for VFA 
to maximise detection of fractures whilst minimising resource implications65 .
3.7 Summary
The work on clinical application of DXA presented in Appendix IV addressed the 
objectives set out in section 3.3.
Objective 1 - The feasibility of population screening by DXA was undertaken 
with the following outcomes:
a) The pencil beam DXA systems were reliable, precise and capable of 
supporting population screening.
b) Age matched reference ranges were established and a threshold derived 
for recommendation of HRT for bone protection.
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c) Screening was acceptable to the GPs (61 of 62 participated) and the 
patients (83% attendance).
d) 2 year compliance with bone protective treatment (HRT) was 48%.
The study led to the establishment of local agreed indications for bone 
densitometry.
Objective 2 - The Effect of Coeliac Disease on BMD was investigated. A study 
of 81 women with coeliac disease demonstrated an adverse effect on BMD even 
after matching for height, weight, menopausal status and menopausal age.
Objective 3 - HRT compliance and effect on BMD was explored:
a) 5 years adherence to HRT in 1,462 with low BMD was 61% with the 
largest discontinuation rate being during the first 2 years.
b) Short courses of HRT can have long-term benefits on bone.
Objective 4 - The data accumulated on over 8,000 women undergoing 
vertebral fracture assessment was examined. This demonstrated vertebral 
fracture prevalence of 20% in women over 65 years, 77% of which were 
previously undiagnosed which would have led to a substantial underestimate of 
their future fracture risk. Attempts to target VFA at only those with indications of 
a possible vertebral fracture proved to be ineffective.
This work confirmed that the strategy to consider VFA in all women over 65 
years presenting for DXA was more effective than targeted screening and 
secured the resources required to continue this approach.
In summary, this chapter demonstrates the author's contribution to knowledge of 
the appropriate role of DXA and VFA in a routine clinical environment.
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CHAPTER 4 
STANDARDS IN DIAGNOSIS OF OSTEOPOROSIS
4.1 BACKGROUND
Some sites in the UK were fortunate to acquire DXA systems in the late 80's and 
early 90's, often through charitable donations or from pharmaceutical companies 
who had a vested interest in encouraging diagnosis and hence increased 
prescribing of bone protective treatments. Being x-ray based, these systems 
were usually located within radiography or nuclear medicine departments where 
staff had the knowledge and expertise of x-ray production and detection and 
radiation safety. The earlier systems were mostly operated by radiographers or 
medical physics technicians who merely required device specific instruction. 
Since osteoporosis is a multi-causal and therefore multidisciplinary disease, 
there remains a range of professions and disciplines involved in diagnosis and 
management with no egislation on minimum training requirements and, until 
recently, no guidance on use of the diagnostic equipment. Peripheral bone 
densitometers in particular are marketed as being simple to use, the implication 
being that specialist technical or scientific knowledge is not required. As a 
relatively new diagnostic technique, measurement of bone mineral density is not 
included in the syllabus of existing medical technology courses. There is no 
legislation restricting use of such devices except where ionising radiation is 
involved 66 67 which can be fairly readily satisfied but difficult to enforce. Clinicians 
in both primary and secondary care faced with an unmet need for diagnosis with 
limited resources are turning to available staff and low cost equipment. With 
little guidance to the contrary, commissioners and administrators support these 
developments. The consequences are that highly specialised equipment used to 
aid the clinician in making treatment decisions sometimes lies in inexperienced 
hands. Without appropriate guidelines and training, there is a potential for 
misuse and misdiagnosis.
As minor changes in BMD are known to reflect major changes in fracture risk, 
attention to standards in use of DXA is critical to ensure optimal precision, 
minimum follow-up interval and to maximise the possibility of detecting the true 
treatment effect.
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4.2 Outline of the motivation and significance of the work 
undertaken
The motivation for the work presented in Appendix V was to contribute to 
improving the standards of clinical DXA services in the UK.
Objective 1 - Raise the background knowledge and technique of DXA
operators.
This objective is addressed in Section 4.3.
Objective 2 - Provide guidance on use of DXA in the clinical environment. 
This objective is addressed in Section 4.4.
4.3 National Osteoporosis Society Training Scheme (NOS)
The need for improving standards of bone densitometry was raised at meetings 
of the Bone Densitometry Forum of the NOS. Consequently, a sub-group was 
formed to consider the feasibility of introducing a national training scheme that 
could be accessible to all healthcare professionals involved in operating DXA 
equipment. The result was the NOS National Training Scheme for bone 
densitometry delivered and examined by the NOS Bone Densitometry 
Certification Panel (BDCP). The author is a founder member, contributor to the 
contents of the rules and regulations and syllabus (Appendix V: Scheme 
Literature) and is a lecturer of the course. The scheme is now endorsed by the 
major professional bodies concerned, the College of Radiographers and the 
Institute of Physics in Engineering and Medicine and recognised by the Royal 
College of Physicians.
4.3.1 Course Outline
The aim is to improve standards for bone densitometry measurements through 
an accredited scheme that is recognised by the appropriate professional 
colleges and institutions. The course is open to operators who have undergone 
initial on-site training and have at least 6 months experience of using the 
diagnostic equipment in a clinical setting. The scheme consists of a 2 day 
lecture course which must be attended, including an IRMER module to meet the 
requirements of the Ionising Radiation in Medical Exposure Regulations. Those 
wanting to continue to certification must pass an examination followed by 
submission of a portfolio of work in bone densitometry.
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4.3.2 Lecture Programme
Training is provided in the theory and application of bone densitometry 
measurement techniques through a two day taught course which includes 
scientific, technical and clinical lectures and panel discussions (Appendix V: 
Lecture Programme). The author delivers two of the lectures, participates in the 
panel discussions and assists with on-site arrangements.
Feedback is sought from the students at the end of each lecture course. This 
has been positive and constructive in helping the BDCP to develop and adapt 
the course to changing needs.
4.3.3 Supporting Material
A Fundamentals Booklet is provided which includes sections on The Bone 
Densitometry Service' and 'Data Management and Report Generation' written by 
the author (Appendix V). The former chapter aims to provide the student with a 
summary of the fundamentals of a good service from receipt of request to 
patient handling and quality assurance through to final reporting. The chapter is 
well referenced and indicates relevant legislation that must be adhered to. The 
second chapter provides advice on data management and security and the 
production of a meaningful report to the referrer. This booklet is now provided in 
CD format. Printed copies of all slides used in the lectures are collated in a 
course manual which is provided to all candidates.
Candidates are also encouraged to undertake recommended reading before 
sitting an examination. The author contributed to the development and regular 
review of a reading list.
4.3.4 On-line Examination
As candidates attend the course from all over the UK, the exam is carried out 
on-line at several sites simultaneously across the country. The NOS 
commissioned the University of Glamorgan to construct the online National 
Bone Densitometry Online Testing System (NBDOTS) during 2002. The 
examination is a Web-based application that uses the Internet and Web 
browsers to deliver the tests anywhere in the world. It is based on the online 
software 'Perception' (QuestionMark http://www.questionmark.com). The BDCP 
produce 3 sets of objective testing questions which reflect the modules of the
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lecture course: Core Clinical, Core Technical and DXA The author has 
contributed questions to the Core Technical and DXA sections and evaluated 
and selected those on the Core Clinical section. Both multiple choice and 
multiple response formats are used, with all correct responses required in the 
latter for a full mark for the question. Following the candidate's submission of 
their completed answers, results are automatically marked against pre-defined 
correct solutions.
NBDOTS produces an analysis of the performance of each examination and its 
questions. The range of difficulty is determined by the proportion of candidates 
answering correctly. The ability of each question to discriminates between a high 
scoring group (the top 27% by assessment score) and a low scoring group (the 
bottom 27% by assessment score) is also determined. These factors enable 
review of the questions by the BDCP in order to consider exclusion of 
misleading or confusing questions when reviewing results. Correlation of a 
question score to overall examination score is also derived which, if very low, 
may indicate the question should be excluded.
Being computerised enables results and detailed analysis of results to be 
available to the examiners almost instantaneously. This successful exam format 
has been developed in conjunction and with the continued support of the Faculty 
of Advanced Technology, Department of Computing and Mathematical Science 
of the University of Glamorgan. The author contributed to the format and content 
of the on-line examination and acts as invigilator at one of the examination sites.
4.3.4 Portfolio Submission
Candidates passing the exam are able to submit a portfolio of practical work for 
assessment by the examination panel. The author contributed to decisions 
regarding the content of the portfolio which is designed to test the candidates 
understanding of equipment quality assurance and the results printout, their 
scan and analysis technique and the role of DXA in patient management. Due to 
the popularity of the scheme with around 100 registrants per course, a number 
of portfolio markers are required. In order to minimise variability, the author 
developed a marking scheme and associated instruction for markers. Also, all 
portfolios failing to meet the required pass marks are subject to a second, 
independent review.
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To date 589 have attended the lecture course with 264 successfully completing 
the scheme and achieving certification. Employers are now including successful 
completion of the scheme as a requirement for new employees in bone 
densitometry and the qualification is also proving useful within the new 
knowledge and skills framework of professional development.
4.4 Guidelines
Writing groups of the Bone Densitometry Forum currently chaired by the author 
were nominated to develop guidelines and position statements associated with 
DXA. These documents are subject to regular review to reflect emerging 
evidence and changing clinical guidelines.
4.4.1 Guidelines for the Provision of a Clinical Bone Densitometry Service
This document included in Appendix V B designed by the author to provide a 
benchmark for practitioners, commissioners and service providers when 
developing or comparing DXA services. The numbered list with key 
recommendations summarised at the beginning delivers the minimum 
requirements for a clinical DXA service in a succinct, easy to read format. A 
service conforming to these standards would meet current guidance on the 
appropriate use of DXA and legislation governing ionising radiation and data 
protection. Compliance with Clinical Governance and Health and Safety issues 
would also be addressed. The reader is directed to sources of supporting 
information about each of these topics.
4.4.2 Position statement on the reporting of dual energy x-ray 
absorptiometry (DXA) bone mineral density scans
This document with contributions from the author provides the first national 
guidance on interpretation and reporting of spine and hip DXA scans. The aim is 
to reduce the confusion and variability of interpretation of the results. There is an 
emphasis on checking the image for artefacts or positioning errors that may 
affect the result. Advice is given on the role of T- and Z-scores in diagnosis, 
interpretation and patient management. The document also includes guidance 
on appropriate follow-up intervals and provides a proposed structure for 
reporting of DXA scans. This document was published in 2004 and is currently
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undergoing revision to incorporate new developments particularly around the 
proposal to incorporate other risk factors in producing a fracture risk score for 
the individual and how to use this in therapeutic decision making.
4.5 Summary
The initiatives presented are aimed at improving standards in the diagnosis and 
monitoring of the osteoporotic patient and meet the objectives set out in section 
4.2.
Objective 1 - The NOS National Training Scheme for bone densitometry has 
helped raise the background knowledge and understanding of the diagnosis and 
treatment of osteoporosis amongst operators, clinicians and managers. 
Examination of portfolios of practical work has assured operator technique 
meets appropriate standards or has been improved through detailed feedback 
and resubmission.
Objective 2 - The guidance documents provide concise, evidence based 
recommendations for users, providers and commissioners of DXA services. 




5.1 Meeting the Aim
The original aim of the author was to help integrate DXA within the clinical 
environment in a safe, effective and efficient manner. The results of the work 
presented in this thesis achieve this aim from three aspects summarised below.
5.1.1 Independent Equipment Evaluation
Dual Energy X-ray Absorptiometry (DXA) was introduced in the late 1980s 
followed in by the introduction introduced in the early 1990's of new therapeutic 
agents for bone protection. With the adoption of BMD by DXA in 1994 to provide 
a definition of osteoporosis 75 , there was a rapid deployment of DXA equipment. 
This was a new fast developing quantitative digital imaging technique in 
medicine which had been the subject of little independent evaluation and 
validation.
The work presented in this thesis provides an independent evaluation of the 
technical capabilities and limitations of the technology. The findings were 
applied locally when designing appropriate accommodation with consideration 
being given to environmental conditions to ensure equipment stability and room 
layout to meet Ionising Radiation regulations. The work also provided a 
benchmark of equipment precision and factors that may affect accuracy.
The phantoms developed for hand and vertebral morphometry were the first 
available for quality assurance of these techniques and provide a means of 
evaluating the accuracy, precision and long-term stability. This helped the 
author's centre become be an early implementer of VFA which enabled further 
research on the clinical use. Evaluation of the peripheral DXA techniques 
contributed to advice on their appropriate role and to the proposed triage 
thresholds.
Accuracy of DXA equipment is initially assured through calibration in the factory 
against known bone standards. The phantom supplied with the equipment acts
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as a secondary standard to check the accuracy of the scanner calibration 
throughout its operational life. Repeated phantom scans on the same day will 
also provide a measure of precision and regular scans of the phantom, 
preferably every working day, will provide an indication of any drift of the results 
over time. As part of the commissioning and acceptance testing of new 
equipment, in-house precision should be determined both in-vitro and if possible 
in-vivo using the now recommended method of root mean square standard 
deviation as percent coefficient of variation (rms CV%)68 . From this can be 
calculated the least significant change which must be exceeded in serial 
measurement to be reasonably confident of a true change. This will help 
determine the minimum follow up interval.
The manufacturer supplied phantoms do not reflect all factors encountered in- 
vivo that may affect accuracy and precision. Findings of the work presented in 
this thesis demonstrate the influence of tissue thickness and non-uniformity of 
lean and fat tissue composition across the region of interest. Excessive or 
reduced tissue thickness may lead to an over- or under-estimate of BMD 
respectively, although the errors may be minimised through use of appropriate 
scan modes. The age-related increase in the proportion of fat in bone marrow 
may lead to an underestimate of BMD and there is currently no mechanism for 
correcting this error. Although much of the work was conducted on older 
technology, these characteristics are a feature of x-ray attenuation at the 
energies used and therefore largely applicable to all DXA devices. The phantom 
used for routine quality assurance does not capture these potential sources of 
error. More thorough evaluation of new generation DXA devices is 
recommended using a range of phantoms reflecting the variability of BMD and 
soft tissues encountered in-vivo. This should preferably be an independent 
evaluation for each new model released and should include determination of the 
effects of tissue depth and variation of soft tissue composition across the region 
of interest at a range of BMDs encountered in clinical practice. A knowledge of 
the anticipated errors in accuracy and precision for each scenario will help when 
interpreting the DXA results and considering patient management.
5.1.2 Informing Clinical Application
The identification of a new, preventable or treatable disease had educational, 
logistical and financial consequences for the National Health Service in the UK.
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It was unclear in the early days whether the technique would be acceptable, 
which patient groups should be offered a DXA scan, whether it could be utilised 
to monitor BMD changes and whether this would influence medical 
management. There was also little data on what factors were associated with 
attainment of bone mass or bone loss.
The work on equipment evaluation provided the baseline characteristics of 
accuracy, precision and potential sources of error of the technique. This helped 
in establishing a rigorous quality assurance procedure and developing standard 
operating procedures for patient preparation and scan technique to optimise 
results. Consequently, the population screening feasibility study proved 
successful the findings of which were essential in establishing the local service 
in 1992. Local guidelines were developed based around referral criteria derived 
from this study and DXA interpretation was initially based on the local population 
reference derived. With the later addition of manufacturers' reference data and 
the introduction of the T-score concept, the WHO definition was adopted 
although other risk factors for fracture were taken into consideration when 
recommending treatment.
The investigation on the effect of coeliac disease contributes to the growing 
body of knowledge of factors thought to be associated with low bone mass. The 
studies of HRT demonstrate good adherence to treatment and a sustained 
beneficial effect on bone of short courses, a timely report in view of concerns 
over long-term use of HRT. More recent safety data on HRT have become 
available, including re-analyses of results from the Women's Health Initiative trial 
which suggest the increased risks of breast cancer, stroke and cardiovascular 
disease reported previously are associated with increasing age when 
commencing HRT and duration of treatment69 . Also, the risks are significantly 
reduced following cessation of treatment70 . The current recommendations from 
the Royal College of Obstetricians and Gynaecologists (www.rcog.org.uk) 
support the use of HRT in the immediate post-menopause for as short a time as 
needed for control of rnenopausal symptoms. The Medicines and Healthcare 
Products Regulatory Agency (www.mhra.qov.uk) support its use for prevention 
of osteoporosis only in women who are unable to use alternative bone protective 
therapies. The findings reported in this fiesis, indicate that a short course of 
HRT in the immediate post menopause, such as used for control of symptoms, 
can have long term benefits for bone health.
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Following the technical evaluation of VFA, research was conducted on the 
clinical role of the technique which provides advice to others based on the 
largest cohort of patients at the time. The findings indicate that the best strategy 
is to consider VFA in all women over 65 years where possible.
5.1.3 Improving Standards
Due to the multi-causal and hence multidisciplinary nature of osteoporosis, 
operators, users and clinicians are from a range of professions and disciplines. 
As a relatively new diagnostic technique, measurement of bone mineral density 
was not included in the syllabus of existing medical technology courses. Also, 
inclusion of osteoporosis diagnosis and management in the training 
programmes of relevant professional bodies may be configured to meet specific 
professional requirements and not address all aspect or reach all disciplines. 
Without appropriate guidelines and training, there is a potential for misuse and 
misdiagnosis.
The NOS Training Scheme has improved standards nationally as evidenced by 
the quality of submitted portfolios of work from DXA operators and inclusion of 
evidence of successful completion of the scheme within the person specification 
for advertised posts. The National Guidelines and Position Statements set a 
benchmark against which existing services can be measured and direction for 
those developing new services. Adherence to this guidance will ensure 
compliance with relevant National policies and legislation.
In summary, reliability of the equipment is assured through appropriate 
environmental conditions, regular maintenance and a rigorous quality assurance 
procedure. Together with high quality training and adherence to written 
procedures and protocols, this ensures reliability of clinical results. Safe use of 
the technology is addressed through the high standards of equipment and 
operating protocols and knowledge of the radiation burden to patients and staff 
to ensure adherence to Ionising Radiation Regulations. Targeting of appropriate 
populations for investigation through use of the referral criteria derived ensures 
efficient use of the technique.
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5.2 Future Work
In the absence of a reasonably priced prophylactic therapy with no unwanted 
side effects, better targeting of bone protective treatments to prevent a 
significant proportion of fragility fractures in the most cost-effective way remains 
the goal. Although a measure of BMD by DXA is considered the best predictor of 
fragility fracture, the technique is still imperfect with a degree of overlap of those 
defined 'at risk' or 'not at risk' and the incidence of fracture. BMD is a 
quantitative measure that has been shown to be related to bone strength. 
However, other structural and qualitative aspects also play a role. Some work 
has already been done on measurement of hip structural parameters from a 
DXA image but more research is needed to determine whether this combined 
with BMD is a better predictor of hip fracture (Figure 5.1).
Figure 5.1 DXA image showing Hip Axis Length (HAL)
Other work is needed to refine the non-invasive in-vivo determination of bone 
strength.
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Figure 5.2 Risk of hip fracture increases with decreasing BMD and increasing 
age
Other patient-related factors are also known to play a role independent of BMD, 
such as age (Figure 5.2) and prior fragility fracture, particularly vertebral fracture 
with 19.2% risk of further fracture within 1 year71 . The World Health Organisation 
developed a computer based algorithm for calculating fracture risk which 
combines BMD, if available, with known risk factors for fracture (FRAX 2008: 
www.shef.ac.uk/FRAX). The impact of this on clinical services and patient 
management remains to be assessed.
Interventional techniques are available to stabilise and reduce the pain of 
vertebral fractures. Vertebroplasty involves injecting a material into the fractured 
vertebra and has been shown to reduce pain in both in the short72 73 and long 
term74 . However, a recent report in 2009 75 suggests no benefit of the technique 
and others report it may lead to increased hcidence of fracture particularly of 
adjacent vertebrae 76 . More research is needed to determine the appropriate role 
of vertebroplasty in clinical practice.
With advancement in technology and emergence of new evidence in the 
prevention, diagnosis and treatment of osteoporosis, educational needs will 
change. This will require regular review of the guidelines and content of courses 
and the mechanism of delivery. Engagement of the professional colleges and 
other educational providers needs to be explored and encouraged.
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APPENDIX I 
X-RAYS AND DUAL ENERGY X-RAY ABSORPTIOMETRY
1. PRODUCTION AND ATTENUATION OF X-RAYS
This section is included for information only as it sets the scene for the 
development of DXA.
1.1. Introduction
The discovery of x-rays is attributed to Wilhelm Roentgen, Professor of Physics in 
Wurzburg, Bavaria. In 1895 he was experimenting with a cathode ray tube 
covered in black paper when he discovered previously unknown electromagnetic 
rays which were capable of passing through the paper and causing a nearby 
screen to fluoresce. He found the rays were able to penetrate other objects 
including the human body, leaving the bones and any metal visible.
1.2.X-ray Production
Modern day x-ray tubes are based on the same principle as the one used by 
Roentgen. A negatively charged filament is heated emitting electrons which are 
accelerated through an evacuated tube under the influence of a high voltage to 
collide with a positively charged anode (figure A1.1).





Figure A1.1 Diagram of an x-ray tube
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The electrons are decelerated by the high atomic number target material, 
usually tungsten or molybdenum, resulting in 'Bremsstrahlung' (braking 
radiation) of a continuous spectrum of x-ray energies ranging from zero to the 
maximum voltage applied across the x-ray tube (Figure A1.2). Many of the lower 
energy x-ray photons do not escape due to absorption within the target material 
itself or within the x-ray tube. If the electrons have sufficient energy, they can 
knock an electron out of an inner shell resulting in the emission of characteristic 
x-ray photons with precise energies determined by the electron energy levels.
Target atom
20 40 60 80 
Photon Energy (keV)
TTie X-ray photons have a wide range of energies up to the maximurr 
possible determined by the voltage applied across the X-ray tube.
Figure A1.2 Diagrammatic representation of interactions in x-ray tube target 
(left) and x-ray continuous spectrum (right).
1.3 X-ray Attenuation
As the x-rays pass though the body, they are absorbed or scattered to varying 
degrees dependent upon the energy of the incident x-rays and properties of the 
material they are passing through. The primary interaction for diagnostic x-rays 
is the photoelectric effect which is highly dependent upon the atomic number of 
the material. High atomic number material will absorb more x-rays. The different 
absorption characteristics of tissues in the human body allows them to be 
distinguished from one another, providing the contrast needed for routine clinical 
radiography (Fig A1.3 left). The linear attenuation coefficient, which describes 
the proportion of xrays absorbed per unit thickness of material, provides a 
measure of x-ray attenuation. Often, the mass attenuation coefficient, the 
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Figure A1.3 Transmission of X-rays through different materials (left) and mass 
attenuation coefficients of materials in the body (right)
The intensity of the transmitted x-ray beam is given by the equation:
l=l 0e MX Equation A1.1
Where I 0 is the intensity of incident x-rays, I the intensity of the transmitted x-­ 
rays and jj. is the linear attenuation coefficient which is the fractional change in 
intensity of the incident beam per unit thickness of the attenuating material. The 
linear attenuation coefficient is specific for a given material of thickness x at a 
given x-ray photon energy. The mass attenuation coefficient um is related to the 
linear attenuation coefficient by the density of the material:
um = u/? Equation A1.2
Equation A1.1 then becomes:
I=l 0e l Equation A1.3
The variation of the mass attenuation coefficient for bone and soft tissue differs 
markedly with x-ray photon energy such that the ratio is greatest at the lower 
energies (Figure 1.3 right). Capitalising on this, a new quantitative digital x-ray 
technique, Dual Energy X-ray Absorptiometry (DXA), was introduced in 1987 to 
determine, in-vivo, the density of bone, an important determinant of fracture risk. 
Note also from figure 1.3 that there is a slight difference in the attenuation of 
lean and fat tissue.
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2 DUAL ENERGY X-RAY ABSORPTIOMETRY
This section provides a description of the technology studied in this thesis
2.1 Introduction
DXA was designed to provide a quantitative assessment of bone mineral, a 
measure of bone strength and propensity to fracture. This is unlike diagnostic 
radiographic equipment which is designed to optimise image resolution in order 
to qualitatively assess structures within the body.
2.2 Dual x-ray production
DXA is based on the assumption that there are only two materials in the body, 
bone and soft tissue. The differential attenuation of the two xray energies 
effectively provides two simultaneous equations (2.5: Equations A1.4 and A1.5) 
which can be solved to quantify the attenuation due to bone and that due to soft 
tissue. The x-ray energies are chosen to optimise the differential attenuation 
between bone and soft tissue whilst minimising the radiation dose to the patient.
Production of two energy xrays may be achieved by rapidly switching the 
voltage supply to the x-ray tube between two different voltages (Figure A1.4). 
This technique produces two continuous spectra of x-ray energies with two 
different peaks around 50keV and 85keV and was adopted by one of the major 
manufacturers of DXA equipment (Hologic, Bedford, Massachusetts, USA). An 
x-ray detector records the signal for each part of the cycle. An alternative 
method is to use a rare earth filter (usually Cerium or Samarium) to selectively 
absorb x-rays of a particular energy through interactions with the electron in the 
inner, k-shell of the atom (k-edge filtration). The continuous x-ray spectrum is 
split into high and low energy parts with maximum intensities of around 40 and 
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Figure A1.4 Dual energy x-rays produced by continuous switching of tube voltage 
between high and low values (left) or by use of a metal filter to selectively attenuate 
X-rays of a specific energy so splitting the continuous X-ray spectrum.
2.3 DXA Beam Shapes
The x-ray beam passes through a collimator which shapes the beam as 
required. Standard radiographic systems use cone beam geometry which leads 
to magnification and distortion towards the edges of the field of view. The 
original DXA systems incorporated a pin-hole collimator to produce a pencil 
beam of x-rays but newer systems are based on a fan beam. The Lunar Expert- 
XL utilises a wide angle fan beam across the width of the patient, a higher 
output of x-rays and an array of solid state detectors. This provides faster, 
higher resolution images than the pencil beam systems. The later Prodigy 
systems use a narrow fan beam cranio-caudally (Figure A1.5) and again solid 
state detectors.
Wide Angle Fan Beam Pencil Beam Narrow Fan Beam
Pencil-beam
Figure A1.5 DXA beam geometry
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2.4 DXA Detectors
The emitted x-rays are stopped and measured by means of an x-ray detector 
which for pencil beam systems is in the form of a scintillation detector (Figure 
A1.6). This consists of a crystal (generally Nal activated by a small amount of 
thallium) which converts ionising radiation into a light photon. The light photon 
strikes the photosensitive surface which ejects low energy electrons. These are 
collected and amplified through the photomultiplier tube. The size of the pulse 
which emerges is proportional to the energy of the x-ray photon which was 
absorbed in the crystal. It is therefore possible to distinguish between photons of 










Figure A1.6 Diagram of a scintillation detector
The signals are digitally processed and assigned to a high- or low-energy x-ray 
window. In the rapidly-switched voltage systems, the current produced by the 
detector is collected during each part of the cycle. This integrated current is 
proportional to the intensity of the incident x-rays.
Newer, fan beam systems use an array of solid state detectors where a semi­ 
conductor material, such as ZincCadmiumTelluride (ZnCdTe), replaces the 
scintillator. The x-rays are absorbed producing electron-hole pairs in the semi­ 
conducting material. The negative and positive charge carriers move, in 
opposite directions, under the influence of the applied electric field to be
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collected and counted electronically. The electrical pulse is proportional to the 
energy of the incident x-ray. These devices are more efficient and improve 
image resolution.
The x-ray tube and detector are mounted onto a gantry such that the two may 







Figure A1.7 Diagram of x-ray tube and detector assembly
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Figure A1.8 Diagram of typical DXA pencil beam system (Hologic, Bedford, 
Massachusetts)
2.5 Software Algorithm
Transmission profiles are effectively produced for each line' of the scan for the 
two photon energies (Figure A1.9). On passing through the human body, the low 
energy x-rays are attenuated more than the high energy, but especially so by 
bone. The high energy profile is multiplied by a factor (k) which equates the soft
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tissue attenuation to that of the low energy-x-ray. This factor is derived from the 
ratio of attenuation coefficients of high and low energy x-rays within the soft 
tissue area. Subtraction of this corrected profile from the low energy profile 
leaves a profile of attenuation due only to bone.
'•~~~~-\ bone
£ -^- soft tissue 
*^-^____
Intensity profile -high 
energy
Intensity profile -low 
energy
K* intensity profile - 
high energy
subtraction
Figure A1.9 Diagram of DXA transmission profiles for 
high and low energy x-rays
Mathematically, the intensity of the incident x-rays for low (IOL) and high (U ) 
energies are reduced exponentially after passing through bone (B) and soft 
tissue (S) according to the following equations:
IL = IOL exp -(uSL Ms + u BL M B ) Equation A1.4 
IH = IOH exp -(USH Ms + MBH MB ) Equation A1.5
Where : |j is the mass attenuation coefficient of the material 
M is the mass per unit area
DXA provides a bone mineral density (BMD) measurement based on a two- 
dimensional projection of a three-dimensional structure. Bone mineral content is 
assessed from a single projection and adjusted for bone area to give an areal 
density in gem"2 . One source of error is therefore bone size which is especially 




Mineral Weight 16 54
Volume (cm 3 ) 8 27
Projected area (cm2) 4 9
Volumetric BMD (gem-3 ) 2 2
Areal BMD (gem-2 ) 4 6
Figure A1.10 Illustration of size effect of areal BMD 
(from A Practical Guide to Bone Densitometry in Children, A/OS 2004;
Attempts to correct this error by using dimensions of bone from a lateral 
projection improve facture risk prediction at the spine 77 but not at hip of 
forearm78 79 .
2.6 Calibration
The system is calibrated to give bone mineral density (BMD) in gem"2 using bone 
and tissue standards of known density. These are either embedded in a 
calibration block (GE-Lunar) or may be fitted within the x-ray tube housing 
(Hologic) (Figure A1.11).
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Figure A1.11 Calibration devices for DXA systems: a) GE-Lunar external block, 
b) Hologic internal wheel, c) Hologic internal drum
Initial factory and on-site calibration during installation is performed to ensure 
accuracy against factory standards. The systems then require a simple daily 
calibration procedure to be carried out prior to patient scanning to enable 
software adjustment to accommodate minor deviations due to changes in 
environmental conditions.
2.7 DXA Digital Storage
The evolution of the personal computer (PC) during the 1980's provided more 
rapid processing and improved software applications for manipulation of digital 
clinical images. This enabled storage and display of images of a resolution 
sufficient to identify anatomical features and analysis at a speed compatible with 
clinical applications. The PCs at the time, such as the IBM PS/2 using Intel 8086 
16-bit microprocessors, were adequate for handling the scan speeds and 
resolution of the original pencil beam DXA systems introduced in the late 1980's. 
Improvements in DXA scanner hardware providing rapid scan times and 
improved image resolution were mirrored by further improvements in computer 
hardware and software. During the early days of DXA, scan times were typically 
15 minutes and processing time about 3 minutes. Modern systems have scan 
times 20 to 30 seconds and processing times in seconds despite the much 
improved resolution and larger image file sizes. Many DXA installations also
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now utilise computer networking to enable a second 'workstation' PC to be used 
for analysis and results printing. Some are linked to the main hospital network 
for transfer of patient biographic details to populate the scanner patient details 
file and for transmission of electronic scan reports.
2.8 DXA Technique
The standard anatomical sites used for determination of BMD by DXA are the 
lumbar spine and the hip. These are accessible in terms of having no overlying 
bone structures and are important sites for determining bone strength 
associated with osteoporosis. The images produced are a pixel by pixel map of 
BMD (Figure A1.12).
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Figure A1.12 DXA images of lumbar spine and femoral neck and associated 
results produced by a Lunar Prodigy system
The DXA software identifies each pixel as composing primarily bone or soft 
tissue based on the differential attenuation of the 2 x-ray energies. Where this is
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uncertain due to partial volume effect around the edges of the bone, the pixels 
are 'typed' as neutral and any high attenuating materials such as metal 
components are 'typed' as being an artefact. Only the 'bone' and soft tissue 
areas are used in the determination of BMD. The regions of interest shown by 
the black lines on the scan images in figure A1.12 are placed automatically but 
are adjustable by the operator when required.
2.9 Quality Assurance
DXA provides a quantitative measure of BMD that is used directly in decision 
making over clinical management. It is therefore essential that this value is 
accurate and that any changes observed during longitudinal follow-up represent 
real changes in BMD. Because of the steep gradient of the relationship between 
BMD and fracture risk, with a doubling of risk for every one standard deviation 
change4 the degree of precision required of these systems is higher than that for 
many other technologies associated with clinical diagnosis. Optimal results are 
obtained by use of well trained operators, good technique, reliable, well 
maintained equipment and adherence to a rigorous quality assurance 
programme. The daily calibration procedures include checks on scan arm 
movement, x-ray output and detector sensitivity and discrimination. Following 
the calibration, an independent scan is recommended using a phantom 
representing the lumbar spine to confirm that any variation in BMD remains 
within acceptable limits. Appropriate phantoms are provided with the DXA 
scanners by the manufacturers (Figure A1.13).
Figure A1.13 Examples of spine phantoms provided with Lunar (left) and 
Hologic (right) DXA scanners
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Reliability of results can also be compromised by patient related factors. 
Excessive tissue volumes within the scan region due to obesity increase the 
attenuation of x-rays, particularly those of low energy, leading to decreased 
counting statistics and inaccuracies due to a shift in spectral distribution to 
higher effective photon energies (beam hardening). Reduced tissue volumes 
may also lead to inaccuracies due to too many x-rays reaching the detector 
leading to detector saturation. Alternative scan modes are usually provided to 
minimise these errors. The presence of external or internal artefacts or 
anatomical abnormalities such as fractures may affect determination of BMD 
and these should be removed where possible or excluded from the areas used 
in the calculation. The scan image displayed on the computer is used to check 





Bone is composed of an outer cortical shell and inner trabecullar bone, with the 
proportions varying by site. Bone is constantly being replenished by a cyclical 
process involving osteoclasts (bone absorbers) and osteoblasts (bone builders) 
which ensures good bone health and ability to withstand normal stresses and 
strains (A2.1).
Source: Pablo Tebas, MO
Figure A2.1 Diagram of bone turnover cycle
This metabolic activity occurs on the surface of bone and hence is greater in 
trabecullar bone which has a larger surface to volume ratio. When these 
processes are in balance there is preservation of bone but if the balance is 
disturbed, such as during the menopause, there may be a net loss of bone mass 
at the end of the cycle. This eventually results in thinning of the bone structure 
and loss of trabecullar connectivity (Figure A2.2), weakening the bone's ability to 
withstand the stresses of normal activity and increasing the risk of fracture.
Figure A2.2 Magnified images of trabecullar bone structure: a) normal and b) 
osteoporotic
In the normal skeleton around 75% of the bone volume is bone marrow and fat, 
the proportions varying by site and age. These components have different x-ray 
attenuating properties at the energies used in DXA. Consequently, an excess of 
yellow (fatty) marrow as seen with aging can give a falsely low BMD.
2 Changes in bone mass with age
Bone mass increases with age until a peak is achieved around 25 years of age. 
There is then a plateau during adulthood with an age related decline 
commencing around 45 years which is compounded in women by the 
menopause related loss80 81 . The loss of oestrogen at this stage leads to an 
increase in osteoclast numbers with consequent larger than normal resorption 
cavities which are incompletely filled. Factors mediate bone development, 
maintenance and decline, some of which are modifiable lifestyle factors but 
some are not (Figure A2.3).
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Figure A2.3 Age related changes in bone mass and factors influencing bone 
status.
As bone mass declines so fractures increase in both women and men (Figure 















Figure A2.4 Sites of fracture (from Cooper C. Epidemiology of Osteoporosis. 
Chapter 49:IV. Metabolic Bone Diseases. Am Soc for Bone & Min Research 
2003)
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3 Definition of Osteoporosis
In 1994, a quantitative measure of bone strength was chosen by the WHO to 
provide a definition of osteoporosis 83 . The definition is based on DXA of the 














Figure A2.5 World Health Organistion (WHO) quantitaive definition of 
osteoporosis: based on T-score by DXA (number of standard deviations from 
young normal mean).
Osteoporosis is defined as a skeletal disease characterised by low bone mass 
and microarchitectural deterioration of bone tissue with a consequent increase in 
bone fragility and susceptibility to fracture 84 . It is a prevalent disease affecting 1 
in 2 women and 1 in 5 men85 and is a major drain on healthcare resources due 
to the high burden of morbidity and mortality associated with low trauma 
fractures86 . Hip fracture in particular often leads to loss of independence with a 
consequent strain on social services and has a 25% mortality rate within one 
year82 87 . Osteoporosis affects primarily females as they reach a lower peak 
bone mass and suffer oestrogen deficiency related bone loss following the 
menopause.
4 Other Risk Factors for Fracture
The definition of osteoporosis by BMD was never meant to be used as a 
treatment threshold in individuals. It is estimated that 70% of the variability in 
bone strength is determined by bone mass but there are other factors in addition 
to BMD that are associated with bone strength and fracture risk. These include
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age, propensity to fall and bone geometry (Faulkner 1993). It is also known that 
steroid use or prior fragility fracture is associated with increased risk of future 
fracture independent of BMD. These factors should be taken into consideration 
in individual patient management.
5 Bone protective treatments
Over the last 25 years, pharmaceuticals have been developed with bone 
protective properties and effectiveness in preventing fragility fractures (Figure 
A2.6).









• HRT Ir Hormonal agents
• SERMs (raloxifene) J
• PTH (1-34)
• PTH (1-84)
• Strontium ranelate -i Dual mechanism
J of action
SERMs = selective oestrogen receptor modulators 
PTH = parathyroid hormone
Figure A2.6 Treatments available for protection against bone loss
These developments went hand-in-hand with the introduction of DXA which 
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Abstract Dual-energy x-ray absorptiometry (DXA) is a widely used technique for measuring 
bone mineral density for the identification and management of osteoporotic subjects. The original 
DXA pencil beam systems expose patients to an effective dose of ionizing radiation of around 
2 /nSv and require no additional protective shielding for staff. The new fan beam densitometers 
incorporate solid state detectors and have a higher photon flux, enabling faster acquisition times 
and giving improved resolution. However, this may be at the expense of higher radiation dose. 
This study was conducted to assess the radiation dose to patients and staff from the standard 
scan modes using a Lunar Expert-XL fan beam densitometer. This is, we believe, the first dose 
assessment of the Expert-XL. The results indicate that the scatter dose at 1 m from the scan 
table, assuming four AP spine and femoral neck examinations per hour, is about 4 /zSv h~'. 
This is well below the limit of 7.5 /iSv h~' set by the UK's Ionising Radiation Regulations for 
defining a Controlled Area but above the lesser limit of 2.5 fiSv h" 1 for a Supervised Area. 
Typical effective doses to patients are 59 MSv for an AP lumbar spine scan, up to 56 nSv 
for AP femoral neck, 71 /j.Sv for lateral spine moiphometry and 75 /iSv for whole body. 
Although exceeding those of pencil beam DXA machines, these doses are less than for standard 
radiographic procedures, particularly of the lumbar spine. Where reduced scan time, improved 
image resolution or morphometric analysis of the spine are required, the patient doses from the 
Lunar Expert-XL are not prohibitive.
Keywords: DXA, dosiraetry, fan beam, BMD
1. Introduction
Dual-energy x-ray absorptiometry (DXA) is an accurate, precise and widely used technique 
for measuring bone density to identify and monitor osteoporotic subjects and to assess 
the effectiveness of treatment. The original DXA systems use a pencil beam x-ray and 
a sodium iodide scintillation detector moving, in unison, in a rectilinear fashion over the 
region of interest. With the advent of new fan beam densitometers, incorporating solid 
state detectors, faster acquisition times and improved resolution is made possible, although 
possibly at the expense of higher radiation dose. The Ionising Radiation Regulations (IRR 
1985) and Approved Codes of Practice (ACOP 1985) aim to maintain radiation doses 'as low 
as reasonably achievable' (the ALARA principle). In order to comply with these regulations 
an assessment of the risk to staff and patients is required.
The quantity used to assess radiation hazard is the effective dose, which is the sum of the 
absorbed doses to each irradiated organ, weighted for the radiation type and radiosensitivity 
of the organ. The intention of this weighting process is to produce a value that is proportional
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to the risk of inducing cancer or hereditary disease. This study was conducted to assess the 
effective dose from a Lunar Expert-XL fan beam densitometer (Lunar Corp., Madison, WI 
USA).
Such an assessment has been performed by others (Njeh el at 1996). However, this 
work was performed on a prototype machine (the Lunar Expert) using a now obsolete scan 
mode. Also, no mention is made in the paper about the contribution of scattered radiation 
to organs outside the primary beam.
2. Method
2.1. Lunar Expert-XL
The Lunar Expert-XL uses a fan beam of x-rays and an array of solid state scintillation 
detectors. The x-ray tube operates at a maximum continuous voltage of 134 kV and 
maximum tube current of 5 mA with 2 mm aluminium filtration. Original DXA systems 
use either a k-edge filter or kV switching to produce two discrete x-ray energies, of around 
40 and 70 keV, chosen to optimize the differential attenuation between bone and soft tissue. 
The Expert-XL achieves this by dual-energy discrimination at the detector with one row 
of elements recording the low-energy and one the higher-energy x-rays. The x-ray tube 
and detector are mounted on a C-arm which may be rotated to enable lateral imaging. The 
distance from focal spot to image receptor is 112 cm. The system is capable of performing 
bone densitometry measurement of the lumbar spine, femoral neck, whole body, forearm, 
hand and morphometric assessment of the thoracic and lumbar vertebrae.
2.2V Rando anthropomorphic phantom
A Rando anthropomorphic phantom (Alderson Research Laboratory, Stamford, CT, USA) 
was used to determine doses at different depths within the body. The Rando phantom 
consists of a human skeleton embedded in a soft tissue equivalent material (density 
0.985 g cm"3 , effective atomic number 7.30). Air-expanded material (density 0.3 g cm""3 ) 
is incorporated to represent the lungs. The proportions of the phantom were determined 
from a survey of United States Air Force personnel, and the overall stature scaled to match 
the civilian population (height 1.73 m, weight 73.5 kg). It may be considered to represent a 
standard man as defined by the International Commission on Radiological Protection (ICRP 
1975). The phantom is of standard male form, although breast attachments are available 
and were utilized for this study. The phantom is separated into 35 slices, which have an 
array of holes into which dosimeters or tissue equivalent pegs may be placed.
2.3. Measurement of half-value layer
The phantom is designed for use with photons generated at applied potentials greater than 
70 kV, and doses may be significantly overestimated if used with lower energies (IPSM 53 
(Wall et al 1988)). The phantom may therefore be inappropriate for use with the pencil 
beam DXA systems. Also, Shrimpton et al (1981) recommend that the phantom only be 
used with radiation with a half-value layer (HVL) of greater than 2 mm aluminium. To 
validate its use for the assessment of doses from the Lunar Expert-XL, the HVL of the x-ray 
beam was measured. A 6 cm3 thimble ionization chamber (MDH 10X5-6) was placed in 
the beam path and a lead collimator placed above to minimize contributions from scatter. 
Measurements were performed using a 5 mA service mode. This allowed exposures to be
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made with both the x-ray tube and detector stationary. The exposure was repeated with 
increasing layers of 99.8% pure aluminium filters until the electrometer reading was half 
that for the unfiltered beam.
2.4. Measurement of dose to staff
Scatter dose rates were measured, at I m horizontal distance from the central axis of the 
scan table, using an Autoness Szintomat 6134A dose rate meter. The uncertainty in dose 
rate measurement for this instrument does not exceed 20% at the x-ray energies used. A 
tank of water (width 23 cm, length 35 cm, depth 20 cm) was placed on the table to simulate 
the scattering that would occur with a patient in situ. A scan mode using the maximum 
tube current of 5 mA was selected.
2.5. Measurement of patient dose
Patient dose was determined using lithium fluoride thermoluminescent dosimeters (TLDs) 
embedded in the Rando phantom, for whole body, AP spine, lateral spine and femur 
scans. For each scan mode, TLDs were placed at positions and depths within the phantom 
corresponding to those of major organs in the primary beam and also in adjacent areas just 
outside the primary beam to give an estimate of the contribution to the effective dose made 
by radiation scattered outside the primary field. The numbers of TLDs used to assess each 
organ/tissue dose for each scan type are listed in table 1. In order to obtain a satisfactory 
cumulative dose to the TLDs, 30 scans were performed using each scan mode. However, 
doses recorded on some TLDs outside the primary beam were still found to be below 
the dose error of 6 j^Sv stated by the Medical Physics Service, Lincoln, UK who were 
responsible for the calibration and reading of the TLDs. These doses were still included in 
the calculations but contribute little to the effective dose per scan. The above service also 
specifies a 3% standard deviation error due to TLD to TLD variation and about 2% error 
in the calibration procedure. The cumulative effective of the above on the final effective 
doses is estimated at 6%.
Table 1. Number of TLDs used for each scan mode.







































































Total 65 30 52 21
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2.6. Calculation of effective dose
The locations of major organs in the Rando phantom were determined using the drawing of 
reference man from NRPB-R250 (Jones and Shrimpton 1991). The weighting factors for 
each organ were taken from ICRP 60 (ICRP 1990, 1991). The effective dose is given by
where HT is the equivalent dose in the organ or tissue T and WT is the weighting factor 
for tissue T.
The calculation of effective dose requires a knowledge of: the proportion of each organ 
within the primary and scatter fields; the extent of scatter; and the average dose to the 
organs from primary and scatter fields. The above are dependent on the scan area. For the 
purposes of this assessment the manufacturers recommended scan widths and lengths for 
each scan mode were used.
By overlaying a rescaled scan field size on the NRPB drawing, the proportion of each 
organ or tissue within the primary field was determined.
The proportions of skin, red bone marrow and bone within each slice of the phantom 
were calculated using factors previously determined by Huda and Sandison (1984). The 
percentages of red bone marrow and bone in the primary beam were calculated by identifying 
the slices of the Rando phantom exposed to the primary beam. For the femur scan, the 
percentage calculated was divided by two as only one hip is scanned.
A similar method to that for bone surfaces and red bone marrow was used to calculate the 
'remainder' organs in the scan field. This method, however, assumes a uniform distribution 
of remainder organs in the body. The average dose to these organs is calculated and a 
weighting factor of 0.05 applied to calculate the contribution to the effective dose. Any 
remainder organs receiving a dose of greater than the highest dose to any other organ should 
be considered separately and a weighting factor of 0.025 applied to that organ and 0,025 
to the average of the rest of the remainder organs (ICRP 1990, 1991). Therefore, for AP 
spine, the doses to the intestines, kidneys, spleen and pancreas were calculated to determine 




The manufacturer specifies that the Lunar Expert-XL has 0.5 mm inherent filtration, an 
additional 2 mm aluminium added filtration and a half-value layer of greater than 2.5 mm 
aluminium. Our results indicate that the half-value layer is 5.1(±0.1) mm aluminium.
3.2. Dose to staff
The dose rate at 1 m from the central axis of the table, at scan table height, using the 
maximum tube current of 5 mA, was 50 /iSv h" 1 . A peak dose rate at 1 m of 120 /iSv h~ 
was measured at about tube height. The dose rate at the operator's chair, 2.25 m from the 
scan table axis, was 17 (j.S\ h~ l .
The UK's Ionising Radiation Regulations (1985) require that, 'a Controlled Area be 
designated, in most circumstances, where the time averaged dose rate (averaged over an 
8 h day) is greater than 7.5 /J.Sv h"1 '. Such a dose rate for 8 h a day, five days a week
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for 50 working weeks a year would result in a dose of 15 mSv, which is the legal dose 
limit for unclassified radiation workers. Although the maximum legal limit for unclassified 
workers is 15 mSv, there is no threshold for risk. Risk is proportional to radiation dose 
therefore doses must be as low as reasonably achievable (ALARA) or as low as reasonably 
practicable (ALARP, IRR 1985). From our results, the numbers of scans required that 
would give time averaged dose rates of 7.5 ^Sv h" 1 , at 1 m from the table axis, were 
calculated for various scan modes (table 2). The anticipated workload is considerably less 
than the limits indicated in table 2, and therefore it was decided that the Controlled Area 
could safely be limited to within 1 m of the couch. Assuming four fast mode AP spine 
and femoral neck examinations per hour (eight scans), the scatter dose at 1 m would be 
4 ]U,Sv rT 1 . This exceeds the IRR limit for a Supervised Area but is well within that for 
a Controlled Area. As an additional precaution, and to conform to the ALARA principle 
a lead-acrylic screen of 0.5 mm lead equivalence, and height 1.54 m was placed between 
the operator's chair and the scan table. This screen will attenuate in excess of 95% of the 
scattered radiation incident upon it.









































3.3. Effective dose to patients
An isodose line of 50 ftSv after 30 scans was used to define the extent of the scattered 
radiation field to be considered for each scan mode. The percentage of tissues and organs 
within the primary and scatter fields for each scan mode are shown in table 3. For the 
whole body scan mode, the organ doses have combined primary and scatter components. 
Tables 4 to 7 show the calculated organ doses, and how they contribute to the final effective 
dose per scan. Effective doses per scan are summarized in table 8. The total uncertainty 
for these dose values is estimated at 6%. The effective doses for other scan modes were 
derived using the calculated effective dose per mA s (table 9).
4. Discussion
The time averaged maximum scatter dose rate at 1 m from the central axis of the scan table 
is 4 fj,Sv h~ 1 assuming four patients per hour undergoing 5 mA fast AP spine and femur 
scans. This exceeds the scatter dose of 1.06 M$V IT 1 stated by Mazess (1996), but his 
figures are based on the shorter scan times of 6 s of the recently introduced turbo mode. 
After correcting for difference in scan tunes, there remains a significant difference in scatter 
doses, but it is not clear at which height the latter doses were recorded. The results of this 
study are similar to those stated by Patel et al (1996) of 5 /iSv h~' . The difference may
22 S A Steel et al


















































































































































Calculations performed assuming one ovary within primary field * and excluded from primary
field **.
*** Dose to pancreas in AP spine mode found to be higher than that to other organs, therefore,
as stipulated in ICRP 60 (ICRP 1990, 1991), a separate assessment was performed in order to
calculate effective dose. This assumed that 50% of organ in primary beam and 0% in scatter
region.















































































be due to the measurements being performed with patients in situ for the latter compared 
with the use of a tank of water as the scattering medium in this study.
With an expected workload of four patients per hour, steps should be taken to reduce 
the dose to the operator by increasing the operator's distance from the scan table and
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Table S. Organ/tissue doses using right femur fast scan mode on Lunar Expert-XL, 



























































































Effective dose 40 ^Sv














































































consideration given to installation of a protective screen. In our centre, operators are 
positioned behind a protective screen at about 2 m from the scan table. Monthly monitoring 
of operator doses over a period of 1 year using personal film badge dosimeters, demonstrate 
doses below the limits of detection, i.e. less than 50 /iSv per month (0.6 mSv per year). 
This is well below the current UK legal limits and also below the latest recommended limits
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Calculations performed assuming one ovary within primary field * and excluded from primary 
field •*.
for both radiation workers and the general public which are expected to be implemented in 
January 2000 (ICRP 60 1990, 1991).
Results from this study suggest that scatter doses are higher than those of 2.4 /zSv 
reported by others (Patel et al 1996) for the Hologic QDR 4500. However, the different 
system specification, geometry (e.g. below-table x-ray tube) and choice of scan technique 
make a direct comparison complex.
The HVL of the Lunar Expert-XL was found to be 5.1 mm aluminium at a set voltage 
of 134 kV. This quality of radiation is within recommended guidelines for use with the 
Alderson Rando anthropomorphic phantom. The total effective dose for an AP and lateral 
morphomerric study of the spine was found to be 130 ^Sv compared with a typical effective 
dose of 1230 /x.Sv for a lumbar spine radiological examination involving AP and lateral views 
(table 10). Although the radiation dose to patients from the Expert-XL exceeds that of the 
standard pencil beam DXAs more than 100 fold (Spencer et al 1994, Njeh et al 1996), 
scan time is reduced and the improved resolution provides additional information. Also, the
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Calculations performed assuming one ovary within primary field * and excluded from primary 
field **.
Table 10. Some typical effective doses from common radiographs, calculated using typical 
entrance surface doses measured for adult patients at a random sample of 20 English hospitals" 
and NRPB Monte Carlo datab . _________________
Typical effective dose 
Examination per film (mSv)
Lumbar spine— AP 0.88
Lumbar spine — lateral 0.35




1 NRPB 1992 National Protocol for Patient Dose Measurements in Diagnostic Radiology.
b NRPB-SR262 Normalised Monte Carlo Doses for Medical X-ray Examinations Calculated
using Monte Carlo Techniques (NRPB-SR262).
vertebral morphometry capability may reduce the need for much higher dose radiographic 
procedures in order to determine degree and extent of vertebral deformities.
The greatest contribution to effective dose from femur and whole body scans is the 
dose received by the ovaries. However, the genetic risk considered here is not relevant 
for the majority of the population undergoing bone densitometry assessment since they are 
generally post-menopausal women. Also, careful positioning by the operator may exclude 
the ovaries from the primary beam during a femoral neck scan, reducing the effective dose 
by 16 AiSv (29%).
5. Conclusion
We have performed what we believe is the first dose assessment of the Lunar Expert-XL. The 
results indicate that, where a throughput of four or or more patients per hour is anticipated, 
a protective screen for the operator may be required.
The effective dose to patients, although exceeding that of pencil beam DXA machines, 
is much less than standard radiographic procedures, particularly of the lumbar spine. The
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pencil beam DXA machines are to be recommended where a standard assessment of bone 
mineral density is required. However, the Expert-XL has the advantage where reduced scan 
times, unproved image resolution or morphometric analysis of the spine are required and 
may reduce the need for higher-dose radiographic procedures.
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Original Article
Image Resolution of the Lunar Expert-XL
J. A. Thorpe and S. A. Steel
Centre for Metabolic Bone Disease, Hull Royal Infirmary, Hull, UK
Abstract The Lunar Expert-XL is an example of the 
latest generation of fan beam densitometers, with the 
X-ray source and detector array mounted on a C-arm to 
enable supine lateral imaging. Image resolution for 
anteroposterior (AP) spine, femur, hand, forearm and 
lateral morphometry on the Expert-XL were assessed in 
vitro with the 07-541 Nuclear Associates line pair test 
pattern. Each scan type was investigated at all available 
tube currents and scan speeds, and at the maximum, 
minimum and default bed heights. The effect of soft 
tissue thickness on resolution was investigated by using 
varying amounts of Perspex attenuator. The in vitro 
median lateral (x-axis) resolutions at the default bed 
height for the default scan types were 0.9 line pairs (Ips)/ 
mm for the 5 mA fast AP spine and femur scans, and 1.0 
Ips/mm for 1 mA fast hand, forearm and 5 mA fast 
morphometry scans. This equates to a resolution of about 
1 mm. The best resolution achieved was 1.2 Ips/mm 
(0.83 mm), obtainable on all scan modes with the bed at 
maximum elevation, but only consistently with the 
forearm mode. Lower tube current did not affect 
resolution but did change the range of soft tissue 
thickness over which an image could be resolved. 
Turbo scan modes greatly reduced longitudinal (j-axis) 
resolution but had little effect on lateral resolution. This 
study demonstrates the importance of including an 
assessment of resolution when validating new equip­ 
ment, especially if morphometric investigations are to be 
conducted.
Keywords: Expert-XL; Densitometry; DXA; Quality 
assurance; Resolution
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Introduction
Effective assessment of bone fracture risk by dual- 
energy X-ray absorptiometry (DXA) requires accurate 
and precise information, derived from bone mineral 
density (BMD) or morphometric examination. The 
image resolution of DXA limits both image clarity and 
the ability of edge detection algorithms to distinguish 
between bone and soft tissue. Digital imaging produces a 
coarse representation of bone edges, with any edge pixel 
of an area containing both soft tissue and bone appearing 
in the image as a composite of both. This produces errors 
in edge detection, and so leads to inaccuracy in the 
measured bone area and potentially in calculated BMD
[1].
Fan beam densitometers employ an array of detectors 
for rapid image acquisition. The use of an array 
eliminates the rectilinear motion required with tradi­ 
tional pencil beam densitometers, so the emitter/detector 
assembly has only to be moved longitudinally [2]. The 
increased speed of this system permits the improvement 
of resolution by the use of smaller detectors in the array 
and shorter incremental movements of the emitter/ 
detector assembly. Maintaining the same number of 
counts per detector requires an increase in the overall 
photon flux and so increases the administered radiation 
dose, although the effective dose to patients remains well 
below that of equivalent radiographic procedures [3]. 
Improved resolution provides more anatomic detail, 
sufficient to allow morphometric assessment of the 
spine, although still not sufficient for differential 
diagnosis.
DXA images are derived by an emitter projecting the 
object onto the detector. Pencil beam densitometry 
produces an image of the same relative dimensions as 
the object. Fan beam densitometry distorts and magnifies 
the lateral (x-axis) dimension of the image by an amount 
dependent on the distance from the emitter to the object
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Detector 
Plane
Fig. 1. Diagrammatic representation of the penumbra effect.
and the emitter to the detector. Fan beam distortion 
produces a lateral penumbra, whose width is determined 
by the focal point width, the object thickness and the 
object-to-focal point distance [4] (Fig. 1). However, the 
longitudinal (y-axis) dimensions remain unchanged. 
Conventional radiographic cone beams distort both the 
lateral and longitudinal dimensions.
Little work on the resolution of fan beam densi- 
tometers has been conducted. Lunar Corporation 
(Madison, WI) have produced the Expert series of fan 
beam densitometers, with the initial Expert system 
released in 1992 being superseded upon the release of 
the Expert-XL in 1994. Felsenberg et al. [5] have 
reported a resolution of between 0.95 and 0.7 line pairs 
(lps)/mm (1.05 and 1.43 mm) for the Expert and 0.7 and 
0.5 Ips/mm (1.43 and 2.00 mm) for the Hologic QDR 
2000+ (Hologic Inc., Waltham, MA). No resolution for 
the Expert-XL has yet been reported outside the 
proprietary literature, which states a range of maximal 
resolutions varying from 2 to 1.6 Ips/mm (0.5 mm to 
0.625 mm). The aim of this investigation was therefore 
to measure the image resolution of an Expert-XL in 
routine clinical use at a district general hospital.
Equipment and Method
Lunar Expert-XL
The Lunar Expert-XL is an example of the latest 
generation of fan beam densitometers, with both X-ray
Table 1. Range of settings available for each scan type
emitter and detector array mounted on a rotatable C-arm 
to enable both anteroposterior (AP) and lateral imaging 
[6]. The emitter assembly consists of a Varian A-I 46 
rotating anode X-ray tube, operating at a voltage of 134 
keV, with 1 mm of aluminum filtration and a focal spot 
size of 0.3 mm. The distance from the focal point to the 
detector array is 112 cm. The detector array contains 288 
solid state detectors, each 0.8 mm x 1.6 mm, arranged 
in two rows. A layer of copper over one row of detectors 
prevents low energy X-rays from reaching it, thus 
providing the required discrimination between high and 
low energies. The Expert-XL can perform eight different 
investigative procedures at five different sites. It is also 
possible to vary the X-ray tube current, scan speed and 
scan width for most procedures. The available investiga­ 
tions are summarized in Table 1. In addition, the 
scanning table is motorized and the height can be 
varied between 15.9 cm and 39.2 cm above the detector 
for optimal image registration and resolution for the type 
of investigation being performed. The accompanying 
workstation at this center is equipped with a 21-inch Dell 
Ultrascan 21TE monitor.
Resolution Test Pattern
Resolution was assessed subjectively using the 07-541 
Nuclear Associates (Carle Place, NY) line pair resolu­ 
tion test pattern (Fig. 2a). The 07-541 test pattern 
contains 15 sets of lead line pairs, arranged horizontally 
and vertically, covering a range of 0.6 to 3.4 line pairs 
per milimeter. The test pattern is 0.1 mm thick and is 
encapsulated in a 3 mm thickness of material mimicking 
soft tissue.
Method
The five scan types most commonly used in clinical 
practice were investigated (AP spine, AP femur, 
forearm, hand, lateral morphometry). The test pattern 
was imaged at the minimum, maximum and default bed 
heights for each appropriate scan type. For AP spine and
Scan type Tube current (mA) Scan speed (s) Scan width (cm)


















































Tube voltage, 134 fceV; focal spot size, 0.3 mm; software version, 1.63.
Default scan speeds and widths are shown in bold type. Default current settings are dependent on subject mass.
MM: morphometry mode.
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\P femur, both 5 mA and 2 mA tube current options 
rere assessed at the default bed heights, but only the 5 
nA option was used at the maximum and minimum bed 
eights. Similarly, when both fast and turbo scan speeds 
rere available, both were used at the default bed height 
mt only the fast speed was used at the maximum and 
ninimum bed heights. For AP spine and AP' femur, 
mages were acquired both with and without the mattress 
>n the bed.
The required energy attenuation was achieved by 
jositioning the test pattern between sheets of Perspex 
polymethylmethacrylate, also known as Lucite or 
feiglas) which, at the relevant energy levels con- 
;emed, have a mass attenuation coefficient of 0.92 
:elative to lean tissue. Perspex was chosen as it was 
sadily available and simple both to handle and to
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machine accurately. The initial thickness was deter­ 
mined from that which might be expected clinically for 
the particular type of scan. The thickness was varied for 
each scan type in an attempt to determine both the effect 
on resolution and the range of tissue thickness that could 
be successfully imaged. For spine and femur scans, the 
total range of Perspex used was 4-28 cm and 4-20 cm 
respectively, with 4-8 cm placed beneath the test 
pattern. For forearm and hand scans, the total range 
used was 0-12 cm and 0-9 cm respectively, with the 
Perspex beneath the test pattern varied from 0 to 6 cm 
for the forearm and 0 to 1 cm for the hand. For hand and 
forearm acquisitions, the mattress was removed and the 
forearm positioner placed on the bed, in accordance with 
normal operating procedure. For the morphometry scan 
mode, both Perspex and test pattern were stood vertically
0,6 0,7 0,8 0,9 1,0
III ill
1,2 1,4 1,6 1,8 2,0
2,2 2,5 2,8 3,1 3,4
•MIC; ASSOC.-CARLE PLACE,N.Y.07-541
Fig. 2a-c. The Nuclear Associates 07-541 line pair resolution test 
pattern, a Photograph, b Resolution on forearm scan mode at 
maximum bed height, with 3 cm Perspex. c Resolution on AP spine 
mode at default bed height, with 20 cm Perspex.
on a single horizontal Perspex sheet. The total amount of 
attenuator was varied from 20 to 27 cm, with 10-14 cm 
on the side closest to the X-ray tube.
Images were analyzed immediately, to allow sufficient 
time for the X-ray tube to cool before the next 
acquisition. A single operator manually adjusted the 
image levels (displayed range), contrast and brightness 
controls until an optimal resolution was reached. The 
achieved resolution was measured from the screen, with 
the image at 300% magnification, and was denned as the 
last bar section in which a clear distinction could be seen 
between lines and spaces. The image magnification was 
sufficient to allow individual image pixels to be easily 
seen. The expected geometric lateral magnification was 
also calculated for each scan, taking into account the set 
bed height and the thickness of underlying Perspex. 
When the mattress was used for spine and hip 
acquisitions, an additional 1 cm was added to allow for 
the thickness of the mattress under compression. For 
hand and forearm scans, the height of the forearm 
positioner was added.
Results
The median and range of the resolutions achieved for 
each scan mode at the default bed height using different 
depths of Perspex are shown in Table 2. Sample images 
are shown in Fig. 2b and c. Both 5 mA and 2 mA image 
acquisitions were found to require a minimum thickness 
of soft tissue, below which an image could not be
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formed. As the thickness of soft tissue was then 
increased, the image became degraded by an increasing 
scatter component. Although the 2 mA images were 
visibly poorer than the 5 mA tube current images at large 
tissue thickness, the measured resolution was found to be 
approximately equal up to 24 cm of Perspex. Beyond 
this point the 2 mA images suddenly deteriorated in 
quality and the resolution was reduced to a level poorer 
than that which could be measured on the test pattern 
(i.e., <0.6 Ips/mm), whilst the 5mA tube current 
produced images of 0.7 Ips/mm resolution at the 
maximum soft tissue thickness of 28 cm. The 1 mA 
hand and forearm modes produced images of 1.0 Ips/mm 
resolution at the maximum tested soft tissue thickness of 
12 cm. Resolution was not affected by either the mattress 
or the forearm positioner.
Tube current had little effect on the achievable 
resolution, provided the current chosen was appropriate 
for the amount of soft tissue present in the region of 
interest. Accordingly, the tube current did change the 
range of tissue thickness over which an image could be 
resolved: from 9 to at least 28 cm Perspex for 5 mA, 
from 5 to 24 cm for 2 mA, and from 0 to at least 12 cm 
for 1 mA. The use of the turbo scan speed dramatically 
degraded the longitudinal resolution but did not cause 
any significant decrease in lateral resolution.
Scan speed did not appear to have much effect on 
lateral resolution. The median and range of lateral 
resolution for the AP femur scan were the same for both 
fast and turbo scan speeds at both 5 mA and 2 mA 
(median 0.9 Ips/mm, range 1.0-0.8 Ips/mm). For the AP






















































































































"There are 15 discrete line pairs on the 07-541 test pattern, ranging from 0.6 to 3.4 line pairs per millimetre (Ips/mm). Resolution in Ips/mm =
I/resolution in mm). In the table, 0,6, 0.7, 0,8, 0.9, 1 and 1.2 Ips/mm correspond to 1.67, 1.43, 1.25, 1.11, 1.00 and 0.83 mm.
''Ratio of attenuation coefficients between Perspex and lean tissue = 0.92.
"Acquisitions that did not produce viable images were excluded from median calculations.
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"As defined by Lunar Software, where height = 0 is the minimum height permitted by the hardware. Software limits the height to 0.2 cm above this, 
'includes thickness of underlying Perspex. Hand and forearm scan modes include elevation caused by the forearm positioner. AP spine and femur 
calculations assume a compressed mattress thickness of 1 cm. 
"Calculated from: focal point-to-detector distance/focal point-to-object distance. Distance from the tube focal point to the detector array = 112 cm.
spine scan, the median lateral resolution of the 2 mA fast 
scan was slightly inferior to the turbo mode (0.8 Ips/mm 
for 2 mA fast, 0.9 Ips/mm for 2 mA turbo). However, 
scan speed produced a clear effect on longitudinal 
resolution, with no turbo scan achieving a resolution that 
could be measured on the test object (resolution <0.6 
Ips/mm).
Bed elevation produced a direct effect on the lateral 
resolution, as shown in Table 3. Included in the table is a 
calculation of the geometric fan beam lateral magnifica­ 
tion for each bed height. The estimate takes into account 
the thickness of Perspex underlying the test pattern, and 
the height of the forearm positioner is included for the 
hand and forearm modes. A maximum lateral resolution 
of 1.2 Ips/mm was achieved on the forearm, hand and 
morphometry scan modes with the bed at the default 
height, and on all modes with the bed at the maximum 
elevation. The median lateral resolutions varied at the 
maximum bed elevation, with 1.1 Ips/mm for AP spine, 
1.0 Ip/mm for AP femur and hand, and 1.2 Ips/mm for 
the forearm. As expected, the poorest lateral resolutions, 
of 0,9-0.7 Ips/mm, occurred at minimum bed elevation.
Surprisingly, longitudinal resolution was also im­ 
proved slightly by bed elevation. The median resolutions 
for the AP spine scan improved from 0.8 Ips/mm (range: 
0.9 to <0.6 Ips/mm) at the minimum bed height to 0.9 
(1.0 to 0.8) Ips/mm at the maximum. The median 
resolutions for the AP femur scan were the same (0.9 Ips/ 
mm) at both minimum and maximum bed heights, but 
the range varied from 0.9-0.7 Ips/mm at the minimum 
bed height to 1.0-0.8 Ips/mm at the maximum. The hand 
mode also showed improvement, from a median and 
range of 0.9 (1.0-0.9) Ips/mm at the minimum bed 
height to 1.0 (1.2-0.9) Ips/mm at the maximum. The
forearm mode was an exception to the trend, with no 
change in median or range of resolution over the full 
variation in bed height.
Discussion
This investigation has demonstrated the image resolution 
achievable on the Expert-XL over the range of investig­ 
ations that may typically be performed as part of a 
clinical investigation. Lateral resolution was found to be 
strongly influenced by bed height, whilst longitudinal 
resolution was slightly influenced. For comparison, we 
attempted to determine the resolution of the Lunar 
DPXL pencil beam using the same phantom, but failed. 
Even on the highest resolution mode the DPXL was not 
able to image the coarsest line pair pattern of 0.6 Ips/ 
mm, thus indicating a resolution of poorer than 1.67 mm. 
The 07-541 test pattern provides only a discrete and 
subjective measure of resolution within a limited range. 
Assessment of pencil beam resolution would require a 
coarser line pair test pattern.
It was expected that as soft tissue thickness increased, 
the resolution of lower tube current scans would 
deteriorate faster than those performed with a higher 
tube current. Although increasing thickness of soft tissue 
visibly produced more random scatter in the image, the 
07-541 line pair test pattern did not reveal the effect of 
scatter on the resolution. As a result, it was not possible 
to identify the optimum ranges of soft tissue thickness 
for each tube current, only the absolute range. A hole 
phantom might better demonstrate the effect of scatter
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but would be less susceptible to the penumbra effect, 
making it inappropriate for measuring the effect of bed 
height upon resolution.
At a tube current of 5 mA, the Expert-XL produced a 
viable image in vitro at a Perspex thickness ranging from 
9 cm to at least 28 cm. However, under normal use BMD 
values are calibrated to be accurate within an expected 
thickness of soft tissue, based on the subject's weight 
and the anatomic region of interest. If the actual 
thickness of soft tissue differs greatly from the expected, 
the calculated BMD value will be inaccurate. Although 
Perspex provides a close attenuation match to lean tissue 
at the X-ray energies used, the difference is sufficient to 
require caution when extrapolating between in vitro and 
in vivo applications.
Lateral resolution showed improvement with increas­ 
ing bed elevation, although not to the extent that might 
be expected for the degree of geometric magnification. It 
seems likely that the degradation of the image was due to 
the thickness of soft tissue used, but this could not be 
demonstrated convincingly with the 07-541 test pattern. 
In general, although lateral resolution can be improved 
by the elevation of the object, there is a limit. As an 
object is moved toward the source of a fan beam, the 
beam is concentrated on a smaller target area, increasing 
the localized dose. Additionally, if the object is of finite 
depth, layers of the object at different depths are 
magnified by different amounts, so producing a 
penumbra (area of partial shadow) around the object. 
The width of the penumbra depends on the thickness of 
the object and the width of the focal spot, as well as the 
distance from the object to both the source and the 
detector. Penumbra, projection and radiation dose 
increase as an object approaches the source. Optimal 
lateral resolution is therefore a balance between the 
positive influence of the projection effect against the 
negative factors of the penumbra effect and radiation 
dose. The manufacturer's default bed heights for each 
scan mode place the region of interest at an imaging 
plane determined, presumably, from consideration of 
these factors.
Unexpectedly, the longitudinal resolution also showed 
some improvement witfi bed elevation, most noticeably 
with the range of resolutions achieved with the AP spine 
and femur investigations. This was most probably due to 
scatter, as the AP spine and femur investigations 
included the greatest thickness of soft tissue. Resolution 
is degraded when a photon interacting with an object is 
deflected rather than absorbed, and still reaches the 
detector. If the angle of deflection is too great, the 
photon misses the detector altogether, so is not present in 
the final image. As the distance from the detector to the 
object decreases, the range of angles of scattered photons 
reaching the detector is increased, reducing resolution. 
The longitudinal resolution is therefore dependent on 
detector element length and scan speed, as well as the 
object's distance from the detector and relative 
attenuation characteristics.
Clinically, resolution is important for both BMD and 
morphometric studies. BMD studies employ an edge
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detection algorithm to differentiate between bone and 
soft tissue, but the efficacy of the algorithm is limited by 
the resolution. Poor resolution produces a coarse 
representation of bone edges, leading to a potential 
misidentincation by the automated point-typing algo­ 
rithm. Higher-resolution densitometry systems should 
therefore provide better estimates of bone area. This has 
been demonstrated by Barenholdt et al. [7], who found a 
better bone area estimate for the Expert than for the 
QDR 4500, although other factors may still be involved. 
Vertebral morphometry studies depend on good resolu­ 
tion to adequately identify the edges of the vertebral 
bodies. A large-scale MXA reference data study by Rea 
et al. [8] compared MXA with radiography and found 
some difference with corresponding wedge and bicon­ 
cave ratios, but not with crush ratios. In addition, they 
also reported small but statistically significant differ­ 
ences between the DXA systems used (three Hologic 
QDR 2000+ and one QDR 4500). Two phantom-based 
studies at this center have demonstrated that the Expert- 
XL underestimates the severity of biconcavities by an 
average of 8% [9], and furthermore that small angles of 
spinal malalignment (2.5°) can produce an increase in 
the measured vertebral height [10]. The system 
resolution was identified as a potential cause of both 
errors. Resolution varies between modalities (MXA and 
radiography) and between DXA systems; therefore 
machine-specific MXA reference data may be required. 
The resolutions across the width of the fan beam that 
might be expected using the Expert-XL at the respective 
default bed heights are 0.9 Ips/mm for the AP spine and 
femur, and 1.0 Ip/mm for the hand, forearm and vertebral 
morphometry investigations. For the fast scan speed, the 
longitudinal resolutions at the respective default bed 
heights are 0.8 Ips/mm for die AP spine, 0.9 Ips/mm (at 5 
mA) or 0.8 Ips/mm (at 2 mA) for the AP femur, 1.0 lp/ 
mm for the hand and forearm, and 0.7 Ips/mm for 
vertebral morphometry. Using the turbo scan speed, the 
longitudinal resolution is always poorer than 0.6 Ips/mm, 
irrespective of the site of interest. The maximum lateral 
and longitudinal resolution achieved by this investiga­ 
tion is 1.2 Ips/mm, equivalent to 0.83 mm, but only the 
lateral resolution of forearm scans with the bed at 
maximum elevation consistently achieves this level. The 
resolution attained with the machine at this district 
general hospital does not concur with the 2-1.6 Ips/mm 
(0.5-0.625 mm) reported by the manufacturer, but the 
resolution achieved is superior to that of the DPXL 
pencil beam densitometer. However, even at the highest 
bed elevation, the measured resolution of the Expert-XL 
does not approach the approximately 3.5 Ips/mm (0.29 
mm) resolution reported for lateral spine radiography by 
Felsenberg et al. [5]. When considering use of improved 
DXA technology for morphometric purposes, determina­ 
tion of the resolution should be considered as part of the 
validation procedure.
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Abstract. Dual-energy x-ray absorptiometry (DXA) is a precise, widely used method for 
measuring bone mineral density (BMD). usually of the lumbar spine and femora] neck. Recent 
developments, such as a lower x-ray tube current and pixel by pixel analysis, enable smaller 
bones and thinner tissue volumes, as in the hand, to be measured. Measurements of hand 
bone mineral content (BMC) and BMD could be useful in assessing disease severity in 
early rheumatoid arthritis and in monitoring disease progression and response to therapeutic 
intervention. A. phantom is required for evaluating the software, measuring long-term precision 
and comparing with other DXA methods.
This note describes the design and evaluation of a hand phantom for use on a Lunar DPX- 
L dual-energy x-ray absorptiometer. The phantom consists of three sections represeming the 
metacarpals, and proximal and distal phalanges, using aluminium and Perspex as the bone and 
lean tissue equivalents respectively. The BMD of the three sections is approximateiy 1.0, 0.6 
and 0,3 g cm"2 . The phantom demonstrates limitations in the potential accuracy of BMD 
determination at low densities using the Small Animal Software on the Lunar DPX-L. Improved 
recognition of low-density regions was obtained with the Lunar EXPERT with precision values 
of 0.9, I.I and 2.0% for the three sections of the phantom respectively.
Keywords: hand, phantom, bone densitometry, DXA
1. Introduction
Dual-energy x-ray absorptiometry (DXA) is a precise, widely used method for measuring 
bone mineral density (BMD, g cm~2) to assess osteopenia and osteoporosis, usually of the 
lumbar spine and femoral neck. DXA is based on the attentuation of two x-ray energies 
by the body. The degree of attenuation depends on the beam characteristics in addition to 
the thickness and density of the material through which the rays pass. The theory of DXA 
assumes that there are only two substances in the region being measured, i.e. bone and soft 
tissue, requiring therefore two different energies to allow discrimination. The soft tissue 
is assumed to be of constant composition within the region being measured. The x-ray 
energies are chosen to optimize the differential attentuation between bone and soft tissue 
while minimizing the radiation dose to the patient. The optimal energies are 40-45 keV for 
the lower-energy photons and 75 keV for the higher (Rutt 1985). The DXA system in our 
centre, the Lunar DPX-L, uses a tube current of 750 or 3000 fj.A. for performing scans of the 
lumbar spine and femoral neck. The analysis software identifies the regions of interest, for
§ Correspondence address: Centre for Metabolic Bone Disease, H S Brocklehurst Building, Hull Royal Infirmary, 
220-236 Anlaby Road. Hull HU3 2RW. UK.
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which BMD values will be calculated, and the soft-tissue baseline, to enable the attenuation 
due to soft tissue to be subtracted from the calculation. A minimum of 12 cm soft tissue 
throughout the scan region is required to calculate correct tissue baselines (Lunar). Recent 
developments in DXA such as a lower tube current of 150 //A and pixel by pixel analysis 
enable smaller bones and thinner tissue volumes to be measured.
The software available for the Lunar DPX-L machines utilizing these developments is 
called Small Animal Software and is intended for research use in assessing BMD, BMC 
(bone mineral content) and area of total body or appendicular bones in small animals. This 
software is designed for animals of 0.15-5 kg but with a minimum of 3.8 cm tissue depth 
within the region being measured for total-body composition (Lunar). This suggests that 
soft-tissue equivalent material may need to be added when using this technique for the 
human hand. Measurement of hand BMC and BMD could be useful in assessing disease 
severity in early rheumatoid arthritis, in monitoring disease progression and response to 
therapeutic intervention (Deodhar et al 1994, Peel et al 1994, Florescu et al 1993). A 
phantom is required for evaluation of this software for use in the measurement of BMC and 
BMD in the human hand, for measuring long-term precision and for comparison with other 
DXA methods.
An aluminium spine phantom is supplied with the Lunar DPX-L. This is a 16 cm x4 cm 
block of aluminium of varying thickness representing the first four lumbar vertebrae. The 
lowest BMD of this phantom is approximately 0.9 g cm""2 and the phantom has raised edges 
to facilitate edge detection. This, therefore, cannot assess the precision of the system in the 
range of BMD encountered in the human hand and does not provide the same challenge 
to the edge detection algorithm as the small, almost rounded phalanges. The European 
Spine Phantom (ESP), although being anthropomorphic in shape with respect to the spine, 
is not designed to approximate the situation in the hand. Consequently, the lowest BMD 
(0.5 g cm~2) is also too high and the soft-tissue equivalent block in which the vertebral 
components are imbedded provides soft-tissue attenuation which approximates that of 20 cm 
of human tissue, far more than is present in the human hand. The European Forearm 
Phantom (EFP) is similarly designed to approximate the forearm. Again, the BMD of 0.5- 
1.5 g cm~2 does not encompass the lower values found in the hand. This paper describes 
the specification and design of a hand phantom for use with the Lunar DPX-L Small Animal 
Software and includes results of measurement on the Lunar DPX-L and the newer Lunar 
EXPERT fan beam densitometer.
2. Methods and results
2.1. The Hull hand phantom
2.1.1. Phantom requirements. The aim was to design a phantom to assess precision and 
linearity of the system at low BMD values (0.3-0.9 g cm"2). A simple geometric shape 
was desired rather than an anthropomorphic one as the phantom is also required to monitor 
long-term precision. A more complex shape would introduce more operator variability at 
the analysis stage. It was decided with this pilot design to use a mean of 3.8 cm of soft- 
tissue equivalence as recommended. This also enabled us to correlate the results with those 
of the forearm software on the same machine.
2.1.2. Choice of materials. The phantom was constructed from two materials simulating 
homogeneous soft tissue and bone mineral respectively. The choice of material was 
based upon the attenuation co-efficients, availability, construction considerations and cost.
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Aluminium was chosen as the bone mineral substitute. The ratio of the mass attenuation 
co-efficient (|t//o) for aluminium to bone mineral is about 0.9 at x-ray energies of 10 keV- 
1 MeV. Perspex was chosen as the soft tissue and bone marrow substitute. The ratio of 
mass attenuation co-efficient for Perspex to lean tissue rises from 0.8 at 35 keV to 1.04 at 
1 MeV (HPA 1977). Perfect tissue substitutes would have ratios of 1.0.
2.7.3. Design and construction. The design consists of aluminium tubes with a Perspex 
core simulating bone marrow within the medullary cavity. Hollow cylindrical tubes were 
chosen so as to mimic the cross sectional attenuation profile of the metacarpals and 
phalanges. The ability of the software to correctly detect the edges of a structure, closely 
resembling that encountered in the bones of the hand, can thus be tested. The relative 
diameters of aluminium tubes to Perspex rod were determined experimentally to give BMDs 
of about 0.8, 0.5 and 0.2 g cmT2 . The external dimensions of the 3 sets of tubes are 
20 mm x 100 mm, 15 mm x 50 mm and 12 mm x 50 mm. These are embedded in a 
Perspex block to ensure mean equivalent soft tissue thickness of 3.8 cm as recommended 
when using the Small Animal total-body mode (Lunar). The phantom consists of three 
sections, representing the metacarpals, proximal phalanges, and middle and distal phalanges. 
Each section was also designed to be of different BMD representing the healthy normal and 
early and late stages of rheumatoid arthritis.
Figure 1. A photo of the hand phantom positioned on the DPX-L couch.
The phantom was constructed from a single block of Perspex drilled for insertion of 
the aluminium tubes (figure 1). Perspex spacers are positioned between the three sets of 
tubes, simulating the joint spaces. The dimensions of the aluminium tubes, and the inter- 
tube dimensions are, of course, known and this enables checking of the accuracy of, for 
example, measurements of joint spaces.
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Figure 2. A DPX-L image achieved using Small Animal Software in high-resolution, slow 
mode with the three regions of interest identified.
2.2. Hand phantom measurement on a Lunar DPX-L
The phantom was placed directly on the scan table, aligned with the central axis and 
scanned using the Lunar Small Animal total-body software on a Lunar DPX-L, Ten scans 
of the phantom were performed over a period of 2 weeks using detail medium- and detail 
slow-scan modes. The scan and processing time involved using the other scan modes (high- 
resolution medium and high-resolution slow, of 45 min and 1 h respectively) was considered 
prohibitive in terms of the additional information this would provide. Only five scans were 
performed for the latter two modes, each over a period of 1 week. Analysis was performed 
using rectangular regions of interest placed over the three sections of the phantom. The 
regions of interest were of the same dimensions and locations on all scans (figure 2). The 
mean (standard deviation) BMD of the high-density region rises from 0.947 (0.021) g cm"2 
using detail medium-scan mode to 0.990 (0.003) g cm"2 using the high-resolution slow-scan 
mode. There is a similar rise in the BMD of the medium-density area from 0.564 (0.019) to 
0.609 (0.004) g cm"2 . The BMD for the low-density area falls from 0.310 (0.008) to 0.266 
(0.003) g cm"2 using the detail medium and high-resolution slow mode respectively. The 
mean BMDs and precision, as percentage coefficients of variation, are shown in table 1. 
The mean values for the BMC of all three regions increased slightly from detail medium to 
high-resolution slow mode (table 2). The area within each region of interest defined by the 
software as containing a bone equivalent material is shown in table 3. The actual projected 
areas were 62.4 cm2 for region one, 22.76 cm2 for region two and 17.29 cm2 for region 
three.
BMD measurement of the forearm using DXA is an accepted, widely used procedure. 
For comparison, the hand phantom was also scanned using the forearm software (fast speed) 
on the same machine. The forearm acquisition mode uses the same tube current of 150 /tiA 
and pixel size of 0.6 by 1.2 as the Small Animal high-resolution slow mode. The phantom
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Table 1. Mean (standard deviation) and precision (% CV) of BMD for the three regions of 

































































Table 2. Mean (standard deviation) and precision (% CV) of BMC for the three regions of 















































Table 3. Mean (standard deviation) and precision (% CV) of measured area for the three regions 
of interest assessed using the four scan modes of the Lunar Small Animal Software. Actual 















































was scanned with and without the Delrin forearm positioning plate. By fixing the scan 
width to encompass only two of the aluminium rods, mimicking the radius and ulna, the 
phantom was suitable for use with the forearm analysis software. Rectangular regions of 
interest were positioned over the highest-BMD section (metacarpal), yielding BMD values 
of 0.767 and 0,755 g cm"2 with and without the positioning plate respectively. These are 
significantly lower than the BMD value of 0.992 g crrr2 obtained for the same region using 
the highest-resolution scan mode within the Small Animal Software.
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2.3, Hand phantom measurement on a Lunar EXPERT
The Lunar EXPERT calculates BMD values using dual-energy x-rays as for the Lunar 
DPX-L machine but, using a higher tube current and smaller sampling size, producing 
high-resolution images of almost radiographic quality. This system has acquisition and 
analysis capabilities specifically for the hand. The hand phantom was placed on the forearm 
positioner and scanned using the 1 /zA fast mode with the table set at the manufacturer's 
recommended height. Analysis was performed using three rectangular regions of interest 
as for the DPX-L (figure 3). The analysis software on the EXPERT machine incorporates 
a facility to display the characterization of individual pixels, i.e. whether the software has 
coded them as bone, soft tissue, air, neutral or artefacts. Any pixel incorrectly characterized 
can be manually redefined.
Figure 3. An EXPERT image achieved using hand acquisition mode with the three regions of 
interest identified.
The Lunar EXPERT correctly categorized all pixels as being bone or soft tissue and 
no adjustments were required. The hand phantom was scanned daily over 23 weeks on 
the EXPERT machine: the mean BMD (precision, CV %) values are 0.972 g cm-2 (0.9%) 
for the metacarpal region, 0.646 g cm""2 (1.1%) for the proximal phalanges region and 
0.292 g cm"2 (2.0%) for the distal phalanges region.
3. Discussion
Using Lunar Small Animal Software on the DPX-L, the BMD for the metacarpal and 
proximal phalanges regions increases slightly with increasing resolution of the measurement 
but that for the distal phalanges region decreases. The mean precision (% CV) for each scan 
mode was 2.7% for detail medium, 2.6% for detail slow, 0.43% for high-resolution medium
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and 0,69% for high-resolution slow. The difference in BMD between the different scan 
modes may be due to a difference in measured BMC and/or area. The bone mineral content 
of the three regions follows a similar pattern with a slight increase with increasing resolution. 
This may be due to the partial-volume effect of the larger pixels of lower-resolution scans 
containing part bone and part soft tissue at the boundaries.
The areas determined by the software to contain bone or bone equivalent material 
within the metacarpal region of interest and the proximal phalanges region of interest were 
approximately equal to the actual areas of aluminium within each of those regions using 
ail four scan modes. The software thus appears to correctly identify the boundaries of the 
aluminium tubes in these two regions of the phantom having BMD of approximately 0.95 
and 0.6 g cm""2 . However, the areas determined for the distal phalanges region, of actual 
area 17.3 and BMD of 0.3 g cm"2 , were at best an underestimate of 21% (13.6 cm2 ) and 
at worst 62% (6.5 cm2 ). The system, therefore, is not defining the whole of the aluminium 
tubes within this area as 'bone' and, as BMD is BMC/area, the measured BMD may also be 
inaccurate. As the software does not enable display or adjustment of pixel categorization, it 
is difficult to determine whether the error is occurring at the outer edges or in the Perspex 
filled centre of the tubes and there is no mechanism to correct for it. The density of these 
smaller tubes appears to be below a software defined bone threshold on the DPX-L machine.
The Small Animal high-resolution slow mode and forearm software (fast) use ihe same 
tube current of 150 ,uA and pixel size of 0.6 mm x 1.2 mm and the software determined 
areas in each case are similar to the actual area. However, there is a significant difference 
in the estimate of BMD between the forearm and Small Animal Software.
Using the point typing facility on the Lunar EXPERT it was possible to confirm that 
all the aluminium components of the hand phantom were correctly identified as being bone 
pixels even at densities as low as 0.3 g cm""2 . The long-term precision as percentage 
coefficient of variation for the high-, medium- and low-BMD regions over a period of 23 
weeks was 0.9, 1.1 and 2.0% respectively. The BMD estimated by the Lunar EXPERT is 
similar to that of the DPX-L for both the metacarpals and distal phalanges. However, the 
BMD of the proximal phalanges region appears significantly higher on the EXPERT. Due 
to inaccuracies noted in area determination on the DPX-L, this discrepancy is more likely 
to be due to an underestimate of BMD on that machine.
4. Conclusion
The hand phantom described covers the range of BMD likely to be experienced in clinical 
practice and enables monitoring of precision and linearity at these low densities. It was 
designed for use on the Lunar DPX-L but should be suitable for dual-energy x-ray machines 
using similar x-ray energies. Studies are now under way involving the measurement of this 
phantom on a range of machines. It is not designed as a truly anthropomorphic phantom 
and cannot be used to assess accuracy of BMD measurement as it has not been calibrated 
against standards of known bone density.
The phantom demonstrates some limitations in the potential accuracy of BMD 
determination at low densities using the Lunar DPX-L. A facility to display profiles, as is 
available with DPX-L AP spine software, or point typing as on the EXPERT, could enable 
these errors to be detected and corrected. The phantom also demonstrates differences in 
BMD when estimated using different software packages on the Lunar DPX-L.
The Lunar EXPERT correctly identifies all aluminium components as being bone pixels 
even at densities as low as 0.3 g crrT2 with a precision of 0.9-2% at the range of BMD 
values used in the phantom.
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tract. Morphometric X-ray absorptiometry (MXA) 
ides the potential to assess vertebral deformity using 
dinique with much lower radiation dose to the 
jnt than standard radiographic procedures. MXA
•comes many other limitations such as cone beam 
3rtion observed in conventional plane radiographs. A 
itom has been designed to assess the accuracy of the 
A technique, to monitor long-term precision and to 
ss inter- and intra-operator variability. The phantom 
sists of two columns of 12 cylinders representing the 
ebral bodies, one of regular components and one 
esenting vertebral deformities. Each column may be 
rted, as required, into a Perspex torso-mimicking 
:k. Initial assessment on the Lunar Expert-XL 
lonstrates that the phantom provides image para- 
ers reflecting those found clinically. Measurement of 
ebral height was found to be consistently under- 
mated by 4.9%. Operator precision ranged from 0.6% 
posterior height measurement to 1.0% for middle 
;ht measurement of the regular component column. 
| corresponding precision range for the column 
resenting vertebral deformation was 0.6% (posterior) 
1.1% (middle). Analysis of 10 scans of each column 
two independent operators demonstrated a few 
lificant differences in height assessment confined to 
'thoracic' region of the regular column. However,
•r-operator variability was found to increase with 
teasing complexity of vertebral shape producing 
eral differences, particularly in posterior height 
3ssment of the deformed column.
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Introduction
Osteoporosis-related fractures usually occur in the wrist, 
hip or spine. Those of the wrist and hip are usually 
readily confirmed using standard X-ray procedures, but 
those of the spine rarely present for clinical diagnosis. 
Vertebral deformity fractures are identified as a change 
in vertebral shape and may be classified as wedge, 
biconcave or crush and as grade 1, 2 or 3 [1,2] (Fig. 1). 
The grading may be based on percentage reduction in 
anterior, middle and/or posterior height [1], deviation 
from a denned normal range [2] or as a ratio of height to 
predicted height based on that of adjacent vertebrae [3]. 
Generally a 25% reduction in height or 3 SD from 
normal or predicted values is used as the cut-off point for 
defining a fracture.
The standard method of assessing vertebral deformity 
using lateral radiographs of the lumbar and thoracic 
spine is associated with a radiation dose to the patient of 
about 800 uSv [4]. Two exposures are necessary due to 
differences in attenuation in the lumbar and thoracic 
regions. The images produced are prone to magnification 
and distortion due to the cone beam geometry. The 
consequent elliptical appearance of the upper and lower 
borders of each vertebra and the relative distortion of 
vertebral height can make measurement problematic and 
therefore assessment of vertebral compression difficult. 
Patients are placed in the decubitus position for this 
technique making positioning difficult and repeat films
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Fig. 1. Classification of vertebral deformities.
frequent, which adds to the radiation dose. Interpretation 
of lateral spine radiographs is generally a visual semi- 
quantitative assessment by a radiologist. More quantita­ 
tive assessment may be performed by digitizing the 
radiograph and obtaining the anterior, posterior and 
mid-vertebral height, and several studies have investi­ 
gated the correlation with readings performed by 
radiologists [5,6].
The recent development of morphometric X-ray 
absorptiometry (MXA) potentially overcomes some of 
the limitations of conventional plane radiographs. One of 
the machines providing this capability is the Lunar 
Expert-XL (Lunar, Madison, WI). This uses a fan beam 
of X-rays and a solid state detector. The X-ray tube and 
detector assembly are mounted on a C-arm which may 
be rotated to enable lateral imaging of the spine with the 
patient in a supine position, hence reducing distortion 
due to vertebral sagging in the lumbar region sometimes 
seen on conventional X-ray images. The C-arm scans 
axially from the level of L5 up to T4 producing a single 
image of the spine, making identification of vertebral 
levels easier. The superior to inferior distortion with this 
method should be negligible and any anteroposterior 
(AP) magnification should not interfere with assessment 
of vertebral height. We have assessed the effective dose 
from this technique to be 71 u.Sv [7], about 9% of that 
for conventional lateral spine radiographs. However, due 
to the lower resolution of the Expert-XL of approxi­ 
mately 1 line pair per millimeter (measured on our 
system), compared with the 3.5 line pairs per millimeter 
of conventional radiography [8], X-ray images are 
considered mandatory where other pathology is sus­ 
pected.
A phantom is required to assess the accuracy of the 
MXA technique, to monitor long-term precision and to 
assess inter- and intra-operator variability. Currently 
there is no suitable phantom available. The aluminum 
spine phantom supplied with the machine is in the form 
of a step wedge and designed to measure accuracy and 
precision of AP bone mineral density (BMD) only. The 
more anthropomorphic Hologic spine phantom (Hologic, 
Waltham, MA) is similarly designed for assessment of 
AP BMD and, although when viewed laterally has the 
appearance of normal vertebrae, the components are of 
uniform density and would not provide a clinically 
representative image for morphometric analysis. Also, 
only four vertebrae (LI to L4) are represented in the 
phantom. The European Spine Phantom simulates only 
LI to L3 [9] and Felsenberg et al. [8] found the image 
quality obtained not entirely suitable for morphometry. 
All three of these phantoms have insufficient vertebrae 
for a full MXA procedure.
A phantom for use in MXA should be constructed of 
materials with similar attenuating properties to bone and 
soft tissue at the X-ray energies used. The design of the 
phantom should reflect clinically observed vertebral 
shape and range of deformities. It should enable 
validation and monitoring of the dependent parameters 
for MXA. These include mechanical parameters such as 
the alignment of the X-ray tube and detector, rotational 
position and longitudinal movement of the C-arm and 
registration of the image. Misalignment of the X-ray 
tube, in addition to affecting image quality, may result in 
the X-ray beam becoming non-parallel to the endplates 
of the vertebrae. This would result in an overestimate of 
vertebral height on morphometric images. The same 
effect would occur with misalignment of the C-arrn 
relative to the central axis of the bed. If alignment 
changes with time, it may affect longitudinal assessment 
of vertebral deformity. Changes in the speed of 
movement of the C-arm during the scan procedure or 
in the system's image registration could result in 
misdiagnosis of vertebral collapse. For example, if the 
synchronization ratio between image position and actual 
position is correct at the beginning of the scan (1:1) but 
changes during the scan to a ratio of 1:2 at the end, then 
the thoracic vertebrae will appear foreshortened by a 
factor of 2.
Reproducibility of bed height should have minimal 
effect on vertebral height assessment but may result in 
distortion of the vertebral shape relative to a previous 
scan. Finally, in cases of vertebral deformity, accuracy 
confirmation is required, i.e., that the degree of wedging 
or collapse determined from the anterior/posterior or 




The phantom consists of three components: two 
aluminum and Perspex insert columns and a Perspex 
block with a drilled core (Fig. 2). The columns are 
constructed of 12 cylinders of aluminum, with phosphor- 
bronze endplates and a Perspex core, interspersed with 
Perspex disks. Aluminum was chosen for its bone- 
equivalent attenuation properties at the X-ray energies 
used and phosphor-bronze for its higher density and 
machinability to achieve thin endplates. Sharply defined 
endplates are required to maximize image clarity for the 
assessment of precision. The thicknesses of aluminum 
and phosphor-bronze were determined experimentally to 
give a similar morphometric image appearance as seen 
clinically.
The first column (column 1) is designed to check 
alignment, positioning and mechanical movements of 
the bed and C-arm. The cylinders are of the same height,- 
28 (±0.05) mm, including the endplate thickness of 0.05 
mm (±0.005 mm), and are separated by an 'inter- 
vertebral space' of 7 mm. The second column (column
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lines on the bed. Scanning was performed using the 
standard Lunar Expert-XL MXA acquisition with a bed 
height of-15 cm and scan length of 49 cm. Each column 
was scanned 10 times with repositioning between scans. 
Analysis was performed using the standard semi- 
automated MXA technique with manual adjustment of 
endplate markers as required, with points being long­ 
itudinally adjusted to the middle of the brightest pixel 
rows of the vertebral endplates, as currently recom­ 
mended in the manufacturer's documentation. The scans 
were analyzed independently by two medical technical 
officers following the protocol recommended by the 
manufacturers. An image magnification of 300% was 
used to aid manual adjustment of the markers during 
analysis. To prevent fatigue errors, half the scans were 
analyzed from inferior to superior and half from superior 
to inferior.
Statistical Analysis
Analysis was performed using Microsoft Excel (version 
5.0). Precision is expressed as percent coefficient of 
variation (CV %) with incorporation of RMS values for 
standard deviation [11]. Inter-operator variability was 
determined using Student's paired /-test, with a p value 
of less than 0.05 considered significant.
fig. 2. a Phantom for use in morphometric X-ray absorptiometry. 
i Details of columns.
'.) consists of three sets of cylinders: four of decreasing 
leight, four of increasing anterior wedge and four of 
ncreasing biconcavity. The types and degree of 
leformities represent those found in the early stages of 
:stablished osteoporosis, as described by others [2,10]. 
Wore severe deformities were not represented as 
iiagnosis in these cases is generally beyond dispute. 
Each column may be inserted into the Perspex torso- 
mmicking block as required. Locating pins enable 
column 2 to be positioned at two predetermined angles 
relative to the plane of the X-ray beam, allowing the 
simulation of vertebral column rotation. All components 
of the phantom were carefully machined to ensure no air 
gaps, which could interfere with image quality by 
reducing X-ray attenuation in the 'soft tissue' regions.
The Perspex block incorporates radio-opaque markers 
at each end for monitoring X-ray beam alignment, C-arm 
position and bed height. An aluminum strip is 
incorporated posterior to the central core to simulate 
the posterior processes of the vertebrae.
Measurement
The phantom was placed along the central axis of the 
bed, mattress removed, with accurate positioning assured 
by aligning the locating markers with the positioning
Results
The mean BMD of the 'vertebrae', assessed using a 
standard AP spine scan, was found to be 0.97 g/cm2. 
MXA images of the two columns achieved with the 
Lunar Expert-XL are shown in Fig. 3. Using the semi-
Fig. 3. Images of column 1 (left) and column! (right) obtained using 
the Lunar Expert-XL MXA.
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automated analysis it was found that the software did not 
place the circular locating markers in the centre of the 
'vertebrae'. The markers were generally placed anterior 
to the vertebrae and were incorrectly spaced, particularly 
in the upper part of the phantom corresponding to the 
thoracic region (Fig. 4). Manual adjustment was hence 
required to centralize the markers. The software then
41
uses edge detection algorithms to locate the endplates 
and place identification points at the corners of each 
vertebra and in the centre of each endplate. Although the 
images are clearer than those often seen in clinical 
practice, the point placement was inaccurate and 
required manual adjustment to all 'vertebrae', again 
particularly in the 'thoracic' region. However, in our
Fig, 4. Stages during MXA standard analysis showing: a automatic placement of circular locating markers, b subsequent automatic placement of 

















Fig. 5. Measured heights (mean ± SD) for each component of column 1 compared with actual heights. Results shown are the mean of anterior, 
middle and posterior heights from 10 scans performed using the Lunar Expert-XL MXA.
perience, the Lunar semi-automated analysis techni- 
e makes similar errors with clinical images, frequently 
sidentifying vertebrae and misplacing identification
ints.
The mean heights (anterior, middle and posterior) of 
luirm 1 were on average 1.4 mm (4.9 %) ± 0.8 mm 
is than the actual heights (Fig. 5). The height and 
jcision of anterior, mid and posterior height for each 
rtebra are shown in Table 1. There were few 
>nincant differences in height assessment between 
; operators for column 1, with those that were 
served tending to be associated with the upper thoracic 
rtebrae.
ble 1. Mean and precision (CV%) of measured heights determined 
each operator for column 1
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For column 2, expected ratios were calculated for each 
of the deformities. The degree of crush deformity was 
determined as a ratio of the posterior height to the mean 
measured height of L4 (non-compressed), for wedge 
deformities as anterior/posterior height and for bicon­ 
cave deformities as middle/posterior height. The crush 
deformities (L4 to LI) were generally overestimated by 
2% and the wedge deformities underestimated by 2%. 
On average, biconcavity was underestimated by 8% (Fig. 
6). Mean and precision of measured heights for column 2 
are shown in Table 2. There was found to be an increase 
in inter-operator variability, as would be expected, with 
the increased complexity of shape. Several significant
Table 2. Mean and precision (CV%) of measured heights determined































































































































































































































































































































































































































































































NK phantom was scanned 10 times with repositioning on a Lunar 
ixpert-XL and analyzed using semi-automated MXA analysis 
'P<0.05; **p<0.01 using paired r-test.
Actual heights are given in the table. The column was scanned and
analyzed as per column 1.
*p<0.05; **p<0.01 using paired Mest.
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(Ratio = Middle : Posterior)
Wedge Deformities
(Ratio = Anterior: Posterior)
Crush Deformities
(Ratio = Posterior: Mean L4)
Fig. 6. Measured height ratios (mean + SD) form MXA of column 2 compared with actual: middle/posterior (biconcavities), anterior/posterior 
(wedges), posterior/posterior height L4 (crush),
differences were found in vertebral height measurement, 
particularly in posterior height assessment.
Discussion
A phantom has been designed that is suitable for 
determining the accuracy and precision of MXA 
vertebral height assessment and for monitoring long- 
term equipment stability. The phantom was designed for 
use on the Lunar Expert-XL but should be suitable for 
similar MXA machines and could provide a comparison 
with radiographic morphornetric procedures. This is not 
a truly anthropomorphic phantom and has not been 
designed to validate the aspects of the proprietary 
software concerned with comparison to reference data. 
However, the phantom could be used to investigate inter- 
machine variability, which is a critical factor where 
reference data are to be accumulated or multicenter 
studies conducted.
The columns currently constructed have BMDs in the 
osteopenic range. MXA images obtained in osteoporotic 
subjects are generally of poorer quality, making analysis 
more difficult and reducing precision. However, the 
modular design of the phantom enables the construction 
and insertion of columns representing a range of 
densities and deformities, as found in clinical practice.
MXA of the phantom on the Lunar Expert-XL 
demonstrates incorrect placement of the circular locating 
markers by the semi-automated analysis. This suggests
that the software is making assumptions about the shape 
of the vertebral column and relative dimensions of the 
vertebrae. Once the markers are manually adjusted to the 
correct location, the edge detection process places the 
endplate markers. The well-defined vertebral endplates 
on the image enabled accurate manual adjustment of the 
points where required.
Measurement of anterior, posterior and middle 
vertebral heights was consistently underestimated. This 
differs from the findings of Felsenberg et al. [8], who 
reported a mean overestimation of about 1.7% in 
vertebral height assessment on the Lunar Expert from 
MXA images of the European Spine Phantom. This may 
have been due to different scattering properties of the 
materials, but is more likely due to a difference in the 
protocols for the positioning of vertebral marker points. 
The observed underestimation of vertebral height may 
not be clinically significant, as the degree of vertebral 
deformity is generally determined relative to the heights 
of L2 to L4. However, this may have implications for the 
establishment of reference data. Normative data estab­ 
lished by radiographic technique would have to be 
appropriately scaled. If reference data were to be 
accumulated on MXA machines, it would be important 
to ensure the comparability of results both within and 
between systems.
Mean precision of vertebral height measurement in 
vitro was found to be 0.84%. Using the method 
described by the British Standards Institution [12], a 
change in vertebral height of 2.38% would be required in
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er to be reliably detected. This represents a mean 
nge in vertebral height of 0.7 mm, which corresponds 
htheMXA image pixel size (0.7 mm x 0.5 mm) on 
Lunar Expert-XL.
ncreasing complexity of vertebral shape caused a 
rease in accuracy and an increase in inter-operator 
iability. In particular, placement of points at the 
iter of the endplate of a biconcavity was found to be 
st accurate, producing an underestimate of deformity. 
;o, location of the center of a wedged component is 
ijective and any AP displacement will directly 
luence height assessment.
The initial findings using this phantom suggest that the 
aar Expert-XL MXA technique provides a precise 
asure of vertebral height. Defined protocols for 
irphometric analysis may reduce operator variability, 
ihough the absolute heights are underestimated, this is 
t considered detrimental as it is the ratio of heights 
it defines the morphometric status. If reference data 
: to be accumulated or multicenter studies conducted 
these machines, such a phantom may be required to 
;ess inter-system performance and provide cross- 
iibration.
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A phantom based study on the effect of subject 
positioning on morphometric X-ray absorptiometry 
using the Lunar EXPERT-XL
J A THORPE, MSc, BSc, S A STEEL, MSc, BSc and C M LANGTON, PhD
Centre for Metabolic Bone Disease, Royal Hull Hospitals NHS Trust and University of Hull, 
Hull Royal Infirmary, Anlaby Road, Hull HU3 2RW, UK
Abstract. Morphometric X-ray absorptiometry (MXA) relies on accurate measurement of vertical 
dimensions of vertebrae from a lateral perspective. Deviations resulting from scoliotic curvature 
or poor patient positioning produce distortions of visible vertebral dimensions and may lead to 
analysis error. This study utilized a phantom developed at this centre to assess the effect of 
vertebral malalignment on the accuracy of the MXA technique on the Lunar Expert-XL. Measured 
vertebral heights were found to be consistently underestimated by an average of 3.7%. Precision 
ranged from 0.79% for anterior height measurement to 1.03% for middle height measurement. 
Vertebral malalignment was investigated as the effect of rotation around the anteroposterior, 
lateral and superoinferior axes. Rotation around the lateral axis produced little discernible effect. 
However, superoinferior axial rotation showed a change of more than two standard deviations in 
the mid/posterior ratios of biconcave vertebrae at comparatively small angles of rotation. 
Anteroposterior axial rotation produced an increase in observed height at small angles of rotation, 
and a rapid decrease in vertebral height as rotation increased. The results suggest that whilst 
kyphosis or lordosis of up to at least 5.8° has a minimal effect on MXA, scoliosis of 4.6° or above 
produces a distinctive effect on the defining crush height ratios.
Osteoporosis is a degenerative bone disease 
resulting in increased porosity and thinning of 
bone. Individual trabeculae may erode sufficiently 
to cause perforation with the resultant loss of 
supporting trabecular structure, greatly reducing 
mechanical integrity. This leads to a significantly 
increased risk of fracture, particularly in bones 
with a high trabecular content and stress bearing 
role such as the femur, radius and vertebrae. 
Studies have shown that vertebrae are likely to be 
the first sites of osteoporotic related fracture [1] 
and, unlike those of the femoral neck or radius, 
only about one-third of affected individuals present 
for clinical attention [2].
Examination of vertebral shape rather than den­ 
sity allows the assessment of the prevalence of 
vertebral fracture, which can aid the interpretation 
of bone mineral density (BMD) results, so assisting 
the overall assessment of the degree of osteopor- 
osis. Vertebral fractures can be qualitatively ident­ 
ified radiographically from a change in the 
vertebral shape but, without previous radiographs 
for comparison, identification must be made from
Received 12 February 1998 and in revised form 12 June 
1998, accepted 29 June 1998.
Funding for J Thorpe provided by the local osteoporosis 
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a comparison with other vertebrae on the same 
radiograph. Vertebral morphometry provides a 
quantitative method of assessing vertebral shape.
Vertebral morphometry depends on reliable 
measurement of vertebral height at three positions 
on the vertebrae: anterior, middle and posterior; 
with each height calculated from defining points 
positioned by the operator. Ratios defining the 
shape of the vertebrae are derived from these 
heights. Wedge and biconcavity deformations are 
defined by the ratios of the anterior/posterior 
heights and the middle/posterior heights, respect­ 
ively. Crush deformations are detected by compari­ 
son of the posterior vertebral heights with the 
posterior heights of reference vertebrae (normally 
the lumbar vertebrae). Typically, a 3 standard 
deviation (SD) [3] or a 20% [4] or greater 
reduction in a particular height ratio is classified 
as a fracture.
Vertebral morphometry may be performed by 
conventional radiographic means with an excellent 
resolution of approximately 0.1 mm [5]. However, 
the X-ray cone beam geometry produces images 
with both magnification and projection distortion, 
especially towards the edges of the film. The projec­ 
tion distortion gives the vertebral endplates an 
elliptical appearance that can make measurement 
awkward and therefore assessment of vertebral
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compression difficult. The reproducibility of the 
technique is also reduced by the difficulty of placing 
the patient in the decubitus position. Recent tech­ 
nological developments such as CT lateral scout 
scans may eliminate distortion and positioning 
problems, but at the expense of poorer resolution.
Vertebral morphometry may also be performed 
using the morphometric X-ray absorptiometry 
technique (MXA) provided on some dual X-ray 
absorptiometry (DXA) systems. The Lunar 
Expert-XL (Lunar Corporation, Madison, WI, 
USA) is an example of the latest generation of 
DXA imaging densitometers, utilizing an X-ray fan 
beam and an array of solid state detectors, 
mounted on a C-arm to enable lateral imaging. 
The Expert-XL is capable of producing fast and 
high resolution images (40 s and 0.6 mm) of the 
thoracic and lumbar spine with the patient lying 
supine. MXA has a good patient acceptability and 
a low patient dose, 71 uSv for the Lunar Expert-XL 
[6], compared with typically 800 uSv for a stan­ 
dard lateral radiograph of the lumbar and thoracic 
spine [7]. The use of a fan beam overcomes the 
longitudinal distortion produced by a cone beam; 
whilst the supine patient position prevents the 
lumbar sagging that sometimes causes distortion 
in conventional X-ray procedures.
The Lunar Expert-XL software provides semi- 
automated analysis of the MXA image. Initially, 
circular location markers are automatically placed 
as labels for the vertebral bodies, then the vertebral 
endplates are located by an edge detection algor­ 
ithm. The software places three diamond shaped 
denning pointers on each vertebral endplate, one 
point at each end and a point in the middle. The 
operator is able to make adjustments at each stage, 
and once adjustments are complete, the MXA 
software provides a comparison with reference data 
and indicates position and type of vertebral 
deformity.
Vertebral morphometry and MXA depend on 
the accurate measurement of the vertical dimen­ 
sions of vertebra from a lateral perspective. 
Deviation from this perspective may result in
distortion of visible vertebral dimensions and hence 
produce an error in the image analysis. Deviations 
result from a combination of spinal curvature, such 
as scoliosis, and patient positioning. This could 
conceivably cause large deviations in measured 
vertebral heights, possibly leading to the misclassi- 
fication of vertebral compression by the automated 
software. Little work has been conducted on the 
effect of such factors on MXA. This has been due 
in part to the lack of an appropriate phantom that 
would allow a methodical investigation on the 
effect of projection angle on the results of clinical 
investigation. This study utilized a recently devel­ 
oped phantom [8] to assess the effect of patient 
positioning and spinal malalignment on the accu­ 




The phantom was developed in this centre to 
assess the accuracy and precision of MXA [8]. 
It consists of a Perspex block (15 cm x 15 cm 
x 50 cm), a drilled core and two interchangeable 
aluminium and Perspex columns (Figure 1). The 
Perspex block mimics the torso and the two col­ 
umns mimic vertebrae of varying morphometric 
characteristics. Each column contains 12 artificial 
vertebral bodies, each constructed from a cylinder 
of aluminium, with a Perspex core and phosphor- 
bronze endplates. The artificial vertebrae of the 
first column (column 1) are all 28 mm high by 
37 mm wide, representing the average dimensions 
of the lumbar vertebrae found in adult females. 
The 12 vertebral bodies of the second column 
(column 2) represent four varying degrees of crush, 
wedge and biconcavity fractures.
Simulation of vertebral rotation
The effect of vertebral malalignment on MXA 
was investigated by rotation of the phantom 
around three orthogonal axes (Figure 2). The
Figure 1. (a) Phantom for use in morphometric X-ray absorptiometry. (b) Details of columns.
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phantom was designed to be placed longitudinally 
on the bed, and rotation required the use of an 
underlying plastic board to correct for the lateral 
curvature of the scanning bed. For standardization, 
the sheet was used for all images and the mattress 
was removed. Positional reproducibility of ± 1 mm 
was achieved with the aid of location markers, the 
angle of rotation being calculated by trigonometry. 
The standard "lateral MM" acquisition mode was 
used throughout the procedure, with the longitudi­ 
nal starting position of the C-arm set at 7.6 cm, 
the scan length at 46 cm and the bed height at 
-14 cm. Images were analysed immediately after 
acquisition, allowing sufficient time for the X-ray 
tube to cool ready for the next acquisition.
For calculation of accuracy and precision and 
provision of comparative data for the rotational 
images, each column was placed within the phan­ 
tom block, with the block in an unrotated position. 
10 images were then taken of each column, with 
repositioning between each acquisition.
For rotation around the anteroposterior axis, 
the Perspex block was positioned on the plastic 
sheet with the block turned sideways a set amount, 
measured by 1 cm markings placed on the sheet 
(Figure 2a). Imaging was conducted at 1 cm inter­ 
vals between 0 and 7 cm and was repeated using 
both columns for both clockwise and anticlockwise 
rotation.
Only the wedged column was used for rotation 
around the superoinferior axis as the endplates of
BOTTOM
(b)
Figure 2. Diagram of the three axes of rotation investi­ 
gated, (a) Rotation about anteroposterior axis (above 
view), (b) Rotation about superoinferior axis (end view), 
(c) Rotation about lateral axis (side view).
the straight column would always present the same 
profile to the X-ray beam. The wedged column 
was rotated both clockwise and anticlockwise 
within the phantom block, with imaging being 
conducted between 1 and 5 cm around the circum­ 
ference of the bore of the block, at intervals of 
1 cm (Figure 2b).
Rotation around the lateral axis was achieved 
by the elevation of the superior end of the phantom 
with Perspex sheets of known thickness. Additional 
Perspex was placed in the underlying airspace to 
prevent artefact. Imaging was conducted with both 
columns at elevations of 1-5 cm and increments of 
1 cm (Figure 2c).
Image analysis protocol
MXA images of the two columns are shown in 
Figure 3. In the clinical situation, images are indi­ 
vidually adjusted to optimize the display for analy­ 
sis, thus the manufacturer (Lunar Corporation) 
does not give recommended display parameters. 
However, as this was a phantom investigation, a 
more rigid protocol was adopted to help stan­ 
dardize the procedure and minimize operator error. 
For analysis, the upper and lower values of dis­ 
played pixels were adjusted, so that edges of the 
vertebral bodies resolved as only single column 
thickness of white (maximum value) image pixels. 
For our system, this corresponded to upper and 
lower values of 6275 and 8000, respectively, with
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Figure 3. Images of column 1 and column 2 obtained 
using Lunar Expert-XL MXA.
pixels below this range displayed as black, and 
those above displayed as white. Brightness and 
contrast modification controls were both set to 
zero. The homogeneity of the phantom gave a 
narrower range of pixel values; clinical images 
typically cover a wider range of around 4000 to 
around 14000.
Images were displayed on a 54 cm Dell monitor 
and analysed under subdued lighting conditions 
by a single operator. To prevent fatigue from 
affecting operator variability during analysis, suc­ 
cessive images were alternately examined from the 
top of the image to the bottom and from the 
bottom of the image to the top.
Following the manufacturer's recommendations, 
the circular location markers were manually 
adjusted into position over the centre of the ver­ 
tebral bodies, with extra markers added if required. 
The positions of the denning pointers were also 
adjusted where required. For point adjustment, a 
more rigid protocol was used than that rec­ 
ommended by the manufacturer, which simply 
stated that marker points should be placed at the 
four corners of the vertebrae, and on the middle 
of the endplates.
Pointers were adjusted at maximum image mag­ 
nification (500%) and positioned centrally on the 
brightest image pixels at the posterior, middle and
anterior of each endplate. Where rotation of the 
phantom caused more than one edge of the same 
endplate to be visible, the mid-endplate pointers 
were positioned at the point of maximum separa­ 
tion, halfway between the two visible edges of the 
endplate (Figure 4).
Results
From the 10 control scans for column 1, the 
mean posterior vertebral height at zero rotation 
was found to be 26.9 mm (+0.21) giving a precision 
of 0.8%. This height was 1.1 mm less than the 
actual mean vertebral height of 28 mm. Similarly, 
for the middle and anterior measurements, the 
mean heights were 27.2 mm (±0.28) and 26.8mm 
(±0.25), respectively; 0.8 mm and 1.2 mm less than 
the actual. A similar underestimation was observed 
for the individual vertebral heights of column 2.
For column 2, the calculated posterior/predicted 
posterior ratios for the crushed vertebrae were 
overestimated by an average of 1.0%, based on a 
predicted posterior height calculated from the 
mean posterior heights of L2 to L4 of the 10 
control scans of column 1. The anterior/posterior 
ratio of the wedged vertebrae and the mid/posterior 
of the biconcave vertebrae was on average under­ 
estimated by 1.3% and 6.2%.
On a vertebral by vertebral basis, there was a 
slight variation in the measured heights along 
the length of column 1. A linear regression fit 
(r2 = 0.698) showed a trend of increasing posterior
UNAH EXPERT [CWEStt :s
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Figure 4. Enlarged image of rotated vertebral body from 
column 1 showing position of defining pointers.
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Figure 5. Images of column 2 at maximum angles of 
rotation. Left: at +15.8° rotation around the antero- 
posterior axis. Centre: at +5.9° rotation around the 
lateral axis. Right: at +23.0° rotation around the supero- 
inferior axis.
height from T5 to L4, with the mean L4 being 
0.64mm (2.3%) greater than the mean T5.
Figure 5 shows images of column 2 at maximum 
positive angles of rotation for each of the three 
axes (anteroposterior, lateral and superoinferior). 
The effect of increasing anteroposterior axial 
rotation on the mean measured height for the 
three defining vertebral dimensions (posterior, 
middle and anterior) of column 1 is shown in 
Figure 6.
Anteroposterior axial rotation produced a clear 
effect on the measured vertebral heights of column 
1. With positive rotation, vertebral height initially 
increased, reaching a mean peak of 27.9 mm at 
4.6° before falling back to 25.7mm at 15.8°. 
Negative rotation produced a similar effect for the 
posterior and anterior heights, reaching a peak at 
an average of 28.0mm at —2.3", but the middle 
height initially dropped to 26.5 mm at -2.3'J before 
reaching a peak of 27.9 mm at —4.6°.
Rotation of column 2 showed a similar trend to 
that seen with column 1, with the mean heights 
increasing with small angles of rotation, before 
decreasing at larger angles. The middle measured 
height also showed a corresponding drop at -2.3°.
The effect of rotation around the anteroposterior 
axis on the defining vertebral ratios for column 1 
and column 2 are shown in Figures 7 and 8. The 
observed change in vertebral heights produced 
variation in both posterior/predicted posterior 
ratios and the mid/posterior ratios, but little vari­ 
ation in anterior/posterior ratios. These effects 
were observed for both deformed and non- 
deformed vertebrae, as was the very sharp drop in 
the mid/posterior ratio at —2.3°.
Rotation of a column of vertebral bodies around 
the anteroposterior axis changes both the projec­ 
tion angle and the distance from individual ver­ 
tebrae of the column to the X-ray source. Those 
vertebrae farthest from the point of rotation would 
be displaced by the greatest distance. If the distance 
from the vertebrae to the source produced the 
observed effect on measured vertebral height, the 
visible heights of those vertebrae farthest from the 
point of rotation would change more than those 
closer to the point of rotation. Examination of the 
data on a vertebra-by-vertebra basis showed that 
this was not the case. Thus source distance was 
not a factor in the observed change in vertebral 
height.
Figure 6. Variation in posterior, middle and anterior mean vertebral heights with rotation of column 1 around the 
anteroposterior axis, with actual values as comparison. Mean heights and standard deviations at zero rotation 
calculated from 10 control scans. Angular error calculated assuming a ± 1 mm positional inaccuracy.
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Figure 1. Variation in defining ratios for biconcave, wedge and crush deformities with anteroposterior axial rotation 
of column 1, with actual values as comparison. Ratio error at zero rotation calculated from control scans assuming 
±1 SD in both numerator and denominator. Angular error calculated assuming a + 1 mm positional inaccuracy.
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Figure 8. Variation in defining ratios for biconcave, wedge and crush deformities with anteroposterior axial rotation 
of column 2, with actual values as comparison. Ratio error at zero rotation calculated from control scans assuming 
± 1 SD in both numerator and denominator. Angular error calculated assuming a + 1 mm positional inaccuracy.
Increasing angles of rotation of both column 1 
and column 2 around the lateral axis produced 
only slight deviations in the mean vertebral heights 
from the unrelated means. At the maximum angle 
of rotation of 5.9° degrees, the posterior, middle 
and anterior heights varied from the unrotated 
heights by only -0.24, +0.26 and +0.05 mm for 
column 1 and +0.02, +0.22 and +0.45 mm for 
column 2, respectively. Taking into account the 
respective standard deviations of operator error of 
+ 0.21, 0.28 and 0.25 mm for column 1 and +0.26, 
0.23 and 0.33 mm for column 2, only the posterior 
height of column 1 and the anterior height of 
column 2 deviated from the average by more than 
1 SD, and no mean height varied by more than 
2SD.
Correspondingly, all defining vertebral ratios 
calculated from the anterior and posterior vertebral 
heights of column 2 were within 2 SD of those 
expected. There was no systematic error in the
results associated with degree of deformity. All 
other defining ratios, including all of those calcu­ 
lated for column 1, were within 1 SD of those 
expected.
The effect of positive and negative rotation 
around the superoinferior axis produced little vis­ 
ible effect on the combined mean heights of ver­ 
tebrae in column 2. However, separate examination 
of the defining ratios for the three types of vertebral 
deformity revealed that there was some pattern of 
variation, as shown in Figure 9. From this it can 
be seen that crushed and wedged vertebrae showed 
almost no variation with rotation, but biconcave 
vertebrae showed a noticeable change in the defin­ 
ing mid/posterior ratio, although with no clear 
pattern. The change in the ratio exceeded 2 SD at 
+ 9.8° and -4.9° and 1 SD at +4.9° and -9.8° 
but was less than 1 SD at +14.5° or more. 
Additionally, the effect did not appear to increase 
with the increasing severity of biconcavity.
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Figure 9. Variation in defining ratios for biconcave, wedge and crush deformities with superoinferior axial rotation of 
column 2, with actual values as comparison. Ratio error at zero rotation calculated from control scans assuming ± 1 
SD in both numerator and denominator. Angular error calculated assuming a ± 1 mm positional inaccuracy.
Discussion
Vertebral morphometry relies upon accurate 
assessment of vertebral height from a lateral per­ 
spective. Deviation from this perspective can pro­ 
duce a change in the projected image, with such 
deviations potentially occurring through poor 
patient positioning or spinal deformity. Until now, 
little work has been carried out to measure the 
effect of poor positioning, but the MXA phantom 
developed at this centre has allowed the systematic 
evaluation of the effect of such positional errors 
on the results of MXA examination.
The phantom was designed with a BMD within 
the osteopenic range (0.97 g cm~ 2 ). Also, the phan­ 
tom vertebral components provide more clearly 
denned endplates than might typically be seen with 
actual vertebrae, so the actual in vivo precision of 
osteopenic and osteoporotic subjects is likely to be 
less. It is also possible that operator error increases 
with the angle of rotation, but testing this would 
require a prohibitive number of repeat scans at 
each angle.
The underestimation of the mean vertebral 
heights of the phantom by the Lunar Expert-XL 
differed from the results of Felsenberg et al [5], 
who found that the earlier Lunar Expert over­ 
estimated vertebral height of the European Spine 
Phantom by about 1.7%. Although it is possible 
that this difference was due either to differences 
between the machines used, or to scatter differences 
between the two phantoms, it seems more likely 
that it was due to a difference in the image analysis 
protocols.
The unexpected upward trend in observed pos­ 
terior vertebral height of around 0.64 mm from T5 
to L4 was considerably larger than the mean 
operator variability, so was unlikely to be due to 
chance. Later investigation, with additional 
Perspex for attenuation, showed that this effect
was probably due to accumulating saturation of 
the detector as the acquisition progressed towards 
T5. Increasing the thickness of the Perspex used 
to 25 cm eliminated the upward trend in vertebral 
height. A phantom of this size would be impracti­ 
cal, but additional Perspex may be added prior to 
use. The reduction in vertebral height due to 
detector saturation would be unlikely to produce 
an effect on the results of this investigation as the 
saturation would be present in all images. 
However, the lack of visible distortion in the 
individual images does demonstrate the insidious 
nature of detector saturation, and care should 
therefore be taken to reduce it in both the in vivo 
and in vitro application of MXA.
The effects of rotation around the three primary 
axes: anteroposterior, superoinferior and lateral, 
were investigated. It was expected that rotation 
around the anteroposterior axis would follow a 
simple cosine relationship between the angle of 
rotation and the vertebral height. From the results 
it could be seen that this was not the case, as the 
mean vertebral height increased with small angles 
of rotation, before decreasing at a more expected 
rate for a cosine function. In the images, small 
angles of rotation caused displacement of the proxi­ 
mal and distal edges of the endplate sufficient to 
show a double thickness of pixels but insufficient 
to resolve them separately. The presence of an 
extra row of pixels on each endplate effectively 
increased the measured vertebral height by their 
combined thickness. As the longitudinal resolution 
of the Lunar Expert-XL is 0.7 mm, the potential 
height increase would be about 1.4 mm, which was 
as observed. If this supposition were correct, a 
similar result would be expected clinically.
An exception to this occurred at -2.3° of antero­ 
posterior rotation. At this point, one row of bright 
pixels at each endplate was slightly darker than
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the other, causing the operator to reposition the 
mid points accordingly. This might explain the 
sharp drop in the observed middle heights at that 
angle of rotation. If so, the resulting drop in the 
measured height can be dismissed as an artefact 
produced by the rigid image analysis protocol.
As rotation had a similar effect on the anterior, 
middle and posterior vertebral heights, the mid/ 
posterior and anterior/posterior ratios varied only 
slightly; although the mid/posterior ratio at —2.3° 
was an exception to this owing to the previously 
described effect. The crush ratio, however, depends 
on a comparison of the posterior height with a 
predicted posterior height and as such was seri­ 
ously affected by rotation, with a significant devi­ 
ation in the ratio at only +4.6° of rotation. The 
Lunar software corrects for this by using the 
measured heights of L2-L4 for calculating the 
predicted height. Hence, if the subject was pos­ 
itioned with the whole spine at one angle of 
rotation, the predicted posterior height would be 
reduced by a similar amount to the other individual 
posterior heights. However, a scoliosis can produce 
anteroposterior rotation of only a limited area of 
the spine, making correction ineffective in these 
cases. It therefore follows that at greater than 
±4.6° of anteroposterior (scoliotic) rotation, the 
posterior/predicted posterior ratio for detecting 
crush fractures is unreliable and so the use of MXA 
in such cases is questionable.
It was found that, as expected, superoinferior 
rotation did not produce any effect on the vertebral 
heights of the crushed vertebrae L1-L4, greater 
than that explicable by 1 SD of operator error. 
Unexpectedly, the same was also found to be true 
for the wedged vertebrae T12-T9. However, sig­ 
nificant changes of greater than 2 SD in vertebral 
height were observed for the biconcave vertebrae 
of T5-T8 at some angles of rotation.
Superoinferior rotation corresponds to twisting 
of the vertebral body and could have an anatomical 
or positional cause. This study has shown that the 
diagnosis of biconcavities can be affected by small 
angles of rotation, and caution should therefore be 
taken to ensure that the patient is lying anatom­ 
ically supine prior to imaging.
Vertebrae rotated around the lateral axis appear 
diagonal in the image, with some of the vertebral 
height expressed as width (see Figure 5). The Lunar 
Expert-XL software automatically compensates for 
this by calculating the diagonal height. However, 
the lateral fan geometry of the X-ray beam causes 
a magnification of the width of an object, with the 
degree of magnification increasing with distance 
from the centre of the beam. In practice we found 
that rotation around the lateral axis had little 
discernible effect on either the measured vertebral 
height or the ratios for either column. The results
therefore suggest that any angle of kyphosis or 
lordosis of up to 5.8° would not produce any 
significant change in vertebral height.
The observed changes were proportional to the 
overall vertebral height, so results of rotation 
should be applicable to all patient sizes. However 
the phantom used in this study is not truly anthro­ 
pomorphic, so caution should be taken in applying 
the results of this investigation to the clinical 
situation.
In view of the detector saturation observed in 
this investigation, care should be taken during 
clinical acquisitions to reduce to a minimum the 
number of unattenuated photons reaching the 
detector. The tube current selected should therefore 
be appropriate for the amount of soft tissue present 
in the target area, whilst for lateral acquisitions, 
an appropriate bed height should be ensured to 
reduce the airspace above and below the subject 
in the resultant image.
Overall, these results demonstrate that great care 
should be taken to align the patient along the 
central axis of the scanning couch. This could be 
achieved with the aid of the positioning laser and 
confirmed with an anteroposterior spine scan. 
Additionally, the application of the MXA tech­ 
nique becomes questionable in scoliosis of above 
4.6°, but can compensate for degrees of kyphosis 
or lordosis of up to at least 5.8°. Care should 
therefore be taken to distinguish and exclude scoli­ 
otic vertebrae from the results of any MXA 
examination.
Acknowledgments
The authors gratefully acknowledge the finan­ 
cial support provided for this study by the local 
osteoporosis charity OSPREY.
References
1. Cummings SR, Black DM, Rubin SM. Lifetime risk 
of hip, Colles' or vertebral fracture and coronary 
heart disease among white postmenopausal women. 
Arch Inter Med 1989; 149:2445-8.
2. Cooper C, Atkinson EJ, O'Fallon WM, Melton 
LJ. Incidence of clinically diagnosed vertebral frac­ 
tures: a population-based study in Rochester, 
Minnesota, 1985-1989. J Bone Miner Res 1992; 
7:221-7.
3. Eastell R, Cedel SL, Wahner HW, et al. Classification 
of vertebral fractures. J Bone Miner Res 1991; 
6:207-15.
4. Genant HK, Wu CY, Kuijk CV, Nevitt MC. Vertebral 
fracture assessment using a semiquantitative tech­ 
nique. J Bone Miner Res 1993;8:1137-48.
1160 The British Journal of Radiology, November 1998
Effect of subject positioning on MX A
5. Felsenberg D, Gowin W, Diessel E, et al. Recent 7. Shrimpton PC, Wall BF, Jones DG, et al. A national
developments in DXA. Quality of new DXA/MXA- survey of doses to patients undergoing a selection of
devices for densitometry and morphometry. Eur routine X-ray examinations in English hospitals,
J Radiol 1995;20:179-84. NRPB-R200. London: HMSO, 1986.
6. Steel SA, Baker AJ, Saunderson JR. An assessment g. Steel SA, Walker R, Howey S, Langton CM. Phantom
of the radiation dose to the patients and staff from a for evaluating vertebral morphometry using the
Lunar Expert XL fan beam densitometer. Physiol Lunar Expert. Osteo Int (in press) 
Meas 1998;19:17-26.
The British Journal of Radiology, November 1998
The British Journal of Radiology, 79 (2006), 336-341
The DXL Calscan heel densitometer: evaluation and diagnostic 
thresholds
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ABSTRACT. The DXL Calscan (Demetech AB) is a new dual energy X-ray absorptiometry 
device for determining heel bone mineral density (BMD). The system is based on the 
standard technique of dual energy X-ray absorptiometry (DXA), using a fan beam 
configuration, but introduces an additional laser measurement of heel thickness 
intended to improve accuracy. We have examined the utility, in vitro and in vivo 
performance of the DXL Calscan and established triage thresholds based on the UK's 
National Osteoporosis Society guidelines on peripheral densitometry. The Calscan 
proved convenient, easy to use and was stable over time and within a range of 
operating temperatures. Short-term in vitro precision as %CV, with phantom 
repositioning, was 0.75% and long term precision 0.73%. Precision in vivo, determined 
from duplicate right heel scans of 67 subjects, was 1.19%. Effective radiation dose to 
the patient was <0.1 uSv per scan. 140 white females (70 osteoporotic and 70 non- 
osteoporotic), aged 55-70 years underwent scans of both heels. Subjects were defined 
as osteoporotic or non-osteoporotic on the basis of axial DXA (spine L2-L4 and total 
hip). Triage thresholds for reassurance-referral or referral-treatment were 0.391 g crrT 2 
and 0.306 g cm" 2 for non-dominant and 0.395 g crrT2, 0.294 g cm~ 2 for dominant 
heel, respectively. The non-dominant heel proved slightly superior to the dominant for 
triage purposes. Of the seven non-osteoporotic subjects misclassified as osteoporotic by 
Calscan of either heel, six had severe axial osteopenia. If operated by trained personnel 
and used in appropriate populations exhibiting risk factors, the Calscan is well suited 
for use in the management of post-menopausal osteoporosis.
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Measurement of bone mineral density (BMD) by dual 
energy X-ray absorptiometry (DXA) is now well estab­ 
lished as the method of choice for osteoporosis assess­ 
ment [1-3]. BMD assessment of the lumbar spine and hip 
by DXA represents the current gold standard due to the 
greater associated morbidity and mortality of fractures at 
these two sites, superior fracture prediction [4, 5] and 
response to treatment [6]. In addition to axial assessment, 
there are a variety of DXA devices available for 
measuring BMD in the forearm, heel and hand.
The DXL Calscan (Demetech AB, Solna, Sweden) is a 
new peripheral device for calcaneal BMD assessment, 
based on fan beam DXA. The Calscan also incorporates a 
laser measurement of heel thickness to improve the 
accuracy of calcaneal BMD. Standard DXA assumes a 
two compartment model of tissue masses, the first bone 
and the second a composite of lean and adipose tissue at 
an assumed constant ratio. This assumed ratio does not 
allow for fluctuations in lean and adipose tissue propor­ 
tions that have been demonstrated to occur at the spine [7] 
and are likely to occur at the calcaneus or elsewhere [8,9]. 
This leads to calcaneal DXA providing a precise but 
potentially inaccurate estimate of BMD, with the degree of 
inaccuracy dependent on body mass index [8].
This study has been funded in part by Demetech AB, Solna, 
Sweden. Additional funding for J Thorpe provided by the local 
osteoporosis charity, OSPREY.
336
These inhomogeneities can be corrected by solving the 
BMD equation as a three component model of bone, lean 
and adipose tissue. Swanpalmer [10,11] described how a 
third X-ray energy could achieve this, but concluded that 
a significantly higher photon count (and hence scan 
times) would be required to maintain an acceptable 
degree of precision.
Jonson [12] deduced that if the combined width of all 
three components were known, e.g. the width of the heel, 
the ratio of soft to lean tissue could then be derived and 
corrected for. The laser heel width measurement on the 
Calscan provides this additional dimension allowing the 
derivation of BMD from a three component model, 
whilst theoretically maintaining DXA precision [13].
As with other peripheral DXA (pDXA) devices [14], 
the Calscan is smaller, portable, cheaper and has a lower 
radiation dose than axial densitometers. However, 
pDXA results at the calcaneus cannot be interpreted 
using the WHO definition [15] and do not correlate 
perfectly with bone density at either spine or hip. The 
imperfect correlation can lead to pDXA misclassifying 
subjects to the opposite diagnostic group to which they 
would have been classified by axial DXA [16-18], 
particularly for subjects with BMD scores close to 
diagnostic thresholds. Hence considerable debate 
remains over how such peripheral devices might best 
be employed in the clinical setting. The UK-based 
National Osteoporosis Society (NOS) has recently stated
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that current evidence supports the use of peripheral 
devices in a triage rather than diagnostic role, and has 
established a method for determining the required triage 
thresholds [19, 20]. The aim of this study was to 
determine the in vitro and in vivo operating conditions 
of the Calscan and to establish triage referral thresholds 
based on the NOS guidelines.
Materials and methods
The DXL Calscan bone densitometer (Figure 1) utilizes 
a fan beam, dual energy X-ray source and a solid state 
detector to perform a scan of the heel. A region of interest 
is positioned automatically by the software to derive 
BMD. A concomitant measure of heel thickness is 
obtained using the laser reflection to correct for varia­ 
tions in the soft to lean tissue ratio. The Calscan, at 25 kg 
in weight and 80 cm long by 43 cm wide and 33 cm tall, 
is relatively compact and easy to transport and includes 
wheels at one end and a carry handle. As with all X-ray 
equipment, the Calscan is potentially subject to changes 
in tube temperature after performing an acquisition, and 
as a portable device it may also be subject to fluctuations 
in performance due to environmental changes. To 
counter this, the software (version 1.3.1) requires a 
warm-up acquisition when the device is switched on 
and a 4 min cooling down period after each acquisition.
In vitro methodology
Phantom based studies were conducted to test the 
effect of temperature, stability following relocation and 
to determine in vitro precision. The DXL-Calscan comes 
with a manufacturer-supplied phantom, made from 
shaped pieces of aluminium depicting the calcaneus, 
embedded in acrylic. Short term precision was deter­ 
mined as percent coefficient of variation (%CV) from 30 
scans with phantom repositioning and 30 without. The 
device was operated according to the manufacturer's 
instructions. All measurements were taken on the same 
day. Accuracy was calculated from comparison with the 
phantom's stated BMD of 0.347 g cm" 2, established from 
a central reference machine, corresponding to a T-score
of -2.1. Long term in vitro precision was determined 
using daily single phantom scans acquired over a period 
of 6 months as part of routine quality assurance.
Sixteen tests were conducted to assess the effects of 
ambient temperature, device movement or tube hearing 
on accuracy or precision. For each test the device was 
disconnected, moved to a different room, warmed up 
and a phantom scan acquired as soon as the warm-up 
was complete. The device was given a further 30 min to 
stabilize, then a second phantom scan was acquired and 
the device powered down and allowed to cool for 30 min 
before beginning the next test. Temperature was mea­ 
sured on an alcohol room thermometer throughout. 
Electrical, laser safety and radiological protection sur­ 
veys were also carried out.
In vivo methodology
Subjects
Females attending for routine BMD of spine and hip 
were approached for participation in this study. These 
were referred on the basis of agreed local risk criteria 
which are broadly in agreement with those of the Royal 
College of Physicians [1]. The study was approved by the 
local research Ethics Committee and informed consent 
was obtained. All subjects were white and between the 
ages of 55 years and 70 years (Table 1). A total of 140 
women were recruited.
Axial DXA assessment
Subjects underwent BMD of lumbar spine and hip 
using a GE-Lunar Prodigy (GE-Lunar, Madison, WI) as 
part of their routine examination and clinical manage­ 
ment was determined on the basis of the results. In our 
centre, DXA of the right hip is performed unless 
contraindicated. For the purposes of this study, if the 
lower of either L2-L4 spine or total hip BMD T-score 
values was below -2.5, the subject was classified as 
osteoporotic. Otherwise they were classified as non- 
osteoporotic. When lumbar vertebrae showed clear signs 
of degenerative changes, the individual vertebrae 
affected were excluded from the lumbar spine results. 
Four subjects had individual vertebrae excluded - one 
osteoporotic and two non-osteoporotic subjects with 
degenerative changes of L4 and one non-osteoporotic 
subject with changes at L3. For eight other subjects (four 
osteoporotic, four non-osteoporotic by final diagnosis), 
two or more vertebrae on the same subject showed
Table 1. "Evaluation and Diagnostic Thresholds of the DXL 
Calscan". Mean (standard deviation) subject demographic 
variablesfor whole group, osteoporotic and non-osteoporo­ 
tic subjects, respectively
Figure 1. The Demetech DXL Calscan and phantom. 
























BMI, body mass index.
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degenerative changes. For these eight subjects the spine 
results were disregarded and diagnosis was made by 
total hip DXA alone. In one case this caused the subject to 
move from the osteoporotic to non-osteoporotic group. 
Recruitment continued until 70 osteoporotic and 70 non- 
osteoporotic subjects were enrolled.
Calcaneal DXA assessment
BMD of both heels was obtained using the DXL 
Calscan. To determine in vivo precision, 67 of the 140 
subjects underwent a repeat acquisition of the right heel, 
with repositioning between each. The calcaneal regions 
of interest (ROI) were manually checked and, if deemed 
necessary, ROI position was corrected as per the user 
manual instructions. For the repeat Calscan acquisition, 
the second scan for each subject was analysed on a 
separate day to the first to reduce the possibility of 
operator bias during any ROI repositioning.
Results
Operational utility
The time from scan initiation to appearance of the 
results is 94 s, with an additional 4 min required to allow 
the X-ray tube to cool before another acquisition can be 
taken. The Calscan is able to image either heel from the 
same side of the device making it easier for the patient 
and minimizing floor space required where both heels 
are to be scanned. As for all equipment using ionizing 
radiation, the Calscan requires a standard radiation 
safety assessment but also an additional laser safety 
assessment. The footwell of the Calscan was of an open 
design, and had the advantage of allowing the operator 
to manually assist the positioning of the heel. The open 
design allowed easy access for the operator and was 
comfortable for the patient, but did require some 
attention to achieve the ideal positioning.
In vitro results and environmental effects
Short term in vitro precision (coefficient of variation) 
was 0.76% CV (mean BMD 0.347 + 0.0026 g cm" 2) with 
phantom repositioning, 0.75% (0.347 ± 0.0025 g cm"2 ) 
without. Long term precision was 0.73%. The device 
was accurate, with no measurable difference between 
mean phantom BMD as measured on our machine 
compared with that of the central reference machine.
Average phantom BMD and precision for the 32 
environmental scans was 0.347 g cm"2 and 0.62% CV. 
Average phantom BMD and precision for the 16 scans 
taken as soon as possible after a warm-up scan, i.e. after 
the enforced 4 min cooling down period between scans, 
was 0.347 g cm~2 and 0.65% CV. For the 16 scans 
acquired after the tube had been allowed to cool for half 
an hour, average BMD was 0.348 g cm" 2 and 0.61% CV.
During the 32 scans of the 16 environmental tests, the 
room temperature varied from 21.3°C to 26.9°C, the 
upper value being slightly outside the manufacturer's 
recommended operating range of 15°C to 25 °C.
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Comparison of the results recorded at the 16 highest 
temperatures (range 23.8 °C to 26.9 °C) with the results at 
the 16 lowest (21.3°C to 23.8°C) did not change phantom 
BMD or precision significantly. For the 16 higher 
temperature scans, phantom BMD and precision was 
0.347 g cm" 2 and 0.64% CV, respectively. For the 16 
lower temperature scans, phantom BMD and precision 
was 0.348 g cm"2 and 0.58% CV, respectively.
Radiation and laser safety
The effective radiation dose to the patient was 
<0.1 jaSv per scan and a controlled area of 0.5 m was 
defined around the device in order to comply with IRR 
1999 [21]. At this distance, scatter dose to the operator 
would not exceed annual dose limits, even at maximum 
scan throughput. The laser assessment found the Calscan 
laser itself to be class 2 by UK/European/US standards 
and thus capable of causing eye damage, but the location 
of the laser within the footwell removed the possibility of 
accidental exposure and so the laser was deemed to be 
safe (class 1), provided the Calscan outer casing was in 
place. The permanent filtration and laser class were not 
marked on the casing as is required to comply with UK/ 
EU standards [22, 23]. A laser warning label was added 
to the Calscan and local rules were established that 
reflective objects should be kept clear of the footwell, as 
stated in the user manual. No other laser precautions 
were deemed necessary. No safety problems with the 
laser occurred during the project, but it was noticed that 
opaque black hosiery could produce spurious BMD 
results, although other hosiery did not.
In vivo results
Subject demographics and bone density results are 
summarized in Tables 1 and 2, whilst coefficients of 
determination (adjusted R2) between key variables are 
shown in Table 3. Mean in vivo BMD of the right heel for 
all 67 subjects (19 osteoporotic, 48 non-osteoporotic) 
given repeat measurements was 0.357 g cm" 2 (range 
0.186-0.518 g cm~ 2, standard deviation 0.074 g cm"2). 
Mean absolute difference between paired results was 
0.0046 g cm"2 (range 0-0.018 g cm" 2). Calscan precision 
for the 67 subjects as %CV (derived from root mean 
square) was 1.19%.
Taking the osteoporotic and non-osteoporotic preci­ 
sion groups separately, mean BMD for the 19 osteopo­ 
rotic subjects was 0.299 g cm" 2 (0.186-0.437 g cm~ 2, SD 
0.065). Mean absolute difference was 0.0042 g cm" 2 (0- 
0.012 g cm" 2 ). Precision was 1.30%CV. For the 48 non- 
osteoporotic precision subjects mean BMD was 
0.392 g cm 2 (range 0.281-0.518 g cm" 2, SD 0.061). 
Mean absolute difference was 0.0048 g cm" 2 (0- 
0.0018 g cm" 2). Precision was 1.09%CV.
Establishing triage thresholds
In the revised NOS guidelines on peripheral DXA, 
Blake et al [20] recommend the use of peripheral devices 
in a triage role as an adjunct to axial DXA and suggest a
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Table 2. "Evaluation and Diagnostic Thresholds of the DXL Calscan". Mean (standard deviation) DXA bone density and T-score 








































Units: BMD (g cm 2); T-score (St Dev) 
BMD, bone mineral density.
Table 3. "Evaluation and Diagnostic Thresholds of the DXL 

























method for defining the two triage thresholds required. 
The upper of the two thresholds is set at a point above 
which only 10% of osteoporotic subjects would fall, 
whilst the lower threshold is a point below which only 
10% of non-osteoporotic subjects would fall. Subjects 
who fall above the upper threshold would be assumed 
non-osteoporotic, whilst subjects who fall below the 
lower threshold assumed osteoporotic. Subjects falling 
between the two would be recommended for referral for 
axial DXA.
Using the 140 subjects in this study, the upper and 
lower thresholds for Calscan for the non-dominant and 
dominant heels are shown in Figure 2. The proportion of 
subjects hi the equivocal group, and therefore requir­ 
ing axial DXA, is shown in Table 4. Based on these 
thresholds of 0.391 g cm"2 and 0.306 g cm" 2 for the 
non-dominant and 0.395 g cm" 2 and 0.294 g cm~ 2 for
the dominant heel, the referral rates for the Calscan in 
this group were 52.9% (non-dominant) and 58.6% 
(dominant), but with an error margin of ±9% due to 
the small sample size. Of the seven non-osteoporotic 
subjects misclassified as osteoporotic by Calscan of either 
non-dominant or dominant heels, six had severe osteo- 
penia (axial T-score <-2).
A better estimate of the expected referral rate can be 
drawn from comparing our derived thresholds (and 
confidence intervals) to the mean and standard deviation 
of the Calscan reference data. The reference data are 
drawn from a population of 993 Swedish women 
between 15 years and 85 years of age [24] (381 between 
50 years and 69 years), albeit a population without 
known risk factors. If we assume a hypothetical referral 
group with an even distribution of subject ages from 
55 years to 70 years and the same spread and trend in 
BMD results as the Swedish reference group, the 
expected mean referral rate at the non-dominant heel 
would be 36.7%. Adjusting for the distribution of ages 
seen in our 140 subjects, the figure would be 36.8%.
Discussion
The Calscan proved reliable, precise, accurate and easy 
to use. Calscan performance was stable -within a normal 
range of room temperatures, and was not affected by 
























Figure 2. (a) DXL Calscan upper and lower triage thresholds for the non-dominant heel, (b) DXLCalscan upper and lower triage 
thresholds for the dominant heel.
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Table 4. "Evaluation and Diagnostic Thresholds of the DXL Calscan". Referral by number of subjects
Non-dominant heel Dominant heel
Thresholds:
Units: BMD (T-score). BMD in g cm" 
Above upper threshold: reassure
Between thresholds: refer 
Below lower threshold: treat





























in performance when acquiring scans in quick succes­ 
sion, or with 30 min breaks between them, with the 
enforced 4 min period between scans appearing suffi­ 
cient time for the X-ray tube to cool. Radiation dose to 
patient and scatter dose to operator were low and the 
device requires only a small controlled area. There is no 
lower limit of applicability and the Ionising Radiation 
Regulations still apply, requiring therefore the advice of 
a radiation protection advisor, device risk assessment, 
production of local rules, written procedures and 
appropriate training of staff.
At 1.19% CV, precision in vivo for our 67 precision 
subjects as a whole was slightly superior to the 1.24% for 
the Calscan and 1.28% for the GE-Lunar Pixi reported by 
Hakulinen et al [8], who performed repeat scans on 38 
(18 male, 20 female) subjects with a mean (SD) age of 
59.7 years (±9.4 years). Although at 1.30% CV the 
precision for our 19 Osteoporotic precision subjects is 
poorer than the 1.09% for the 48 non-osteoporotic 
subjects, at 0.0042 g cm"2 versus 0.0048 g cm"2, the 
mean absolute error per repeat measurement was 
actually lower for the Osteoporotic than for the non- 
osteoporotic group, and so the difference in precision can 
be explained by the difference in the mean BMD scores 
for the two groups. As with all DXA systems, attainment 
of good precision requires technical staff to be trained, 
experienced and to practice good technique.
We found the coefficient of determination (R2) with 
spine and total hip DXA to be 0.28 and 0.35 at the non- 
dominant heel. Correlation at spine was lower than the 
0.59 reported by Martini et al [25], or the 0.61 reported by 
Hakulinen [8]. It is not clear if this is due to differences in 
the sample groups and the small size of the Martini and 
Hakulinen samples.
Using T-scores, the upper and lower triage thresholds 
as defined by the NOS method for the Calscan were at 
-1.4 and —2.7, respectively, for the non-dominant heel. 
These T-scores are only applicable to post-menopausal 
white women aged 55-70 years who meet the normal 
criteria for axial bone densitometry examination. As with 
all T-scores, the exact threshold values depend on the 
reference range. Were this to be changed, then the T- 
scores would need to be recalculated from the under­ 
lying BMD scores of 0.391 g cm"2 and 0.306 g cm" 2 . In 
addition, the T-score thresholds of any peripheral 
devices employed in a triage role are likely to become 
more negative with advancing subject age [20], but the 
unreliability of spine DXA in subjects over 70 years of 
age makes the calculation of peripheral threshold values
problematic for such a group, without resorting to total 
hip BMD alone.
There continues to be a growth in demand for bone 
densitometry services through increased awareness of 
health professionals and the public, rising healthcare 
costs of fragility fractures and the development and 
introduction of new bone protective treatments. The 
provision and availability of such services, however, 
remains patchy and inconsistent. In an area where 
demand on axial DXA is exceeding capacity, peripheral 
DXA could prove useful in a triage role to ensure best 
and most cost effective use of this resource. However, a 
comprehensive analysis of the resource implications of 
such an approach is required. Applying the triage 
thresholds to the population used for this evaluation 
would suggest that over 50% would require referral for 
axial DXA. As indicated, the study was not powered to 
provide an accurate assessment of referral proportion 
and the true figure is probably below 40%. Provided the 
cost per case for the heel DXA measurement is less than 
60% that of a spine and hip measurement, there should 
be a net saving. Where the peripheral device is 
community or primary care based, there may be an 
increase overall in patients identified due to the more 
accessible nature of the service which would reduce the 
potential cost savings and also increase the burden on 
the prescribing budget.
Where there is no access to axial DXA locally, 
peripheral DXA may play a role in identifying those at 
risk of fragility fracture provided it is used with care and 
in appropriate populations with clearly identified clinical 
risk factors. The Calscan device appears suitable for 
either role using the thresholds derived in this study. 
There is a high proportion (95%) of the more metaboli- 
cally active trabecular bone in the calcaneus [15] which 
would suggest that this site is sensitive to mechanisms 
affecting bone metabolism. This, together with the 
advantage of being a weight bearing bone, should better 
reflect the changes occurring at the spine and hip than at 
other peripheral sites. The moderate correlation between 
the heel and axial sites observed in this study may be due 
to sample bias as the subjects were drawn from those 
attending for bone densitometry. The lack of agreement 
observed generally between sites is also partly due to the 
varying trabecular to cortical ratios with the spine being 
50% trabecular and hip 40%.
There is no published evidence to date that patients 
commenced on treatment on the basis of falling below 
the lower triage threshold by pDXA could be monitored
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by pDXA. Ringe et al demonstrated promising results in 
heel BMD with ibandronate [26], but they employed a 
non-standard technique and do not compare the 
observed 15% increase at 2 years with the least sig­ 
nificant change. It is also known that some bone 
protective treatments are only effective in reducing 
fractures in those defined osteoporotic by hip BMD 
[27]. There are no data yet on effectiveness of treatments 
in those targeted by the pDXA triage technique although 
use of the derived lower pDXA threshold provides 90% 
confidence that the patient would be found osteoporotic 
by spine and hip, with almost all the remainder severely 
osteopenic by spine or hip.
Use of peripheral devices in a triage role as an adjunct 
to an established axial DXA service could bring 
substantial benefits to both patient and healthcare 
providers, and the Calscan is well suited for this 
purpose. However, it should be operated only by 
qualified personnel, used in selected populations and 
results interpreted in conjunction with clinical risk 
factors for fragility fracture.
Acknowledgments
The authors wish to acknowledge Vincent Mann and 
Melanie Auty for their technical assistance in the 
environmental measurements for this paper.
References
1. Royal College of Physicians. Osteoporosis: Clinical guide­ 
lines for prevention and treatment. London, UK: RCP, 1999.
2. U.S. Department of Health and Human Services. Bone 
Health and Osteoporosis: A Report of the Surgeon General - 
Chapter 8: Assessing the Risk of Bone Disease and Fracture. 
U.S. Department of Health and Human Services, Office of 
the Surgeon General, 2004.
3. National Osteoporosis Society. Position statement on the 
reporting of dual energy x-ray absorptiometry (DXA) bone 
mineral density scans. Bath, UK. NOS, August 2002.
4. Marshall D, Johnell O, Wedel H. Meta-analysis of how well 
measures of bone mineral density predict occurrence of 
osteoporotic fractures. Br Med ] 1996;312:1254-9.
5. Stone KL, Seeley DG, Lui L-Y, et al. BMD at multiple sites 
and risk of fracture of multiple types: long-term results 
from the Study of Osteoporotic Fractures. J Bone Miner Res 
2003;18:1947-54.
6. Eastell R. Treatment of postmenopausal Osteoporosis. N 
Engl J Med 1998;338:736-46.
7. Formica C, Loro ML, Gilsanz V, Seeman E. Inhomogeneity 
in body fat distribution may result in inaccuracy in the 
measurement of vertebral bone mass. J Bone Miner Res 
1995;10:1504-11.
8. Hakulinen MA, Saarakkala S, Toyras J, Kroger H, Jurvelin 
JS. Dual energy x-ray laser measurement of calcaneal bone 
mineral density. Phys Med Biol 2003;48:1741-52.
9. Hausler KD, Rich PA, Barry EB. Water bath and contact 
methods in ultrasonic evaluation of bone. Calcif Tissue Int 
1997;61:26-9.
10. Swanpalmer J, Kullenberg R, Hansson T. The feasibility of 
triple-energy absorptiometry for the determination of bone 
mineral, Ca and P in vivo. Physiol Meas 1998;19:1-15.
11. Swanpalmer ], Kullenberg R, Hansson T. Measurement of 
bone mineral using multiple-energy x-ray absorptiometry. 
Phys Med Biol 1998;43:379-87.
12. Jonson R, Mansson LG, Rundgren A, Szucs J. Dual-photon 
absorptiometry for determination of bone mineral content 
in the calcaneus with correction for fat. Phys Med Biol 
1990;35:961-9.
13. Swanpalmer J, Kullenberg R. A new measuring device for 
quantifying the amount of mineral in the heel bone. Ann N 
Y Acad Sci 2000;904:115~7.
14. Patel R, Blake GM, Fogelman I. Radiation dose to the 
patient and operator from a peripheral dual x-ray absorp­ 
tiometry system. J Clin Densitom 1999;2:397-401.
15. WHO Technical Report Series 843. Assessment of fracture 
risk and its application to screening for postmenopausal 
Osteoporosis. Geneva, Switzerland: World Health 
Organization, 1994..
16. Grampp S, Genant HK, Mathur A, et al. Comparisons of 
non-invasive bone mineral measurements in assessing age- 
related bone loss, fracture discrimination and diagnostic 
classification. J Bone Miner Res 1997;12:697-711.
17. Lu Y, Genant HK, Shepherd J, et al. Classification of 
Osteoporosis based on bone mineral densities. J Bone Miner 
Res 2001;16:901-10.
18. Faulkner KG, Von Stetton E, Miller P. Discordance in 
patient classification using T-scores. J Clin Densitom 
1999;2:343-50.
19. National Osteoporosis Society. Position statement on the 
use of peripheral x-ray absorptiometry in the management 
of Osteoporosis. Bath, UK: NOS, November 2004.
20. Blake GM, Chirm DJ, Steel SA, Patel R, Panayiotou E, 
Thorpe ], et al. The Revised National Osteoporosis Society 
Position Statement on Peripheral x-ray Absorptiometry: a 
list of device specific thresholds for the clinical interpreta­ 
tion of pDXA examinations. Osteoporosis International; In 
press.
21. The Ionising Radiations Regulations 1999. London, UK, The 
Stationery Office Limited, ISBN 0 11 085614 7; 1999.
22. British Standards Institute (BSI). Medical electrical equip­ 
ment. Particular requirements for safety. Specification for x- 
ray source assemblies and x-ray tube assemblies for medical 
diagnosis. British Standards Publishing BS EN 60601-2- 
28;1993.
23. European Committee for Electrotechnical Standardization 
(CENELEC). Safety of laser products - Part 1: Equipment 
classification, requirements and user's guide. EN 60825-1; 
1994.
24. Kullenberg R. Reference database for dual x-ray and laser 
Calscan bone densitometer. J Clin Densitom 2003;6:367-72.
25. Martini G, Valenti R, Gennari L, Salvador! S, Galli B, Nuti R. 
Dual x-ray and laser absorptiometry of the calcaneus: 
comparison with quantitative ultrasound and dual- 
energy x-ray absorptiometry. J Clin Densitom 2004;7: 
349-54.
26. Ringe JD, Dorst A, Faber H, Ibach K, Preuss J. Three- 
monthly ibandronate bolus injection offers favourable 
tolerability and sustained efficacy advantage over two 
years in established corticosteroid-induced Osteoporosis. 
Rheumatology 2003;42:743-9.
27. Cummings SR, Black DM, Thompson DE, Applegate WB, 
Barrett-Connor E, Musliner TA, et al. Effect of alendronate 
on risk of fracture in women with low bone density but 
without vertebral fractures: results from the Fracture 
Intervention Trial. JAMA 1998;280:2077-82.
The British Journal of Radiology, April 2006
341
The British Journal of Radiology, 81 (2008), 778-783
The Alara Metriscan phalangeal densitometer: evaluation and 
triage thresholds
J A THORPE, MSC, BSC and S A STEEL, MSC, BSC
Centre for Metabolic Bone Disease, Hull And East Yorkshire Hospitals NH5 Trust, Hull Royal Infirmary, Anlaby Road, Hull 
HU3 2RW, UK
ABSTRACT. The Metriscan (Alara Inc, CA) is a compact digital radiographic 
absorptiometry device capable of determining phalangeal bone mineral density in 
arbitrary units (BMDau ) from the second phalanges of the middle three digits. We have 
examined the utility and the in vitro and in vivo performances of the Metriscan, and 
established triage thresholds based on the UK's National Osteoporosis Society 
guidelines on peripheral densitometry. 170 white female participants (70 osteoporotic 
and 100 non-osteoporotic at the hip or spine) aged between 55 years and 70 years 
were recruited from patients attending for routine dual X-ray absorptiometry (DXA) 
examination. All participants underwent two scans of the non-dominant hand (with 
repositioning) and one of the dominant hand. An additional 10 participants were 
excluded owing to finger or hand deformities. Radiation exposure to the patient per 
scan was <0.1 uSv, and a controlled area of 1 m was established around the device. 
Phantom-based in vitro short-term precision (%CV) was 0.17% without, and 0.22% 
with, repositioning. Long-term in vitro precision was 0.31% over a 6-month period. In 
vivo short-term precision was 1.42% for the group as a whole, and 1.30% and 2.23% 
for the non-osteoporotic and osteoporotic groups, respectively. Triage thresholds for 
reassurance/referral or referral/treatment were 54.30 BMDau and 46.89 BMDau, 
respectively, for the non-dominant hand, and 55.02 BMDau and 48.73 BMDau for the 
dominant hand. The dominant side proved superior for triage purposes, with a triage 
referral rate of 44%, compared with 48% for the non-dominant hand. The Metriscan is 
suitable for use on post-menopausal women in a community-based setting preferably 
in a triage role as an adjunct to axial BMD.
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Bone mineral density (BMD) assessment plays an 
important role in the evaluation of patients with 
potential osteoporosis [1] and is typically performed by 
dual X-ray absorptiometry (DXA). BMD of the hip is the 
best predictor of hip fracture risk [2], whereas spinal 
BMD is most suitable for treatment monitoring [3].
Although the hip and spine are therefore the preferred 
sites for BMD measurement, imaging at these sites 
requires an axial DXA densitometer. As an alternative, 
there are a variety of devices available for assessing sites 
in the peripheral skeleton, such as the hand, forearm or 
heel [4]. These peripheral devices are typically smaller 
and cheaper, but correlation with axial hip or spine BMD 
varies among devices and among skeletal assessment 
sites. As such, peripheral assessment alone is not 
typically considered appropriate for the diagnosis or 
treatment monitoring of osteoporosis [4-8]. However, in 
the absence of axial DXA, current guidelines recommend 
that peripheral measurements can be used to aid 
treatment decisions in those with clearly identified 
clinical risk factors [5, 6, 9).
The UK National Osteoporosis Society (NOS) has 
proposed that peripheral devices be adopted in a triage
Address correspondence to: S A Steel, Centre for Metabolic Bone 
Disease, Hull And East Yorkshire Hospitals NHS Trust, 1 lull Royal 
Infirmary, Anlaby Road, Hull HU3 2RW, UK. E-mail: 
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role [9], and Blake et al [4] have defined a method by 
which devices can be evaluated for this purpose. For this 
paper, we have assessed the in vitro and in vivo 
performance of the Alara Metriscan (Alara 
Incorporated, Hayward, CA) and calculated triage 
thresholds using the Blake method.
Methods and materials
The Alara Metriscan
The Metriscan is a compact digital radiographic 
absorptiometry device capable of measuring bone 
mineral content of the second phalanges of the middle 
three digits. The device is small enough to fit on a 
desktop (41 cm wide, 42 cm high, 45 cm deep) and is 
light enough to be transportable (<19 kg).
For an exposure, the patient removes any jewellery 
(when possible) from the non-dominant hand, and 
places the hand on the moulded support plate. Hand 
placement is checked to ensure the fingers are flat but 
not pressed down hard, and that the second phalanges of 
the middle three digits are within the region of interest 
marked on the plate.
The operator is able to take the exposure using either a 
button on the front of the device or a remote button
The British Journal of Radiology, October 2008
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nnected by a 2 m lead. When activated, a cone beam X- 
v image (tube voltage, 60 kV; current, 0.333 mA) of the 
non of interest is projected onto a curved storage 
losphor plate mounted on a rotating drum. The drum 
rotated and scanned by a laser in order to excite 
lOtons from the surface of the exposed phosphor plate, 
ith a photosensitive detector converting these photons 
an electronic signal pulse proportional to the number 
incident photons. A second light source then erases 
e plate ready for the next acquisition. 
An aluminium step wedge of known thickness built 
to the device within the region of interest provides the 
libration for each image. The geometric distortion 
herent to projecting the image onto a drum is corrected 
^software before the final digital image is displayed on 
i LCD screen. Bone mass estimates are determined 
rough comparison with the step wedge, and T- and Z- 
Bres ('•£• the number of standard deviations from 
jnnal young or age-matched individuals, respectively) 
lederived from reference data. Results are expressed as 
MD but, because there is no comparison against a 
rawn bone standard, the BMD score given is an 
tttrary unit (BMD.1U ), rather than the usual g cm'2 . If 
quired, individual phalanges can be excluded from the 
ralysis by the operator. There is no electronic storage of 
t image, but bone mass estimates and derived T- and 
•scores can be exported to a PC via a serial cable.
vitro methodology
The device was operated according to the manufac- 
rer's instructions. Radiation protection was assessed 
rthe local radiation protection advisor and exposure 
fes for both the patient and the operator were 
Iculated. In vitro precision was assessed using a hand 
Bntom provided with the device. Long-term precision 
as calculated from 6 months' combined phantom data, 
ith the phantom being scanned every working day. 
lort-term precision was calculated from 30 phantom 
ans performed on the same day with repositioning, 
id a further 30 without.
vivo methodology
170 white female participants aged between 55 years 
id 70 years were recruited from patients undergoing 
Utine DXA examination of the lumbar spine and hip. 
rial DXA scans were acquired using a GE-Lunar 
odigy scanner (GE-Lunar, Madison, WI). DXA of the 
j|it hip was performed unless contraindicated. The 
al referral criteria for routine axial densitometry are 
nsistent with those of the Royal College of Physicians
(UK) [10], and all participants met at least one of these 
criteria. The study was approved by the local research 
ethics committee, and informed consent was obtained 
from all participants.
For 12 participants, individual lumbar vertebrae 
showed clear signs of degenerative changes on DXA. 
These individual vertebrae were excluded from the DXA 
lumbar spine analysis. For the purposes of this study, if 
the lower of either L2-L4 spine or total hip BMD T-score 
values were below -2.5, the subject was classified as 
osteoporotic; otherwise, they were classed as non- 
ostcoporotic.
Participants underwent three scans on the Metriscan 
— one of the dominant hand and two of the non- 
dominant hand. Scans were acquired in accordance with 
the operator manual. Where possible, rings and other 
jewellery were removed from the hands of the partici­ 
pants. Several participants were unwilling or unable to 
remove wedding or engagement rings but, in such cases, 
it was usually possible to acquire the image after 
pushing the rings to the proximal end of the finger.
In addition to the 170 recruits, there were a further 10 
participants who were excluded owing to the Metriscan 
proving unsuitable for scanning. Of these, five were 
participants with serious rheumatoid arthritis who were 
unable to place their hands flat. Two participants with 
milder rheumatoid disease were able to place their hands 
flat, but had multiple rings that could not be removed 
owing to increased joint diameter; neither could the rings 
be moved proximally to such an extent as to keep them 
out of the image. Three further participants were 
excluded: one who had fused middle and index fingers; 
one with joint misalignment of the middle fingers; and 
one with no second phalanges on the index fingers.
Results
Device performance
The device was simple to operate following minimal 
instruction. Although the actual exposure time was less 
than 1 s, there was an additional 45 s processing time 
required for the phosphor plate to be read and the image 
processed.
Radiation exposure to the patient per scan was 
<0.1 /6v within the image field. Maximum scatter dose 
at 22 cm from the beam central axis was 0.2 /<Gy, giving 
a dose at 1 m of no more than 0.01 /<Gy. Assuming a 
single operator and a high patient throughput of 10 000 
scans per year (~40 per day), total operator exposure 
would still be less than 0.1 mSv per year, and well below 
the recommended dose constraint of 0.3 mSv for
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Table 2. Mean (±standard deviation) axial dual X-ray absorptiometry and phalangeal bone density and T-score results



































































Bone mineral density (BMD) values are given in g cm' 2 for the spine and hip, and in arbitrary units for the hands. T-scores are
given in standard deviations. 
^Derived from the non-dominant reference range.
members of the public. A controlled area of 1 m was 
established around the device and it was recommended 
that the operator remain outside this area by using the 
remote cable to take exposures. The radiation protection 
advisor recommended that direct personal dose mon­ 
itoring was not required for such low levels of 
anticipated dose.
In vitro results
The phantom provided had a nominal BMD of 
58.0 BMDau/ corresponding to a T-score of 0.26. The 
average measured phantom BMD.1U was 57.8 and the 
long-term precision coefficient of variation was 0.31%, 
based on daily scans over a 6-month period. Short-term 
precision was 0.17% without repositioning, and 0.22% 
with repositioning, for the phantom as a whole. Taking 
each digit of the phantom separately, short-term preci­ 
sion was 0.22% and 0.30% without and with reposition­ 
ing for digit one, 0.32% and 0.28% for digit two, and 
0.27% and 0.36% for digit three, respectively.
In vivo results
Subject demographic variables are summarized in 
Table 1. 70 participants were classified as osteoporotic 
by either the L2-L4 spine or total hip, whereas 100 were 
classified as non-osteoporotic. Metriscan and axial DXA 
results are summarized in Table 2; correlation between 
axial DXA and Metriscan results are shown in Table 3. 
Metriscan BMDao of the dominant hand was higher than 
that of the non-dominant hand for the whole group, but 
not significantly so (^=0.052). In vivo precision for the 
non-dominant hand was 1.30%CV for the non-osteo­ 
porotic participants, 2.23%CV for the osteoporotic 
patients and 1.42%CV for the group as a whole. For 
individual digits, the precision was 2.64%CV, 1.91%CV 
and 2.26%CV for the three imaged digits of the 
osteoporotic group, and 1.75%CV, 1.51%CV and 
1-88%CV for the non-osteoporotic group.
Establishing triage thresholds
In the revised NOS guidelines on peripheral DXA [4, 
9], Blake et al [4] suggest the use of peripheral devices in
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a triage role as an adjunct to axial DXA. In doing so, they 
suggested a method for defining the two triage thresh­ 
olds required, which can be applied to any peripheral 
device; indeed, this method has already been applied to 
several devices [9,11]. In the Blake method, the upper of 
the two thresholds is set at a point above which only 10% 
of osteoporotic participants would fall, whereas the 
lower threshold is at a point below which only 107o of 
non-osteoporotic participants would fall. Participants 
who fall above the upper threshold would be assumed 
non-osteoporotic, whereas participants who fall below 
the lower threshold would be assumed osteoporotic. 
Participants falling between the two thresholds would be 
recommended for referral for axial DXA. By definition of 
how the thresholds are set, this method achieves a 
sensitivity and specificity of 90% for osteoporosis 
diagnosis, assuming axial DXA to be the gold standard.
For the Metriscan scanner, the upper and lower 
thresholds for the non-dominant and dominant hands 
are shown in Figure la and lb, respectively. The 
numbers of participants falling into each triage group, 
and the proportion falling into the referral group and 
therefore requiring axial DXA, are shown in Table 4.
Of the 10 non-osteoporotic participants misclassified 
by Metriscan as osteoporotic of the dominant hand, 8 
had severe axial osteopenia (L2-L4 or total hip T-score 
<-2) whereas, of the 10 non-osteoporotic participants 
misclassified by Metriscan as osteoporotic of the non- 
dominant hand, only 1 subject had severe axial osteope­ 
nia (L2-L4 or total hip T-score <-2).
Discussion
The Metriscan was compact, easy to use and took less 
than a minute to complete an examination. In vivo and in 
vitro precision values were good, and the performance 
was stable over the 6 months during which this study 
was conducted. The inability to save images electro­ 
nically may have implications for centres that require 
images to be retained for quality assurance purposes.
In the UK, the Ionising Radiation Regulations [12] 
apply to any device that produces ionizing radiation, 
regardless of the exposure close. Therefore, (i) the advice 
of a radiation protection advisor, (ii) device risk assess­ 
ment, (iii) production of local rules and written proce­ 
dures and (iv) appropriate training of staff are still a
The British Journal of Radiology, October 2008
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e mineral density (BMD) in given in arbitrary units. T- 
ore values are given in standard deviations, 
rived from the non-dominant reference range.
uirement for the Metriscan. That said, the radiation 
e to patients and the scatter dose to operators were 
'; the device required only a small controlled area; 
[operators did not need to be individually monitored. 
MS possible to acquire an image using either a button 
the device or a cable remote. As radiation dose to the 
rator should always be kept to a minimum, the cable 
lote — extended to 1 m — should always be used to 
! an exposure, 
he Metriscan proved unsuitable for use on 10 out of
participants; however, many participants were 
nited from joint rheumatoid/osteoporosis clinics, 
I thus the 7 participants who were excluded owing 
heumatoid disease may represent a higher proportion 
ii would be found in a purely osteoporosis clinic. It 
1 have been possible to include some of these 
ticipants by using the inbuilt Metriscan software to 
lude individual symptomatic digits, but this would 
Itoreduced precision and possibly lower correlation 
llhip and spinal BMD. Hence, the Metriscan cannot 
recommended for use on patients with phalangeal 
t deformity.
i addition, some of the patients may have been 
nous or current users of corticosteroids or bone 
tective therapy, which are suspected to have differ- 
al effects on cortical vs trabecular bone [13, 14]. As 
J. this may affect the relationship between axial and 
pheral bone density in those patients, and hence the 
Ved triage thresholds. 
he average BMD of the dominant hand was higher
that of the non-dominant hand, just as calcaneal
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BMD is higher at the dominant heel [11]. However, the 
dominant hand provided a better correlation with both 
spinal and hip BMD than the non-dominant hand, 
possibly owing to wider variation between non-domi­ 
nant and dominant hand activity between participants. 
Conversely, the calcaneus shows a higher correlation for 
the non-dominant heel [11] but, because both heels are 
load bearing, there is likely to be little variation in 
activity between dominant and non-dominant sides. As 
correlation with axial DXA is better using the dominant 
hand, this would seem more representative of general 
bone health.
At 0.559 and 0.562, the Pearson correlation coefficients 
between Metriscan phalangeal BMD at the dominant 
hand and total hip and spinal BMD values are compar­ 
able to those reported with the Demetech Calscan device 
(0.596 for total hip, and 0.530 for spinal L2-L4) [11], but 
slightly inferior to other peripheral devices, notably the 
Lunar Pixi (0.652 for total hip and 0.657 for spinal L2-L4) 
[15] and Schick Accu-DXA (0.602 for femoral neck and 
0.609 for spinal L2-L4) [16]. As with other peripheral 
devices, there is currently no published evidence on the 
suitability of phalangeal assessment for treatment mon­ 
itoring. The compact size, ease of use and patient 
acceptability of the Metriscan, however, make it well 
suited for use in a triage role in places where time or 
space are at a premium, such as GP surgeries or hospital 
fracture clinics.
From our population, using the dominant hand for 
triage referral and the Blake method, 44% of participants 
would have required referral for axial DXA, whereas 
48% would have required referral if the non-dominant 
hand had been used, with an error margin of +9% owing 
to the small sample size. Therefore, when employing the 
Metriscan in a triage role, it might be better to triage by 
the dominant hand, as the size of the referral group is 
determined by the correlation of the peripheral site to 
hip/spinal BMD [4].
Even though the dominant hand is more suitable than 
the non-dominant hand for triage purposes, the non- 
dominant hand should still be used for direct assessment 
of fracture risk, as the supplied reference range data are 
applicable only to the non-dominant hand. Furthermore, 
as the triage thresholds are derived from women under 
investigation for post-menopausal osteoporosis, they are 
not applicable to men, children or pre-menopausal 
women.
As with all peripheral devices, employing the 
Metriscan in a triage role could bring substantial benefits 
to both the patient and the healthcare provider, assum­ 
ing that the device is operated by qualified personnel 
and is used only on an appropriate population with 
clinical risk factors for fragility fracture. In such a role, 
the Metriscan device could reduce the number of 



















































Figure 1. (a) Alara Metriscan upper and lower triage thresholds for non-dominant phalanges, (b) Alara Metriscan upper and 
lower triage thresholds for dominant phalanges. BMD, bone mineral density.
Acknowledgments
The authors wish to acknowledge John Saunderson for 
the radiation protection assessment performed for this 
paper.
References
1. Blake GM, Fogelman I. Role of dual-energy X-ray absorp- 
tiometry in the diagnosis and treatment of osteoporosis. 
JClin Densitom 2007;10:102-1(>.
2. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, 
Browner WS, et al, Osteoporotic Fractures Research 
Group. BMD at multiple sites and risk of fracture of
multiple typos: long-term results from the study of 
Osteoporotic fractures. | Bone Miner Res 2003;18:1947-54.
3. Fastell R. Treatment of postmenopausal osteoporosis. 
N Engl J Mod 19y8;338:73d-46.
4. Blake GM, Chinn DJ, Steel SA, I'atd R, I'annyiotou E, 
Thorpe J, et al. A list of device-specific thresholds for the 
clinical interpretation of peripheral X-ray absorptiometry 
examinations. Osleoporos Int 2005;16:2149-56.
5. Lewiecki KM, Walts NB, McClung MR, 1'etakSM, Bachwch 
LK, Shepherd JA et al. Official positions of the international 
society for clinic.il densitometry. International Society for 
Clinical Densitometry, I Clin Endocrinol Metab 
2004;89:3651-5.
6. Miller I'D, Njeh CF, Janko\\ ski LG, Lenchik L What are the 
standards by which bone mass measurement at peripheral
782 The British Journal of Radiology, October 2008
valuation and triage thresholds of the alara metriscan
skeletal sites should be used in the diagnosis of osteoporo- 
sjs? J din Densitom 2002;5(Suppl):S39^5.
? Patel R, Blake CM, Fogclman I. An evaluation of the United 
Kingdom National Osteoporosis Society position statement 
on the use of peripheral dual-energy X-ray absorptiometry. 
Osteoporos Int 2004;15:497-504.
) National Institute for Clinical Excellence. Bisphosponntcs, 
selective oestrogen receptor modulators and parathyroid 
hormone for the secondary prevention of osteoporotic 
fragility fractures in postnienopausal women. Technology 
Appraisal 87. 2005:27(4.3.6).
I National Osteoporosis Society. Position statement on the 
use of peripheral x-ray absorptiometry in the management 
of Osteoporosis. Bath, UK; 2004.
I. Royal College of Physicians. Osteoporosis: clinical guide­ 
lines for prevention and treatment. London, UK; 
1999:11(44).
Thorpe JA, Steel SA. The DXL Calscan heel densitometer: 
evaluation and diagnostic thresholds. Br J Radiol 
2006:79:336-41.
12. The Ionising Radiations Regulations 1999. London, UK: The 
Stationery Office Limited, 1999: Part 1, Section 3: 
Application l(a).
13. Natsui K, Tanaka K, Sucla M, Yasoda A, Sakuma Y, O/asa 
A, et al. High-dose glucocorticoid treatment induces rapid 
loss of trabecular bone mineral density and lean body mass. 
Osteoporosis Int 2U06;17:105-8.
14. Qin L, Choy W, An S, Fan M, Leung P. Alendronate 
increases BMD at appendicular and axial skeletons in 
patients with established Osteoporosis. J Orthop Surg 
2007;2:9.
15. Pearson D, Vlasud T, Sahota O, Earnshaw S, Hosking D. A 
comparison of calcaneal dual-energy X-ray absorptiometry 
and calcaneal ultrasound for predicting the diagnosis of 
Osteoporosis from hip and spine bone densitometry. J Clin 
Densitom 2003;6:345-52.
16. Picard D, Brown JP, Rosenthall L, Couturier M, Levesque J, 
Dumont M, et al. Ability of peripheral OXA measurement 
to diagnose osleoporosis as assessed by central DXA 
measurement. J Clin Densitom 2004;7:lll-8.
Wish Journal of Radiology, October 2008 783
APPENDIX IV
Clinical application 
(Papers 8 to 12}
Osteoporosis Int (1996) Suppl. 3:531-836
© 1996 European Foundation for Osteoporosis Osteoporosis
International
The Technical and Logistical Feasibility of Population Densitometry 
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Introduction
The concept of the primary prevention of disease by 
screening-directed intervention is as attractive in princi­ 
ple as it is difficult in practice. In order for any screening 
programme to be acceptable, many criteria need to be 
satisfied [1], and these broadly reduce to three: there 
shall be a suitable disease, there shall be a valid test, and 
there shall be an acceptable intervention. If an inquiry 
as to the availability of any one of these three central 
requirements produces a negative response, then any 
screening exercise must be seriously flawed.
Osteoporosis is a prevalent disease in western Euro­ 
pean and North American populations and is associated 
with significant morbidity, particularly among post- 
menopausal women. It is characterized by low bone 
mass, microarchitectural derangement of bone tissue 
and a consequent increase in bone fragility and risk of 
fracture [2]. Quantitatively, the World Health Organiz­ 
ation (WHO) has defined Osteoporosis as being present 
when a site-specific bone mineral density (BMD) is 
shown to be more than 2.5 standard deviations (SD) 
below the mean of the young adult population [2],
In the United Kingdom the burden of the disease is 
substantial, with an estimated 60000 fractures of 
femoral neck in England per year, together with 50000 
distal forearm fractures and 40'000 vertebral fractures 
which come to clinical attention [3]. The implication for 
National Health Service expenditure is also substantial, 
with an estimated £742m being utilized to deal with the 
acute care and aftercare of osteoporosis-related frac­ 
tures. In the United States, Cummings et al. [4] have 
estimated that white women have a 15% lifetime risk of 
hip fracture and of Colles' fracture, while in Europe 
Jensen et al. [5] showed a 21% prevalence of vertebral 
fracture among 70-year-old Danish women. The trend 
in fracture incidence is also disquieting. Epidemiologi-
Correspondence and offprint requests lo: Prof. D. W. Pordie, Centre 
for Metabolic Bone Disease, University of Hull, H. S. Brocklehurst 
Building, Hull Royal Infirmary, Anlaby Road, Hull HU3 2RW, UK.
cal data indicate that the increasing incidence of frac­ 
tured neck of femur is only partially accounted for by 
the increased longevity of the population [6]. In other 
words, there may be a trend towards lower bone mass or 
density among elderly persons which, in conjunction 
with increased longevity, will place a severe strain on 
health resources in the next century. It should be 
emphasized that the disease is not only morbid but may 
be mortal. Within 6 months of a femoral neck fracture, 
patients exhibit a mortality which is 20% in excess of 
that expected for the age-specific control population [4].
The natural history of Osteoporosis presents a prima 
facie case for examining the potential of- primary pre­ 
vention by screening. The disease has a relatively long 
"lead time" which may be taken to commence about the 
end of the fifth decade when BMD values begin to fall. 
Whether or not an individual becomes osteopenic 
(T-score 1-2.5 SD below the young normal mean) or 
osteoporotic (T-score >2.5 SD below the young normal 
mean) broadly depends on her individual peak bone 
mass, rate of postmenopausal loss and longevity. Thus 
there is a relatively broad window of opportunity during 
which a valid test might be applied to detect that sector 
of the general population who could be deemed to be at 
risk of Osteoporosis.
The validity of such testing using bone densitometry 
has been the subject of considerable debate. It has been 
argued by some [7] that the clear overlap in BMD values 
between hip fracture patients and age-matched controls 
precludes the use of densitometry in assigning risk. 
However, BMD measurements have never been used to 
detect fracture itself but to stratify continuing risk, and 
some recent prospective data support the use of densito­ 
metry for this purpose. Wasnich and colleagues [8] 
showed that each 1 SD reduction in BMD at the spine 
was associated with an odds ratio for spinal fracture of 
3,6 (95% CI 1.7-7.9). More recently Cummings et al. 
[9] have shown prospectively that, in respect of hip 
fracture, a 1 SD reduction in BMD at the femoral neck 
is associated with an odds ratio for hip fracture of 2.6 
(95% CI 1.9-3.6). To date, BMD is the best available
uis of predicting osteoporosis and there is now 
eral agreement that for a decline of 1 SD in bone 
ss the risk of fracture at that site doubles. The 
Unique of dual-energy X-ray absorptiometry (DXA) 
enerally acceptable to patients and is rapid, precise 
[ safe as detailed below. It was, therefore, in our 
nion a suitable test to examine for validity as part of a 
mary screening programme.
[he third element to be considered in evaluating such 
irogramme is the effectiveness of the intervention, 
ere is little merit in predicting, however precisely, the 
set of a morbid condition |f the patients found to be at 
Ic cannot, or will not, comply with the preventive 
.aiment offered. The primary treatment for the pre- 
ntion of bone loss in the immediate postmenopause is 
strogen. However, several studies have shown that, 
en where the indication for hormone replacement 
arapy (HRT) is valid, the incidence of non-com- 
iance is substantial [10]. The principal reasons for such 
m-compliance usually cited are the return to cyclic 
eeding and a fear of breast cancer. It remains to be 
tablished to what extent personal awareness of an 
dividual's risk of osteoporosis would result in 
;ceptance of, and compliance with, an HRT regime. 
The effectiveness of oestrogen in preventing bone 
iss is now well attested. Epidemiological data have 
isociated the use of oestrogen with a 50% fall in the 
icidence of femoral neck fracture and those oestrogens 
ad their delivery regimes that exert an osteoprotective 
ffect are known. Lindsay [11] has shown that the 
nmediately postmenopausal skeleton is exquisitely 
snsitive to oestrogen and responds by stabilizing bone 
urnover and.eventually BMD, after producing a modest 
;ain in density with the filling of resorption spaces. 
Specifically, and in the light of the present study, 
Jaganffli-Hili et al. [12] showed that the odds ratio for 
emoral neck fracture in women taking oestrogen for 5 
/ears was 0.42. In respect of vertebral fracture a 
^respective study in oophorectomized women sug­ 
gested a reduction in fracture incidence of 90% [13]. 
Thus it was felt that while the debate continues as to 
the.advisability of instituting a population-based screen­ 
ing programme for osteoporosis, a useful contribution 
to that debate might be made by determining the 
practicality of such a measure. In the absence of the 
technical and logistic ability to deliver a screening 
programme the question of advisability becomes rather 
academic. Specifically, this study sought to assess the 
response of a perimenopausa] population (aged 50-54 
years) and their primary care physicians to an offer of 
perimenopausal densitometry. It also sought to examine 
the response to and compliance with the offer of an 
osteoprotective HRT regime over a follow-up period of 
2 years, and to examine the claims made for current 
DXA equipment by manufacturers that it was poten­ 
tially capable of handling the high-volume patient traffic 
required in the performance of a population-based 
study.
Approval for the study was obtained from the Hull 




From the earliest phase of the experimental design of 
this project, it was clear that the collaboration of the 
general practitioner (GP) body would be of the utmost 
importance. To this end, a full list of the 62 general 
practices serving the city of Kingston-Upton-Hull was 
obtained from the Family Health Services Authority 
(FHSA). From this list an initial pilot group of practices 
reflecting the broad socio-economic spectrum of the 
population were selected. All were practices with a 
particular interest in preventive healthcare and whose 
data archiving was of a high order. The principals in 
these practices were invited to visit the densitometry 
laboratory and take part in a seminar covering the aims 
and experimental design of the project. Their obser­ 
vations and comments on the draft communication 
procedures were solicited and incorporated into the 
final design plan. The FHSA supplied a. list of all women 
aged 50-54 years in practices agreeing to participate. 
This list was then sent to the practice for verification and 
a final collated master list was drawn up, The exclusions 
applied to this list included: the presence of terminal 
illness, an inability to lie supine for 15 min, or a weight 
in excess of the densitometry couch limit of 125 kg. 
Patients were then invited by individual letter to attend 
densitometry laboratory for a measurement of hip and 
spine BMD. The invitation, written in standard English, 
included a description of osteoporosis and the nature 
and design of the research project. The wording of this 
information was discussed, amended and agreed with 
both GP principals and individual patients. Together 
with each letter, the patient received a proposed date 
and time for attendance at the laboratory which allowed 
for the patient to modify the date and time by a 
dedicated telephone line if the proposed time was 
inconvenient or she did not wish to attend.
As the study progressed general practices in groups of 
five or six were progressively brought into the study. 
Their participation began with an invitation for the 
partners, the practice manager and other members of 
the primary care team who would be in contact with 
screened patients, to come to the laboratory and see at 
first hand the technique of bone mineral densitometry 
and the preparation of results information. At each of 
these visits a full seminar was conducted which des­ 
cribed the nature of osteoporosis, the experimental 
design of the study and the precise implications for the 
practice in the event of participation. The latter 
involved the communications which would be sent from 
the laboratory to the practice and the history and clinical 
examination of patients which would have to precede 
the prescription, if indicated, of HRT.
During the recruitment phase a high profile for 
osteoporosis and the screening project was maintained 
by the use of local radio stations, the local daily 
newspaper and by invited talks to interested women's 
groups.
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A series of seminars approved, for the postgraduate 
educational allowance was inserted into the Continuing 
Medical Education programme of the local Postgradu­ 
ate Education Centre. These meetings proved invalu­ 
able and covered the clinical areas of menopause, the 
pathophysiblogy of bone loss and ihe management of 
HRT and other osteoprotective regimes in the primary 
care sector.
Laboratory and Densitometric Procedures
On attendance'at the laboratory the women were asked 
to complete a questionnaire which sought details of 
medical and social factors thought to influence BMD. 
These data and their relationship to BMD in this cohort 
will be the subject of a separate communication. In 
particular, details were sought of age at menarche, age 
at menopause, occurrence of medical conditions known 
to affect bone and mineral metabolism, and fractures. 
Additionally a history was taken of hysterectomy or 
oophorectomy and of exposure to any agent known to 
affect bone mineral metabolism. Lifestyle factors 
including a history of dietary calcium intake and physi­ 
cal exercise were also sought. The questionnaires were 
initially administered to the patients for self completion 
and the completed questionnaires were then checked 
and reviewed by a member of the research staff.
Densitometry
The BMD of the lumbar spine (L2-4) and of the femoral 
neck were measured in each individual. The technique 
used was that of DXA and the systems used were two 
Lunar DPX systems (Lunar, Madison, WI) located at 
the Princess Royal Hospital, Kingston-Upon-Hull.
Normal Values
At the outset of the study, in 1990, the normal BMD 
ranges for the 50- to 54-year-old population of the 
United Kingdom were unknown. An early objective of 
the study, therefore, was to establish the normal range 
through patients who exhibited no clinical abnormality 
or medical history likely to influence bone mineral 
metabolism. As the study advanced and as patients 
numbers accumulated, those patients exhibiting clinical 
and historical normality were progressively incorpor­ 
ated into a group eventually numbering 1022 from 
which identification of the centile ranges was obtained.
Normative data were also established for young 
adults using 250 women aged 20-25 years. These data 
were used to derive T-scores (number of standard 
deviations from the young normal mean) .for the local 
population as subsequently initiated by the WHO [2] for 
the definition of osteopenia and osteoporosis.
Women attending for osteoporosis screening whose 
spine or femoral neck BMD was in the lowest quartile
compared with the local age-matched normal range 
were deemed to be at risk of developing osteoporosis. 
The choice of the 25th centile as the intervention level 
was to a degree empirical but was influenced by the 
stochastic mathematical model of Horsman and Burch- 
inall [14] which predicted inter alia that some 66% of 
femoral neck fracture would occur in individuals whose 
BMD at age 50 years had been in the lowest quartile. 
Report letters were generated using locally developed 
computer software and sent to the GPs with recommen­ 
dations regarding HRT where appropriate. The patients 
were instructed to contact their GP within 2 weeks for 
the results of their BMD measurement and to discuss 
any preventive treatment that may be required. The 
final decision on prescription of HRT was left to the GP 
who was, however, requested to choose a regime known 
to be osteoprotective. This entailed the use of 2 mg 
oestradiol orally or 0.625 mg of conjugated equine 
oestrogen orally or the 50 jig transdermal patch. 
Standard progestogen regimes were used in all non- 
hysterectomized women.
Quality Assurance of Densitometry
A rigorous quality assurance programme was initiated. 
This involved the daily quality assurance procedure 
recommended by Lunar to test the voltage setting, 
mechanical movements of the scan arm and X-ray 
source and the deviation of area and density measure­ 
ments performed on a quality assurance standard con­ 
taining blocks of tissue-equivalent and bone-equivalent 
materials of known mineral content. This procedure 
calibrates the machines for bone mineral content 
(BMC) and BMD against the standard.
The long-term precision of the densitometers was 
monitored by daily scanning of an aluminium phantom 
supplied by Lunar. This phantom consists of four 
segments of different sizes and thicknesses simulating 
the lumbar vertebrae LI to L4 with two smaller end 
segments representing T12 and L5. Such a phantom was 
supplied with both densitometers, one with a nominal 
BMD for L2-4 of 1.283 g/cm2 and the other of 1.583 
g/cm2 . Both were scanned on each machine daily.
Results
Lunar DXA Performance
The densitometers proved robust, coping satisfactorily 
with a.load of up to 12 patients per working day plus 
phantom scanning. Down-time as a result of mechanical 
or software malfunction was minimal, which was in part 
due to their operation of the machines within a medical 
physics environment where specialist engineering and 
computing personnel were at hand. Long-term pre­ 
cision (as percentage coefficient of variation) based on 
daily measurements of the aluminium spine phantoms, 
was about 0.7%. Measurement of the same phantom on
D. W. Purdiect a).
machines demonstrated a difference between 
n of about 0-7%.
and Public Response
the 62practices invited to participate one refused. A 
il of 7965 women aged 50-54 years were invited to 
•nd for densitometric examination, of whom 6282 
;nded - a crude acceptance rate of 79%. Repeat 
itations to non-attenders were not issued. A random 
vple of 55 non-attendees was contacted and invited to 
te their reason. Of these, 47 (85.5%) gave reasons for 
^attendance and 8 proved to have changed address, 
justing for a global address error as indicated by the 
nple, the corrected response rate for the overall study 
s82.9%.
>rnative, and Population Data
trmative data were established using the Lunar DPX 
the Princess Royal Hospital. The age-matched data 
ie based on a sample of 1022 women attending for 
•eening and excluding those with previous medical 
nditions or drug treatments known to affect bone and 
meral metabolism. The 25th centile value for lumbar 
ine BMD was 1.035 g/cm2 (T-score 1.31) and for 
moral neck 0.840 g/crr/(:T-score 1,37) (Table 1). The 
eaa (SD) age, height, weight and body mass index 
iMI) of the 6282 patients examined were recorded, 
milarly, after correcting for inter-machine variation, 
e mean BMD (SD) of this cohort was found to be 
143 (0.179) at the spine and 0.920 (0.134) at the 
moral neck (Table 2).
sble 1. Local normative data
k n Age Mean (SD) 25th Z-score T-score 


















































Utilising the 25th centile values described previously, 
2282 (36%) women were deemed to be at risk of 
developing osteoporosis (11% at the spine only, 10% at 
the femoral neck only and 15% at both sites). The linear 
correlation coefficient between spine and femoral neck 
BMD was 0.64 (95% CI 0.63-0.66). The relative risk of 
a femoral neck BMD being below 25th centile when the 
spine is below the 25th centile was 4.1 (95% CI 3.78- 
4.44).
HRT Acceptance and Compliance
Of the 1640 women "at risk" followed up at 2 years, 
some 215 (13%) were not offered a start or continuation 
of HRT therapy for the reasons shown in Table 3. Of the 
1425 women who were offered a start or continuation of 
HRT, a total of 1127 (69%) accepted the offer. How­ 
ever, 298 women rejected the offer for the reasons cited
Table 3. Reasons for failure to prescribe HRT
Lost to follow-up
Breast-related condition











Table 4. Reasons for patient rejection of offered HRT (n=298)
Return to cycle 
Fear of breast cancer 
Fear of other side effects 
Acceptance of osteoporosis risk 
Rejection of treatment 
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in Table 4. At formal clinical and densitometric follow- 
up 2 years later, 792 women were compliant with the 
HRT regime, 335 women having stopped treatment for 
the reasons shown in Table 5. Thus, of the group of 1640 
women deemed at risk and followed up, only 48% were 
receiving appropriate treatment 23 months later.
Discussion
In order for the procedure of densitometry to have value 
in the prevention of osteoporosis, and for its use to be 
worthy of further scientific discussion, it is essential to 
demonstrate three precepts, which relate to the clinical 
importance of the condition, the validity of the test and 
the acceptability of the intervention.
The condition of osteoporosis is prevalent and the 
clinical cost of related fracture is a burden on the public 
.health as is the financial cost upon the public purse. The 
overall cost of the condition to the UK National Health 
Service was estimated in 1994 by the Chief Medical 
Officer to be £750m.
For a British woman at 50 years, the age of natural 
menopause, the lifetime (c. 30 years) risk of any 
osteoporosis-related fracture is 20-40% [15], the risk of 
femoral neck fracture being 15.6-17.5% [16]. Given the 
increasing longevity of our population and that mean 
life expectancy in England and Wales is approaching 80 
years, it is unlikely that, in the absence of effective 
countermeasures - however applied - the overall inci­ 
dence of osteoporosis-related fracture will fall. How­ 
ever, there are some data which suggest a slowing of the 
rate of increase in the incidence of osteoporosis-related 
fracture [17,18].
The validity of bone mass measurement as a predictor 
of subsequent osteoporosis-related fracture has been 
examined prospectively in recent studies. Cummings et 
al, [19] showed prospectively that a 1 SD fall in BMD 
was. associated with a consequent doubling of the 
fracture risk. These data are broadly supportive of the 
findings of Hui et al. [20] and of Wasnich et al. [21]. The 
technical ability of current DXA equipment to examine 
a perimenopausal population has been explored in the 
present study. It was found that each of the two 
densitometers utilized was capable of examining up to 
12 patients per working day, with an acceptably low 
down-time (resulting from maintenance or technical 
malfunctions) of c. 2 days per annum. Patient 
acceptability was naturally high due to the non-invasive 
nature of the technique and few patients were found to 
violate the protocol because of extreme obesity or the 
presence of neurological disease preventing stillness. 
The precision achieved was satisfactory in view of the 
necessity of follow-up measurements and the quality 
assurance programme, run daily, did not intrude signifi­ 
cantly upon patient scanning time. We conclude that the 
DXA technique is potentially acceptable to patients, 
clinicians and health authorities as a technique for the 
densitometric examination of populations. Further 
developments should include a reduction in unit cost,
reduction in scan times and provision of vertebral 
morphometry. However, a major weakness in the appli­ 
cation of DXA to populations is the problem of data 
storage. The sheer volume of data accumulated on the 
processing system resulted in a serious degradation of 
the ability of the standard computer supplied (IBM 
Personal System/2 Model 70) to analyse newly added 
data sets in reasonable unit time. Additionally, the 
original floppy microdiskettes used for data archiving 
have had to be replaced by a higher-capacity (500 Mb) 
optical disk system. However, the ease with which the 
Lunar DPX system formulated data transfer from the 
machine-based PC to our statistical analysis system was 
a positive feature given the higher number of patients 
examined.
Four-fifths of the 50- to 54-year-old population com­ 
plied with the invitation to attend over the life of the 
study. After the rate had been corrected for erroneous 
addresses, we therefore concluded that only about 1 in 7 
of the invited population rejected the invitation to 
attend. Assiduous attention to written, oral and media- 
presented material describing the project ensured that 
patients were advised in clear English of the aims and 
objectives of the study. Clarity in language is always an 
asset and, we believe, has been repaid in the above 
compliance data.
With regard to GPs, 61 of 62 practices serving our 
population agreed to participate in the study. Close 
collaboration involving visits to the bone research and 
densitometry laboratory by partners, practice 
managers, nurses and some receptionists was found to 
be essential for patient management and the flow of 
information. The majority of GPs collaborated fully in 
reviewing patients 2 weeks after the scan with a view to 
considering HRT in those deemed at risk.
With regard to interventions, these proved to be the 
weakest link in the programme. Overall, of the patients 
who screened positive, i.e. whose BMD value placed 
them in the low quartile at each or both sites, only 48% 
had been receiving HRT continuously for 2 years since 
the initial examination. We have examined and pre­ 
sented above the reasons for non-acceptance or non- 
compliance by patients and for non-prescription by 
GPs. The principal reason for patient rejection of a 
GP-based offer of HRT proved to be return to cyclic 
bleeding and fear of breast cancer.
It was anticipated that the two principal reasons for 
at-risk patients discontinuing HRT would also be the 
return to cyclic bleeding and' fear of breast cancer. 
However, the principal specified reasons for discontinu­ 
ation of started treatment were cycle-related problems, 
headaches and weight gain. In respect of GPs, the initial 
clinical history and examination led to some 13% of 
patients at risk riot being offered HRT. Given the age 
range of 50-54 years some such patients would have 
been premenopausal, but the principal specific reason 
for a non-offer of HRT was the detection by the GP of a 
breast-related contraindication.
The loss from treatment, for whatever reason, of over 
50% of at-risk patients from a screening study is, in our
Y sufficient to invalidate the concept at the present
,' Although our HRT compliance rate is substan-
y higher than in other studies, it is still unacceptably
It is clear that acceptance of the concept of primary
vention of osteoporosis through population bone
atometric screening will require two major
>ancesin HRT delivery systems. First, a safe means
ichieving amenorrhoea on a long-term basis will have
be found. Secondly, the population and its GPs will
mire assurance that the risk of breast cancer during
[duration of the treatment, and thereafter, does not
nificantly differ from that amongst a control popu-
ion.
The institution of this clinical trial in Hull resulted in 
me 15% of perimenopausal women receiving long- 
•m HRT for the indication of low bone mass. Given 
'prevalence of heart disease in UK women and the 
cumulating data on the efficacy of HRT in preventing 
rdiovascular disease [22] it is likely that the principal 
aiefit of this bone protection programme will in fact 
jscend upon the heart.
In conclusion, we would advocate that women at the 
me of menopause should be seen by their primary care 
hysician- not to be given HRT automatically,- but to 
e considered for it. Where the GP or the specialist 
hysician or gynaecologist is persuaded that a signifi- 
ant health gaira'is attainable through its use, then, after 
istory and clinical examination, it should be offered to 
he patient. Where a significant risk of osteoporosis is 
uspected through past medical or past family history, 
lensitometry should be obtained in order to inform the 
iecision regarding the type and duration of the HRT 
•egime to be offered. A direct consequence of this 
jroject was the establishment of agreed indications for 
iensitometry to be funded by the local health purchas­ 
ing authority. Only when further prospective data on 
the predictive value of densitometry, together with 
advances in HRT delivery systems, are in place will the 
scene be setfor the final debate on population screening 
for osteoporosis.
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A cross sectional study was undertaken to 
examine the relationship between coeliac 
disease and bone mineral density. The 135 
female coeliac patients registered on the 
database of the Department of Gastro- 
enterology at Hull Royal Infirmary were 
approached by letter, advising them of 
a potential risk of osteoporosis and invit­ 
ing them to undergo bone densitometry. 
A total of 81 registered women (60%) 
attended the Osteoporosis Laboratory, 
Princess Royal Hospital and underwent 
dual energy x ray absorptiometry at the 
lumbar spine (L2-L4) and femoral neck. 
Historical data relating to the time of 
diagnosis and adherence to a gluten free 
diet were obtained. A control group was 
selected from the local normal population 
and was first matched for height, weight, 
and menopausal status. Postmenopausal 
patients were then further matched to 
controls of equivalent menopausal age. In 
coeliac patients, bone mineral density 
expressed in g/cm2 as mean (SD) was 
significantly lower at the lumbar spine 
(1-076 (0-186)) than in the control group 
(1-155 (0-143), p<0-001). This was also the 
case at the femoral neck (0-887 (0-142) 
versus 0-96S (0-127), p<0-001). When the 
coeliac patients were stratified by 
menopausal status, it was found that 
femoral neck bone mineral density was 
significantly below control values in both 
premenopausal and postmenopausal 
women. Spinal bone mineral density 
exhibited a significant decrement only in 
the postmenopausal group. The age at 
diagnosis of coeliac disease and adherence 
to a gluten free diet did not influence bone 
mineral density at either hip or spine. 
These results confirm coeliac patients' 
higher risk of osteopenia. Coeliac disease 
should be added to the list of medical 
conditions which constitute an indication 
for bone densitometry in order that the 
individual risk of osteoporosis related 
fracture may be determined. 
7: 639-642)
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It has long been recognised that coeliac disease 
may be associated with disorders of the 
skeleton. Over 60 years ago Bennett et al l 
reported major skeletal deformities in patients 
diagnosed in adult life as having.Gee's disease 
or idiopathic steatorrhoea and the presence of
biochemical derangement of calcium metabo­ 
lism was noted by Salvesen and Boe2 in 40 out 
of 90 patients with adult sprue. More recently, 
Harris et al 3 comprehensively examined the 
bone and mineral metabolism of 118 coeliac 
patients utilising Ca47 balance studies, bone 
biopsy, and skeletal x ray. Some 63% of these 
patients had a significant disturbance of bone 
metabolism, the most common of which was 
osteomalacia with or without concomitant 
osteoporosis, the latter condition being rarely 
present alone. In a study of 22 treated adult 
coeliacs, Molteni et al* utilised single photon 
absorptiometry to measure bone mineral den­ 
sity (BMD) at the distal radius. These patients' 
BMD values did not differ from those of age 
matched controls. In 29 untreated adult 
.patients, however, BMD was significantly 
lower than in age matched controls but did not 
correlate with the severity of clinical abnormal­ 
ities. In an intervention study, Caraceni et al 5 
noted that, in 20 untreated coeliac adults, 
BMD at the distal radius was significantly 
lower than in age matched controls and that 
biochemical parameters indicated accelerated 
bone turnover in the coeliac group. They 
further observed that .12 months after the insti­ 
tution of a gluten free diet no significant 
change in BMD had occurred: a result inter­ 
preted by these authors as indicating arrest of 
further bone loss. Equally, no restitution of 
previously lost bone mass was observed. The 
basic pathology underlying mineral metabolic 
derangements in coeliac disease has been well 
reviewed by Cooke and Holmes. 6 These 
workers reported that there is no compelling 
evidence for excessive excretion of calcium 
bound to faecal fat and that the basic anomaly 
is likely to be vitamin D malabsorption conse­ 
quent on raised intraluminal pH. Vitamin D 
dependent calbindin-D9K is severely depleted 
in coeliac disease and may mediate calcium 
malabsorption in this condition. 7 Calmodulin 
activity, however, seems to be unchanged.8
Taking the opposite tack, Lindh et al 9 
observed that of 92 patients with proved osteo­ 
porosis, 11 (12%) exhibited the presence of 
antigliadin IgA, a prevalence significantly in 
excess of that found in the general population. 
Interestingly, these patients displayed no 
anomaly of mineral metabolism or calcium 
malabsorption, and in only three was a histo- 
logical diagnosis of coeliac disease established. 
Subclinical coeliac disease thus seemed to be over 
represented in osteoporotic men and women.
Recently, MacFarlane et al, w using dual 
energy x ray absorptiometry (DEXA) at hip 
and spine, found a decrement of BMD at both 
sites in 50 coeliac patients compared with age 
and sex matched controls. Butcher et al, 11 in a
study of 20 patients concurred that reduced 
BMD was prevalent in women with coeliac 
disease and that the detection of osteopenia 
requires densitometry. In this study, adjust­ 
ment for body mass index (BMI), dietary 
control, or disease duration did not affect the 
overall difference observed between coeliac 
patients and healthy controls.
The above observations suggest a relation­ 
ship between coeliac disease and BMD, the 
latter being the prime determinant of risk of 
osteoporosis related fracture. 12 In order to 
thoroughly examine this relationship we have 
conducted a study of BMD in coeliac patients 
with rigorous control for potential con­ 
founding variables including menopausal age, 
BMI, hysterectomy, and exposure to hormone 
replacement therapy.
Patients and methods
One hundred and thirty five women, aged 
20-70 years, with histologically proved coeliac 
disease and registered with the Department of 
Gastroenterology at Hull Royal Infirmary 
were invited to attend Princess Royal Hospital 
for densitometric examination of the spine 
and hip. Eighty one patients (60%) attended. 
After obtaining informed consent, a clinical 
questionnaire was administered which 
enquired into the presence of factors known 
or suspected to influence BMD. These 
factors included smoking, alcohol use, amount 
of exercise taken, drug therapy including 
hormone replacement therapy (HRT) and 
corticosteroids, or prior hysterectomy. With 
regard to coeliac disease itself, the time since 
diagnosis and the degree of adherence to a 
gluten free diet were also recorded. Weight 
and height were measured and the BMI was 
expressed in standard form as weight (kg) 
divided by height (m2).
BMD at the spine (L2-L4) and hip (femoral 
neck) were measured by DEXA. The 
apparatus used was the Lunar DPX (Lunar 
Radiation Corporation, Madison, Wisconsin, 
USA). Quality assurance studies, have shown 
that in our hands the equipment has a 
coefficient of variation of 0-78% for spine and 
1-2% for hip BMD.
A matched control was selected for each 
coeliac patient. The premenopausal controls 
were selected from 230 healthy women in the 
third decade, attending for BMD measure­ 
ment. The postmenopausal controls were 
selected from our database of values obtained 
from 6426 women age 50 to 70. Matching was 
performed in respect of menopausal status, 
height, and weight. Postmenopausal patients 
were then further matched according to the 
time elapsed since the menopause 
(menopausal age). Women within 10 years 
post menopause were matched exactly for 
menopausal age, women between 10 and 25 
years post menopause were matched for 
menopausal age i2 years, and those over 25 
years post menopause were matched for 
menopausal age ±6 years. Each control patient 
was selected to match the study patient to 
within ±2 cm of height and ±2 kg of weight.
. —,™, u«*.iuun, rvnae, ±tea, Homey, Bennett, surto
Five patients could not be matched with im­ 
precision and were assigned controls «* 
BMI were within ±2-5 of the index case
Statistical analyses were performed u« 
Epi Info 5.01 b (World Health Organizati § 
Geneva, Switzerland) and Kwikstat 2 nn 
(Texasoft/Mission Technologies, Cedar Wu 
Texas, USA). Two sided tests were used "i 1' 
the level of statistical significance set at 0-o<? 
Parametric variables were compared usine th ' 
t test (ANOVA and paired r test) and ^ 
parametric variables were compared using th" 
X2 test, or Fisher's exact test where th' 
numbers were too small to allow accurate 
interpretation of the Xz test. Multiple 
regression analysis was performed to test the 
effect of BMI, menopausal age, adherence to 
diet, and duration of coeliac disease on BMD 
All values are stated as mean (3D).
The research protocol was approved by the 
Hull and East Yorkshire Ethics and Clinical 
Trials Committee.
Results
Eighty one coeliac disease patients attended for 
measurement of bone mineral density. Fifty 
two were premenopausal and 29 post­ 
menopausal. The latter had a mean (SD) age 
of 59-2 (8-6) years with a range of 40-77 years. 
There were no differences between coeliac and 
control groups in respect of hysterectomy, 
exposure to hormone replacement therapy, 
corticosteroids, exercise, or tobacco or alcohol 
consumption (Table I). Age at diagnosis of 
coeliac disease and institution of a gluten free 
diet ranged from 0 to 41 years with a median of 
8 years. Fifty eight patients reported they had 
always adhered to a gluten free diet, 17 
patients usually adhered, and six patients never 
adhered. Eighty one matching controls were 
selected from the normal databases described 
above. BMD was expressed using the standard 
area density notation of g/cm2 presented below 
as means (SD).
Overall, the coeliac patients (n=81) showed 
a significantly lower mean (SD) spinal BMD 
(1-076 (0-186)) than the control group (M55 
(0-143); p<0-001). Similarly, BMD at the 
femoral neck in the coeliac group was 0-887 
(0-142) whereas that of the control group was 
0-965 (0-127); p<0-001. When the two groups 
were stratified according 10 their mer.opa-usal 
status, the postmenopausal coeliac patients
TABLE I Occurrence of potential confounding uoriaWes in 
coeliac disease patienu and control subjects
Parameter
Ever smoking
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2 test; ** Fisher's exact test.
mineral denary in adult female patients
TABLE H Bone mineral density (g/cm2) of the spine 
(L2-L4) and femoral neck in patients with coeliac disease 








































(n=29), had a significantly lower spinal BMD 
of 0-924 (0-14) than the control value of 
1-129 (0-70); p<0-001. In' this group, the 
femoral neck BMD of 0-785 (0-72) was also 
significantly below the control group value of 
0-885 (0-55);p<0-001.
The premenopausal coeliac patients (n=52) 
did not show a significantly different spinal 
BMD (1-160 (0-151)) when compared with 
their controls (1-169 (0-117)). However, at the 
femora] neck, the premenopausal coeliac 
patients did show a significantly lower BMD 
(0-943 (0-129)) than their controls (1-010 
(0-I14);p<0-01) (Table II).
Using multiple regression analysis, neither 
the time since diagnosis of coeliac disease nor 
reported adherence to gluten free diet was 
found to exert any significant influence upon 
BMD. However, BMI was positively correlated 
with spinal but not femoral neck BMD. 
Menopausal age correlated significantly with 
both spinal arid femoral neck BMD (Table IH).
Discussion
This study confirms that coeliac disease 
adversely affects bone mineral density, and 
that the relationship holds when female coeliac 
patients are compared with strictly selected 
controls matched for sex, height and weight, 
menopausal status and, where applicable, 
menopausal age. It can be argued that the pre­ 
menopausal controls should be age matched 
too. Published reports are divided about the 
impact of age as a single factor on BMD in the 
healthy premenopausal patient, however, 13 u 
and for practical purposes it is generally agreed 
that peak bone density, achieved in the early 
third decade is essentially the value with which 
women later approach the climacteric.
The exact mechanism of the development of 
osteopenia and osteoporosis in the coeliac 
patient is incompletely understood;19 There is 
no direct correlation between bone derange­ 
ments and steatorrhoea, 15 although the institu­ 
tion of a gluten free diet has been reported to
TABLE m Multiple regression analysis between body mass 
index (BMI), menopausal age (MEN), adherence to diet 
(ADH), duration of disease (DUR), and bom mineral 
density (BMD) of the lumbar spine and femora! neck









have a beneficial effect on BMD.4 I6 Possible 
but unproved mechanisms leading to osteo­ 
penia in the coeliac patient include a reduced 
intestinal surface area due to the characteristic 
villous atrophy, 17 saponification of intestinal 
calcium with unabsorbed fats with increased 
faecal calcium excretion, 6 secondary hyper- 
parathyfoidism due to reduced absorbtion of 
calcium, 3 and decreased absorbtion of vitamin 
D. 18
Present lack of understanding of the exact 
mechanisms involved, makes it difficult to 
explain our observation that coeliac disease in 
the premenopausal patient seems to affect the 
femoral neck BMD alone. This could reflect a 
differential impact of the calcium/vitamin D 
malabsorption of coeliac disease on the mainly 
conical bone of the femoral neck compared 
with its effect on the mainly trabecular bone 
of the lumbar vertebrae. The latter, in the 
presence of adequate endogenous oestrogen, 
may be able to maintain BMD in the face of 
malabsorption of mineral. After the 
menopause, the loss of endogenous oestrogen 
removes the spinal protection and both sites 
then exhibit substantial decrements on BMD 
when compared with matched non-coeliac 
controls. On the other hand, this apparent 
difference could be anefactual, due to the 
different populations used for selecting the 
premenopausal and postmenopausal control 
groups. We would caution that the use of 
postal recruitment of a registered coeliac 
population may incur bias. For example, 
knowledge that BMD was to be measured may 
have encouraged attendance by a sample par­ 
tially selected by a positive family history of 
osteoporosis or a previous history of fractures.
What advice should be offered to patients 
with coeliac disease to protect them against 
osteoporosis? Although our multiple regression 
analysis did not show a significant affect of 
dietary adherence upon BMD, the numbers of 
non-adherers was small and the true influence 
of a gluten free diet upon BMD will require to 
be assessed in a larger, and ideally, prospective 
study. But consideration should be given to 
performing bone mineral densitometry either 
.at the time of diagnosis or at the time of 
menopause, in order to establish basal values 
of mineral density at the key areas of spine and 
hip. The premenopausal patient may then be 
followed up with two repeat. densitometry 
examinations at yearly intervals in order to 
establish that BMD is stable. Such patients 
may then be discharged from densitometric 
follow up until menopause when a further 
examination will determine if her BMD 
requires intervention with HRT or an alterna­ 
tive bone-sparing regime. All postmenopausal 
patients with coeliac disease should undergo 
BMD measurement at hip and spine and 
should be considered for treatment with 
specific bone-sparing regimens, should a 
diagnosis of osteoporosis be established.
It should, however, be emphasised that the 
natural history of bone mineral density in the 
coeliac patient will remain obscure until 
prospective studies utilising precise measuring 
techniques such as DEXA become available.
Pislorius, Sweidan, Purdie, Steel, Howey, Bennat Su'•ami
For the moment coeliac disease should be 
added to the list of medical conditions whose 
presence constitutes an indication for bone 
densitometry.
1 Bcnnett TI, Hunter D, Vaughan JM. Wiopathic 
steaiorrhoea (Gee's disease). A nutritional disturbance 
associated with tetany, osteomalacia and anaemia. QJM 
1932; 1: 604-77.
2 Salvcsen HA, Boe J. Ostcomalacia in sprue. Aaa Med Scand 
1953; 146: 290-9.
3 Hams OD, Warner M, Cooke WT, Povcr WFR. Calcium 
studies in adult coeliac disease and other gastrointestinal 
conditions with particular reference to osteomalacia, 
SamdJGastnenterol 1970; 5t 169-75.
4 Moltcni N, Caraceni MP, Bardella MT, Ortolani S, 
GaodoHni GG, Bianchi P. Bone mineral density in adult 
celiac patients and the effect of gluten-free diet from 
childhood. Am3 Gastromiml 1990; 85: 51-3.
5 Caraceni MP, Moltcni N, Bardella MT, Ortolani S, Nogara 
A, Bianchi PA. Bone and mineral metabolism in adult 
celiac disease. Am J Gaaroenterol 1988; 83: 274-7.
6 Cooke WT, Holmes GKT. Clinical presentation. In: 
CoeKac disease. Edinburgh: Churchill-Livingstone, 1984; 
90-5.
7 Staun M, Jamum S. Measurement of the 10 000-molecular 
weight calcium-binding protein in small-intestinal biopsy 
specimens from patients with malabsorption syndromes. 
ScaudJGasmetiKnl 1988; 23: 827-32.
8 Amoah J, Williams C, Long RG. Calmodulin content and
activity in normal and coeliac duodenum G*,, i Q DO 
303-6. "> M;
9 Lindh E, Ljunghall S, Larsson K, Lavo B. Screenin 
andbodies against gliadin in patients with osti-n« r 
JlMemMed 1992; 231: 403-6. OSK°Pwosls ,
10 McFarlane X, Bhalla A, Morgan L, Reeves D R0s
DAF. Ostcoporosls: a frequent finding in ireiwH j n 
coeliac disease. Out 1992; 33: S48. M ad»lt
11 Butcher GP, Banks LM, Walters JEF. Reduced h 
mineral density in coeliac disease - the need for K c 
dcnsitomtny estimations. Gut 1992; 33i S54 nc
12 Cummings SR, Black DM, Nevitt MC, a a!. Bone Jen « 
at various sites for prediction of hip fractures r *•* 
1993; 341: 72-5. "w«
13 Hansen MA. Assessment of age aad risk factors on b 
density and bone turnover in healthy prcmenoDau^'i 
women. Ostcoporosis International 1994; 4: 123-8.
14 Baran DT. Magnitude aad determinants of premenopm, I 
bone loss. Ostcoporosis International 1994; 4 (suppi iy
15 Moss AJ, Waterhousc C, Terry R. Gluten sensitive 
entcropathy with osteomalacia but without stcatonh 
NBnglJMed 1965; 272: 825-30.
16 Mora S, Weber G, Barera G, Bellini A, Passolini D, Prinstcr 
C, et al. Effect of gluten-free diet on bone mineral content 
in growing patients with celiac disease. Am 7 dm Nm 
1993; 57: 224-8.
17 Trier JS. Celiac sprue. NiwEnglJ MedlWl; 325: 1709-jg
18 Thompson GR, L«wis B, Booth CC. Absorbtion of 
vitamin D in control subjects and patients with intestinal 
malabsorption. J Clin Invat 1966; 45: 94-102.
19 Walters JRF. Bone mineral density in coeliac disease Ow 
1994; 35: 150-1.
CLIMACTERIC 2003:6:96-103
Factors affecting long-term adherence 
to hormone replacement therapy after 
screening for osteoporosis
S. A. Steel, P. Alberlazzi, E. M. Howarth and D. W. Purdie 
Centre for Metabolic Bone Disease, University of Hull, UK
Key words: SCREENING FOR OSTEOPOROSIS, LONG-TERM ADHERENCE TO TREATMENT, HORMONE REPLACEMENT 
THERAPY
ABSTRACT
Objective To investigate factors likely to influence adherence to hormone replacement 
therapy (HRT) in women known to have low bone mass.
Study design This was a prospective study of bone mineral density screening in 6282 
women aged 50-54 years.
Results Low bone mass at either the hip or spine was found in 1462 women. The 
principal route of HRT delivery, transdermal or oral, as well as the presence of climac­ 
teric symptoms before starting treatment, did not influence adherence. However, 
adherence to HRT type was significantly superior in hysterectomized women taking 
unopposed estradioi (median 32 months) compared with those on sequential HRT 
(median 28 months; p = 0.011), Overall, a 5-year adherence to HRT of 61% was 
achieved.
Conclusion Approximately 34% of women starting HRT are likely to stop in the first 
2 years of use. Following this, the discontinuation z-ate is low. The combination of 
knowledge of risk for osteoporosis and regular follow-up positively influences long-term 
adherence to HRT.
INTRODUCTION
Hormone replacement therapy (HRT) is one of 
the treatments of choice for the prevention of 
bone loss, and there are recent data to confirm its 
long-term effectiveness in the reduction of hip 
fracture 1 . It confers additional benefits such as the 
relief of physical and psychological symptoms of 
the climacteric. Universal treatment of osteo- 
penia - low bone mass - with HRT has been 
advocated2, but has proved unrealistic. Such a 
strategy would have considerable financial and 
human-resource implications, and its effectiveness 
would be compromised by poor adherence. 
Climacteric symptom relief thus remains the
most common reason for prescribing HRT3 . How­ 
ever, among women who receive prescriptions, 
only 25-40% will adhere to therapy for more 
than 1 year and, within 3 years, 75-80% will have 
stopped treatment4 . The return of cyclic or 
unscheduled bleeding, together with fear of breast 
cancer, is one of the most commonly cited reasons 
by patients for discontinuation5 '6 . Period-free 
HRT regimens may thus conceivably influence 
adherence, and have been reported to improve 
adherence in some but not all studies7' 8 . Interest­ 
ingly, prior hysterectomy does not appear to 
affect the rate of discontinuation4, an apparent
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challenge to the central issue of bleeding as a 
disincentive to adherence6 . Transdermal regimens 
are more likely to be discontinued than oral ones4 .
Awareness of the risk of osteoporosis might 
significantly influence adherence. In one study, 
96% of women interviewed said that they would 
consider HRT if their bone densitometry scan 
disclosed an increased risk of osteoporosis3 . In 
another, however, only 78% of women at risk 
accepted HRT following densitometric screening, 
and of those almost 40% discontinued treatment 
within 8 months9 ,
In this study, we have examined how an 
individual patient's knowledge of her risk of 
osteoporosis, plus regular scheduled follow-up 
for up to 5 years, influence acceptance and long- 
term adherence to HRT regimens.
METHODS
Between 1989 and 1993, 6282 women aged 
50-54 years underwent femoral neck and spinal 
bone mineral density (BMD) assessment by dual 
energy X-ray absorptiometry (DXA) as part of a 
collaborative exercise to determine the technical 
and logistical feasibility of a population-based 
osteoporosis screening program. The study was 
approved by the local ethical committee. All 
general practitioners (GPs) were approached 
regarding participation in this study, and attended 
a presentation and discussion with the principal 
investigators. The GPs were instructed in the 
methods to be used in this study for the interpreta­ 
tion of bone densitometry results, and identifica­ 
tion of patients at high risk of future fragility 
fracture. The benefits and risks of HRT and 
dietary and life-style issues affecting bone density 
were also presented. The GPs were instructed to 
see and advise those women defined as being at 
risk, and, where appropriate, offer HRT from 
a menu of bone-protective regimens. The study 
protocol was not prescriptive in terms of con­ 
tinued support and counselling of the patient by 
primary care, as the aim was to observe compli­ 
ance under standard clinical practice.
In this large cohort of women, 2282 (36%) 
were found to have BMD at either the hip or spine 
below the 25th centile and, following the guide­ 
lines applicable at the time, were classed as being 
at risk of osteoporosis. According to the World 
Health Organization (WHO) classification, these 
women are all below the osteopenic threshold10 . 
Entire 5-year data sets for HRT acceptance and 
adherence were available for only 1462 women 
(23%), who were hence considered in this article.
The 61 general practices collaborating in the study 
were provided with a menu of HRT regimens 
which were known, through clinical trials, to 
be osteoprotective. These were Prempak C®, 
Cycloprogynova®, Menophase®, Estrapak® and 
Estracombi® for non-hysterectomized women and 
Premarin® and Estraderm® patches for women 
without a uterus". The practitioners were asked 
to recommend commencement of HRT if the 
patient was agreeable and clinically suitable. 
Similarly, if HRT had already been started, its 
continuation was advocated. The types of HRT 
preparations used at baseline are reported in 
Table 1. Changes in HRT regimen were allowed 
if, at any time, the current therapy proved to be 
unacceptable or intolerable.
On attendance for DXA, data were collected 
by questionnaire on relevant medical and social 
factors, presence of menopausal symptoms and 
HRT exposure. Patients were informed of their 
bone density results by their GP, who was then 
responsible for the initiation of treatment and for 
its day-to-day management. Patients were offered 
further densitometry assessment at 2 and 5 years. 
At each follow-up visit, patients were questioned 
on adherence to treatment.
Statistical analysis was performed using Epi 
Info 6 (Centers for Disease Control and 
Prevention, Atlanta, GA) and Statistical Package 
for the Social Sciences (SPSS, Chicago, IL) soft­ 
ware. Demographic data were analyzed using 
an independent two-sample t test for normally 
distributed data and the Wilcoxon two-sample 
test for other comparisons. The %2 test was used 
to compare prevalence of menopausal symptoms 
and prior hysterectomy. Differences were con­ 
sidered to be statisticaliy significant if p < 0.05.
Table 1 Number of women using specific hormone 
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Treatment adherence analyses were conducted 
on an intention-to-treat basis for all eligible 
patients. Survival was measured from the date of 
first starting the treatment to date of discontinua­ 
tion of that particular treatment. Patients still 
on the original treatment at 57 months had their 
treatment duration time censored at 57 months. 
The original recommendation to GPs was to 
maintain the patient on HRT for 5 years only. 
At the time, this was thought to be the optimal 
time to incur bone-protective effects with minimal 
increased breast cancer risk. Patients were gener­ 
ally commenced on their treatment 3-12 weeks 
following their densitometry assessment; hence, at 
the 5-year follow-up, de novo patients adherent to 
HRT would report treatment adherence times of 
57-59 months. Survival estimates were calculated 
using the Kaplan-Meier method, and survival 
curves were compared using the log-rank test for 
equality.
RESULTS
Entire 5-year data sets for HRT acceptance and 
adherence were available for only 1462 of the 
2282 women who were considered at risk of 
osteoporosis. Of these women, 180 (12%) were 
already taking HRT at the commencement of the 
study and continued with their regimen, while 838 
(57%) of the remainder were found to be suitable 
for HRT and, after consultation with the practi­ 
tioner, on the basis of the densitometric result 
were advised to start treatment de novo. A total 
of 444 (30%) women were not commenced on 
treatment, since 179 had a contraindication to its 
use and 265 (60%) rejected the offer. The 180 
women who were current HRT users at entry had 
been on treatment for an average of 50.3 months 
(standard deviation (SD) 28.4 months), and, of 
them, 159 (88%) were still on treatment 2 years 
after screening, compared with only 550 (66%) of 
the de novo group. This difference was statisti­ 
cally significant (%z = 36.12; p < 0.01). However, 
after the first 2 years of use, HRT discontinuation 
became similar in the two groups at 11% for 
established HRT users and 9% for those starting 
HRT de novo (Figure 1).
The baseline anthropomorphic characteristics 
of women who were established or de novo users 
of HRT are presented in Table 2. There were no 
statistically significant differences in age, body 
mass index (BMI) or BMD at the hip between the 
two groups. However, spine BMD was, on 
average, 3% higher in established HRT users
(1.029g/cm2 ) than in women starting de novo 
(0.997 g/cm2 ) (p = 0.004). One hundred and 
fifty-seven women (87%) who were established 
HRT users had climacteric symptoms before 
starting HRT, compared with 550 (65%) de novo 
users (p< 0.001). Established HRT users were 
also more likely to have undergone hysterectomy: 
62 women (34%) versus 180 (21%) women who 
were de novo starters (p < 0.001) (Table 2).
Information on the presence or absence of 
climacteric symptoms before starting HRT was 
available in 1012 (99%) of the 1018 women who 
either started HRT de novo or were on HRT at 
the time of densitometry screening. Their baseline 
anthropomorphic characteristics are presented in 
Table 3. There were no differences in age, BMI 
or BMD at the hip or spine between the symptom­ 
atic and asymptomatic groups. As expected, those 
with symptoms had a lower mean menopausal 
age (years of amenorrhea) than those without.
Climacteric symptoms, which are mainly vaso- 
motor or psychological, might have influenced 
uptake and continuation of HRT in a total of 
708 (70%) women, while 304 (30%) women were 
asymptomatic and thus based their decision to 
start or continue HRT solely on the basis of the 
bone density results.
At the 5-year follow-up, 445 (63%) symptom­ 
atic and 178 (58%) asymptomatic women were 
still taking HRT. The difference was not statisti­ 
cally significant (%2 = 1.66; p = 0.20).
A total of 242 women (24%) in the study 
group had undergone hysterectomy at a mean age 
of 41.3 (SD 6.1) years. The adherence rate to 
treatment at 5 years was 66% (n = 160) among 
hysterectomized and 60% (n = 465) among non- 
hysterectomized women (%2 = 2.99; p = 0.08).
For the route of administration analysis, 817 
(87%) of the 945 patients with valid information 
discontinued their initial HRT therapy within 
57 months of beginning: 700 oral and 117 trans- 
dermal (Figure 2). The median duration of time on 
HRT was the same for both routes of administra­ 
tion (oral: median 27 months, 95% confidence 
interval (CI) 25-28 months; transdermal: median 
27 months, 95% CI 23-31 months). As expected, 
the log-rank test showed no statistically signifi­ 
cant difference between the duration times 
(log-rank t = 0.27; df = 1; p = 0.61).
For the type of HRT analysis, 685 (85%) of 
the 807 patients with valid information discon­ 
tinued their initial HRT therapy within 57 months 
of beginning: 542 sequential and 143 unopposed 
(Figure 3). The median durations of time on 
HRT were statistically significantly different from
98
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180 (12%)
were HRT users























Figure 1 Natural history of hormone replacement therapy (HRT) adherence
Table 2 Baseline characteristics for those who started or continued hormone replacement therapy (HRT) on the 
basis of densitometry (n = 1018). Values are expressed as mean ± standard deviation, two-sample t. test, or n (%),
Established HRT users 
(n = 180)
De novo HRT users 
(n = 838) p Value
Age (years)
Body mass index (kg/m 2 )























each other (log-rank i2 = 6.45; df = 1; p = 0.011). 
The duration times for the two groups were, 
unopposed: median 32 months, 95% CI 28-35 
months and sequential: median 28 months, 95% 
CI 26-29 months.
DISCUSSION
The described combination of risk assessment and 
follow-up achieved a 61.3% long-term (5 years) 
adherence to HRT, one of the highest adher­ 
ence rates so far reported. Previous studies have
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Table 3 Characteristics of patients with or without climacteric symptoms before starting hormone replacement 
therapy (HRT) (n = 1012). Values are expressed as mean ± standard deviation, two-sample t test
Symptomatic (n = 708) Asymptomatic (n = 304) ~p Value
Age (years)
Body mass index (kg/m2 )
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Figure 2 Kaplan-Meier estimates for treatment 
adherence by route of administration of hormone 
replacement therapy (HRT): transdermal, 22 (15.83%) 
censored cases; oral, 106 (13.15%) censored cases; 
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Figure 3 Kaplan-Meier estimates for treatment 
adherence by type of hormone replacement therapy 
(FIRT): unopposed, 36 (20.11%) censored cases; 
sequential, 86 (13.69%) censored cases; log-rank 
X2 = 6.45, p = 0.011
evaluated adherence to treatment over relatively 
short periods. Ravnikar 12 in a survey recorded a 
30% adherence rate after 9 months of treatment, 
while Sullivan13 reported that only 40% of 
women in the general population were still taking 
HRT at 1 year. One study evaluated adherence to 
treatment beyond 1 year, and found a poor 4-year 
adherence rate of 20% I4, with the best rates 
recorded in those individuals commenced on HRT 
because of clinical risk factors for osteoporosis. 
Knowledge of the results of bone densitometry has 
been shown to influence osteoporosis-preventive 
behavior substantially15 . Rubin and Cummings 16 
found that 94% of women who had low bone 
density results began at least one type of preven­ 
tive measure, compared with 56% of those who 
had a normal result.
If knowledge of risk influences uptake, the 
central issue becomes that of adherence to 
therapy. In the Postmenopausal Estrogen/ 
Progestin Interventions (PEPI) trial, 81-86% of
participants taking either sequential or continuous 
HRT were continuing after 3 years 17 . In clinical 
trials, participants are often volunteers, whose 
motivation to continue study medication is gener­ 
ally higher than that of the normal population18 . 
Choice of treatment, education and, above all, 
follow-up clinic visits may be important to en­ 
hance motivation and manage side-effects. Dis­ 
continuation with HRT occurs primarily in the 
first few years of use. In the present study, about 
23% of women already established on treatment 
before the start discontinued before 5 years, at a 
rate of about 11.5% between densitometric 
assessments. Women who started HRT de novo 
showed the largest discontinuation rate during 
the first 2 years of treatment (34%), while in the 
subsequent 3 years, the discontinuation rate was 
similar in both groups at 9% in de novo users 
and 11% in established users (p - 0.8). This 
supports the findings of others that, after the 
initial period of adaptation, almost 80% of
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women will continue treatment long term13 . 
Support and regular follow-up is thus required, 
particularly during the first few months of starting 
HRT treatment when side-effects6 are more likely 
to occur and cause treatment discontinuation. The 
main difference between the present study and 
others where lower adherence rates were 
obtained9 was the recall system and repeated 
densitometry. Densitometric follow-up is not 
generally advocated in patients on osteoprotective 
treatment, but regular review, either by densito­ 
metry or by measurement of bone turnover 
markers, may prove important as a regular means 
of feedback to patients to secure adherence, and as 
a means of identifying non-responders. Carton 
and colleagues found that 96% of women would 
be willing to consider HRT if the bone scan 
suggested an enhanced risk of future osteoporotic 
fractures, and as many as 85% would take HRT 
for as long as their doctor recommended it3 . 
Densitometry is thus a powerful tool to enhance 
motivation both to initiate and to continue treat­ 
ment, particularly when this is required long term 
for indications such as osteoporosis prevention.
It has been suggested that treatment adherence 
rates over 30% would make osteoporosis screen­ 
ing cost-effective20. We have achieved continua­ 
tion rates of over 60% at 5 years with HRT alone 
among women in their sixth decade. Adherence 
rates to treatment might have been even higher if 
women had had available, at the time, a wider 
choice of treatment such as bisphosphonates and a 
selective estrogen receptor modulator (SERM) in 
addition to HRT. In this study, only 48% of the 
overall total 1640 women found to be at risk of 
osteoporosis were receiving appropriate treatment 
after 2 years'5 .
It might be argued that women who volunteer 
for bone density screening programs may be an 
intrinsically higher-risk group who are concerned 
about osteoporosis because of previous fractures, 
current risk factors or family history. They would 
hence be more likely to comply with treatment 
compared with women in the general population. 
However, since the offer of densitometric exami­ 
nation was made to a total of 7965 women aged 
50-54 years of whom 6282 (79%) attended, and 
since the corrected acceptance rate to the offer of 
densitometric screening was 6282 (83%) s , this 
sample should be reasonably representative of the 
overall population concerned. Of the 2282 
women who were identified at the initial screening 
visit as being 'at risk', 820 (36%) were lost to 
follow-up; thus, 1462 (64%) are the subject of 
this review. We suspect that the substantial loss to
follow-up is due to multiple factors, including 
breakdown in communication between the 
Centre, the patient and the GP concerned, and this 
will be the subject of a future article.
Patients attending at menopause clinics com­ 
plain primarily of climacteric symptoms21 , and 
many women commence HRT for symptom relief. 
Our data, contrary to those of others22, fail 
to show any positive influence of climacteric 
symptoms, present at the institution of treatment, 
on long-term treatment adherence.
The return of monthly bleeding is often cited 
as one of the main reasons for discontinuation. 
Sequential combined HRT regimens are asso­ 
ciated with cyclic bleeding, while continuous 
combined regimens should achieve amenorrbea. 
We could not reliably compare adherence rates of 
sequential versus continuous combined regimens 
as the latter were only launched in the UK in 
1995, some 5 years after the start of this study. 
Women in this trial were recruited between 1989 
and 1993, and therefore the majority of them 
were offered, and continued with, sequential 
HRT. After 2 years, the difference in continuation 
between hysterectomized women on unopposed 
estrogen and those with a uterus on sequential 
combined regimens became more apparent 
(Figure 3). This is in agreement with the data 
of Ettinger and Pressman4 . Contrary to what is 
commonly believed, regular withdrawal bleeds do 
not appear to affect adherence adversely at the 
start of treatment, but become an issue after 
12-24 months of treatment. Lack of bleeding, 
such as that reliably achieved with hysterectomy, 
may thus enhance treatment adherence23 . Route 
of administration might also conceivably influence 
treatment adherence. Transdermal HRT was 
found to lower adherence in one study4, but not in 
another24 . Among women in the present study, 
adherence at follow-up was similar for trans- 
dermal and oral administration.
In conclusion, clinical risk factors have been 
shown to be unreliable as a means of identifying 
women at high risk of osteoporosis, and the vari­ 
able most strongly predictive of fracture risk is 
bone mineral density25 . The case for screening all 
postmenopausal women by measurement of bone 
mineral density has been unacceptable for several 
reasons, one of which was that adherence to treat­ 
ment following screening was unknown. Our data 
show that targeting treatment to women at risk, 
combined with regular densitometric follow-up, 
can achieve high treatment adherence rates. When 
this study commenced there were few alternatives 
to HRT for the prevention and treatment of
Climacteric
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postmenopausal osteoporosis. Now that there is a 
wider treatment choice, regular follow-up is nec­ 
essary to adjust treatment to the changing needs of 
women as well as conserve motivation. Such high 
rates of adherence to treatment, if confirmed, will 
entail re-evaluation of the cost-effectiveness of 
screening by densitometry in the field of osteo­ 
porosis prevention.
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Abstract
Summary Fracture risk is underestimated in women with 
unknown vertebral fractures. Using VFA, we compared two 
screening methods: targeted (6,388 women) and routine 
(2,176 women). Routine screening detected fractures in 
20%. Targeted screening only required 5% attending for 
DXA to undergo VFA but only detected 9.6% of women 
with fractures.
Introduction BMD alone underestimates fracture risk in 
women with unknown vertebral fractures. We report the 
results of routine vertebral fracture assessment (VFA) 
screening and compare with targeted screening. 
Method Our centre initially targeted VFA at women with 
reasons to suspect a vertebral fracture. Later we changed to 
routine VFA screening for all women over 65. We retrospec­ 
tively compare each screening method's ability to detect 
vertebral fractures.
Results Six thousand three hundred: and eighty-eight women 
over 65 underwent DXA during the period of targeted VFA 
and 2,176 during routine VFA. Routine VFA detected 420 
(20.0%) women with fracture. Most vertebral fractures 
(56.2%) occurred in women with osteopenia. Routine VFA 
would be expected to alter the management of 1 in 6 
osteopenie women. Targeted VFA was performed in 332 
(5.2%) women detecting 122 (1.9%) women with fractures. 
It was estimated that targeted VFA only detected 9.6% of 
women with a vertebral fracture. Targeted VFA failed to 
detect fractures in 18.1% of the population attending for 
DXA and in 29% of those with osteoporosis.
E. T. Middleton (El) - S. A. Steel
Centre for Metabolic Bone Disease, Hull Royal Infirmary,
Brocklehuist Building, 220-236 Anlaby Road,
Hull HU3 2RW. UK
e-mail: etmiddleton@doctors.org.uk
Conclusion Routine VFA detects vertebral fractures in 20% 
of women over 65. Targeted VFA greatly reduces the 
number of VFAs performed but only detects a minority of 
the women with vertebral fractures.
Keywords Bone mineral density • Screening • 
Vertebral fractures • Vertebral fracture assessment
Introduction
Vertebral fractures are the commonest osteoporotic frac­ 
tures [1], are strongly associated with low bone mineral 
density [2, 3] and are often considered the hallmark of 
osteoporosis. The prevalence of vertebral fracture increases 
with age and in women aged over 50 the overall prevalence 
of vertebral fracture is 20-25% [4], Vertebral fractures are 
associated with considerable morbidity [5, 6] and mortality 
[7J. As the number of prevalent vertebral fractures in­ 
creases, the risk of suffering an incident vertebral fracture 
increases dramatically [8]. Furthermore, it has been 
demonstrated that vertebral fractures also predict future 
non-vertebral and hip fractures independent of bone mineral 
density (BMD) [9, 10]. It is therefore important to know s. 
woman's vertebral fracture status in order to assess her risk 
of future fracture and guide treatment decisions. This is 
particularly important in osteopenie women where a preva­ 
lent vertebral fracture may make the difference between the 
woman receiving anti-resorptive therapy or not.
Despite the high prevalence of vertebral fractures it has 
been demonstrated that two thirds of women with fractures 
are unaware of them [4], and in these women their future 
fracture risk will be substantially underestimated by BMD 
alone. The only way to detect these asymptomatic vertebral 
fractures is radiologically and spinal x-rays are considered
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the gold standard for vertebral fracture detection. Modern 
dual energy x-ray absorptiometry (DXA) scanners are able 
to perform a vertebral fracture assessment (VFA) of the 
spine which can detect vertebral fractures. Compared to 
spinal x-rays, VFA has the advantages of being less expen­ 
sive, having a lower radiation dose and being performed at 
thesametime as DXA [11]. VFA has besn demonstrated to 
have a good sensitivity and specificity for vertebral fracture 
detection when compared to spinal x-rays [11-14]. This 
makes VFA a potential screening tool which can be per­ 
formed on women attending for DXA.
We report the results of screening all women over the 
age of 65 for vertebral fractures with VFA. We aim to 
compare two potential screening strategies: screening all 
women (routine screening) and screening only those 
women with reasons to suspect a prevalent vertebra! 
fracture (targeted screening). We also aim to examine the 
merits of routinely screening women depending on their 




The Centre for Metabolic Bone Disease in Hull (U.K.) is a 
large regional centre for bone dcnsitomctry. Since 2001 all 
patients attending for bone densitometry have had spine and 
hip BMD measured using a Lunar Prodigy bone densi- 
tometer (GE Lunar, Madison, WI). Basic patient details, 
including age, sex, gender and menopause age, arc rou­ 
tinely recorded on the Prodigy's database at the time of 
attendance. Using this database we identified all women 
over the age of 65 at the time of their first DXA scan.
VFA screening method
Our centre initially adopted a targeted approach to vertebral 
fracture screening where women with reasons to suspect 
a possible fracture underwent a VFA. Indications for a 
targeted VFA were reported height loss (>2.5 cm, 1 inch), 
Dowager hump, suspected fracture on anterior-posterior 
spine DXA and known vertebral fracture. In August 2005 
our centre changed to a routine screening program under 
which all women who attended for DXA underwent VFA if 
they were over 65 and physically able to do so.
Vertebral fracture assessment
Our centre has three Lunar Prodigy bone densitometers 
with VFA capability, all using software version 10.5. The 
scanners are subject to a rigorous quality assurance pro­
cedure, which includes weekly scanning of a purpose 
designed phantom for VFA [15]. The scans are performed 
and analysed by qualified, experienced bone densitomet- 
rists following standardised protocols.
VFA is performed with the woman positioned in the left 
lateral decubitus position. Initially, T4-L4 are assessed by 
the densitometrist for fractures using the semi-quantitative 
method described by Genant et al. [16]. All densitometrists 
are fully trained and experienced in performing VFA acqui­ 
sition and evaluation. Any vertebra which are considered to 
be fractured subsequently undergo a six point quantitative 
assessment using the Prodigy computer software to measure 
the posterior, middle and anterior vertebral height. Fractures 
are graded as mild (grade 1), moderate (grade 2) or severe 
(grade 3) if there is a 20-25%, 25-40% or greater than 40% 
reduction in vertebral height, respectively. VFA has been 
demonstrated to correlate well with spinal x-ray for grade 2 
and 3 fractures [11-13] as such these fractures are iden­ 
tified. Of the mild fractures detected by VFA, 50% are 
normal on x-ray [13]; therefore, grade 1 fractures are not 
identified. The VFA and DXA scan are then validated by a 
clinical scientist specialised in bone densitometry before the 
data are finally entered in to the database. A final report to 
the women's general practitioner is issued by an osteo- 
porosis consultant who may also review the VFA qualita­ 
tively, but this report is not recorded on the database.
Analysis
We retrospectively identified all women over the age of 65 
at the time of their first DXA scan. Depending on the- 
screening policy at the time of attendance, women were 
identified as either the targeted screening group (pre- 
August 2005) or the routine screening group (post-August 
2005). For each group, basic population demographics were 
determined and compared using two sample t-test or Mann- 
Whiteey U test depending on the distribution of the data. 
CM-square was used for categorical data. The routine 
screening group was used to determine the prevalence, 
type and site of vertebral fractures in our local population. 
Using these prevalence data, we estimated the number of 
women with vertebral fractures that remained undetected by 
targeted screening.
The routine and targeted screening groups were then 
divided by hip BMD at the neck of femur (NOF) into 
normal, osteopenic or osteoporotic. Hip BMD was used to 
define BMD category as this avoids the artefactual increase 
in spine BMD due to vertebral fracture and is the recom­ 
mended site for the diagnosis of osteoporosis [17]. Using 
these data, we determined the number of osteopenic women 
in whom the knowledge of vertebral fracture status may 
influence the treatment decision. Finally, the number of 
women with vertebral fractures that remained undetected by
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targeted screening For each category of BMD was esti­
mated. Statistical analysis was performed using SPSS for
Windows (version 14.0 SPSS, Inc., Chicago, IL). Our




A total of 8,564 women over the age of 65 when attending
for their first DXA were identified. Six thousand three





































hundred and eighty-eight attended during the period of 
targeted VFA while 2,176 women attended during the 
routine screening period. The routine screening group 
were slightly, but significantly, older (mean age 74.3 vs. 
72.5 years). The routine screening group also had a slightly 
older menopause age, lower hip BMD and higher spine 
BMD. Although these differences were statistically signif­ 
icant, the absolute difference between the groups for these 
characteristics was only 1-2%. Subject demographics are 
demonstrated in Table 1.
Routine VFA screening for the detection of vertebral 
fractures
Of the 2,176 women attending during the period of routine 
screening, 2,098 (96.4%) women underwent VFA. Grade 2 
and 3 vertebral fractures were identified in a total of 420 
women (19.3% of the population, 20.0% of VFAs) of 
whom 185 (44.0%) had two or more vertebral fractures 
(Table 2). Routine screening detected a total of 755 grade 2 
and 3 vertebral fractures. Wedge and biconcave fractures 
were more frequent than compression fractures. Table 3 
demonstrates the frequency of each type of vertebral frac­ 
ture. Vertebral fractures were commonest around T7 to T9










































and the thoracolumbar junction, Til-LI. Figure 1 shows 
the frequency of fracture at each vertebral level.
Targeted VFA screening for the detection of vertebral 
fractures
Of the 6,388 women in the targeted group, a total of 
332 (5.2%) underwent VFA resulting in the detection of 
122 women with grade 2 or 3 vertebral fractures. Targeted 
screening resulted in a higher detection rate per VFA 
performed (36.7%), although only 1,9% of the total popu­ 
lation attending for DXA had vertebral fractures detected. If 
it is assumed that the overall vertebral fracture prevalence 
rate was similar between the two groups then 1,277 women 
in the targeted group would have been expected to have one 
or more prevalent vertebral fractures on VFA. Only 122 
(9.6%) of these women with fractures were detected by 
targeted screening leaving undetected vertebral fractures 
in an estimated 1,155 women, 18.1% of the population 
attending for DXA.
Vertebral fracture detection by category of BMD
In the targeted and routine VFA groups similar proportions 
of women were in the three categories of hip BMD: normal 
(29.7 vs. 28.7%, p=0.37), osteopenia (55.1 vs. 55.6%, 
p=0.70) and osteoporosis (15.2 vs. 16.6%, p=0.10). In the
Table 3 Type and severity of vertebral fractures detected in women 
undergoing routine VFA
































Fig. 1 Number of fractures 
detected at each vertebral level 











routine screening group, 300 of the 420 (71.4%) women 
with prevalent vertebral fractures did not have BMD 
compatible with ostcoporosis. The majority of fractures 
occurred in women with osteopenia (236/420, 56.2%). In 
the routine screening group the prevalence of vertebral 
fractures was 10.3% of those women with normal BMD, 
19.9% for osteopenic women and 33.2% in those with 
ostcoporosis (Table 4). For the 420 women with fractures 
detected on VFA a history of known vertebral fracture was 
obtained from 8/64 (12.5%) of women with normal BMD, 
53/236 (22.5%) of osteopenic women and 34/120 (28.3%) 
of osteoporotic women.
In the targeted screening group vertebral fractures were 
detected in 1.3%, 1.7% and 3.9% of the normal, osteopenic 
and osteoporotic women, respectively. If it is again assumed 
that the actual prevalence of vertebral fracture was similar 
between the two groups, then targeted screening under­ 
estimated vertebral fracture prevalence in each BMD cate­ 
gory. The proportion of women with undiagnosed vertebral 
fractures increased with decreasing BMD: 9% of women 
with normal BMD, 18% with osteopenia and 29% with 
osteoporosis (Table 5).
Discussion
We report the actual application of VFA as a screening tool 
for the detection of vertebral fractures in women over 65 
referred for bone densitometry. To our knowledge, this is 
the largest study of routine population screening with VFA, 
and there are no previous studies comparing routine and 
targeted screening methods. Vertebral fractures are common 
with the prevalence increasing with age from around 10% 
in women aged 50-59 to over 50% in those aged over 80 
[4]. Furthermore, knowledge of vertebral fracture status 
provides important information for assessing fracture risk 
as prevalent vertebral fractures increase the risk of future 
fracture independent of BMD [9, 10]. However, despite 
their high prevalence and clinical relevance only one third 
of women with vertebral fractures are aware of them [4J. 
This suggests that there is a need for screening for vertebral 
fractures. Although thoracic and lumbar spine x-rays are the 
gold standard for vertebral fracture detection, VFA provides 
a more practical screening tool due to the lower radiation 
dose, lower cost and its availability at the point of sendee 
for women attending for DXA.
Table 4 Prevalence o£ verte­ 
bral fractures detected by WA 
in each category of BMD
"BMD category relates to 
BMD at NOR Spine BMD is 
used in cases with no data for 
NOF BMD («=207) 
1 woman was unable to lie 
supine for axial BMD although 
a WA was obtained























































Table 5 Estimated number of women with undiagnosed vertebral 
































*Estimate derived from the prevalence of vertebral fractures in the 
routine screening group
When used routinely, over 95% of women were willing 
and physically able to undergo VFA at our centre demon­ 
strating that (he procedure was acceptable for most women. 
Overall, routine screening of all women over 65 identified 
one woman with grade 2 or 3 vertebral fractures for every 
five VFAs (20%) performed, and almost half of these 
women had multiple fractures. The majority of fractures 
detected by routine screening occurred in the mid-thoracic 
region and thoracolumbar junction, which is consistent with 
previous reports using both x-ray [14, 18] and VFA [11, 
16]. As with previous reports, the majority of fractures 
detected were wedge or biconcave [12, 19], although we 
found biconcave fractures to be the most common.
As would be expected, when women, were divided up by 
BMD category, the number of women with vertebral frac­ 
tures detected by routine screening increased as BMD 
decreased, VFA is performed after axial DXA, and as such 
it would be possible to perform routine VFA screening only 
in women with certain categories of BMD. Adopting a 
policy of routine VFA screening for women over 65 only if 
they have osteoporosis on (heir axial DXA would require 
VFA to be performed in only 16% of women and would 
increase the rate of vertebral fracture detection to 1 in 3 
women screened. Routine VFA in this category would also 
allow the identification of women with the highest risk of 
future facture i.e., both osteoporosis and vertebral fractures 
[20], However, adopting this policy would miss the 
majority of women with vertebral fractures as 71% of the 
women with vertebra! fractures detected by routine screen­ 
ing did not have BMD compatible with osteoporosis. This 
confirms the findings of two smaller studies in which 60%- 
70% of women with vertebral fractures did not have 
osteoporosis [21, 22]. Furthermore, knowledge of vertebral 
fiacture status in osteoporotic women is less likely to alter 
the patient's management as, over the age of 65, the major­ 
ity of these women would receive treatment anyway.
Vertebral fractures may have more significant therapeutic 
implications in women without osteoporosis. Osteopenie
women would not normally be considered for bone pro­ 
tective treatment based on BMD alone. The presence of a 
vertebral fracture would increase the risk of subsequent 
fracture making treatment appropriate. We found that 20% 
(1 in 5) of osteopenic women had vertebral fractures 
detected by VFA. A similar 14%-20% fracture prevalence 
in osteopenic women has been previously reported although 
direct comparison is difficult as these studies included 
grade 1 fractures and women less than 65 years of age [21, 
22]. Only 22.5% of osteopenic women with a fracture on 
VFA gave a history of known vertebral fracture. Therefore, 
vertebral fractures were identified for the first time in 
15.8% of osteopenic women suggesting that routine VFA 
will directly alter the management of around 1 in 6 osteo­ 
penic women. It has been demonstrated that anti-resorptive 
therapy is effective at reducing the risk of future fracture in 
women with osteopenia if they have a vertebral fracture 
[23, 24] and a recent analysis suggests that this treatment is 
cost effective [25]. Osteopenic women are most likely to 
benefit from routine screening with VFA given the high 
prevalence rate, the therapeutic and clinical implications of 
a vertebral fracture and the cost effectiveness of treatment.
In our population, 10% with normal BMD had vertebral 
fractures, which is again similar to previous reports [21, 
22]. There is little evidence to suggest that bone protective 
treatment is of benefit or cost effective in women with 
normal BMD. As such the clinical relevance of finding 
vertebral fractures in women with normal BMD is less clear 
and the case, for routine VFA in these, women is weaker.
In addition to affecting the initial treatment decision, 
routine screening may also aid monitoring and future treat­ 
ment decisions as it provides a pre-treatment image of the 
spine. This is a reference for the future from which incident 
fractures occurring despite treatment can be diagnosed. 
Osteoporotic women have the highest incidence of vertebral 
fracture [23], and as such routine VFA in osteoporotic 
women will provide valuable baseline information, even 
though it may not affect the initial treatment decision. 
Incident fractures are especially important in countries like 
the United Kingdom, where anabolic bone agents, such as 
teriparatide, can only be prescribed to women who have 
been proven to suffer further fractures despite treatment.
We also report the outcomes of a targeted vertebral frac­ 
ture screening policy for which only women with reasons to 
suspect the presence of a fracture undergo a VFA. Adopting 
this approach to screening women over 65 greatly reduced 
the number of VFAs performed as only 5% of the 
population underwent screening. With a targeted approach 
1 in 3 women undergoing VFA has vertebral fractures 
detected compared to 1 in 5 with routine screening. How­ 
ever, using the targeted approach to screening, only around 
10% of women with fractures are detected. Of all the 
women referred for DXA daring the period of targeted
•£) Springer
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VFA, 18% are estimated to have had vertebral fractures 
which remained undetected. The proportion of women with 
vertebral fractures which remain undetected increased to 
almost a third in women with osteoporosts. We therefore do 
not consider our targeted screening policy to have been 
effective. These figures were calculated using the assump­ 
tion that the vertebral fracture prevalence was fee same 
during the two screening periods. There were statistically 
significant differences between the groups in terras of age 
and BMD, which arc risk factors for vertebral fracture. 
These differences may have arisen due to the non- 
randomised nature of this study and/or the two different 
time periods studied. However, the women were drawn 
fiom the same local population, from the same age group, 
and the difference in these factors was only l%-2%, thus 
unlikely to be of clinical significance or have a major effect 
on fracture prevalence.
The women underwent screening as part of normal 
clinical practice, which, combined with the targe number of 
women involved, means that it was not possible to confirm 
the VFA findings with x-rays. However, our screening pro­ 
gram only identifies grade 2 and 3 fractures. When com­ 
pared to X-ray, VFA has been reported-to have a sensitivity 
of 80-95% for detecting grade 2 and 3 fractures and a 
specificity of 82%-96% for excluding vertebral fractures 
[12, 13, 26, 27]. Therefore, we believe that the majority 
of grade 2 and 3 fractures we detected were identified 
correctly. Our approach to screening is consistent with 
a recent position paper by the International Society of 
Clinical Densitoraetry which recommends that only grade 2 
and 3 fractures should be identified by VFA [28].
It is well recognised that some vertebrae are uninterpret- 
able on VFA. This can be due to poor image quality, which 
most frequently occurs above T7, or due to the presence of 
severe scoliosis or degenerative changes although similar 
limitations are recognised with x-ray [28]. Previous studies 
report that around 90-95% [12, 21, 26, 27] of vertebra are 
interpretable. The majority of uninterpreiable vertebra occur 
above T7 [13, 21], where the prevalence of fracture is low, 
preserving the negative predictive value of VFA [14]. On 
our database any fractures which occulted in uninterpret­ 
able vertebra would not have been labelled as fractured, 
which may have reduced the number of fractures we 
detected. This has less of an impact when categorising 
women, rather than individual vertebra, as fracture or non- 
fracture cases. Women with fractures in uninterpretable 
vertebra would still be correctly classified if they also had a 
fracture in an interpretable vertebra. At our centre, the final 
report issued by the osteoporosis consultant provides an 
opportunity to recommend x-rays in women with un­ 
interpretable VFAs, although these data are not available 
on our database.
With our screening program grade 1 fractures are not 
routinely identified and flagged. Previous studies have 
demonstrated that around one third of vertebral fractures 
arc grade 1 fractures [12, 19], and as such (his approach 
reduces our apparent yield from screening. This is reflected 
in our 20% vertebral fracture prevalence, which is lower 
than 33% prevalence on x-ray reported by Genant et al. 
[18] who included grade 1 fractures. However, this is 
compensated for by the increased accuracy of our screening 
method. Including grade 1 fractures in VFA reduces the 
sensitivity from 80-95% to 50-70% [12,13, 26]. This is in 
part because of difficulties in differentiating mild fractures 
from degenerative vertebral remodelling due to the lower 
resolution of VFA [13]. The impact of this is minimised by 
our exclusion of grade 1 fractures. Grade 1 fractures may 
have less clinical significance. Although there is an 
increased risk of subsequent fracture in women with grade 
1 fractures, the incidence is lower than in women with 
grade 2 and 3 fractures [29]. Furthermore grade 1 fractures 
are associated with less morbidity [30j. Again, when the 
VFAs and DXA scans undergo their Snal report by the 
osteoporosis consultant, possible grade 1 fractures may be 
identified and an x-ray recommended, but these data are not 
available.
We. report the results of two screening programs actually 
used as part of normal clinical practice at our centre 
involving a large number of women referred for routine 
bone densitometry. Despite these strengths there are certain 
limitations. We have already discussed the lack of x-ray 
confirmation of fracture, the differences between the two 
groups and that some fractures may have remained 
undetected if they occurred in uninterpretable vertebra or 
were grade 1. Our results are only applicable to women 
over the age of 65. VFA screening of men or younger 
women would be expected to result in a lower yield as the 
prevalence of vertebral fracture is lower. Furthermore, we 
only targeted women with reasons to believe that a fracture 
was actually present. If our targeted screening program had 
also included women with risk factors for vertebral fracture, 
such a<? steroid use or prior non-vcrtcbral fracture, then 
more women would have undergone VFA and a greater 
proportion of the women with fractures may have been 
detected.
Although spinal x-rays remain the gold standard for 
vertebral fracture detection and differentiation, VFA is a 
more practical screening tool for the detection of women 
with grade 2 and 3 fractures. Overall, routine screening 
results in the detection of a woman with vertebral fractures 
for every five VFAs performed. The majority of women 
with fractures have osteopenia on their axial DXA and in 
these women the knowledge of their fracture status may 
directly affect their treatment. As well as potentially
Osteoporos Iht
affecting the initial treatment decision, routine VFA allows 
better assessment of fracture risk, provides a baseline record 
of fracture status and can indicate the need for spinal x-rays 
in women with possible grade 1 fractures or uninterpretable 
VFA. It is possible to greatly reduce the number of VFAs 
performed by attempting to target screening at those 
women in whom there is reason to suspect a vertebral 
fracture; however, this only detects around 10% of women 
with fractures. For women over 65 who are referred for a 
DXA scan, routine screening for vertebral fractures with 
VFA is more effective than targeted screening.
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The effects of short-term hormone 
replacement therapy on long-term 
bone mineral density
E. T. Middleton and S. A. Steel
Centre for Metabolic Bone Disease, Hull Royal Infirmary, Hull, UK
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ABSTRACT
Introduction Short-term hormone replacement therapy (HRT) relieves menopausal 
symptoms and increases bone mineral density (BMD), but bone loss reoccurs upon 
discontinuation. This study assesses whether short-term HRT provides long-term BMD 
benefits.
Method This was a prospective study of women aged 50-54 years followed up for 9 
years. Women were categorized into three groups according to the treatment they 
received: No-HRT (n = 340), Short-term HRT (2-4 years, n = 60), and Long-term HRT 
(9 years, w=187).
Results BMD increased significantly at the hip (2.4%, p < 0.001) and spine (8.0%, 
p < 0.001) over 9 years in the Long-term HRT group. Women without treatment lost 
BMD at the hip (-4.2%, p < 0.001) and spine (-3.5%, p < 0.001). Women in the 
Short-term HRT group had no significant loss of BMD at the hip (—1.6%, p = 0.08) or 
spine ( — 1.4%, p = 0.18) over 9 years. BMD in the Short-term HRT group was 
significantly higher at 9 years than in the No-HRT group at both spine (difference 
0.023 g/cm2, p = 0.048) and hip (difference 0.016 g/cm2, £=0.042).
Conclusion After 9 years, women who had taken short-term HRT had no significant 
loss of BMD and were better off in terms of BMD than those left untreated. Short-term 
HRT in the early postmenopausal period provides long-term BMD benefits.
INTRODUCTION
Previously, hormone replacement therapy (HRT) 
was the cornerstone of osteoporosis treatment in 
women. In 2002, the Women's Health Initiative 
(WHI) study confirmed that HRT, taken for an 
average of 5.6 years, was indeed effective in 
preventing osteoporotic fractures overall and spe­ 
cifically of the hip1 *2. Unfortunately, these benefits 
were offset due to an increased incidence of breast
cancer and vascular events2. This, combined with 
the advent of other effective treatments for osteo­ 
porosis, resulted in long-term HRT no longer being 
considered an appropriate treatment option for 
osteoporosis. Bisphosphonates are now first-line 
therapy, although HRT is still licensed for short- 
term use around the time of the menopause for the 
relief of menopausal symptoms.
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Bisphosphonates are effective treatments for 
osteoporosis, but, lately, concerns have been 
expressed regarding their efficacy and safety in 
the long term3 . If there are concerns about long- 
term bisphosphonates, how should we treat 
osteoporotic women in their fifties who poten­ 
tially require 30-40 years of treatment? As HRT 
does not have the prolonged effects on bone seen 
with bisphosphonates4, one option may be initi­ 
ally to use a short course of HRT. However, when 
HRT is stopped, bone mineral density (BMD) 
decreases and the long-term effects on bone of 
short-term HRT have not been fully established.
The aim of this study is to investigate whether 
women who take short-term HRT around the time 
of the menopause have long-term gains in their 
BMD compared to those who take no treatment.
METHODS 
Background
In the 1990s, the Centre for Metabolic Bone 
Disease at Hull Royal Infirmary commenced a 
feasibility study to investigate the logistics of 
population screening for osteoporosis5 . All wo­ 
men in the local area aged 50-54 years were 
invited by letter for a BMD assessment by dual- 
energy X-ray absorptiometry (DXA) of the spine 
and hip using a Lunar DPX-L densitometer (GE 
Lunar, Madison, WI, USA). The only exclusions 
from screening were terminal illness, weight in 
excess of 125 kg and physical inability to comply 
with the standard DXA scanning technique. 
Information was collected regarding menopause 
age, medical conditions, family history, smoking 
status, fractures and medications.
Treatment
As this study commenced prior to the World 
Health Organization definition of osteoporosis, 
women were deemed 'at risk' if their BMD was in 
the lowest quartile for their age-matched popula­ 
tion. These women were recommended for treat­ 
ment with HRT, the bone-protective treatment of 
choice at the time for the early postmenopausal 
period. The subject's general practitioner (GP) 
made the final choice of HRT preparation from a 
list of HRT regimens then known through 
interventional studies to be osteoprotective. Thus, 
treatment regimens contained either 2 mg estra- 
diol, 0.625 mg conjugated equine estrogen or a 
50 ug transderrnal patch. Progesterone was pre­ 
scribed to women with a uterus.
Follow up
Those women considered at risk, and an equal 
number of randomly selected women not recom­ 
mended for treatment, were invited back for 
repeat assessment 2, 5 and 9 years later. Patients 
were free to stop or change therapy under the 
guidance of their GP in between visits. Patients 
were blinded to the 2-year scan results. As such, 
those discontinuing HRT early did so due to 
intolerance rather than BMD changes; full reasons 
for discontinuation are described in the original 
study . At each follow-up visit, a medical history 
was taken documenting general health, medica­ 
tions (including HRT) and clinical fractures. A 
repeat DXA was performed using the same DXA 
machine as for the baseline visit. All details were 
recorded on the database at our Centre.
Subjects for present analysis
The present analysis uses all women who were 
followed up for 9 years after the screening program. 
From the database, we identified all women who 
could be allocated to one of three groups: those who 
took no HRT (No-HRT group); those who took 
24-48 months of HRT prior to the 5-year visit with 
no subsequent HRT use (Short-term HRT group); 
and those who took at least 8.5 years of HRT 
during the 9-year follow-up period (Long-term 
HRT group). The only exclusion criteria were the 
use of bisphosphonates or raloxifene before or 
during the follow-up period, and not meeting the 
above HRT treatment group requirements. Cal­ 
cium supplementation was permitted. The duration 
of treatment chosen for the Short-term HRT group 
was selected to represent patients who had received 
HRT for enough time to be able to detect a change 
in BMD (2 years) but less than the time taken for the 
incidence of breast cancer to differentiate from 
placebo in the WHI study2. The discontinuation 
rates and the reason for HRT discontinuation for 
this cohort of patients have previously been 
reported5'6 .
The primary end-point was the difference in 
BMD at 9 years at the spine (L2-4) and hip (neck 
of femur) in the No-HRT group compared to the 
Short-term HRT group. The primary analysis was 
carried out on these two groups only, as long-term 
HRT is no longer a treatment option and the aim 
of the study was to compare short-term HRT to 
no treatment. Secondary end-points were change 
in BMD over 9 years within each group (in- 
tragroup analysis) and fracture rates in the No- 
HRT and Short-term HRT groups.
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The local ethics committee approved both the 
original screening program and the present 
analysis of the 9-year data.
Statistical analysis
Baseline characteristics were analyzed using a one­ 
way analysis of variance (ANOVA) for continuous 
data and Pearson's x2 test for categorical data. 
Means within groups were compared using a 
paired f test. A Multivariate General linear model 
adjusted by covariates (Multivariate ANCOVA) 
was used to examine the effect of treatment after 
9 years of follow-up on the dependent variables and 
to obtain adjusted means; the dependent variables 
were Spine BMD and Neck of femur BMD mea­ 
sured after 9 years' follow-up; covariates were 
Spine BMD and Neck of femur BMD at baseline. 
Bonferroni adjustment for multiple comparisons 
was made. A •£ test or a Fisher exact test was per­ 
formed to test the association between Fractures 
and HRT. The significance level chosen was 0.05. 
The program package used was SPSS for Windows 
(version 12.5 SPSS, Inc., Chicago, IL, USA}.
RESULTS
A total of 1303 women were on the database and 
had been followed up for 9 years; 125 women 
were excluded due to bisphosphonate use. Of the 
remaining 1178 women, a further 591 women 
were excluded due to HRT use incompatible with 
the required groups. Finally, 587 (49.8%) women 
could be allocated to one of the three groups: 340 
No-HRT (57.9%); 60 Short-term HRT (10.2%); 
and 187 Long-term HRT (31.9%). Relevant 
characteristics of each group are shown in Table 1. 
The mean (standard deviation) duration of HRT 
use was 34.7 (8.5) months in the Short-term HRT 
group and 107.4 (2.3) months in the Long-term
HRT group. There was no significant difference in 
the mean age when starting HRT (52.6 and 52.4 
years, respectively, p — 0.76)
Intragroup analysis
The absolute 9-year changes in BMD in each group 
are shown in Table 2 and the percentage changes 
from baseline at each visit are shown in Figures 1 
and 2. Over the 9-year period, those treated with 
long-term HRT sustained a significant increase in 
BMD at the spine (+8.0%, p< 0.001) and hip 
(+2.4%, p < 0.001). Those not taking HRT lost a 
significant amount of BMD at the spine ( — 3.5%, 
p < 0.001) and hip (-4.2%, p < 0.001). Despite 
a downward trend, the Short-term HRT group 
had no significant change in BMD over the 9 years 
at the spine (-1.4%, p = 0.18) or hip (-1.6%, 
!> = 0.08). There was no significant difference in 
weight gain between the three groups to confound 
the measurement of BMD (No-HRT +3.6 kg, 
Short-term HRT +3.8 kg, Long-term HRT 
+3.6 kg; p= 0.97).
Intergroup analysis
The BMDs in the No-HRT group and the Short- 
term HRT group were compared after adjusting 
for the difference in baseline BMD. At 9 years, 
those women taking short-term HRT had a 
significantly higher spinal BMD than those taking 
no HRT (adjusted BMD: 1.091 g/cm2 vs. 1.068 
g/cm2; p = 0.048). The hip (neck of femur) BMD 
was also significantly higher in the Short-term HRT 
group (0.865 g/cm2 vs. 0.849 g/cm2; p = 0.042).
Fractures
All fracture types were grouped together for 
analysis, as the sample populations were too small
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to allow specific fracture sites to be compared. In 
the No-HRTgroup, 54 (15.9%) women suffered a 
total of 64 fractures compared to six (11.7%) 
women suffering a total of seven fractures in the 
Short-term HRT group. After 9 years, there was a 
lower incidence of fractures in the Short-term



















































*p < 0.05; BMD, bone mineral density; NOF, neck of 
femur
HRT group compared to the No-HRT group, 
although this was not statistically significant 
(relative risk (RR) = 0.51, 95% confidence inter­ 
val (CI) 0.16-1.62; p = 0.35). Logistic regression 
was used to correct for the baseline differences in 
spinal BMD. Correction for baseline BMD had 
little effect on the observed fracture incidence with 
short-term HRT (RR = 0.46, 95% CI 0.14-1.57; 
p = 0.22).
DISCUSSION
The WHI study has confirmed the bone-protective 
effects of HRT, with a 33% reduction in hip 
fracture 1 , but this is offset, in women taking 
combined HRT preparations, by an increase in 
vascular events and breast cancer . The increase in 
breast cancer was not apparent until after 4 years 
of treatment2 and hence HRT is still licensed for 
short-term use for the relief of menopausal 
symptoms. The present study suggests that women 
who take between 2 and 4 years of HRT in the 
early postmenopausal period have a prolonged 
benefit in terms of BMD, as, 4-5 years after 
discontinuing HRT, they had a higher BMD than 
the non-users. Furthermore, over 9 years, there 
was no significant loss of BMD in short-term 
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Figure 1 Percentage change in spine bone mineral density (BMD) from baseline
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Figure 2 Percentage change in bone mineral density of neck of femur from baseline
lower incidence of fractures associated with short- 
term HRT use. This did not reach significance, 
although the study was underpowered to detect a 
difference in fracture rates. Short-term HRT has 
previously been demonstrated to reduce the risk of 
all fractures in early postmenopausal women by 
52%7. The present study demonstrated a similar 
magnitude of fracture reduction.
Short-term HRT may have a role to play in the 
overall treatment strategy for women with low 
BMD during the early postmenopausal period. 
Recently, concerns have been raised regarding the 
long-term safety and efficacy of bisphosphonates . 
The 10-year data for alendronate from the FLEX 
trial suggest that there are no benefits in continued 
treatment beyond 5 years in terms of non- 
vertebral fractures or morphometric vertebral 
fractures8. A smaller 10-year study also demon­ 
strated that stopping alendronate at 5 years 
resulted in little difference in terms of vertebral 
fracture compared to continuing alendronate9. Of 
more concern is the possibility of harm due to 
long-term bisphosphonates. Osteonecrosis of the 
mandible has been repeatedly reported10' 11 . A 
recent paper reported a series of patients, with low 
trauma fractures occurring after long-term 
bisphosphonates, who had severely suppressed 
bone turnover on bone biopsy12. Animal models
also demonstrate microdamage accumulation 
with bisphosphonate exposure13 . If there are 
concerns about long-term bisphosphonate use, 
what treatment should be offered to women with 
low BMD in their fifties who are at risk of 
developing osteoporosis and require a treatment 
strategy for the next 30-40 years? BMD will 
continue to decline if treatment is delayed, as in 
the No-HRT group in this study. Raloxifene could 
be used if the site of concern is the spine, but this 
could exacerbate the menopausal symptoms com­ 
mon in the early postmenopausal period and has 
no proven benefits in terms of non-vertebral 
fractures14. Our study suggests that short-term 
HRT in the early menopausal period may provide 
both relief of menopausal symptoms and preser­ 
vation of BMD, thus allowing bisphosphonate 
therapy to be delayed.
One previous paper by Bagger and colleagues7 
has examined the effects of short-term HRT in the 
early menopausal period. As in the present study, 
those women treated with short-term HRT had 
long-term benefits in terms of BMD, and this study 
also demonstrated a significant reduction in both 
vertebral and all-fractures. The women in both 
studies were of similar age and in the early 
postmenopausal period but there are several differ­ 
ences in the methodology. Bagger and colleagues
261
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amalgamated four randomized, controlled trials in 
which only otherwise healthy women were re­ 
cruited and set treatment regimes were used. Our 
study, was an observational one in which the 
general population was screened, appropriate 
clinical advice regarding treatment was given and 
the women were free to change or stop their HRT 
under their GP's guidance. As such, our study is 
more representative of real clinical practice and 
suggests that the benefits of short-term HRT 
predicted by Bagger and colleagues still occur 
when an unselected population is studied. This is 
important as recent studies have demonstrated 
how patient selection can bias the characteristics 
of study populations15'16. Bagger and colleagues 
also had to use different models of DXA 
scanner throughout their study, thus requiring 
the use of a conversion factor, whereas, in our 
study, each patient was scanned on the same 
machine at each visit, allowing direct comparison. 
We also prospectively followed up the patients at 
2, 5 and 9 years, whereas Bagger and colleagues 
followed up all patients at one point in time, either 
5, 11 or IS years after the end of their original 
trial.
There are limitations to our study. Women were 
treated as clinically indicated and were not 
randomized to each treatment arm. Although this 
mirrors clinical practice, it resulted in significant 
differences between the groups at baseline in 
terms of BMD, weight and menopause age. This 
is largely expected as women with an earlier 
menopause and lower weight are more likely to 
have a lower BMD, be recommended for treat­ 
ment and persist with the treatment for longer. It 
is interesting to note that, compared to the No- 
HRT group, the Short-term HRT group had a 
lower weight and higher prevalence of smoking. 
These factors are associated with an increased rate
of BMD loss17'18, yet, in spite of this, the Short- 
term HRT group lost less BMD over the 9 years. 
Any effect these factors had on the present 
analysis should be to increase the BMD loss in 
the Short-term HRT group, thus making our 
results conservative. Finally, despite having a 
low BMD for their age, the women in this study 
were not osteoporotic by the WHO definition, t 
Scores at baseline were —0.75 and —1.17 in the 
No-HRT group and Short-term HRT group, 
respectively. Bagger and colleagues7 also looked 
at women with normal BMD and, as such, there 
are no studies assessing the effect of short term 
HRT on osteoporotic women in the early post- 
menopausal period.
When considering HRT, it is important to 
balance the benefits of treatment with the risks 
of vascular disease and breast cancer. The type 
of HRT required also needs consideration as 
estrogen-only HRT, recently confirmed to provide 
fracture protection19, does not have the increased 
incidence of coronary heart disease and breast 
cancer associated with combined HRT20. Clearly, 
HRT is not a suitable treatment option for all 
patients. However, for women with low BMD in 
the early menopausal period, short-term HRT 
may provide a useful initial treatment option and 
have lasting benefits.
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Raising of standards through education and guidance
National Training 
Scheme /or Bone 
Densitometry
The only formal certification scheme for competence in bone 
densitometry in the UK
Approved by the College of Radiographers (COR) and the 
Institute of Physics and Engineering in Medicine (IPEM)
Visit www.nos.org.uk for more information
Theoretical Lecture Course on Osteoporosis and Bone Densitometry 
16th & 17th March, 2009 - Novotel, Birmingham Centre
The lecture course is open to all health professionals with an interest in osteoporosis and 
bone densitometry e.g. physicians, nurses, radiographers, technologists or clinical scientists
Day 1: Core Module: Introduction to 
Osteoporosis and Bone Densitometry
An educational update:
• Epidemiology and pathophysiology of bone
• Diagnosis, treatment and prevention of 
osteoporosis
• Overview of methods for bone densitometry
• How to run a densitometry service
• Clinical interpretation and reporting of bone 
density measurements
Day 2: DXA / pDXA (morning)
An in-depth look at:
• The techniques of axial and peripheral dual energy x-ray
• absorptiometry (DXA)
• Special applications of bone densitometry
• Quality control, quality assurance, errors and artefacts
Day 2: Radiation Protection IR(ME)R 2000 (afternoon)
• Radiation hazards and dose
• Patient and staff protection
• Statutory requirements and legislation
Certification
Certification is aimed at healthcare professionals who operate bone densitometry equipment in the UK.
3 steps to certification:
1. attend the lecture course plus the IR(ME)R course (unless this training has already been acquired) (March 2009)
2. pass the examination (taken online at regional centres) (Summer 2009)
3. submit a portfolio of work demonstrating competence in your chosen method of bone densitometry (Autumn 
2009)
4. upon successful completion of all three elements a Certificate of Competence is awarded.
The National Training Scheme for Bone Densitometry is approved by the College of Radiographers and the 
Institute of Physics and Engineering in Medicine (IPEM).
Candidates wishing to pursue certification must have 6 months full time or 12 months part time scanning 
experience, be employed in clinical practice and have received local training.
The Training Scheme Rules and Regulations are available at www.nos.orq.uk
Registration for Lecture Course
To register, complete the form overleaf and return with payment to: The Training Scheme Administrator, National 
Osteoporosis Society, Camerton, Bath, BA2 OPJ, Tel: 01761 473132 Fax: 01761 471104. 
Website: www.nos.orq.uk Email: courses@nos.orq.uk
Closing date for registration is 25th February 2009
National 
Osteoporosis
society Lecture Course Registration Form
PLEASE COMPLETE IN BLOCK CAPITALS





DAYTIME TELEPHONE ................................................................ DAYTIME FAX ................................
EMAIL......................................................................................................................................................
CORRESPONDENCE ADDRESS (IF DIFFERENT FROM ABOVE)........................................................
....................................................................................................... POSTCODE ..................................................
PLEASE DELETE AS APPROPRIATE (please complete all sections)
I HAVE/HAVE NOT READ THE RULES & REGULATIONS, AND DO/DO NOT INTEND TO SEEK CERTIFICATION
I HAVE/HAVE NOT RECEIVED LOCAL TRAINING IN ONE OR MORE TECHNIQUES OF BONE DENSITOMETRY
I AM/AM NOT CURRENTLY EMPLOYED IN CLINICAL PRACTICE
I WILL/WILL NOT HAVE 6 MONTHS FULL TIME OR 1 2 MONTHS PART TIME SCANNING EXPERIENCE BY 16/03/2009
I WOULD LIKE TO REGISTER FOR THE FOLLOWING (PLEASE TICK)
NATIONAL OSTEOPOROSIS SOCIETY
PROFESSIONAL MEMBER 1 REDUCED FEE2 ' 3 STANDARD FEE3
CORE MODULE (one day) £165
DXA/pDXA MODULE (half day) £125




1 National Osteoporosis Society Professional member number: .........................................
2 The reduced fee is available to all NHS employees, university employees and students.
3 All those who pay the reduced or standard fee will automatically receive 6 months free Professional Membership of 
the National Osteoporosis Society, which entitles you to a range of benefits including reduced fees for the National 
Osteoporosis Conference and copies of 'Osteoporosis Review'. To find out more about membership call 01761 473118.
Registration fees include lunch, refreshments, Fundamentals of Bone Densitometry CD ROM and course folder. 
'Additional fees apply for the examination and portfolio submission - available from www.nos.org.uk *
Please list any dietary or access requirements you have......................................................••..••.••••••••••••••••••••••••••••••
If you are attending the IR(ME)R module, please state whether you will require a Practitioner's or Operator's certificate:-
I I PRACTITIONER I——I OPERATOR
I ENCLOSE A CHEQUE FOR A TOTAL OF £.............................
PLEASE MAKE ALL CHEQUES PAYABLE TO NATIONAL OSTEOPOROSIS SOCIETY
I WISH TO PAY BY DEBIT OR CREDIT CARD - PLEASE DEBIT MY VISA/MASTERCARD £..........................................
VISA/MASTERCARD NUMBER....................................... VALID FROM ................... EXPIRY DATE...............................
ISSUE NUMBER ....................SIGNATURE OF CARDHOLDER .................................. TODAY'S DATE.........................
Cancellation policy: 30+ days notice - 80% refund, 15-29 days - 50% refund, 14 days or less - no refund. Registration is non-transferable.
Q The National Osteoporosis Society may contact you to keep you informed of future appeals and promotions. If you are NOT happy 
to be contacted, please tick this box.




1.1 The National Osteoporosis Society is the only UK national charity dedicated to improving the
prevention, diagnosis, and treatment of osteoporosis. As part of our work we aim to ensure that the 
different strands of people working with osteoporosis patients have adequate information and training 
to meet patient needs.
1.2 The Bone Densitometry Certification Panel (BDCP) is a group of voluntary Scientific Advisors 
who are responsible for overseeing the National Training Scheme for Bone Densitometry. 
The Bone Densitometry Certification Panel reports to the charity's Medical Board.
2. Aim
2.1 The National Training Scheme for Bone Densitometry ('the Training Scheme 1 ) provides an accredited 
scheme, recognised by the appropriate professional colleges and institutions, that offers an 
opportunity for bone densitometry operators to demonstrate their competency. In doing so it is 
hoped that consistently high standards in bone densitometry are achieved across the UK.
2.2 Successful completion of the Training Scheme leads to certification by the National Osteoporosis 
Society. This offers proof of competence to perform clinical bone densitometry measurements in the 
applicant's chosen bone densitometry technique(s).
3. Approval
3.1 The content of the Training Scheme has been approved by the Institute of Physics and Engineering 
in Medicine (IPEM) 1 and the College of Radiographers (COR) which represent the majority of 
healthcare professionals involved in clinical bone densitometry in the UK. Their recognition ensures 
that professional standards of teaching and examination are maintained.
4. Eligibility for certification
4.1 The Training Scheme is aimed at healthcare professionals who are currently employed in clinical bone 
densitometry practice and are:
• State registered healthcare professionals 
Or
• Healthcare professionals or graduate scientists working in clinical practice under the supervision 
of a registered practitioner
All applicants must also have received local training in one or more techniques of bone densitometry 
and have had at least 6 months full-time or 12 months part-time (minimum 1 whole day per week) 
scanning experience at the time of the lecture course.
4.2 Any applicant not meeting the above criteria should complete a Certification Admission Appeal Form, 
available from the National Osteoporosis Society, and include a copy of their CV. The Bone 
Densitometry Certification Panel will consider such applications on a case-by-case basis.
4.3 The National Osteoporosis Society reserves the right to refuse an applicant entry to the certification 
process at its absolute discretion.
' Currently applying for renewal for approval of IR(ME)R course 
President: HRH The Duchess of Cornwall
Ttie National Osteoporosis Society is a registered charity no. 1102712 in England and Wales and no. SC039755 in Scotland
Registered as a company limited by guarantee in England and Wales no. 4995013 Page 1
5. Admission requirements for certification
5.1 Applicants must complete a registration form, which will require details of previous training and 
experience relevant to bone densitometry.
5.2 Applicants must attend the lecture course which comprises: 'Core Module' and 'DXA/pDXA Module' 
(1 1/2 days).
5.3 In addition, all applicants who have not already received professional training according to the 
requirements of IR(ME)R 2000 are required to attend the charity's IR(ME)R course, held on the 
afternoon following the lecture course.
5.4 Evidence of IR(ME)R certification will be required from applicants who have completed a course 
delivered by another training body.
6. Exemptions
6.1 In the absence of an equivalent accredited training scheme in bone densitometry in the UK, 
no exemptions are available for this Training Scheme.
7. Certification Process
7.1 Full attendance at the lecture course (plus the IR(ME)R course as appropriate) is compulsory for all 
candidates pursuing certification.
7.2 Candidates must pass both examination modules prior to submission of a portfolio relating to their 
densitometry specialty.
7.3 A portfolio must be submitted by the agreed deadline.
7.4 Candidates must achieve a pass mark for both the examination and the submitted portfolio to 
achieve certification.
7.5 If a candidate fails to achieve a pass mark for the examination they can apply to re-sit the
examination. Failure at the third attempt will require the candidate to attend the lecture course for 
a second time before re-sitting the examination.
7.6 Resubmission of failed portfolios:
7.6.1 If a candidate achieves a satisfactory pass mark in at least one of the four portfolio sections at their 
first attempt, they will be permitted two resubmissions of the failed sections.
7.6.2 If a candidate fails all four sections at the first attempt they will be permitted one resubmission of 
the complete portfolio. Candidates passing at least one section at a second attempt will be 
permitted to have one final attempt at the failed sections. Candidates failing all four sections at a 
second attempt will be advised to attend the lecture course again before having one final opportunity 
to submit a portfolio.
7.6.3 In none of the above circumstances will a candidate be asked to retake the examination.
7.6.4 All submissions must be made by the relevant dead-line set by the National Osteoporosis 
Society.
7.7 The National Osteoporosis Society reserves the right to refuse certification to individuals who 
failed to meet the required criteria, at its absolute discretion.
8. Fees and cancellation
8.1 Course fees are payable in three parts: lecture course, examination and portfolio.
Places are only guaranteed on receipt of payment. Payments must be made by the registration 
deadlines.
8.2 All cancellations must be made in writing. Cancellation charges are as follows:
Over 30 days notice before the date of the lecture course/exam/portfolio submission deadline -
80% refund;
15 to 29 days notice - 50% refund;
14 days notice or less - no refund.
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8.3 Registration is non-transferable.
8.4 If payment is not received by the date of the lecture course we reserve the right to make an 
additional administration charge of £50 per delegate.










Monday 16th March: Core Module
8.30 am Registration and Refreshments
9.30 am Welcome and Introduction
Professor Francis Ring, Bone Densitometry Certification Panel
9.45 am Pathophysiology of Bone
Professor Roger Francis, Consultant Physician, Freeman Hospital, Newcastle upon Tyne
10.15 am Epidemiology of Osteoporosis
Professor Roger Francis, Consultant Physician, Freeman Hospital, Newcastle upon Tyne
10.45 am Questions
11.00 am Refreshment Break
11.20 am Diagnostic Assessment of Osteoporosis
Professor Judith Adams, Clinical Academic Group Leader, Department of Diagnostic Radiology, 
University of Manchester
11.50 am Prevention and Treatment of Osteoporosis
Dr Nicky Peel, Consultant in Metabolic Bone Medicine, Sheffield Teaching Hospitals 
NHS Foundation Trust
12.20 pm Questions 
12.30 pm Lunch
1.30 pm Overview of Methods and Instruments for Bone Densitometry
Dr Wil Evans, Consultant Physicist, University Hospital of Wales, Cardiff
2.00 pm Overview of the Bone Densitometry Service
Ms Sue Steel, Consultant Physicist, Hull & East Yorkshire Hospitals Trust
2.30 pm Terminology Used in Bone Mass Measurement
Dr Karen Knapp, Senior Lecturer, School of Physics, University of Exeter
2.45 pm Questions
3.00 pm Refreshment Break
3.30 pm Clinical Interpretation and Reporting of BMD Results
Dr Nicky Peel, Consultant in Metabolic Bone Medicine, Sheffield Teaching Hospitals 
NHS Foundation Trust
4.15 pm Questions
4.30 pm Certification Procedures: Eligibility, Examination and the Portfolio
Hilary McWilliam, Clinical Training Officer, National Osteoporosis Society
5.00 pm Questions & Comments to the Bone Densitometry Certification Panel 
5.30 pm Finish
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Tuesday 17th March: DXA/pDXA Module
8.30 am Refreshments
8.45 am Principles of Dual Energy X-Ray Absorptiometry (DXA)
Ms Sue Steel, Consultant Physicist, Hull & East Yorkshire Hospitals Trust
9.05 am Techniques of Axial DXA
Dr Karen Knapp, Senior Lecturer, School of Physics, University of Exeter
9.50 am Techniques of Peripheral DXA
Dr Rajesh Patel, Head of Academic Bone Densitometry & Clinical Studies, 
Imperial College, London
10.10am Special Applications: Total Body DXA, Vertebral Fracture Assessment 
and Bone Densitometry in Children and Young Women
Dr Glen Blake, Consultant Physicist, Guy's Hospital, London
10.40am Refreshment Break 
11.00am Questions
11.10 am Errors and Artefacts in DXA and pDXA
Professor Francis Ring, Director of Medical Imaging Research Unit, 
Faculty of Advanced Technology, University of Glamorgan
11.35 am Quality Control, Quality Assurance, Commissioning and Radiation Protection for DXA
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Tuesday 17th March 2009
1.30pm Introduction
Dr David Pye, Radiation Protection Advisor, 
Nottingham University Hospitals NHS Trust
1.45 pm The Use of X-Rays in Bone Densitometry
Dr Wil Evans, Consultant Physicist, University Hospital of Wales, Cardiff
2.30 pm Radiation Hazards and Radiation Dose
Dr Glen Blake, Consultant Physicist, Guy's Hospital, London
2.50 pm Statutory Requirements and Legislation
Dr Wil Evans, Consultant Physicist, University Hospital of Wales, Cardiff
3.20 pm Questions
3.30 pm Refreshment Break
4.00 pm Radiation Protection of Patients
Dr David Pye, Radiation Protection Advisor, 
Nottingham University Hospitals NHS Trust
4.45 pm Radiation Protection of Staff
Dr Glen Blake, Consultant Physicist, Guy's Hospital, London
5.15pm Questions 
5.30 pm Finish
President: HRH The Duchess of Cornwall
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The Training Scheme Syllabus comprises two compulsory modules: Core Module and DXA/pDXA Module. 
All applicants who have not already received professional training according to the requirements of 
IR(ME)R 2000 are also required to attend the IR(ME)R course (syllabus overleaf).
Core Module Syllabus
Pathophysiology of bone
• Definitions of osteoporosis
• Skeletal structure, peak bone mass, bone remodelling
• Aetiology of osteoporosis
• Clinical consequences of osteoporosis
Epidemiology of osteoporosis
• Incidence of osteoporosis in men and women
• Pattern of fracture incidence
• Contribution of BMD to fracture risk
• Morbidity and mortality related to fracture
Diagnostic assessment of osteoporosis
• Indications for bone densitometry
• Diagnostic evaluation of osteoporosis
• Radiology
• Bone density measurements
• Blood and urine tests, bone biopsy, bone markers
Treatment and prevention of osteoporosis
• Prevention versus treatment
• Drugs to improve bone mass
• Bisphosphonates, SERMS, parathyroid hormone, 
Calcium & vitamin D
• Anabolic agents
• Non-drug interventions to reduce fracture risk
• Lifestyle modification
• Prevention of falls and trauma
Overview of methods and instruments 
for bone densitometry
• Physical principles of X-radiation and ultrasound
• Quantities to measure: attenuation and velocity
• Nature of X-rays: waves and photons, X-ray spectrum
• X-ray attenuation: absorption and scatter
• X-ray absorptiometry: bone mineral, soft tissue, area density
• SXA: Average photon energy, peripheral sites, BMC, BMD
• DXA: spectrum modification, axial sites, BMC and BMD
• QCT: slice reconstruction, CT numbers, BMD
• Nature of ultrasound: longitudinal waves, continuous/pulsed
• QUS velocity: bone length, ultrasound transit time
•QUS attenuation: broadband pulse, frequency dependence, BUA
• BMD vs. surrogate quantities
Overview of the bone densitometry service
• Procedures and Organisation: accommodation, referral 
guidelines, request receipt, appointment, questionnaires, patient 
handling, reporting, clinics
• Protocols and Equipment: written procedures, quality 
control, data collection and audit, scan procedures, archiving, 
equipment maintenance, safety, radiation protection, choice of 
equipment
• Staffing: operators, scientific support, clinical, clerical, 
reception, nursing, Radiation Protection Advisors (RPAs)
• Example of 'best practice'
Terminology used in bone mass measurements
• Commonality of terms between the different technologies
• Explanation and calculation of BMD and BMC, areal and 
volumetric ionising radiation techniques
• Standardised BMD and its use
• Explanation of U/S terminology
• Reference ranges: collection, causes for differences 
between populations/scanners, NHANES III database
• Adjustments for race and weight
• Comparison of the use of scores between the BMD 
technologies
Clinical interpretation and reporting of BMD results
• Relationship between BMD and fracture risk
• Site-specificity
• Technique used
• Definition of osteoporosis and osteopenia
• WHO criteria
• Independent risk factors for fracture
• Principles of reporting
• Technical, clinical
• Management and follow-up
President: HRH The Duchess of Cornwall
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DXA/pDXA Module Syllabus
Principles of Dual Energy X-ray Absorptiometry (DXA)
«Principal components of a DXA system
• DXA detectors: scintillation, solid state, energy discrimination
• Differential attenuation in bone and soft tissue
• Use of appropriate scan modes
• Determination of BMD: empirical, mathematical
i Beam geometry: pencil beam, fan beam, cone beam
Techniques of Axial DXA
• Patient preparation - prior to scan appointment and at the 
appointment
• Pregnancy status for ionising radiation techniques- IRMER
• Previous examinations - barium studies/ IV contrast/ radionuclide 
imaging
• Patient measurements - weight/ height: forearm length
• Aftercare of patient
• DXA- Lumbar spine (PA and Lat): positioning, acquisition 
and analysis (differences between Hologic & GE-Lunar)
• Problems in spinal analysis
• DXA - Proximal femur: positioning, acquisition and analysis 
(including differences between Hologic & GE-Lunar)
• Aftercare of patient
• Obtaining an optimum scan
• Follow-up scans and special requirements
Techniques of pDXA
• Patient preparation - prior to scan appointment and at the 
appointment
• Previous examinations to hand - ensures same scan mode: 
identifies previous problems
• Peripheral measurements - handedness: non dominant wrist
• Heel measurements - cleaning foot etc.
•Positioning, acquisition and analysis
• Aftercare of patient
• Obtaining an optimum scan
• Follow-up scans and special requirements
Special applications
• Lateral vertebral assessment (LVA)
• Total body
• Challenges of paediatric scanning
• Scanning in young women
Error and artefacts in DXA and pDXA
• The Instrument - calibration, quality assurance
• The Operator - patient positioning, image analysis, operator 
intervention, intra operator variation
• The Patient - anatomical problems e.g. extra vertebrae, paget's 
disease, metal artefacts, prostheses etc
• The Report - lack of clarity, misunderstanding the data, relevance 
of reference data, age, ethnicity
Quality control, quality assurance and radiation protection
• Quality control for DXA scans
• Performance of DXA QC
• Phantoms for DXA QC
• Interpretation of QC plots
• Maintenance, repair and replacement of DXA scanners
• In-vivo precision and its affect on patient follow-up scans
• Procedure for patient follow-up scans
• Radiation dose to patient and operator from DXA scans
• Ionising Radiation (Medical Exposure) Regulations 2000
• Local rules for bone densitometry
• Hazards of ionising radiation
• Radiation hazards to the patient and the operator
• Radiation protection of the patient and the operator
• Difference between accuracy and precision
• Factors affecting accuracy and precision
• Operator and scanner dependent factors affecting QC
• Purpose of instrument QC
NB Please note that delegates will not be examined 
on mathematical equations or manufacturers' specific 
information. The examination requires knowledge of general 
principles rather than details about specific devices.
Radiation Protection (IR(ME)R Syllabus
he use of X-rays in bone densitometry
I'The electromagnetic spectrum
f Production of X-rays in a diagnostic X-ray tube
{Spectrum of X-rays from an X-ray tube
1 Interaction of X-rays and matter
jrPhysical principles of DXA
[ Production of dual-energy X-rays for DXA
| Fan-beam and pencil-beam DXA
8 Table top and peripheral DXA
J Physical principles of pQCT
ation hazards and radiation dose
1 Biological effects of radiation 
j Non-stochastic and stochastic effects 
I Ways of measuring radiation dose 
H Radiation risk to patients
utory requirements and legislation
! Source of legislation and guidance notes 
f Health and Safety at Work Act 1974 
|lonising Radiation Regulations 1999 
[Framework for radiation safety 
nising Radiation (Medical Exposure) Regulations 2000
Radiation protection of patients
• Justification of radiation exposure of the patient
• Dose optimisation - ways to minimise patient dose
• Importance of correct analysis of scan
• Clinical evaluation of outcome
• Patient identification and consent
• Pregnancy and potential pregnancy
• Investigations in children
• Medical and biomedical research
• Health screening
• Medico-legal issues
• Use of previous scans and alternative techniques
• Untoward incidents and notification of faults
Radiation protection of staff
• Principles of radiation protection
• Hazards from primary and scattered radiation
• Dose limits to staff in IRR 1999
• Reduction of exposure to scattered radiation
• Dose rates due to scattered radiation during scanning
• Dose monitoring
• Ionising Radiation Regulations
• Controlled areas and local rules
• Writing local rules for bone densitometry
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CERTIFICATION ADMISSION APPEAL FORM














D Private Health 






| | Clinical Scientist
I I Nurse
[ | Medical Doctor
| | Other (please specify)
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b) QCT / pQCT
c)QUS
| J hours | | days/week
| J hours | | days/week
| | hours | | days/week
|__| months full time
| | months part time*
| | months full time
I I months part time*
| | months full time 
I I months part time*
*Part time is defined as 1 or more days per week
| | hours | | days/week
| | hours | | days/week
| | hours | | days/week
I__| months full time
| | months part time*
| | months full time
I I months part time*
| | months full time
I I months part time*
BRIEFLY EXPLAIN WHY YOU FEEL YOU SHOULD BE ACCEPTED TO PROCEED TO CERTIFICATION:
SIGNATURE DATE
Please return to Judith Wraight, National Osteoporosis Society,
Manor Farm, Skinners Hill, Camerton, Bath, BA2 OPJ, as soon as possible.
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National Training Scheme .
for Bone Densitometry fOf fsteoporos.s
7 Society
PORTFOLIO REQUIREMENTS 2009
A. Purpose of the portfolio
The portfolio should contain evidence that demonstrates your understanding and practical ability in 
bone densitometry such as, quality control, techniques of data acquisition and analysis and the scan 
print out, providing evidence that shows safe and effective practice.
B. Portfolio submission
Please submit TWO COPIES of your finished portfolio, in the blue folders provided, to the 
National Osteoporosis Society, Camerton, Bath, BA2 OPJ, by 7th October 2009. We recommend 
that you send them by recorded delivery. The master copy must include original scans and should be 
labelled as such. The second copy can include photocopies. It is important that you also keep a third 
copy for your own records. The National Osteoporosis Society will provide delegates with feedback 
from the examiners but not return the portfolios.
The majority of candidates who do not pass the portfolio do so because they do not follow 
the instructions given in this document. Please read carefully.
C. Portfolio compilation and other important information
1 . The contents of the portfolio should be included in the order outlined in section D (below) 
and separated into sections using labelled dividers.
2. The pages of the portfolio should be numbered and a detailed index, with section headings, 
included. Each case should also be numbered.
3. Scan images should be presented in black and white and in such a way that regions of interest 
and bone edges are clearly seen. Graphs are acceptable in colour. Photocopies are not acceptable 
in the master portfolio but can be included in the second copy. Scan images should be of the original 
area scanned and in the case of GE Lunar scans, magnified if necessary (e.g. the femoral shaft must 
be clearly seen on a hip scan). GE Lunar users should contact the application specialist for local 
advice on how to achieve this. Hologic users need to include 2 printouts when excluding a vertebra 
for technical reasons - one showing all vertebrae and one with vertebra excluded
4. Do not write or type your name on any pages of the portfolio (with the exception of the candidate 
information sheet and signed declarations) but please include your initials on the scan printouts (as 
confirmation that you carried out each scan; note, previous scans in a repeat series need not have 
been carried out by yourself). Please remove/cross out (using a black pen) patient names and patient 
ID included in the portfolio.
5. All written work should be typed.
6. The portfolio must be all your own work and described in your own words. Information provided 
by physicians or manufacturers is not acceptable.
Please note that any communication to the National Osteoporosis Society regarding the training course 
should be made by email (courses@nos.org.uk) or by post. The committee will respond to queries as 
quickly as possible.
President: HRH The Duchess of Cornwall
The National Osteoporosis Society is a registered charity no. 1 102712 in England and Wales and no. SC039755 in Scotland
Registered as a company limited by guarantee in England and Wales no. 4995013 CONTINUED...
D. Portfolio contents
Each portfolio must contain all of the following in the correct order:
• Signed Statement by candidate and local supervisor (forms provided)
• Candidate Information Sheet (form provided)
• Index
Section 1. QC information on your densitometer
a. A graph of QC BMD data/time over 3 months. QC scans should not pre-date the lecture course 
The graph may be system generated, plotted in Excel or hand drawn. The graph should be 
sufficiently clear to see the individual points, variations and trends. Include a paper printout of one 
of the QC scans of the phantom used to monitor your machine. For GE-Lunar machines use the 
aluminium spine phantom.
b. In approximately 500 words describe the following:-
• how the phantom is scanned and analysed
• comment on the results shown on your graph
• indicate how these results are used to monitor the performance of your densitometer
• With reference to the QC graph you have provided, comment on the mean, Standard Deviation, 
trends over time and any sudden changes.
c. This information need only be supplied for one scanner.
Section 2. Scans:
a) Describe in your own words the standard procedure i.e. positioning and analysis of scans used in 
your department for each anatomical site used in this section (approximately 500 words per site).
b) Include:
20 cases, each with scans from two anatomical sites (e.g. spine and hip, spine and forearm,
spine and heel, spine and total body, hip and forearm, hip and heel) 
or
40 single-site cases
All scans must have been performed and analysed by yourself
Images acquired for vertebral assessment may be included if they help to clarify spinal problems, 
but will not count as one of the two anatomical sites.
Scans must not pre-date the lecture course. Include as wide a variety as possible to 
demonstrate some of the clinical and technical issues that are encountered in your work e.g. 
degenerative disease, scoliosis, or metal artefacts. Where follow-up cases are presented, provide a 
copy of the previous scans and the trend graphs, even though another operator may have performed 
this. Lunar users must include the ancillary print out sheet (height/width of vertebrae of the spine).
For each case supply the following:
• A complete set of printouts for each scan (noting the instruction in paragraph C.3), with one 
image per printout. Composite printouts that show both the spine and hip on a single page are not 
acceptable.
  On a separate sheet of paper:
• reason for referral
• brief discussion of any difficulties with patient positioning, scanning, choice of scan mode and 
analysis of the data, with reference to any deviations from the norm
• brief comment on any aspects of the process or result which might render its normal interpretation 
unreliable.
If scans are obtained from more than one machine please ensure they are from the same 
manufacturer
CONTINUED...
Section 3. A copy of the scan print out for one anatomical site from your equipment on a 
chosen patient including scan image, reference graph, normative data. You should comment on the 
relevance of the information and explain how it helps with determining the reliability of the result or the 
status of the patient's bone strength.









• % of normal
• choice of reference population data and reasons for choice
Your print out should include all of the above, if not, please ensure that an explanation is given.
Section 4. Three contrasting case studies with a description for each study including: 
a. Reason for referral and brief clinical history
b. Description of technique (scan and analysis) and explanation of scan sites and modes used 
c. Discussion of any problems with patient positioning 
d. Discussion of any difficulties with scan acquisition 
e. Description of scan analysis and result
f. Brief summary of clinical outcome i.e. the effect of scan on patient management 
g. At least one case study should be a follow-up study with print outs, trend graphs and analysis 
(please include previous print outs for all follow-up studies included in this section)
Please include all scan printouts including any previous scans, even though another 
operator may have performed the scans.
E. Portfolio Marking
The portfolio will be marked on the following criteria:
Quality Control
1. Adequate number of points on the QC plots
2. Details of technique (scan and analysis)
3. Comments on measured mean compared to manufacturer's stated value
4. Comments on the use of data to monitor the performance of your particular machine 
(even if no problems arise)
Scans
1. Correct number and adequate range of scans
2. Details of reason for referral
3. Correct positioning of patient and comment on any problems encountered
4. Comments on scan parameters
5. Correct analysis and comment on any problems encountered
6. Comment on artefacts or unusual features
CONTINUED..
Scan Information Analysis
1. Image, scan information, results and graph printouts included
2. Satisfactory comment on all demographic, image, graphical and technical data given 
in report
3. Level of understanding of BMD result, T-scores, Z-scores, % of normal and reference 
data used
Case Studies
1. Reason for referral and brief clinical history
2. Description of technique (scan and analysis) and explanation of scan sites and modes used
3. Discussion of any problems with patient positioning
4. Discussion of any difficulties with scan acquisition
5. Description of scan analysis and result




National Training Scheme for Bone Densitometry
Pre-Course Recommended Reading
If you are interested in undertaking some reading in the areas of osteoporosis and bone densitometry before starting the course, the following selection of 
reference materials are recommended:
National Dsteoporosis Society
Ihe National Dsteaporosis Society website www.nos.orq.uk contains useful information about osteoporosis. Of particular interest will be the Position 
Statements and Guidelines on bone densitometry (nttp://www.nos.grq.uk/NetCommunity/Page.aspx?pid=299Ssrcid=24D). (Please note, copies are sent to 
all new Professional Members of the National Dsteoporosis Society).
Other reading
1. Nigel K Arden. Osteoporosis, Publisher: Remedica. ISBN: I-85D092- 05-2
2. Glen M Blake, Heinz W Wahner 5 Ignac Fogelman. The Evaluation of Dsteoporosis: Dual Energy X-ray Absorptiometry in Clinical Practice. 
Publisher: Ta/lor & Francis. ISBN: 1-85317-472-B
3. Sydney Lou Bonnick S Lori Ann Lewis. Bone Densitometry for Technologists. Publisher: Humana Press. ISBN 1-58829- 020-4
4. Sydney Lou Bonnick. Bone Densitometry in Clinical Practice - Application and Interpretation, Second Ed. Publisher: Humana Press. 2DD4.
5. Cummings, S. R. and Melton III. L. J. Dsteoporosis I: Epidemiology and outcomes of ostenporotic factures. Lancet 2002:359:1761-1767. 
B. Oelmas. P. D. Qsteoporosis IV: Treatment of postmenopausal osteoporosis. Lancet 2002:359:2018-2026.
7. Fordham. J. N. Manual of Bone Oensitometry Measurements: An Aid to the Interpretation of Bnne Densitometry Measurements in a Clinical 
Setting. Publisher: Springer. 20DD.
8. HK Genant, G Guglielmi B M Jergas. Bone Oensitometry B Ostenporosis. Publisher: Springer. 1998.
0. Graham D.T. and Cloke P. Principles of Radiological Physics (2003: 4th edition). Churchill Livingstone. ISBN: D-443- 07D73- 3.
ID. Kanis. J. A. Osteoporosis III: Diagnosis of Osteoporosis and Assessment of Fracture Risk. Lancet 2DD2: 359:1929-1936.
11. Paggiosi, M. Quantitative Ultrasound for the Assessment of Bone Status. Synergy. 2002: 33:22-28.
12. Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. London, England: Royal College of Physicians. 1999. 
www.rcplondon.ac.uk/
13. Royal College of Physicians and 8one and Tooth Society of Great Britain. Dsteoporosis: c inical guidelines for prevention and treatment. Update 
on pharmacological interventions and an algorithm for management. London, England: Royal College of Physicians, 2000. www.rcplondDn.ac.uk/
14. Seeman, E. Osteoporosis II: Pathogenesis of bone fragility in women and men. Lancet 2D02:359:I84I-I85D.
15. Anne Sutcliffe. Osteoporosis - A Guide for Healthcare Professionals. Publisher: Whurr. 2DOB
IB. Journal of Clinical Densitometry, Volume II No I. This contains the latest International Society for Clinical Densitometry (ISCD) position 
statements and background papers on their derivation. Please note that where there is a conflict. UK guidance should be adhered to.
Further recommendations
0 It may be helpful to familiarise yourself with the work being done on clinical standards in your country: NICE (England and Wales) / SIGN (Scntland) /
GAIN (Northern Ireland). 
2) International Osteoporcsis Foundation (IDF) Vertebral Fracture Initiative http://www.iofbonehealth.org/health-prDfessiDnals/educatiDnal-toDls-anJ-
slide-kits/vertebral- fracture-teaching- program.html
3 To review any training you have already received including information from the manufacturers.
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PLEASE CIRCLE AS APPROPRIATE
• I HAVE/HAVE NOT READ THE RULES & REGULATIONS
• I HAVE/HAVE NOT READ THE PORTFOLIO REQUIREMENTS DOCUMENT
• I HAVE/HAVE NOT RECEIVED TRAINING IN ONE OR MORE TECHNIQUES OF BONE DENSITOMETRY
• I AM/AM NOT CURRENTLY EMPLOYED IN CLINICAL PRACTICE
• IWILLAA/ILL NOT HAVE SIX MONTHS FULL TIME OR 12 MONTHS PART TIME (1 DAYA/VEEK OR MORE 
SCANNING EXPERIENCE BY 16th March 2009)
PLEASE TICK AS APPROPRIATE
I have attended the following modules of the lecture courses:
CORE D DXA/pDXA G
I have completed the following IR(ME)R training:
NOS IR(ME)R COURSE D \arna registered Radiographer G Other Radiation Course G
(attach details)
I enclose the following documents in support of my application: (NB: Your application cannot be 
processed unless these documents are enclosed)
A copy of my registration certificate | |
or
A copy of my professional qualifications | |
plus
A letter from my current employer confirming my position G
plus
My course passport I I
President: HRH The Duchess of Cornwall
The National Osteoporosis Society is a registered charity no. 1102712 in England and Wales and no. SC039755 in Scotland
Registered as a company limited by guarantee in England and Wales no. 4995013 Page 1
EXAMINATION REGISTRATION
The on-line examination is on Tuesday 7th July 2009
| would like to register for the examination of the Core module and DXA/pDXA Module
I would like to sit the exam at the following centre:
Glamorgan O LeedsO London Q Dublin* O Edinburgh I I
'This centre will only be offered if there is sufficient interest
My second choice is.........................................................................................
I am unavailable to sit the exam in July 2009 and would like to sit it in London on Tuesday 8th September 
2009 (please provide explanation)
PORTFOLIO REGISTRATION (Portfolio Submission date - Wednesday 7th October 2009)
CANDIDATE SIGNATURE........................................................................ DATE ......................
LOCAL SUPERVISOR SIGNATURE. ...................................................... DATE ....................




Examination Re-sit fee: £70 £70
Per Portfolio: £75 £75 All prices are inclusive of VAT
I enclose a cheque (payable to: National Osteoporosis Society) for a total of C..................
Please debit my Visa/Mastercard £......-..-.-
VISA/MASTERCARD NUMBER __ _______________ ISSUE NUMBER
VALID FROM ______ EXPIRY DATE ______ ̂  THREE DIGIT SECURITY NUMBER












National Training Scheme far Bone 
Densitometry
Instructions for Portfolio Marking (2007/8 Round)
1) Fill in the Student Number, Initials of Examiner, Date, Technique and Machine Type on the Portfolio Score 
Sheet.
2) Question Scoring
Using the scoring criteria below , insert your mark for each component within a section on the Portfolio Score Sheet. At the end of 
each section add up the total score.
Storing criteria
a) Yes/No questions:




Not acceptable or not attEmpted
Attempt mads but does not fully meet requiremBnt or does not appear to fully understand
Acceptable, meets requirements and demonstrates good understanding






NB please refer to Portfolio Requirements form given to candidates and the comments on the attached Portfolio Score Sheet
3) Score Summary
Fill in the score summary table on the final page of the Portfolio Score Sheet. For each section please include the section score 
and whethBr you consider the sBctinn tn bs a pass or fail. Please give the total score for the portfolio and state if you consider the 
portfolio as a whole to bfi a pass or fail. NB All four sEctions must be passEd for an overall pass to be awarded.
Portfolio sections pass marks 2DD7/8
Section I 15 out of total passible of 22
Section 2 12 "" 17
Sections 15 "" 30
Section 4 13 "" 37
All fails will be sent for second marking.
4) Sign, Print your Nome and date the Score Sheet.
National Dstepporasis Society, June 2DDB Page I of 2
5) Portfolio Feedback Form
Fill in the candidate's ID number an the sheet. Please provide detailed constructive comment on the portfolio especially 
highlighting areas where improvement is required. The information on this form should be typed. This feedback will be passed 
back to the candidate regardless of pass/fail status.
National Osteoporasis Society. June 2DDB
Overview of the Bone 
Densitometry Service
Ms. Sue Steel, 
Consultant Physicist, 





NOS standards for a hospital 
based densitometry service
Procedures and organisation 




Procedures and organisation 1
•Written guidelines for referral









Procedures and organisation 2
Reception & waiting area 
Provision for patient privacy and dignity 
Information should be available on: 
o Osteoporosis and support groups
Patient advised to contact referring 
doctor for result
Scan to be reported by experienced 
medical practitioner




Protocols and equipment 1
Written procedures required on:
•All aspects of service
•Women of childbearing age
•Quality control
Ostwporoiii













o Supervision & analysis of QC
data
o Troubleshooting
o Training«•* .-i- Hj-.ionjt
Staffing 2
Medical Practitioner should:
• Be clinically responsible for service
• Be responsible for validation of 
requests (protocols)




• Be familiar with principles of DXA 
including precision, anomalies, 
artefacts
• Report scans - be familiar with 
clinical utility of DXA and relevance of 
WHO definition, T & Z-scores, 
significant change













•Approval of premises and 
procedures











































Ms. Sue Steel, 
Consultant Physicist, 





Dual energy X-ray 
absorptiometry (DXA)
• Two different energy X-rays 
'Absorbed by the body to varying 
degrees dependent upon 
characteristics of the X-rays and 
the tissues
NiiionaL







An X-ray tube is a vacuum tube in which X-rays are produced 






radiation L '9ht photon Photomultiplier tube_x^ ———
Sodium-iodi 
crystal











f( Jl Ostropoiosii 
\ & Soctetj
Environmental considerations











The transmission of X-rays depends on the material 













2 4 6 8 10
Thickness through body (cm)
...... and their photon energy
Soc-eTy
X-ray interactions
Incident beam (I0 )
• X-rays which enter 
Transmitted beam (I)
• X-rays which exit 
Attenuation
x = thickness of material 








Variation of mass attenuation









1 Differential absorption by bone and 
soft tissue
• 30-50 keV
o Bone mineral attenuation » soft 
tissue
• >70 keV






1 Two simultaneous equations 
quantify:
o Attenuation due to bone
o Attenuation due to soft tissue
Calibrated to give BMD (gem 2 ) using 
known bone and tissue standards:
o In calibration block (Lunar) 




^Bone = "Low " •* ("High)
Factor K = ratio of ST attenuation 
coefficients for low and high energies
Effect of body size
X-rays of all energies are increasingly 
attenuated on passing through tissue.
Thin subjects:
• Many X-rays reach 
detector
• Good counting statistics 
(if detector can cope!)
I I I I I I
Obese subjects:
• Few X-rays reach detector
• Selective attenuation of low 






Alternative scan modes provided that:
• Decrease number of X-ray photons for 
thin subjects (decrease X-ray tube 
current and/or increase scan speed)
• Increase number of photons for obese 
subjects (increase current and/or 
decrease scan speed)
© Society
Shape of X-ray beams 
in DXA
Fan beam Pencil-beam
Since the introduction of DXA the most important
advance has been the replacement of pencil-beam








Differences between pencil 
and fan-beam DXA systems
Pencil-beam DXA Fan-beam DXA
• Older technology • Later technology
• Scan time 5-10 min • Scan time 10-30 sec
• Good image quality • Better image quality







Differences between table-top 
DXA and peripheral DXA
Table-top DXA
• Used for scanning 
spine and femur
• X-ray tube voltage 
-80-140 kVp
• Low patient dose 
(-10 mSv)
Peripheral DXA
• Used for scanning 
forearm and heel
• X-ray tube voltage 
40-60 kVp
• Very low patient 







The fundamentals of a good clinical bone densitometry service are 
appropriately trained and experienced staff, reliable equipment, rigorous 
quality assurance, evidence based referrals and good communication 
between users, providers and patients.
Overview
A bone densitometry service may take the form of a diagnostic only service within a 
radiography or other appropriate hospital department. Results may be issued with 
perhaps only a technical comment on difficulties with patient positioning or scan 
analysis. This relies on the physicians referring into the service having sufficient training 
and experience in the limitations and potential inaccuracies of the technique to interpret 
the results appropriately. Access to such a service is therefore best restricted to 
specialist clinicians with referrals through a specialist clinic.
Preferably, a bone densitometry service should have the support of a medical 
practitioner proficient in the field of diagnosis, prevention and treatment of 
osteoporosis . Comprehensive clinical reports may then be issued providing an 
interpretation of the bone densitometry results and giving recommendations on patient 
management2 .
Diagnosis is generally based on the use of dual energy x-ray absorptiometry of the 
spine and hip and as such is subject to the Ionising Radiation Regulations requiring 
therefore support and approval of the local Radiation Protection Advisor3
Standard operating procedures should be in place for all aspects of the service from 
receipt of requests to issuing of reports.
Scan requests
The operator should only accept scan requests which are properly authorised 
according to an established protocol. The request should be formally documented by 
an approved referral source and should contain sufficient clinical information to justify 
the examination. As ionising radiation is being used, an approved referral source will be 
a registered medical practitioner who has received adequate training in accordance 
with the Ionising Radiation (Medical Exposure) Regulations 20004 . Usually a consultant 
who has this training agrees to be responsible for referrals from GPs under the agreed 
protocol. The prime considerations are that referrals comply with evidence based 
agreed referral criteria and that the results of the scan will influence subsequent 
medical management of the patient.
The standard protocol for referral will contain a list of clinical parameters within which a 
scan request may be indicated. Evidence based criteria for referral are available5 and 
may be adapted locally dependent upon resources available.
Standard criteria for bone densitometry generally include: 
Previous osteoporosis-related fracture 
Radiological osteopenia
• Corticosteroid use
. Diseases associated with osteoporosis such as thyrotoxicosis, RA
malabsorption
• Untreated oestrogen deficiency such as following an early menopause 
Family history
There may also be a requirement for repeat measurements for monitoring of disease 
progression or treatment effectiveness.
Information for Patients
A written appointment letter should be sent to the patient giving directions to the 
department, the nature and the purpose of the test, information on suitable clothing and 
contact numbers if they have any queries or wish to change the appointment. It is 
helpful to enclose an information leaflet on precisely what the test involves which 
includes pictures to help reassure the nervous patient. An Osteoporosis risk factor 
questionnaire may be completed when the patient attends or could be sent out with the 
appointment letter. Information provided on prior fracture or hip replacement helps the 
operator avoid unnecessary discomfort when positioning the patient and unnecessary 
radiation exposure. Details of relevant medical and lifestyle factors can aid the reporting 
clinician provide an individualised advice.
A diary of appointments should be kept and a policy established for non attendees.
Patient Handling
If the patient has been scanned previously at the same unit every effort should be 
made for the scan to be carried out on the same machine as on previous occasions in 
order to maximise reproducibility.
On attendance the patient should be welcomed and any concerns regarding the scan 
addressed. As for all diagnostic procedures, the operator should ensure that they have 
the correct person as indicated on the request card/letter before proceeding with the 
test. The patient should be called by their first name and surname and prior to scanning 
asked to provide their date of birth and home address. This data should be checked 
against the request card in order to reduce the possibility of scanning the wrong patient.
Women of child bearing age should be asked to confirm that they do not believe 
themselves to be pregnant. How this information is recorded depends on the protocol of 
the institution concerned.
The operator should confirm that there are no metal objects or bulky clothing within the 
area to be scanned. Changing facilities should be available for patients to change into a 
gown if necessary.
The patient should be informed that a small amount of ionising radiation is being used. 
It is useful to place this in perspective by comparing it to naturally occurring background 
radiation.
Implicit informed consent is assumed by virtue of the fact that the patient attends for a 
scan, the reason and nature of which has been explained to them. However consent 
may be withdrawn at any time and the operator should comply and report this to the 
referring clinician6 ' 7 . Children of sound mind between the ages of 16 and 18 are 
assumed to be capable of giving or refusing consent. Scans of younger children are 
generally carried out only in centres specialising in paediatric bone disease and for 
these consent of a parent or guardian may be requested8 9 . The operator does have a 
responsibility to help and encourage all patients to comply with the request for a scan 
but without coercion.
Privacy and dignity should be preserved throughout the scanning procedure. On
completion, the operator should tell the patient how and when they will be informed of 
the results of the scan.
Confidentiality
Any information obtained from a patient in the course of attendance for a scan is strictly 
Confidential. The operator may discuss information with the patient which has been 
obtained as a result of the scanning procedure, provided that this is in line with an 
agreed protocol developed within the employing authority. The patient has a legal right 
to see any personal information being held by the health authority and tie health 
authority has rights of access to the patient's health records 10 ' 11 ' 12 ' 13 ' 14 .
Quality Assurance
Equipment should be regularly maintained and service and repair records kept. It is 
helpful to keep a log of any relevant daily observations. A rigorous quality assurance 
programme should be followed and results carefully monitored. Scientific support 
should be available for supervision and analysis of the quality control data and for 
trouble shooting of faults with the equipment.
Scans should be perform ed and analyzed by trained operators following standardized 
protocols. It is best having dedicated operators performing this type of work to optimize 
results. Operators should be trained health care professionals who must maintain their 
skills and knowledge through continued professional development. They should also 
undergo radiation protection training and have knowledge of the background of 
Osteoporosis.
Reporting
Reporting of bone density results may be based on the WHO criteria but these are 
applicable to post menopausal females only15 . The image should be checked for 
correct poisoning, analysis, artefacts and general technical accuracy. When monitoring 
changes over time positioning, analysis and software versions should be considered. A 
knowledge of measurement error is required to determine whether any change is 
significant16
Results should be interpreted in conjunction with patient specific risk factors such as 
prior fracture, age and steroid use.
Audit
A database of referrals should be maintained to aid clinical audit and help in identifying 
previous patient attendance.
Information on Bone Densitometry and Osteoporosis
The National Osteoporosis Society (NOS) is a good source of information for patients 
and has prepared a free information sheet on bone density measurement which 
answers common concerns raised by patients.
Leaflets and booklets are also available from the NOS for healthcare professionals.
References
Guidelines for the Provision of a Bone Densitometry Service. 2D02. National Osteoporosis 
Society. Bath
2 Position Statement on the reporting of dual energy x-ray absorptiometry (DXA) bone mineral 
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4 The Ionising Radiation (Medical Exposure) Regulations 2000. Statutory Instrument 2000. No 
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5 Osteoporosis. Clinical Guidelines for prevention and treatment. 1999 Royal College of 
Physicians. London
6 A guide to consent for examination and treatment, NHSME.
7 HC (90) 22: A guide to consent for Examination or Treatment.
8 Dept. of Health 1991: The Children's Act. An introductory Guide for the NHS. HMSO, Health 
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9 Medical Defence Union, 1992: Consent to Treatment. The Medical Defence Union Limited, 
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10 Access to Health Records Act 1990.
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12 Access to Health Records Act: A guide for the NHS. NHSME
13 Data protection Act 1984
14 The Patient's Charter.
15 WHO Technical Report Series 843 (1994) Assessment of fracture risk and its application to 






Bone densitometry investigations generally involve computer controlled 
acquisition, processing and analysis of data. The increasing prevalence of 
osteoporosis heightens the need to identify those at risk and can produce an 
unexpectedly high demand on a newly introduced densitometry service. 
This in turn will entail the accrual of copious amounts of data that require a 
comprehensive database structure together with careful storage and backup 
procedures in order to maintain data integrity. The rigorous quality 
assurance procedures that should be implemented to monitor and ensure 
accuracy and precision of the results, add to this burden of data 
management.
Data Management
Most commercially available bone densitometry systems provide software tools for the 
maintenance of both patient and quality assurance data. However, the user needs to be 
aware of the extent and limitations of these tools and how best to employ them to assist 
with the management of their routine referrals and clinical trials. In units with only one 
densitometer, the software provided may suffice. However, in larger centres a more 
comprehensive and automated system is highly desirable.
All computer based clinical systems must provide a file structure, or database, such that 
the record of one patient cannot be mistakenly associated with another. This is an 
essential criterion when considering the purchase of equipment. Data integrity is 
generally achieved with the aid of a unique identifier, a code that is unique to each 
patient, which is allocated by the system and is an integral part of the file containing the 
patient's biographic
information. If the scan or investigation results are subsequertly stored in separate files, 
as in a relational database, this unique identifier is also incorporated in those files in 
order to provide a cross reference. Alternatively the biographic file may contain a 
separate field which indicates the name of the file in which relevant results are located.
Some computer based systems, such as those supplied by GE-Lunar ( GE-Lunar, 
Madison, Wl ) provide facilities for grouping patient files into separate directories 
(computer filing systems) which is useful where several research studies and clinical 
referrals may be conducted on a single machine. Participation in clinical drug trials 
normally requires the setting up of a separate file system for each trial.
Properly organised and separated data files provide ease of access for each particular 
study but have the disadvantage of the need to search several directories to determine 
previous attendance when given only the patient's name. Other systems, such as Hologic 
(Hologic Inc., Waltham MA) store all patient files in one directory but provide user 
defined search routines that enable patients attending for particular studies to be easily 
identified. This
method relies on an initial entry of a unique code related to each study in one of the 
fields provided. It is well worth taking time when setting up a densitometry service to 
ensure, as far as possible, that the database is structured to address future requirements.
A densitometry centre fortunate to have more than one system for determining bone 
density also needs to take steps to ensure that a patient's previous visits can readily be 
identified so that follow up studies can be carried out on the same machine. This is 
crucial even where the machines are of the same type from the same manufacturer as 
inter machine differences may exceed the minor changes that occur in bone density, 
whether as a result of age or menopause related loss or treatment gain 1 . The methods for 
achieving ease of patient identification where multiple databases exist include a card 
index system and a separate patient administration computer database.
The first is slow but useful where requests are received on cards although cards would
need to be made out for those attending for research or clinical trials. Additional details 
regarding the relevant densitometry system and database would need to be manually 
entered and, if easy access to results is required, the densitometry results would also 
need to be included. Manual entry is tedious and a potential source of human error.
The second requires manual entry onto a computer of relevant machine, database and 
patient details and, if required, densitometry results. This is again prone to human error 
and entails a time consuming duplicate entry of patient details. A preferred method 
would provide for amalgamation of the densitometry databases into one patient 
administration database.
Transfer of Quality assurance data from the densitometer facilitates monitoring of 
equipment performance parameters using more sophisticated analysis tools such as 
Microsoft Excel or SPSS. In some densitometry centres, additional data is collected 
from the patient on clinical, social and lifestyle factors thought to influence bone density 
and osteoporosis risk. If these details are entered into an electronic database they may be 
merged with the bone densitometry results and used for automated generation of more 
individualised reports.
Thought should be given to database management at the outset, with due consideration 
for future potential development, as restructuring a poorly designed set up can prove 
difficult and expensive.
Careful attention should also be paid to the establishment of data backup and archive 
procedures to ensure space availability on the computer system and security of patient 
data. Computers are currently a prime target for opportunist thieves. Assuming the 
computer is physically secure, it is still prone to software or hardware failure that may 
incur loss of data. Software should be available on the system to enable novice users to 
achieve copying of data to an appropriate backup media. Consideration should be given 
to the amount of computer memory required for the storage of image files when 
choosing the backup media The manufacturers provide recommendations on backup 
and archive intervals but individual centres should determine their optimum routine 
based on workload and quantity of data at risk. It should also be noted that the backup 
media is not foolproof and it is recommended to keep more than one copy in separate 
locations. These copies may be in the form of daily archive disks of patient investigation 
results and weekly, more comprehensive, backup discs. It is recommended that the 
backup disc be stored in a secure location in a separate room.
Any person responsible for the management of databases containing personal details on 
individuals must be fully informed of the need to ensure confidentiality and safety of 
that data. This is especially important where sensitive medical details are concerned. 
The Data Protection Act of 1984 requires registration of databases and system 
managers. Larger healthcare providers should have a data protection officer who will be
able to advise on
such matters. Due consideration should also be given to confidentiality when disposing
of computers on which patient details have been held.
Report Generation
In order that bone densitometry assessment may assist in the clinical management of the 
patient, a^ meaningful report must be supplied that is understandable to the referring 
physician'. Referrals for densitometry may be received from several sources dependent 
upon the specific contract agreements for each densitometry centre. The service may 
provide for a report of the measurement only or, preferably, for result interpretation and 
patient management guidance.
A technical assessment of the results, including osteoporosis status and possibly fracture 
risk assessment based on patient's results and age, may be given. This would require a 
reasonable understanding by the referring practitioner of bone densitometry, 
osteoporosis risk assessment and management. Where individualised reports are 
produced by an experienced physician, providing a clinical summary and management 
advice, specialist knowledge is made available to the referring practitioner. Ideally, the 
process should be automated.
Where a technical report is to be provided, only limited clinical details are required in 
order to ensure the appropriateness of the request and aid in the interpretation of the 
results. The printing of appropriate criteria for referral on a densitometry request card, to 
be checked off by the referring clinician, may aid in reducing inappropriate referrals. 
Factors influencing the densitometry procedure, such as hip replacements, laminectomy 
or radiologically diagnosed vertebral fracture, should be included on the request card as 
patient obtained history may prove unreliable. When a more comprehensive report and 
guidance is to be given, full details of the patient's relevant history need to be obtained.
Generally, the referring physician, especially if a GP, requires to know "Do they have 
the disease?", "Are they likely to develop the disease?", "Do they require treatment and 
if so for how long?". The scan printout generated by the densitometry system software 
may prove over elaborate and unhelpful. Often, especially with DXA, results are 
expressed in several forms : actual density (g/cm2), relative to young normal (T score), 
relative to age matched (Z score), as a percentage of either young or age matched (% 
young normal/age matched). The World Health Organisation3 define osteoporosis in 
postmenopausal women as a bone mineral density value of the spine, hip or forearm of 
more than 2.5 SD below young normal mean. The T score therefore tends to be used for 
the diagnosis of the disease whereas the Z score or age matched comparison may be of 
use in decisions regarding treatment, especially in the elderly4 . It is helpful for the GP to 
be provided with an interpretation of the results and recommendation on patient 
management.
Investigations not resulting in a prompt, clear, concise, clinically useful report will soon 
fall into disrepute in this age of limited resources and rising demand on healthcare 
services.
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DXA scanning of the axial skeleton is the accepted technique for the diagnosis of 
osteoporosis. The following statement has been prepared to outline the current 
advice from the National Osteoporosis Society (NOS) on the interpretation of DXA f | 






This position statement applies to DXA scans of the proximal femur and PA lumbar 2. §
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1 Bone mineral density (BMD) measurements by DXA at the lumbar spine and proximal femur remain the 
current 'gold standard' for the diagnosis of osteoporosis and intervention with treatment.
2 This report aims to give guidance to physicians providing a DXA scanning service on how spine and 
femur BMD scans may be reported to primary care doctors and other physicians referring patients for 
bone densitometry studies.
3 The basis of the recommended reporting system is the World Health Organization (WHO) study group 
definitions of osteoporosis, osteopenia and normal, based on BMD T scores < 2.5, between -2.5 and - 
1, and > -1 which identify patients with high, intermediate and low risk of fracture respectively.
4 The WHO definitions of osteoporosis, osteopenia and normal, apply only to BMD measurements of the 
spine, proximal femur or forearm and should not be applied to other DXA measurement sites or 
measurements made with technologies other than DXA.
5 Although the clinical diagnosis of osteoporosis is based on T-scores, Z-scores can be helpful in scan 
interpretation, especially in the elderly.
6 Care is necessary when using reference ranges for the calculation of T-scores and Z-scores that the 
data used are relevant and accurate for the population concerned taking into account the gender and 
ethnic origin of the patient. It is recommended that femur BMD measurements are interpreted using 
the total hip region of interest with the reference range derived from the third US National Health and 
Nutritional Examination Survey (NHANES III).
7 GE-Lunar DXA scanners have a default setting that reports a weight-corrected Z-score. It is
recommended that to standardise reporting and maintain consistency between scanners from different 
manufacturers, this default setting is changed so that Z-scores are reported without weight correction.
8 Before reporting a DXA spine study, careful visual scrutiny of the scan image is essential to exclude 
artifacts such as degenerative disease, vertebral fractures or metal artifacts that may affect T-score 
and Z-score values. In elderly subjects the spine scan may be of little value if there is extensive 
degenerative disease. When reporting a femur study the scan images should be inspected for the 
correct rotation and abduction of the leg and correct placement of the standard femur regions of 
interest.
9 When reporting follow-up studies the scan images should be carefully checked to ensure that the 
positioning of the patient and placement of the regions of interest are consistent. Statistically 
significant BMD changes require a change of at least 4.5% in spine or total hip BMD.
10 The proposed structure of DXA reporting is as follows:
• The report should begin with the BMD, T- and Z-scores for the spine and femur.
m Where appropriate the use of one of three standardised reports is recommended based on whether 
the spine and femur T-scores indicate osteoporosis, osteopenia or normal BMD.
a Where necessary the report should end with a free text comment to provide for additional 
interpretation and recommendations or to qualify the standard reports.
Background
Bone densitometry is now well established in clinical practice and it is generally accepted that DXA is the 
'gold standard' technique for the measurement of bone mineral density (BMD). The ability to measure BMD 
has had a major impact on our ability to diagnose osteoporosis and assist in decisions about treatment. 
There are countless articles and reviews relating to DXA, but at a practical level there is often confusion 
among different physicians as to what precisely a DXA result means, and how to apply this to therapeutic 
decision-making for an individual patient. The purpose of this report is to address these issues and to 
provide some guidance on standardised reporting of DXA studies. At the present time recommendations 
will only be made in respect of the spine and the hip. in
DXA
Over the past decade, DXA has established itself as the most widely used method of measuring BMD 
because of its advantages of good precision, short scan times and stable calibration in clinical use. DXA 
equipment allows scanning of the spine and hip, usually regarded as the most important measurement 
sites because they are common types of osteoporotic fractures and cause substantial impairment of 
quality of life, morbidity and mortality. A measurement of hip BMD has been shown to be the most reliable 
way of evaluating the risk of hip fracture12 .
Additionally, since the vertebral bodies are rich in metabolically active trabecular bone, the spine is 
regarded as the optimum site for monitoring response to treatment3 . Note that the relationship between 
bone density and fracture is described by a continuous gradient of risk. Figure 1 shows the relationship 
between hip bone density and risk of osteoporotic fracture when moving from the highest (I) to the lowest 









Figure 1. Comparison of the relationship 
between hip BMD and the risk of hip 
fracture with the relationships between 
blood pressure and the risk of stroke 
and serum cholesterol and the risk of 
myocardial infarction. In each case the 
population is divided into quartiles and 
the relative risk of the higher risk 
quartiles plotted relative to the lowest 
risk quartile (figure reproduced from 
Ref [4] with permission).
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The fundamental principle behind DXA is the measurement of the transmission through the body of X-rays 
of two different photon energies 5 . Since the attenuation coefficient depends on atomic number and photon 
energy, measurement of the transmission factors at two energies enables the 'areal' densities 
[i.e. the mass (g) per unit projected area (cm 2 )] of two different types of tissue to be inferred. In DXA scans 
these are taken to be bone mineral (hydroxyapatite) and soft tissue respectively. The radiation dose to the 
patient from a DXA scan is very low (1 to 10 uSv)6 and is comparable to the average daily dose from 
natural background radiation (7 uSv).
Definition of osteoporosi
; o
In recent years the widespread availability of bone densitometry systems has led to working definitions of 
osteoporosis that are increasingly based on measurements of bone mineral density (BMD). In particular, in 
1994 a World Health Organisation (WHO) study group recommended a definition of osteoporosis based ' 
on a BMD measurement of the spine, hip or forearm expressed in standard deviation (SD) units called 
T-scores7 s .
<| The WHO report also proposed a state of reduced BMD intermediate between normal bone density and
e% osteoporosis called osteopenia. It is important to note that these WHO definitions were derived from BMD
5 1 data from epidemiological studies of Caucasian women in their sixties who had sustained hip fractures,
5 1 and were never intended as treatment thresholds for individual patients.i *
i?> The T-score is calculated by taking the difference between a patient's measured BMD and the mean BMD
g° of healthy young adults at the age of peak bone mass, matched for gender and ethnic group, and
£| expressing the difference relative to the young adult population SD:
IT 8
Jo T-score = Measured BMD - Young adult mean BMD
———————————————————
jw Young adult standard deviation
1 0
A T-score result therefore indicates the difference between the patient's BMD and the ideal peak bone 
9 mass achieved by a young adult.
<?»
mg The WHO definitions of osteoporosis and osteopenia were originally developed for white females and are
» based on T-score values such that a woman with a T-score = -2.5 at the spine, hip or forearm is classified 
" as having osteoporosis, a T-score between -2.5 and -1 is classified as osteopenia, while a T-score = -1 is 
regarded as normal. A fourth state of 'established osteoporosis' was also proposed, denoting 
osteoporosis as defined above, but in the presence of one or more documented low trauma or fragility 
fractures, usually of the wrist, spine or hip.
The WHO study group definitions of osteoporosis, osteopenia and normal are intended to identify patients 
with high, intermediate and low risk of fracture respectively. It is important to recognise that the WHO 
criteria refer only to BMD measurements of the spine, hip or forearm. These definitions cannot 
automatically be applied to other BMD measurement sites, to other technologies such as quantitative 
computed tomography (QCT) or quantitative ultrasound (QUS), or to patients other than Caucasian women 
e.g. men, and to non-caucasians. In particular the use of T-scores is inappropriate in children.
The rationale for the WHO definition of osteoporosis is that it captures around 30% of all Caucasian 
postmenopausal women9 . This figure approximates to the lifetime risk of fracture for a 50 year old woman. 
Furthermore, there is evidence from several recent clinical trials that a T-score of -2.5 is a threshold below 
which treatment produces a reduction in fracture risk10 - 11 . In comparison, it can be argued that the WHO 
definition of osteopenia captures too high a percentage of women to be clinically useful, and nowadays this 
term is being used less often, particularly in the context of making therapeutic decisions. In contrast, the 
WHO definition of osteoporosis has had a major influence on clinical practice, to the extent that the 
question: 'Does this patient have osteoporosis?' is now regarded as a T-score issue.
Alongside the T-score, another useful way of expressing BMD measurements is in Z-score units12 . Like the 
T-score, the Z-score is expressed in units of the population SD. However, instead of comparing the 
patient's BMD with the young adult mean, it is compared with the mean BMD expected for the patient's 
peers, e.g. for a healthy normal subject matched for age, gender and ethnic origin:
Z-score = Measured BMD - Aged matched mean BMD 
Aged matched standard deviation
GE-Lunar DXA scanners have a default setting that reports a weight-corrected Z-score. It is recommended 
that to standardise reporting and maintain consistency between scanners from different manufacturers, 
this default setting is changed so that Z-scores are reported without weight correction, (a)
(a) To turn off the weight correction on GE-Lunar systems click on the Tools menu bar. Then choose Use Options 
followed by Reference Data. For each site (i.e. spine, femur) make sure that the weight box is clear. If there is a tick in 
the box click on the box to remove it. If the scanner is part of a network then this adjustment must be checked on all 
the scanners in the network.
Figure 2. Caucasian female spine BMD reference data for GE Lunar DXA scanners 
with lines of constant T-score and Z-score superimposed.
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Although not as widely used as T-scores, Z-scores nevertheless remain a useful concept because they 
express the patient's risk of sustaining an osteoporotic fracture relative to their peers. T- and Z - scores 
are compared and contrasted in Figure 2 which shows Caucasian female reference data.
Epidemiological studies of the relationship between BMD and fracture incidence are interpreted using a 
'gradient of risk' model in which fracture risk increases exponentially with decreasing BIV1D13 . The findings 
are expressed in terms of the relative risk (RR), which is the increase in fracture risk for each 1 SD 
decrease in BMD. Results for RR values by fracture site and BMD measurement site have been derived in 
a recent meta-analysis of prospective studies 1 . Typically, every reduction of 1 SD in BMD equates to a 1.5 
to 2.5 increase in the likelihood of fracture. It follows therefore that patients with a Z-score < - 1 are at a 












If the WHO criterion of a T-score = - 2.5 is used to define osteoporosis, then it is apparent that any errors 
in the mean BMD or population SD of the reference group might lead to significant differences in the
8 apparent incidence of osteoporosis when applied to other populations. The great majority of centres
providing a scanning service use reference ranges provided by the equipment manufacturers, and issues
? T, over the accuracy of these ranges have caused controversy in the past, especially for femur BMD" In view
51 of the large number of new devices that are being introduced for the assessment of the skeleton the
jo accuracy of the reference data provided is an important issue.
While there is reasonably close agreement between the principal DXA manufacturers for spine BMD T- 
scores and Z-scores, for femur reference data the controversy has been largely resolved after a report by 
the International Committee for Standards in Bone Measurement (ICSBM) 15 which recommended that hip 
BMD measurements should be interpreted using the total hip region of interest (ROI) (Figure 3) and by 
employing the hip BMD reference ranges derived from the third US National Health and Nutritional 





Figure 3. The total hip ROI is shown 
as the area within this line
The NHANES III survey studied a nationally representative sample of over 14,000 men and women with 
approximately equal numbers of non-Hispanic white, non-Hispanic black and Mexican Americans. Data were 
gathered using Hologic QDR 1000 DXA scanners operated from mobile trailers so that subjects from all 
regions of the United States could be included. The ICSBM report recommended use of the total hip ROI, 
instead of the previously widely used femoral neck site because of its larger area and therefore improved 
precision, and the fact that it is the hip region most readily implemented on all manufacturers' systems.
Many centres have already acted upon these recommendations, and the total hip ROI is increasingly being 
used for scan reporting. It is important to note that these changes affect the percentage of patients who 
are diagnosed as having osteoporosis at the hip. Using the total hip ROI and the NHANES III reference 
range, significantly fewer patients will be diagnosed as having osteoporosis than when using the femoral 
neck ROI and the manufacturer's reference range with Hologic instruments 17 . While it is possible to debate 
the best choice of measurement site and reference range, it is important to recognize the advantages of a 
consistent approach, and to have universally accepted DXA BMD criteria for the diagnosis of osteoporosis.
One advantage of presenting bone densitometry results in terms of T- and Z- scores is that they avoid the 
confusion caused by the raw BMD figures that differ for different manufacturers' equipment18 . The ICSBM 
Committee has addressed this latter issue by publishing equations which allow each manufacturer to 
express their BMD values in a consistent fashion in standardised units (sBMD: units mg/cm2 ) 1519 . The 
ICSBM report also included figures for the NHANES III total hip reference data converted into sBMD values. 
It should be noted, however, that sBMD values have not been widely adopted for everyday clinical practice.
Scrutiny of the DXA scan image
Lumbar Spine
A careful visual scrutiny of the scan image is important in the interpretation of DXA studies to ensure that 
the findings are not affected by anatomical artifacts. For spine scans these include degenerative disease 
(Figure 4) vertebral fractures (Figure 5) and metal artifacts (Figure 6). Their effect on scan interpretation 
may be assessed by noting the trend in T- score or Z- score results at each vertebral level.
Figure 4. Spine DXA scan 
from a GE Lunar DPX 
densitometer showing 
changes in BMD in LI and 
L2 due to osteoarthritis. 
The effect of OA on BMD 
can be seen from the 
trends in T-score and 
Z-score values from LI to 
L4 shown in the first four 
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Figure 5. Spine DXA scans from a GE 
Lunar Expert-XL densitometer 
showing the development of a 
vertebral crush fracture in LI 
between November 1996 and 
November 2000
Figure 6. Spine DXA scan from a Hologic 
QDR4500 densitometer showing the effect on 





If the BMD of an individual vertebra is falsely elevated by an artifact, the affected vertebra(e) should be 
excluded from analysis and from the reference range plot of BMD against age. If new vertebral fractures 
are suspected, either by the scan appearance or a change in vertebral height or if there is a large 
discrepancy in BMD between vertebrae, the referring clinician should be advised about the need for further 
investigation e.g. with plain radiographs to identify the cause of this difference.
For spine scans it is also important to check that the correct vertebrae have been chosen for analysis. 
Scan analysis may sometimes be performed by mistake on LI - L3 or L3 ~ L5 instead of L2 - L4 [in the 
case of Lunar machines] and on T12 - L3 or L2 - L5 [in the case of Hologic machines]. Another source of 
confusion is patients with abnormal segmentation e.g. 6 lumbar vertebrae20 .
In elderly subjects the spine scan may be of little diagnostic value if there is extensive degenerative 
disease. In such patients a more reliable measure of skeletal status may be obtained from the BMD of the 
hip and/or a peripheral measurement e.g. forearm or calcaneus.
Proximal Femur
Dareful scrutiny of the scan image is also important for femur studies. The hip can show a range of 
anatomical variants, some of which may make the correct placement of the standard ROI boxes difficult 
3.g. a short femoral neck, Paget's disease of the femur or exuberant osteoarthritis. Incorrect rotation or 
abduction of the leg is also a major source of error21 . Correctly positioned and correctly analysed hip DXA 
scans are shown in Figure 7 for Hologic and Lunar densitometers respectively. Sometimes optimum hip 
positioning cannot be obtained even by the most experienced technicians, due to patient limitations e.g. 
painful osteoarthritis, previous stroke etc.
Rgure 7. Correctly positioned and correctly analysed femur DXA scans for: 
(A) a GE Lunar densitometer; (B) a Hologic QDR densitometer.
Both spine and femur scans need to be checked to ensure that the bone edge markers are correctly 
positioned. The densitometer algorithms which calculate these are not infallible and manual correction of 
bone edge markers and intervertebral markers may need to be performed in some cases. The adjacent 
soft tissue, used in the calculation of the soft tissue baseline, should also be free of artifact. The patient's 
date of birth must be entered correctly into the densitometer database, since this will affect the 
calculation of the Z - score.
Inspection of scan images is particularly important when interpreting follow-up studies. A visual comparison 
should always be made with previous studies. For the spine, a check should be made that the same 
vertebrae have been used in the analysis. For the femur scan, it is important that the angles of rotation 
and abduction of the hip are the same and that the ROI boxes have been placed in a consistent manner.
Repeat scans should be performed on the same machine using the same scan mode. The patient's weight 
also needs to be checked since major weight change can also affect the scan result due to changes in 
body fat22 . It is important to remember that a change in software since a previous scan, or a new X-ray 
tube, may substantially alter the precision of the scanner and add additional variation to the 
measurements which must be allowed for when calculating 'least significant change' (see below).
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The clinical indications for performing BMD measurements are summarized in the Appendix (see page 20).
The remainder of this document outlines a scheme for reporting BMD scans of the spine and femur. The
basis for scan reporting is the WHO definition of osteoporosis, i.e. a T- score = - 2.5 and this is also the **•
threshold for treatment which has been recommended in the recent RCP Guidelines 23 in the case of ___
postmenopausal women.
The use of T-scores for other patient groups, i.e. premenopausal women, men and children is discussed 
below. It should be noted that while three standard reports are suggested, any system should have the « - 
flexibility to provide individual reports and some of the issues relating to this system will be discussed | s 
below. 5-1
It is important to begin by reporting BMD, T- and Z- scores: § 3
Spine = ............ g/cm2 T- score = Z- score = <g =?
Femur = ............ g/cm2 T- score = Z- score = o -§
a %-. cr.
These figures may then be interpreted with the help of one of three standard reports: |-<m
II
1. If the T-scores for the spine and total hip BMD are both greater than - 1.0 o. g
Standard report reads: £. §•< CD
The results are normal and the patient should be reassured. o 8§
3
Ul
2. If at least one T-score for spine or total hip BMD is less than - 1.0 but both are greater than - 2.5 
Standard report reads:
The results show osteopenia and treatment may be considered if:
(a) the patient has previously had a low trauma fracture;
(b) is receiving glucocorticoid therapy; or
(c) has a low BMD for age (Z-score of less than -1).
Even if no treatment is given lifestyle advice to improve BMD should be provided and BMD 
re-measured in 3 to 5 years.
3. If at least one T-score for spine or total hip BMD is less than -2.5 
Standard report reads:
The results confirm osteoporosis and treatment is indicated
It should be noted that while three standard reports are suggested, any system should have the flexibility 
to allow for individual reports. A comments box is therefore included to provide for additional reports or to 
qualify the standard reports.
; o
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The reporting suggestions outlined above are intended primarily for post-menopausal women up to the age 
of 70 or 75 years. They do not cover all situations, and for example are inappropriate for children and pre- 
12 menopausal women. Some caution in interpretation is also required when dealing with men or individuals 
of other races. The rules do not work so well in the elderly, as the majority of individuals over the age of 75 
will have osteoporosis based on the WHO definition, while a Z-score of - 1 is too low a threshold in this
population. However, in the elderly bone density is often only one of several factors that should be taken* 
«o into account when making a decision as to whether treatment for osteoporosis is appropriate.
31 Although there is strong evidence for a reduction in fracture risk with antiresorptive drugs only in patients
j| with vertebral fractures or with a T-score less than -2.5, several authorities (the Royal College of Physicians
I® in the UK, and the National Osteoporosis Foundation in the USA) have proposed that the T-score threshold
< o of -2.5 be raised for patients with a history of low-trauma fractures (23) or in patients receiving
31 corticosteroid therapy24 . For women over the age of 65 years all those with low bone density for age (Z-
!« score of less than -1) will have a T-score of less than -2.5. However, below the age of 65 years some of
§S these women will have a T-score in the osteopenic range. Because of the strong evidence for a reduction in
»3 the rate of bone loss with antiresorptive drugs for patients with osteopenia, some authorities have
jw proposed that women in this latter group should be offered treatment to prevent bone loss. These are the
5° reasons for the special categories included in the osteopenia report above.
Js. Follow-up DXA scans have traditionally been performed to monitor response to anti-resorptive treatment. 
s" The appropriate interval between serial BMD scans is determined from the concept of the 'least significant 
^S change' in BMD. For any change in BMD to be 'true' with 95% confidence, the measured change must 
» exceed 2.8 (or 2v2) times the precision error (or coefficient of variation) of the measurement25 . Although 
" the coefficient of variation for PA spine and total hip BMD measurements is often quoted as 1% it is 
important to realize that this is an idealised figure which applies only to short-term precision 
measurements (i.e. repeated measurements made over periods of a few hours or days) in young adults 
with normal BMD and normal weight for height. In practice the relevant figure for precision is the long-term 
precision error measured over months or years. Patel et al26 reported long-term precision errors of 1.6% for 
PA spine and total hip BMD, thereby producing a figure of 4.5% for the least significant change. This figure 
may be significantly larger, however, in patients with osteoporosis or obesity (i.e. BMI > 30 kg/m 2 ) and care 
is therefore required when interpreting BMD changes in such subjects. Since it is unlikely that such a 
significant change in BMD will be detectable in less than two years, BMD scans are normally not repeated 
more frequently than every two years.
Referring physicians should be aware that in all cases patients require advice about a healthy well- 
balanced diet to ensure adequate calcium and vitamin D intake. Other lifestyle issues such as exercise, 
avoidance of smoking and moderation in alcohol consumption also need to be discussed. In a patient with 
osteoporosis it is important to exclude potential secondary causes of bone loss such as thyrotoxicosis, 
primary hyperparathyroidism, hypogonadism especially in males, inflammatory bowel disease, gluten- 
sensitive enteropathy (which may often be asymptomatic) and myeloma, although such diseases are 
uncommon.
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Referral Criteria for DXA
Clinical indications for BMD measurement are shown in the table below which is reproduced from the 
Royal College of Physicians guidelines 27 :
V ~o
Risk Factors providing indications for the diagnostic use of bone densitometry -SJ |Q) 5' 
& D
1. Presence of strong risk factors o w
-a QJ
i Estrogen deficiency o f
Premature menopause (age < 45 years) - ~v< o




Prednisolone > 7.5 mg/day for 1 year or more %
2L
Q.
s Maternal family history of hip fracture § 
Low body mass index (< 19 kg/m2) gso
3









2. Radiographic evidence of osteopenia and/or vertebral deformity
3. Previous fragility fracture, especially of the hip, spine or wrist
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Guidelines for the provision of
a clinical bone densitometry service
These guidelines are designed to assist practitioners in the development of hospital- 
based bone densitometry services including axial dual-energy X-ray absorptiometry 
(DXA), which is the current technique of choice. The guidelines should also be of 
value to commissioners and service providers when examining the quality of local I f 
bone densitometry provision.
The guidelines should be read in conjunction with the following:
• Position statement on the reporting of dual-energy X-ray absorptiometry bone 
mineral density scans
• Position statement on the use of peripheral dual-energy X-ray absorptiometry in 
the management of osteoporosis
• Position statement on the use of quantitative ultrasound in the management of 
osteoporosis
This statement was prepared for the NOS by Ms SA Steel, Dr JD McCrea and Dr PJ 
Ryan and represents the consensus view of the members of Bone Densitometry 
Forum. The statement is endorsed by the NOS Council of Management.
April 2002
Key recommendations
1 Requests for bone densitometry scans should only be made by registered medical practitioners, or 
other relevant health professionals (eg specialist osteoporosis nurse) who are entitled, under their 
4 employer's procedures, to refer an individual for a scan. The request should be in writing and with 
,_—— adequate clinical information to enable the appropriateness of the scan to be determined by the 
, 0 scanning centre.
51 2 Locally agreed evidence-based guidelines for referral and referral forms should be produced and 
|| updated regularly by the service commissioners, users and providers.
1$ 3 The scanning centre should provide patients with detailed information about osteoporosis and its
J5 treatment, access to an osteoporosis nurse specialist or an equivalent health professional for
i1 * individual discussion, and access by medical referral to a specialist metabolic bone clinic when
|g necessary.
\ vf
J§ 4 Each scanning centre must have prepared full written protocols covering every technical and scientific
Jg, aspect of its service and these must be read by all staff, regularly updated and be available for 
j inspection at all times.
0
' 5 Operators of densitometry equipment should receive adequate training including training in ionising 
radiation in addition to any training supplied by the manufacturers, their distributors or agents.
6 Scans should be reported promptly by registered medical practitioners with special training in the 
scientific and technical aspects of bone densitometry as well as clinical training in the diagnosis and 
management of metabolic bone diseases in general and in osteoporosis in particular.
7 Scan reports should be communicated in writing to the referring practitioner with a medical
interpretation of the results and individualised clinical advice on the further management of each 
patient.
8 All staff participating in densitometry scanning are required to keep their knowledge up to date by 
participating regularly in appropriate continuing professional development including education and 
audit.
Proc '^res and organisation
1 Written guidelines for appropriate referral to the bone densitometry unit should be formulated after 
discussion with commissioners and medical users of the service. The Royal College of Physicians 
Guidelines1 provide nationally accepted and evidence-based referral criteria. Local referral criteria, 5 
based on best scientific evidence, should be widely disseminated and regularly reviewed. ' ____
2 Scans should only be performed following the receipt of a written request from a medically qualified ™ g 
practitioner indicating the reason for referral. A standard request form, which includes the criteria for I §•" 
referral, should be produced and this should be made available to all medical users of the service. 8 $' 
This form should be reviewed and modified at appropriate intervals. o- «% 31
3 Scan requests should be assessed by the medical practitioner(s) responsible for the service. £. $ 
Requests should be graded according to the level of priority; this may be delegated to a suitably ~ ~ 
qualified health care professional e.g. the densitometer operator, working within designated protocols
.
defined by the medical practitioner responsible for the service who will continue to retain overall
responsibility. =j
4 Any unusual requests or those requiring procedures outside the standard protocols should be 3 
discussed with the medical practitioner. Unsuitable requests should be discussed with the referring 8 
doctor.
5 A written appointment should be sent to the patient, with an explanation as to the nature and
purpose of the test, and directions as to how to reach the scanning centre. The appointment letter 
should contain information on suitable clothing and provide contact numbers if the patient has any 
particular requirements or concerns or if the appointment has to be changed.
6 It is suggested that patients receive their appointment letter within two weeks of the scan request 
being received, with routine scans being performed within three months of receiving the scan 
request. Procedures should also be in place to be able to perform scans urgently where necessary.
7 A risk factor questionnaire may be used and either completed when the patient attends for the scan 
or sent to the patient with the appointment letter and discussed on attendance.
8 A diary of appointments should be kept and a daily work schedule should be referred to on each 
working day. There should be a policy established for non-attenders.
9 Each patient should be welcomed upon arrival by the receptionist and any concerns regarding the 
scan addressed. Any delays in the scan appointment should be communicated in a timely manner to 
the patient.
10 A suitable waiting area should be available for patients and their relatives.
11 The scan should be performed in a suitable environment with adequate space, privacy and access to 
changing facilities. Disabled individuals should have access to suitable facilities (e.g. lifts, toilets) and 
to nursing care if necessary. Nursing care should also be available to assist with ill patients. A call 
button should be available for emergencies.
12 Appropriate resuscitation facilities should be available and staff trained to an appropriate level to 
administer resuscitation, as agreed by the organisation's resuscitation officer and other relevant 
responsible bodies.
13 Information on osteoporosis should be freely available at the scanning centre together with details of 
local patient support groups such as those run by the National Osteoporosis Society. Ideally, a nurse 
counsellor should provide advice on lifestyle measures to promote bone health at the time of referral. 
Before leaving the scanning centre, every patient should be advised to contact his or her referring 
doctor to discuss the results.
14 Scans should be reported promptly by a medical practitioner who is proficient in the field of
osteoporosis and bone densitometry. The result should also be sent promptly to the referring doctor 
and should normally include both a medical interpretation of the results and either appropriate advice 
or reference to locally agreed treatment and/or management guidelines. Ideally, scan results should 
be issued within seven to ten days.
15 In addition to the bone density scan, referring doctors should also have the option of sending 
patients to an osteoporosis or metabolic bone clinic for further advice and assessment if this is 
considered necessary for patient management.
Protocols and equipment
1 Local written procedures covering all aspects of the bone densitometry service should be available in
the scanning centre and read by all involved in bone densitometry. These must be kept in a 
6 recognised location and regularly updated. This is now a legal requirement following the introduction
——— of the new Ionising Radiation Regulations2 and the Ionising Radiations (Medical Exposure) 
, o Regulations3 .
0 S.
|| 2 There should be a written procedure regarding women of childbearing age. DXA scans of appropriate
81 sites e.g. forearm or heel, should only be performed in pregnant women with the explicit approval of
J^ the medical practitioner with overall responsibility for the service.
3 0
a £ 3 Written quality control procedures must be established and adhered to, usually as specified by the 
S® manufacturer.
so
J £ 4 An adequate database of the service should be kept to enable review of studies and audit to be
$° performed. Such audits are to be recommended following the introduction of Clinical Governance4 . 
1 g, The provisions of the Data Protection Act5 should be adhered to.
i 5 Scan acquisition and analysis should be performed by trained operators and should be conducted
• according to standardised protocols based on the manufacturer's guidelines. Optimum results are 
obtained by the deployment of a small number of dedicated operators.
6 Before sending scans for clinical reporting, they should be reviewed at the DXA computer workstation 
to ensure that the data have been acquired and processed accurately, that artefacts have been 
identified correctly and to facilitate reprocessing if this is necessary.
7 Results should be both archived and backed-up onto suitable digital media. A hard copy should also 
be retained.
8 Written maintenance procedures should be agreed and a maintenance contract established with an 
appropriately trained individual or company, usually the national distributor or the manufacturer. 
Service and repair records must be kept, including details of any faults discovered, and these must 
be available for inspection at any time.
9 The importance of equipment safety should be recognised. Equipment must be operated according to 
national and local standards for radiation protection, electrical safety, fire regulations and in 
accordance with health and safety legislation. Written evidence of compliance with these standards 
should be kept within the department. The Radiation Protection Advisor (RPA) must approve the site 
where scanning occurs and the Radiation Protection Supervisor (RPS) must ensure compliance with 
Local Rules regarding radiation safety26 .
10 The choice and commissioning of new equipment should be made with expert help and advice from 
suitably qualified individuals e.g. clinical scientist and clinician.
Staff <
Operators
1 Operators should be adequately trained health care professionals, generally radiographers, nurses or 7 
clinical technologists. They should expect to receive equipment specific training by the company 
supplying the scanner. Further training is usually required and they should be encouraged to attend 
courses such as those organised by the National Osteoporosis Society or the International Society for o £ 
Clinical Densitometry (ISCD). Operators must continue to maintain their skills and knowledge. 2. H
2 The Ionising Radiations (Medical Exposure) Regulations3 state that ' ... no practitioner or operator 11
shall carry out a medical exposure ... without having been adequately trained.' This means that ' ... | £?
practitioners and operators shall have successfully completed training, including theoretical o- J
knowledge and practical experience in ... radiation production, radiation protection and statutory | •q
obligations relating to ionising radiation.' 8 §
1 -
3 Operators must have a sufficient grounding in the field of osteoporosis to be able to explain the g 8
purpose and nature of the test to the patient. Operators must also be familiar with the importance of « ° 
good positioning and be able to acquire, analyse and archive studies in accordance with the <. 
manufacturer's guidance and local procedures. They must also be able to recognise artefacts, be 8 
able to perform routine quality assurance with a suitable phantom prior to scanning patients and be 
aware of procedures to be followed when devices are not working correctly.
Scientific support
4 To ensure continued good quality control and performance, a suitably qualified medical physics expert 
should be involved as appropriate. The Ionising Radiations (Medical Exposure) Regulations3 state that 
in respect of a medical physicist the requirement is for' ... a person who holds a science degree ... 
and is experienced in the application of physics to the diagnostic uses of ionising radiation.'
5 There must be a clearly identifiable scientist responsible, whose duties will include the supervision 
and analysis of quality control data, troubleshooting of faults, training of operators and advice on 
radiation protection. The medical physics expert should demonstrate continued professional 
competence through membership of a recognised professional body. Professional membership of the 
National Osteoporosis Society is also recommended.
Clinician
6 Medical practitioners should have clinical responsibility for the service and be suitably proficient in 
the field of bone densitometry and osteoporosis. They should be able to demonstrate adequate 
training and where specified, have complied with Royal College requirements. Training would generally 
be expected to take place in a bone specialist unit with densitometry.
7 They should define a protocol for validation and prioritisation of densitometry requests. They should 
assist with the development of local protocols particularly relating to sites to be measured. Clinicians 
should be familiar with the basic principles of DXA and the operation of their own equipment including 
precision. They should be responsible for the issuing of reports as detailed above.
8 They must be familiar with the clinical utility of the test and the importance and clinical relevance of 
T-scores, Z-scores, the WHO definitions and risk assessment7 . They must be able to recognise 
anomalies, artefacts and confounding pathology. When reporting repeat bone density scans, they 
must make allowance for factors such as expected annual change and precision in assessing the net 
percent change in bone density over time. Similarly, they should recommend repeat scans only at 
intervals at which significant clinical change is likely to be demonstrated.
9 They must be able to demonstrate that they participate in continuing medical education relevant to 
the running of a bone densitometry service. It is recommended that they retain professional 
membership of an appropriate organisation such as the National Osteoporosis Society.
Administrative and Clerical
10 Sufficient administrative and clerical support should be available for the efficient booking of scans, 
sending out of appointments, typing of results and sending these to referring clinicians.





8 3 12 Trained nursing support will be required if services are scanning sick individuals.
ft
I o Radiation protection advice
I-
|§ 13 The RPA must approve the premises and local procedures. The RPS should be identified and should
I §• take responsibility for ensuring adherence to Local Rules6 .
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